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Abstract and Summary 
Introduction: A unique, membrane form of the 70 kDa heat shock (stress) protein Hsp70 is 
expressed on large proportion of tumours and cancer cells, but not on their non-malignant 
counterparts. Although the expression of this membrane Hsp70 expression has been 
associated with poor outcome in some cancers and is associated with aggressive disease (e.g. 
metastatic disease), its expression is enhanced by radiation and certain chemotherapeutics 
and so it might serve as the basis for the development of adjunct therapeutics. Previous 
studies have shown that membrane Hsp70 acts as a targeting structure for activated natural 
killer (NK) cells, and that the NK cell cytotoxicity is mediated via the membrane Hsp70-specific 
uptake of NK cell-derived serine protease granzyme B. The administration of a membrane 
Hsp70-specific monoclonal antibody (mAb, cmHsp70.1) to animals bearing tumours expressing 
membrane Hsp70 reduces the growth of these tumours in vivo via the induction of antibody-
dependent cellular cytotoxicity (ADCC). In addition, preliminary data suggest that a 14-mer 
Hsp70-derived peptide (TKDNNLLGRFELSG) interacts with membrane Hsp70, and this therefore 
provides a potential tool for tumour imaging and targeting. The mechanism, route, kinetics 
and consequence of cmHsp70.1 mAb, 14-mer peptide and granzyme B interaction with, and 
internalisation via, membrane Hsp70 have yet to be fully explored, elucidated and compared.  
Aims of the Study: The aim of the study is to use imaging technology to define the kinetics and 
pathway of internalisation of cmHsp70.1 mAb, the TKDNNLLGRFELSG 14-mer peptide and 
granzyme B) with a view to better understanding their theranostic potential for targeting and 
imaging memHsp70+ breast cancer cell lines. 
Experimental Approach: The binding and internalisation of fluorescently-conjugated 
cmHsp70.1 mAb, the Hsp70-derived TKDNNLLGRFELSG 14-mer peptide and human 
recombinant granzyme B by human (MDA-MB-231, MCF7, T47D) and mouse (4T1) breast 
cancer cell lines expressing varying degrees of memHsp70 was analysed using flow cytometry, 
confocal microscopy and image analysis platforms. Recombinant human granzyme B was 
generated using transfected HEK293 cells, purified using FPLC, and its purity and activity 
confirmed using Western blotting and colorimetric enzymatic activity assays. The yields of 
enzymatically active granzyme B were high (1-4mg/L of cell supernatant). The intracellular 
trafficking path taken by internalised mAb, the TKDNNLLGRFELSG 14-mer peptide and 
granzyme B was interrogated using novel image processing approaches that determined the 
uptake kinetics and quantify the co-localisation of these molecules with intracellular structures 
(endosomes, lysosomes and mitochondria). The influence of granzyme B on cell death-
mediated events was explored by examining its impact on the expression of Annexin V and 
active caspase-3 expression using flow cytometric assays.   
Results: All breast cancer cell lines expressed some degree of memHsp70; the level of which 
was higher in cells those lines which represent a more aggressive, ‘likely-to-metastasise’ 
phenotype. Cells were able to bind and internalise the cmHsp70.1 mAb, the TKDNNLLGRFELSG 
14-mer peptide and granzyme B, with the amount of each being bound and internalised 
increasing in line with the level of memHsp70 expressed increasing. The cmHsp70.1 mAb, the 
TKDNNLLGRFELSG 14-mer peptide and granzyme B were internalised through a similar 
pathway of late and recycling endosomes (as demonstrated by co-localisation, which was 
observed using confocal microscopy imaging and quantified through correlative and Manders 
image analyses), with only a proportion co-localising with lysosomes. Visual and quantitative 
analyses of z-stack confocal images revealed the strong vesicular association and that the 
route of internalisation showed a preference for the adhered surface of cells. The latter finding 
suggests a link between memHsp70 and membrane reorganisation, such as that which occurs 
at adhesive interfaces.  A proportion of the memHsp70-mediated uptake of antibody, the 
TKDNNLLGRFELSG 14-mer peptide and granzyme B was co-localised to the mitochondria, and 
this could be evidence for a specific route of internalisation which is associated with this 
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manner of molecular uptake. The close association of internalised granzyme B with 
mitochondria may offer a way for it to exert cytotoxic effects without the need for perforin. 
The pathway and speed of internalisation was similar for all three molecules, thereby 
suggesting conservation in the mechanism of memHsp70-mediated internalisation. Although 
the uptake of granzyme B promoted cell death on the basis of cell numbers, viability and 
expression of Annexin V, it had no apparent effect on the measurable activation of caspase-3. 
It might therefore be that memHsp70-mediated, granzyme B-induced cell death may occur as 
a result of a different route of internalisation when compared to perforin-dependent uptake of 
granzyme B.  
Discussion: Membrane Hsp70 positive breast cancer cell lines take up the cmHsp70.1 mAb, the 
TKDNNLLGRFELSG 14-mer peptide and granzyme B via memHsp70, and the extent of this 
uptake is proportional to the level of memHsp70 expression on the cell surface. The lack of 
memHsp70 on non-cancerous cells makes this a suitable molecular target on which to base 
new imaging and therapeutic strategies. The antibody or peptide could be used to deliver 
cytotoxic drugs as a direct therapy, or as a way of better imaging the tumour in order to allow 
for prognostic and/or diagnostic improvements. 
Membrane Hsp70 positive breast cancers take up granzyme B, which in turn leads to cell death 
exhibiting apoptotic features. This could be developed as a complimentary therapeutic for use 
in patients undergoing standard care. Granzyme B therapy does not require an active immune 
system to induce apoptosis, and so its use could prove beneficial to immunocompromised 
patients as part of an ‘adjuvant’-based approach which is used in conjunction with current 
therapies. It is also possible that the induction of cell death through granzyme B mediated 
apoptosis could in turn lead to presentation of released tumour antigens and therefore 
promote protective, adaptive anti-tumour immune responses. 
Conclusion: Membrane Hsp70 is widely, and selectively, expressed on tumours and could 
therefore provide an invaluable platform on which to develop new imaging and targeted 
therapies for the large proportion of patients with tumours that express membrane Hsp70. 
This is a particularly exciting area, given that membrane Hsp70 expression is associated with 
aggressive disease and is highly expressed on metastatic disease. Membrane Hsp70 therefore 
has great potential as a platform on which to base new theranostics that can improve the 
management and treatment of patients with cancer.  
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CHAPTER ONE: Introduction 
1.1 The human system and cancer 
1.1.1 Anti-tumour immunity 
The immune system plays an essential role in tumour surveillance and eradication. Meta-
analyses conducted on published data involving almost 1 million people have revealed an 
increased risk of cancer in people in an immunosuppressed state [1, 2], be that as a 
consequence of taking immunosuppressive drugs following organ transplantation [3, 4] or due 
to HIV/AIDS infection [5]. This risk is more pronounced for those cancers that are driven by 
viral infections such human papillomavirus (HPV) infection [2] (which has a well-documented 
association with cervical cancer [6], but has also been implicated in oesophageal squamous 
carcinoma [7], non-small cell lung carcinoma [8] and non-melanoma skin cancers [9]) or 
Epstein-Barr virus (EBV) [1] (which is associated with a range of B and T lymphomas [10]). 
However, there is also evidence that some spontaneous tumours are more common in 
immunosuppressed individuals, including prostate, kidney, thyroid, brain and colorectal cancer 
[1], and also cancers of the stomach and liver [2]. Another common finding has been that the 
rate of commonly arising cancers of epithelial origin does not appear to correlate with an 
immunosuppressed state [1, 2], thereby suggesting that cancers can suppress potentially 
protective anti-tumour immune mechanisms.  
The concept that the avoidance of the immune system by tumours might be key to their 
establishment and continued growth is a relatively recent one. Noticeably absent from a list of 
as six hallmarks of cancer which Hanahan and Weinberg proposed in a seminal paper which 
was published in 2000 [11] was any mention of the immune system.  
• self-sufficiency in growth signals  
• insensitivity to anti-growth signals  
• the ability to invade tissues and metastasise  
• limitless replicative potential  
• sustained angiogenesis  
• capacity to evade apoptosis 
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In a revised model published a decade after their initial proposal, Hanahan and Weinberg 
included an additional four traits listed below [12]: 
Additional hallmarks of cancer 
• deregulation of cellular energetics 
• avoiding immune destruction 
Enabling characteristics 
• tumour-promoting inflammation 





Figure 1.1 The Hallmarks of Cancer and Enabling Characteristics 
The hallmarks of cancer are eight capabilities acquired during the development of human tumours. They explain the 
methods by which tumours can undergo their defining property of unrestricted growth. More recently proposed are 
the two ‘enabling characteristics; traits that promote the hallmark characteristics.   
Figure has been adapted from Hanahan and Weinberg [11, 12]. 
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In response to the original hallmarks publication, and appearing at the same time as the 
revised version, Cavallo et al published their own suggestions of possible immune-based 
hallmarks of cancer [13]: 
• withstanding a chronically inflamed environment 
• evading recognition 
• being able to suppress immune reactivity  
The inclusion of avoidance of the immune system as one of Hanahan and Weinberg’s revised 
Hallmarks, in addition to these traits proposed at the same time by Cavallo, demonstrate the 
growing recognition of the importance of tumour immunity. Having this framework defining 
hallmarks of cancer enables research efforts to be focussed on targeting specific features of 
cancer. 
1.1.1.1 Role of NK cells in anti-tumour immunity  
As indicated above, NK cells comprise 5-20% of human peripheral blood lymphocytes and can 
be categorised into distinct functional subsets based on the expression of CD56 (Neural Cell 
Adhesion Molecule, N-CAM) and CD16 (FcγRIII) [14]. The vast majority (~90%) of peripheral 
blood NK cells are CD56low CD16+. These cells are also termed effector NK cells, as they contain 
cytotoxic granules comprising of granzymes (cytotoxic agents) and perforin which are released 
to induce apoptosis in target cells. Around 10% of peripheral blood NK cells are CD56highCD16- 
NK cells [15]. These NK cells are weakly cytotoxic when resting, however they obtain similar 
cytotoxic capabilities after activation with IL-2 or IL-12 [16]. This subset of NK cells is also a 
prolific producer of IFN-γ, TNF-β, GM-CSF, IL-10 and IL-13 [15].  A negligible proportion of 
peripheral blood NK cells (~1%) are CD56highCD16+ [17], although there is currently little insight 
into whether these represent a subset of cells functionally distinct from CD56highCD16-, with 
some publications linking all CD56high NK cells into one subset [15].  
The traditional view of NK cell maturation proposed that different NK cell subsets comprise 
points along a single maturation lineage, with CD56highCD16- NK cells becoming CD56lowCD16+ 
via an intermediary CD56highCD16+ phenotype [17]. However, another view is that the different 
NK cell subsets represent endpoints of maturation lineages [15]. Observations following bone 
marrow transplantation in humans have demonstrated an early appearance of CD56highCD16- 
NK cells, with a subsequent decline in the prevalence of this population being accompanied by 
a gradual emergence of CD56lowCD16+ NK cells [18, 19]. Although this supports the notion that 
all NK subsets are derived from a single lineage, further studies are required in order to 
confirm if this is indeed the case. 
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CD56highCD16- NK cells represent a minority population in the periphery, although this situation 
is reversed in lymph nodes, in which they are the predominant NK cell population (~90%) [15]. 
Current understanding suggests that this occurs during development rather than simply by cell 
migration [20]. Full details of NK cell precursors and their sites of development have yet to be 
totally elucidated, but knowledge is growing. Although NK cells arise from CD34+ 
hematopoietic progenitor cells, the phenotype of these progenitors differs between different 
sites. Although the majority (>90%) of those NK cells in lymph nodes express low levels of 
CD34 (CD34dim),  this CD34dim phenotype constitutes a small minority of CD34+ progenitor cells 
in blood (~6%) and bone marrow (<1%) [21]. Ex vivo human culture experiments have shown 
that CD34dim progenitor cells isolated from lymph nodes differentiate into CD56brightCD16- NK 
cells in the presence of CD3/CD28 monoclonal antibody (mAb)-activated T cells [21], and that 
CD34dim progenitors isolated from peripheral blood and cultured with IL-2 and IL-15 also 
differentiate into CD56brightCD16- NK cells [21]. Those progenitor cells expressing higher levels 
of CD34 (CD34+) differentiated into CD56lowCD16+ NK cells [21]. Since their activation leads to 
high secretion of the NK activating cytokine IFN-γ, these CD56brightCD16- NK cells serve to 
maintain a pro-NK environment. This subset of NK cells constitutively express the IL-2 receptor 
(CD25) and are activated by T cell derived IL-2 [22], thereby providing a link between innate 
and adaptive immunity. 
Another NK cell population is found in the uterus (uNK) and although on the basis of their 
surface marker expression these bear some resemblance to cytokine-releasing NK cells in the 
periphery (CD56highCD16-) [23], gene microarray analysis suggests that they are a distinct 
subtype by highlighting large increases in expression of over 200 genes in uNK cells, 
particularly relating to surface proteins including lectin-like receptors, killer cell Ig-like 
receptors and integrins [24]. The numbers of uNK cells are linked to menstruation, with only 
sparse numbers being found in the uteri of foetuses, neonates [25] or post-menopausal 
women [26]. The prevalence of uNK cells fluctuates over the uterine cycle, reaching a peak by 
the late secretory phase, when uNK cells can comprise 30% of all endometrial cells [27]. It is 
currently unclear whether uNK cells are the result of the migration and subsequent 
differentiation of peripheral NK cells [23, 28], or if they arise from local progenitor cells that 
are resident in the endometrium [29-31] - current opinion favours the latter [32]. 
NOD/SCID/γcnull mice which received subcutaneous implants of human endometrium that 
were in the proliferative phase of the uterine cycle, followed by 28 days of hormone 
administration (17β-estradiol (E2) and progesterone) to progress the implants to the secretory 
phase, were found to exhibit a significant increase to CD56brightCD16- NK cell numbers in the 
endometrial stroma [29]. Since NOD/SCID/γcnull mice lack NK cells, the observed 
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CD56brightCD16- NK cells are proposed to have originated in the endometrium implant.  Further 
evidence in support of in situ proliferation comes from immunohistochemical staining of 
human endometrium samples which found that during the secretory phase, up 40% of uNKs 
can be found to express the proliferation marker Ki67 [33]. uNK cells have very low cytotoxic 
capacity, but are prolific secretors of cytokines, including IFN-γ, TGF-β, TNF-α, IL-1β, Ang-2, 
PlGF, VEGF and GM-CSF [34, 35]. As for the role of NK cells in the uterus, there is no definitive 
conclusion as yet. Being prolific secretors of pro-angiogenic cytokines, some of which also 
inhibit trophoblast invasion (Ang-2, TNF-α, IFN-γ, TGF-β), it has been speculated that they have 
a role in aiding successful implantation and vascularisation of the embryo, and studies have 
attempted to find a link between uNK cells and spontaneous recurrent miscarriage. Findings 
have been inclusive and contradictory, with both an increase in uNK cell numbers [36, 37] and 
a decrease in uNK cell numbers [38, 39] being positively correlated to the occurrence of 
spontaneous miscarriage. 
NK cell populations express a wide variety of surface receptors, the majority of which 
recognise ligands on the surface of potential target cells. Broadly, their surface receptors fall 
into one of two categories; those which trigger NK cell activation (activating receptors) and 
those which prevent action (inhibitory receptors). Whether an NK cell responds to a particular 
target cell is dependent on a balance of the signals received to the two classes of receptor. If 
the greatest signal comes from inhibitory receptors, then the NK cell will not respond, however 
if activating receptors provide the majority of the signal then the NK cell will be activated to 
either release cytokines or cytotoxic granules depending on NK cell type. The number of 
described NK receptors continues to increase, and for human cells currently stands at 22 [40]. 
The receptors are characterised into different groups current understanding is summarised in 
Table 1.1. 
In terms of tumour immunology, a key class of NK receptors are the killer cells 
immunoglobulin-like receptors (KIRs). A primary ligand for these receptors is the MHC class I 
molecule, the binding of which provides an inhibitory signal which promotes non-reactivity to 
self-cells. However, given sufficient additional activation signals, NK cells are still able to kill 
target cells which express MHC class I. A large proportion of tumours (40-70%) either lack, or 
have down-regulated MHC class I expression, which can impair/prevent the clearance of 
tumour cells by CD8+ T cells (as recognition of specific peptides on MHC class I is required for 
their activation). The effect on NK cells is simply a loss of an inhibitory ligand so, providing the 
tumour cells also offer some activating ligands, NK cells can kill tumour cells.  
 






























Table 1.1 Examples of NK receptor family members and the signals they provide 
Natural killer cells express a wide variety of surface receptors capable of binding a diverse selection of target cell 
ligands. The outcome of successful receptor-ligand binding results in either an activation signal (+), whereby NK cells 
are induced to release cytotoxic granules, or an inhibitory signal (-) where NK cells are not compelled into action. As 
NK cells express many receptors it is possible to recognise multiple different ligands at once, in which case the sum 
total of activation and inhibitory signals received will determine the NK cell action.  
  Signal provided 


















Fc receptor CD16 (FcγIIIA) + 
Glycoprotein DNAM-1 + 
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In addition to recognising ligands on the surface of target cells directly, NK cells can also act in 
conjunction with B cells via Antibody Dependent Cellular Cytotoxicity (ADCC). The high 
expression of CD16 (low affinity Fc receptors FcγRIIIa (CD16a) and FcγRIIIb (CD16b) by effector 
NK cells allows recognition of the Fc region of antibodies that are bound on the surface of 
potential target cells. Activation of the CD16 receptor results in the release of cytotoxic 
granules, in the same manner as recognition of target ligands to activating receptors, and 
subsequent apoptosis of the target.  
Cytotoxic granules contain apoptosis-inducing serine proteases (granzymes), as well as the 
pore forming protein perforin. Prior to their release, the granules are held along intracellular 
microtubule networks. Target recognition and the subsequent formation of an immunological 
synapse triggers intracellular signalling which directs the polarisation of the microtubule 
organising centre (MTOC) and rearrangement of filamentous actin [41] in order to direct the 
release of granules in a highly focused locale just at the immunological synapse [42]. The 
majority of this process is well characterised and has been the subject of in depth review [43]. 
Upon first contact with target cells, the suggestion is that NK cells weakly adhere through 
ligation of CD2 and activation receptors [41, 44, 45], with potential involvement of molecules 
of the selectin family [46], although full details of this first-step interaction have not yet been 
fully described [43].  The next stage is a higher affinity adherence between NK cell and target 
cell, largely involving molecules in the integrin family [41] which contributes to NK cell 
activation [47, 48]. Once these initial steps are complete, reorganisation and polarisation 
processes take place within the NK cell. Surface receptors move to cluster at the synapse with 
macro-clusters of receptors observed at the site of the synapse [49]. The microtubules upon 
which the cytotoxic granules are held are polarised to the synapse, allowing trafficking of the 
granules first to the microtubule-organising centre (MTOC) and then onto the site of release. 
This polarisation occurs under the control of ERK (extracellular-signal-regulated kinase) 
phosphorylation, PYK2 (protein tyrosine kinase 2) and activation of VAV1 [50-52]. Intracellular 
reorganisation of F-actin mediated by Wiskott-Aldrich syndrome protein (WASP) also occurs, 
and this provides a final necessary step in the granule delivery network from the microtubules 
[50] and the creation of a channel at the plasma membrane through which granules can 
secreted [53, 54]. The exact mechanisms of granule docking to the plasma membrane and 
subsequent release remain to be fully elucidated [43]. 
The main constituents of cytotoxic granules are serine proteases from the granzyme family. 
There are five known granzymes in humans; granzyme A, B, H, K and M. Of these, the best 
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characterised, and also the most abundant, is the 32kDa granzyme B. It acts by preferentially 
cleaving at the C-terminal side of aspartic acid residues [55] and has a large number of 
substrates within the intrinsic apoptosis pathway (intracellularly triggered apoptosis 
characterised by mitochondrial membrane permeabilisation, and in contrast to the extrinsic 
pathway which is triggered by signalling through cell surface death receptors such as FAS). 
Caspase-3 was the first substrate to be identified [56, 57]. Caspase-3 exists in the inactive 
precursor (zymogen) form procaspase-3 and is activated as a two-stage process. Granzyme B 
acts in the first of these, by cleaving procaspase-3 into two subunits (p20 and p10). However, 
as apoptosis can occur for numerous reasons and in the absence of granzyme B, upstream 
molecules can also initiate this activation (caspase-8 for example). 
After the initial cleavage of caspase-3, the molecule can self-catalyse p20 to p17 and become 
fully active [58]. Granzyme B has also been shown to act further upstream. This activates the 
zymogen procaspase-8 [59] which can then act to activate capsase-3. Granzyme B can also act 
on substrates downstream of caspase-3, including the Inhibitor of Caspase Activated DNase 
(ICAD) [60], poly(ADP-ribose) polymerase (PARP) [61] and the DNA-dependent protein kinase 
catalytic subunit (DNA-PKcs) [61]. Another substrate for granzyme B is the Bcl-2 family member 
Bid [62], and this is also a substrate for caspase-8. After cleavage, truncated Bid (tBid) locates 
to the mitochondria and in conjunction with Bax and Bak results in mitochondrial membrane 
permeabilisation. One of the many results of mitochondrial membrane permeabilisation is the 
activation of caspase-3. Additionally, granzyme B has been shown capable of cleaving caspase-
7 and caspase-10 [63]. It would also appear that a number of granzyme B substrates have yet 
to be defined, as recent protease proteomics experiments have indicated at least 20 possible 
substrates [64]. 
The next best characterised is granzyme A. Although there have been reports of granzyme A 
exhibiting similar perforin-dependent, apoptosis inducing effects as granzyme B [65], granzyme 
A has also been shown to induce non-apoptotic death that is independent of caspase 
activation via the direct disruption of the mitochondria and nuclear damage [66, 67]. 
Granzyme A does not cleave Bid and acts independently of Bcl-2 [67], but it does lead to 
accumulation of reactive oxygen species (ROS) and causes a loss in mitochondrial membrane 
potential [67]. Granzyme A is trafficked to the mitochondria via intracellular hsp27 and hsp70 
and is able to cleave the mitochondrial protein NDUFS3, which triggers disruption sufficient to 
induce cell death [66].  
The remaining granzymes (H, K and M) are much less well understood. Although they are able 
to mediate cell death and all are reported to induce DNA damage [68-70], there are conflicting 
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reports as to the mechanisms involved. For granzyme H, while reported that it is able to induce 
apoptosis through cleavage of Bid and the subsequent mitochondrial damage [68], other 
findings have shown that apoptosis can be induced through a Bcl-2 mediated pathway and in 
the absence of Bid cleavage [71]. Granzyme H does lead to a loss in mitochondrial membrane 
potential, although there is conflict as to whether this is coupled with the release of 
cytochrome c and activation of caspases [68] or is independent of these [72]. Granzyme K has 
been reported to lead to mitochondrial swelling and to depolarisation of the mitochondrial 
membrane, but the question of cytochrome c release with its occurrence [73] and its absence 
[74] being observed. With respect to caspase activation, there is consensus, with granzyme K 
inducing apoptosis in a caspase-independent manner [75]. Conflicting reports are also evident 
for granzyme M, with discussion as to whether induced cell death is caspase-independent [76] 
or caspase-dependent [70, 77].  Much of the study of these molecules has been conducted in 
vitro, using recombinant proteins derived in a range of sources, and this might account for at 
least some of the variability and apparent inconsistency of results. 
Granules also contain the pore-forming protein perforin. Although perforin is commonly 
thought to facilitate the internalisation of granzyme B into target cells, debate surrounding its 
actual mechanism continues. The initial proposal was that perforin could form pores in the 
plasma membrane of target cells, through which granzyme B (and other lytic components of 
the cytotoxic granules) could pass [78, 79]. Observations that granzyme B could internalise into 
Jurkat and HeLa cells in the absence of perforin [80] challenged this notion and led to another 
suggested mechanism for the involvement of perforin. If cells that had taken up granzyme B 
were treated with perforin 60 minutes later, then granzyme B was seen to translocate to the 
nucleus [80] and fragmentation of the nucleus (a classic sign of apoptosis) occurred. This led to 
the endosomolysin model, which proposed that although cells are capable of endocytosing 
granzyme B (via an as yet unknown mechanism), perforin is required to trigger the release of 
granzyme B from intracellular vesicles [81]. There is much speculation to this model, with no 
clear evidence as to how perforin enters the cell or the mechanism by which endosomal 
membranes are affected. 
A third model of perforin involvement has been proposed. The ‘hybrid model’ [82] suggests 
that perforin forms pores in the plasma membrane which promotes Ca2+ influx. The 
subsequent membrane repair response [83], via which pores are repaired using donated 
membrane from intracellular vesicles such as lysosomes and endosomes, may facilitate the 
endocytosis of perforin and granzymes (although the authors offer no specific suggestions as 
to how this would occur). Perforin could then trigger the release of granzymes from the 
endosomes (again no specifics are given). A study conducted by Veugelers et al which 
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demonstrated that T cell cytotoxicity against HeLa cells was reduced when cells were 
transfected with mutated form of human dynamin cDNA has led to the proposition that the 
endocytosis of granzyme B from cytotoxic granules is facilitated by the GTPase dynamin [84]. 
Dynamin is activated by GTP hydrolysis, and forms a ring which ‘pinches’ the invaginated 
membrane to produce a separate vesicle [85]. It is known to be instrumental in a number of 
endocytic processes that are mediated by caveolae and clathrin, as well some independent of 
either, as well as phagocytic pathways [86]. Consequently, there remains uncertainty as to 
which is/are involved in the uptake of granzyme B and there is still much to be elucidated 
regarding the role of granzymes and perforin from cytotoxic lymphocytes in the induction of 
apoptosis.  
Although classified as being part of the innate immune system, there has been much debate 
about whether NK cells could be better described as bridges between the innate and adaptive 
systems [87] [88-92]. As discussed by Sun et al [87], NK cells have many characteristics that are 
common with T cells. They derive from the same progenitor cells and exhibit many of the same 
surface receptors (including CD25, CD69 and CD62L). Both NK cells and T cells depend on 
cytokines from the IL-2R common-γ-chain family and produce IFN-γ and TNF-α after 
stimulation. The key defining feature of adaptive immunity is the ability to mount a stronger, 
faster response to previously encountered antigen, due to the creation of memory cells. The 
traditional view of NK cells is that they are incapable of this, however some authors are 
proposing evidence as a suggestion of the possible existence of NK cell memory. 
Mice exhibiting hapten-induced contact hypersensitivity (using 2,4-dinitrofluoobenzene and 
oxazolone) then experienced up to four weeks resistance to the same hapten [93]. This was 
true for mice lacking T and B cells (BALB/c SCID), but no resistance was apparent in mice that 
also lacked NK cells (BALB/c SCID beige). In a separate study conducted by Sun et al, NK cells 
from naïve C57BL/6 mice or C57BL/6 mice challenged with murine cytomegalovirus were 
adoptively transferred into neonates who were subsequently themselves challenged with 
murine cytomegalovirus [94] and the result was a significantly increased survival rate in those 
neonates that had received NK cells from previously challenged mice. By adjusting the number 
of transferred NK cells, the authors found that 10-fold more NK cells transferred from naïve 
mice were required to confer protection. Although these studies highlight the overall 
importance of NK cells, they do not offer definitive evidence of memory. 
A key to confirming memory is to show an altered cell phenotype which persists. As Sun et al 
[87] discuss, we do not yet know how ‘memory NKs’ may differ from other NK populations, in 
terms of surface marker expression, cytokine requirement and release, or the specific 
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conditions that are required for the induction and maintenance of these cells. In a mouse 
model of murine cytomegalovirus [94], Sun et al examined NK cells ex vivo and observed an 
increased proportion of virus-specific Ly49H (activating receptor) occurring in the first week 
after infection (from ~50% of circulating NK cells being Ly49H+ to ~ 90%). As the infection was 
cleared, the proportion of virus-specific Ly49H NK cells decreased, returning to a frequency 
similar to that pre-infection after 30-40 days. Interestingly, after 70 days, virus-specific Ly49H+ 
NK cells were detected which differed in surface antigen phenotype to MCMV-naïve Ly49H+ NK 
cells in terms of presenting a ‘more mature’ receptor repertoire having higher expression of 
KLRG1, CD43 and Ly6C along with reduced CD27. Sun et al propose that this altered phenotype 
and longevity could be indicative of NK cell memory, and went on to demonstrate that these 
‘memory’ NK cells were functional ex vivo and even showed enhanced responses in terms of 
increased IFN-γ production and greater degranulation assessed by proxy of LAMP-1 expression 
[94]. Whist these findings are interesting, Ly49H is a mouse-specific NK receptor so could not 
be used to distinguish human memory NK cells. Indeed, the majority of memory NK cell 
experiments have been performed in mice and there is currently little known about whether a 
memory component of NK cells can be found in humans. 
The supposition is that memory NK cells would have distinguishing characteristics from other 
NK cells. A large proportion of humans (60%) come into contact with human cytomegalovirus 
and seroconvert (produce specific antibodies). Seroconverted individuals exhibit a greater 
proportion of peripheral blood CD56lowCD94:NKG2C+ NK cells than individuals who are sero-
negative for human cytomegalovirus [95]. This could indicate an expansion of NK cells which 
exhibit a surface marker phenotype which is specific for an encountered pathogen, and their 
retention in order to boost future responses to a repeat infection. Sun et al have proposed 
that this phenotype could be the human equivalent of the increased Ly49H density on the 
proposed murine memory NK cells [87]. However, as human cytomegalovirus becomes a 
chronic latent infection it could simply be confirmation of a continual battle by the NK cells to 
keep the infection under control. 
Another cell surface marker that has been proposed as potentially indicating memory NK cells 
in humans in CD57. The acquisition of CD57 on peripheral blood NK cells correlates to their 
transition from a CD56high to CD56low phenotype [96], and overall CD57 expression of all NK 
cells increases with age [97, 98]. This could potentially occur via the steady accumulation of 
memory over time. It is difficult to discern whether these observations do actually relate to 
memory or simply NK cell maturation. CD57 expression on T cells correlates with cell 
maturation and memory and a similar situation might exist in the case of NK cells [99]. The 
observation that CD57 expression increases with age could be explained on the basis that it is a 
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memory marker, the expression of which is fostered by accumulated exposure to challenges. 
However, as NK cell maturation is proposed to involve a transition from CD56high to CD56low, 
then the increased expression of CD57 on CD56low NK cells could solely be associated with 
maturation. The concept of memory NK cells is interesting and of potential biological 
significance. If indeed human NK cells can retain a memory leading to a more robust response 
this could potentially be exploited in targeting tumours.  
1.1.1.2 Role of T cells in anti-tumour immunity 
T cells are the most abundant of all circulating lymphocyte populations and are classified into 
different groups on the basis of surface marker expression as well as the profile of cytokines 
that they are capable of releasing and responding to. Classically, T cells were described as 
falling into either CD4+ helper or CD8+ cytotoxic populations, although the division is not that 
easily defined. T cell populations with a surface expression of CD4 comprise around 60% of the 
circulating T cells. Whilst the majority do exhibit ‘helper’ functions, promoting other immune 
responses through the release of cytokines, they are also capable of acquiring cytotoxicity. 
There are three widely accepted classifications for helper T cell populations (TH1, TH2 and 
TH17), as well the emerging, but still little understood, TH22 population. A number of naturally-
occurring and inducible immunosuppressive CD4+ populations (regulatory T (Treg) cells) have 
also been reported [100]. The remaining 40% of circulating T cells express the co-stimulatory 
molecule CD8 and are often described as cytotoxic effector T cells, however a subset of CD8+ T 
cells exhibit immunoregulatory properties similar to the CD4+ Treg cells.  
The distinction between TH1 and TH2 cell populations comes from them exhibiting different 
transcription factor activation patterns following activation and their distinct cytokine 
secretion profiles. The concept of distinct helper T cell sub-populations was first described by 
Mosmann et al in 1986, following the observation of different patterns of cytokine secretion in 
mouse T cells [101].  Differentiation of naïve T cells into TH1 is driven by the presence of IL-2 
and IL-12, which triggers the transcription factors STAT4 (Signal Transducer and Activator of 
Transcription 4), then T-bet [102]. T-bet serves to promote the Ifnγ gene leading to production 
of IFNγ [103]. This can help stabilise the TH1 phenotype, as TH1 cells also respond to IFNγ 
through a positive feedback loop by way of STAT1 activation [104]. The release of IFNγ is 
capable of stimulating macrophages, which aid in clearance of the target cells as well as 
offering further promotion of the TH1 cells via the release of IL-12.  Broadly speaking, a TH1 
response involves pro-inflammatory cytokines, promotes macrophage activation and is 
typically described as providing a more anti-tumorigenic environment. 
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The primary driver of differentiation to a TH2 phenotype is the anti-inflammatory cytokine IL-4 
[105]. Appropriate stimulation of naïve T cells through antigen recognition induces activation 
of the transcription factor NFAT (nuclear factor of activated T cells) which activates STAT6 and 
subsequently promotes GATA3 [106]. Through enhancement to the promotors of il4, il5 and 
il13 genes there is a vast increase to the production and release of the anti-inflammatory 
cytokines IL-4, IL-5 and IL-13 [107]. The production of IL-4 creates a positive feedback loop 
promoting the maintenance of the TH2 phenotype [105]. TH2 CD4+ T cells promote a humoral 
(antibody-mediated) immune response by the activation of plasma B cells 
Once naïve T cells are undergoing the process of differentiation into either TH1 or TH2, then 
various mechanisms exists to inhibit the other. For example, the promotion of the 
transcription factor GATA3 [108] in the conversion of TH2 leads to silencing of the IL12R gene 
inhibiting the response to the TH1 driving cytokine IL-12  [105]. Conversely, promotion of T-bet 
during TH1 differentiation subsequently silences the Gata3 gene and inhibits TH2 
differentiation [109].  
TH17 cells were described by two different research groups in 2005 [110, 111]. The majority of 
TH17 cells are described as being inducible, as naïve immature CD4+ T cells develop the TH17 
phenotype in response to cytokines released in sites of inflammation. This acquisition of 
phenotype occurs over multiple stages, beginning with initiation of the transcription factor 
STAT3 (signal transducer and activator of transcription factor 3), primarily in response to the 
presence of the pro-inflammatory cytokine IL-6 [112] which is secreted by a variety of cells 
including macrophages, monocytes, T cells, B cells and some tumour cells [113, 114]. However, 
in vitro experiments have also demonstrated the ability for intermediate levels of TGF-β to 
mediate conversion to a TH17 phenotype [115] (although at high concentrations TGFβ becomes 
inhibitory to conversion to TH17, due to its ability to suppress IL-23R). STAT3 serves to increase 
transcription of Rorc, lI17 and Il23r genes producing RORγt (retinoic acid receptor related 
orphan receptor), IL-17 and IL-23 receptor respectively [116].  The expression of the IL-23 
receptor allows the cells to respond to IL-23 (another pro-inflammatory cytokine) and this 
completes their transition to full TH17 phenotype [117]. IL-23 can also protect the TH17 
phenotype. The Il17 gene promoter is activated by STAT3, but STAT5 (which would silence the 
gene) can compete for STAT3 binding sites [118]. IL-2 activates STAT5, but IL-23 is able to 
suppress IL-2 signalling [117] and prevent the competition of STAT3 by STAT5 thereby 
maintaining IL-17. By producing IL-17, TH17 cells promote the recruitment of monocytes and 
neutrophils which aids clearance of infection. Once the inflammation has been cleared, the 
loss of IL-23 can trigger the reversal to a naïve phenotype [119]. As well as acquiring a TH17 
phenotype in response to an inflammatory environment (inducible TH17), a population of 
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helper T cells that constitutively express a TH17 phenotype that is RORγt+ and IL-23R+, as well 
as being able to produce IL-17 (natural TH17, nTH17) exist [120] [117]. These nTH17 cells 
develop in the thymus, from weakly self-reactive thymocytes [121], and are maintained by 
TGF-β and IL-23 [122].  
Circulating TH17 cell numbers are low, but comparatively a disproportionately high number are 
found to infiltrate a range of tumours including colorectal carcinoma [123], gastric cancer 
[124], head and neck cancer [125], non-small cell lung cancer [126], prostate cancer [127] and 
breast cancer [128]. For the most part, TH17 cells are reported to play an immunosuppressive 
role and contribute to the promotion of a pro-tumourogenic environment. Indeed in the case 
of colon and pancreatic cancer at least, the infiltration of TH17 cells correlates with poor 
prognosis of patients [129, 130]. Conversely, an increased tumour infiltrate of TH17 cells 
correlates with improved survival of patients with ovarian cancer, thereby suggesting that TH17 
cells are able to act in an anti-tumourgenic manner, depending on the context of the 
immunological environment and the cancer type [131].   
The full role that these cells play in tumour immunity has yet to be elucidated, but current 
evidence proposes an overall pro-tumourogenic effect, as a combination of the suppression of 
anti-tumour immunity and the promotion of tumour angiogenesis [132]. TH17 cells are prolific 
secretors of the pro-inflammatory cytokine IL-17A, as well as IL-23, both of which have been 
demonstrated to promote tumour growth in colorectal cancer mouse models after 
neutralisation of both cytokines led to a reduction in tumour development after implantation 
[133]. The role of TH17 cells on angiogenesis is less well defined. TH17 cells are known for being 
prolific secretors of the pro-angiogenic cytokine IL-17A and in vivo experiments in mouse 
models have shown, through the use of implantation of tumours transfected with IL-17A as 
well IL-17A knockdowns, that IL-17A contributes to an increased pattern of angiogenesis as 
well as more rapid tumour growth [134]. Conversely, TH17 cells also secrete the anti-
angiogenic cytokines IL-17F, IL-21 and IL-22 [135-137]. 
Populations of CD4+ T cells can also suppress immune responses of a wide range of immune 
cells (regulatory (Treg) cells), including both CD4+ and CD8+ T lymphocyte populations [138-
140], NK cells [141], B lymphocytes [142], monocytes/macrophages [143] and DCs [144]. There 
are no unique surface markers of Treg cells in humans, although they are described as 
constitutively expressing high levels of surface CTLA-4 and CD25, as well as the intracellular 
transcription factor FoxP3 and a low surface expression of CD127. There are naturally-
occurring Treg (nTreg) cells, which develop and retain the Treg phenotype within the thymus, 
as well naïve CD4+ T cells which develop the phenotype, the induced Treg (iTreg) cells [145]. In 
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order for iTreg cells to form, the naïve cells require stimulation of the TCR at a low affinity, and 
this can be in response to a self or non-self-peptide [146]. Phenotypic conversion is also 
dependent on co-stimulation via CTLA-4 [147], as well as stimulation from IL-2 [148] and 
immunosuppressive cytokines such as IL-10 [149] or TGF-β1 [150]. Circulating Treg cell 
populations can be formed of a mixture of both nTreg and iTreg cells, although much of the 
published literature continues to refer simply to ‘Treg cells’ and identifies the cells using 
common markers such as CD3, CD4, CD25 and Foxp3. Indeed, it has been proposed that there 
is no reliable surface marker for distinguishing between the two [151], although a variety of 
publications claim there are numerous phenotypic differences to be found [100, 152]. These 
include co-stimulation markers (necessity of CD28 on nTreg cells and CTLA-4 on iTreg cells), a 
higher expression of PD-1 and CD73 on nTreg cells than iTreg cells and the specific expression 
of neuropilin-1 [153] and Helios [154, 155] on nTregs, although the specificity of Helios at least 
is disputed [156].  
Both nTreg and iTreg cells are capable of exerting immunosuppression through a wide range of 
mechanisms (reviewed in detail by [157] and [158]). They are able to produce and release 
immunosuppressive cytokines including TGF-β1 [159], IL-10 [160], IL-35 [161] and IL-9 [162]. 
These cytokines can encourage a positive feedback loop of suppression as they, particularly 
TGF-β1 [163], also cause the transformation of iTreg cells, thereby boosting the overall Treg 
cell population. As well as mediating suppression via the release of immunoregulatory 
molecules, Treg cells are also capable of suppressing via cell-contact mechanisms. Treg cells 
express CD39 and CD73 on their surface which allows for direct inhibition of proliferation of T 
responder populations through adenosine signalling [164, 165]. In mice, Treg cells have been 
shown to utilise surface CTLA-4 to mediate suppression [166], although the exact mechanism is 
not yet fully understood. It is unclear whether this molecule is also involved directly in the 
suppressive properties of human Treg cells. Treg cells are also capable of exerting suppression 
through the induction of apoptosis in effector populations, by way of releasing cytotoxic 
granules in a similar manner to cytotoxic effector lymphocytes. This apoptosis is perforin-
dependent and is mediated by granzymes, with nTreg cells predominantly utilising granzyme A 
[167] and iTreg cells granzyme B [168]. Activated effector T cell populations (both CD4+ and 
CD8+) as well as monocytes and DCs have been shown to be susceptible to apoptosis by Treg 
cells [167]. 
Due to their constitutively high expression of CD25 (the alpha chain of the IL-2 receptor), nTreg 
and iTreg cells are potent consumes of exogenous IL-2 and so are able to deprive other cells (T 
effectors and NK cells) of this vital cytokine [169]. Treg cells themselves do not produce IL-2, so 
rely on their target cells to provide this stimulation, and this creates a feedback loop between 
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the Treg cells and their targets [170]. IL-2 is crucial to the proliferation of T cells, as IL-2 binding 
to the IL-2 receptor triggers progression through the cell cycle. 
CD8+ ‘cytotoxic T cells’ have the capability to elicit cytotoxic responses directly via the release 
of cytotoxic granules and recognised through their surface expression of the co-receptor CD8. 
The expression of the CD8 receptor confers an ability to recognise peptides presented in the 
context of MHC class I molecules that are expressed on the surface of target cells. This involves 
peptide derived from within the cytosol of cells, and can demonstrate when a cell has been 
infected, as virally infected cells will present virus-derived peptides within their MHC class I. 
CD8+ T cells recognising the peptides will initiate release of cytotoxic granules in order to kill 
the infected cell. The cause of around 20% of humans cancers can be attributed to viral 
infections (such as Epstein-Barr or HPV) [171] and it is the CD8+ T cells which are most 
effective, as virus derived peptides are found intracellularly in infected cells and are present on 
MHC class I molecules.  
1.1.1.3 Immunoregulatory effects of tumours and the tumour microenvironment 
Tumours are not simply malignant cells within the environment of an organ of the body, but 
rather entities which create their own micro-environment within the body. For the tumour to 
support any large size it must have a vascular network to deliver adequate respiratory and 
metabolic requirements. The creation of new blood vessels on an existing network is termed 
angiogenesis and is driven by endothelial cells, and is triggered by binding of soluble, pro-
angiogeneic factors (the most potent being vascular endothelial growth factor VEGF, but 
others include fibroblast growth factor FGF, platelet-derived growth factor PDGF, Angiopoietin 
(Ang) -1 and -2) that are released in response to an hypoxic environment binding to tyrosine 
kinase receptors on their surface. Solid tumours are capable of producing VEGF and therefore 
can directly promote the generation of the vasculature which is necessary for sustained 
tumour growth.  
In addition, tumours have been shown to boost angiogenesis by inducing/up-regulating VEG-F 
secretion by local cell populations within the tumour microenvironment [172]. There are 
several factors in the tumour microenvironment which can drive the immune response 
towards one of a pro-tumour, pro-angiogenic manner, including TGF-β, PGE-2, VEG-F, lactic 
acid and adenosine [172]. These can be released by tumours themselves as self-preservation 
and contribute to the conversion of iTreg cells, a reduction in NK cell cytotoxicity by polarising 
towards a CD56brightCD16- phenotype [28, 173] and the promotion of an inflammatory 
environment. Macrophages secrete pro-angiogeneic growth factors such as VEGF, FGF and 
PDGF [174, 175] and are actively recruited by tumours through both CCL2 and CXCL12/CXCR4 
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axes [174-176]. Neutrophils have been found to produce both pro-angiogeneic growth factors 
[177] and vasculature remodelling agents such as MMP-9 [178]. These remodelling agents are 
important, as they disrupt localised areas of the existing vasculature, which is necessary for the 
formation of new vasculature structures. Tumours can promote the infiltration of neutrophils 
through release of CXCL8 [179]. Whilst dNK cells are well documented to secrete pro-
angiogeneic growth factors [180, 181], peripheral NK cell populations do so to a much lower 
degree, but have been shown to up-regulate secretion when infiltrated into non-small cell lung 
cancer environment [182]. In ovarian cancer, tumour infiltrating Treg cells have been shown to 
secrete more VEGF, thus promoting angiogenesis [183]. Myeloid derived suppressor cells 
(MDSCs) are also capable promoting angiogenesis through the secretion of growth factors such 
as VEGF, as well as the secretion of remodelling factors such as MMP9 [184] and will be 
recruited to a pro-inflammatory tumour microenvironment by way of GM-CSF, IL-1β and IL-6 
[185]. Although a highly vascularised network is beneficial to the tumour in terms of delivering 
necessary metabolic requirements for adequate growth, better vascularisation allows immune 
cells, and indeed administered therapeutics, better access to the tumour.  
The activation of both CD4+ effector and CD8+ cytotoxic T cells are augmented by the addition 
of a secondary signal through the co-stimulatory receptor CD28, the main ligands to which are 
members of the B7 family. These have been found capable of providing a stimulatory signal (in 
the case of B7-1/CD80 or B7-2/CD86) or an inhibitory signal (for example, B7-H1 (also known 
as PD-1), B7-H2, -H3, -H4, or -H6). A wide range, between 10 and 95%, of tumour entities have 
been found to present inhibitory B7 family members on their surface [186, 187]. Whilst B7-H2 
and B7-H6 are seen primarily on haematological tumours, the other B7 family members have 
been reported on tumours from different origins. The speculation is that tumours expressing 
ligands which can inhibit T cell activation would present a less favourable clinical prognosis and 
there are a large number of publications surrounding patient observations which support this 
theory. The most widely studied of the B7 inhibitory ligands is B7-H1 (PD-1), the expression of 
which correlated with tumour progression, invasiveness, grade and advanced stage, as well as 
poor patient prognosis, poor survival and increased death across bladder carcinoma [188], 
oesophageal squamous cell carcinoma [189], gastric cancer [190], breast cancer [191], ovarian 
cancer [192], glioma [193], pancreatic cancer [194] and renal cell carcinoma [195]. The 
expression of B7-H2 on AML has been shown to correlate with poor patient survival [196]. 
High expression of B7-H3 correlates with advanced tumour grade and progression in colorectal 
[197] and prostate cancer [198]. Expression of B7-H4 correlates with poor patient survival, 
tumour size, tumour stage and cancer recurrence in gastric cancer [199], non-small cell lung 
cancer [200], oesophageal squamous cell carcinoma [201], melanoma [202], prostate cancer 
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[203] and renal cell carcinoma [204]. The strong correlation between inhibitory ligand 
expression and poor clinical outcome has stirred interest in the possibility of targeted therapy 
to block the inhibition.    
Early experiments using murine models for in vivo investigation of melanoma demonstrated 
that tumour rejection could be achieved if implanted melanoma cells have been transfected to 
express stimulatory B7 ligands [205, 206]. When thinking in terms of translational medicine in 
the clinical setting, it appears that more than just a modification of B7 stimulatory ligands 
would be required to achieve tumour regression. In addition to serving as CD28 ligands, 
members of the B7 family also bind to Cytotoxic T-lymphocyte Antigen 4 (CTLA-4) and 
programmed death ligand 1 (PD-L1), both of which act to suppress T cell function [207]. The 
idea behind the therapeutic targeting of inhibitory ligands such as PD-1 is to remove the T cell 
checkpoint blockade and current headway in this area will be discussed later.    
It has been known that tumours are able to downregulate the expression MHC class I 
molecules on their surface since the 1970’s [208, 209]. Depending on tumour location, up to 
90% have been shown to exhibit either a downregulated MHC class I expression or total loss of 
the molecule [210, 211]. For breast cancers, the frequency of reduced or lost MHC class I 
expression is around 50% [212, 213]. Since CD8+ T cell recognition of target cells can only occur 
via the presentation of relevant peptides in the context of MHC class I, an alteration in the 
expression of these molecules on tumours effectively allows escape from CD8+ T cell-mediated 
cytotoxicity. The altered MHC class I expression on tumours can be categorised into one of six 
different phenotypes ranging from the loss of one haplotype or even the total loss of any MHC 
class I, to the tumour exhibiting a down regulated MHC class I expression [210], and can be 
either irreversible or reversible [214]. 
The irreversible (hard) changes are caused by genetic alterations in genes encoding structural 
information for MHC class I. Most often these result from mutations, deletions or loss of 
heterozygosity in the HLA-ABC genes on chromosome 6 [215] or the β2-microglobulin (β2m) 
on chromosome 15 [216]. Reversible (soft) alterations arise through defects in HLA and β2m 
gene transcription, and have been shown to be driven by oncogenes such as p53 or Her2/Neu 
[217, 218]. An interesting point to note is that the presence of MHC class I provides a major 
inhibitory signal to NK cells through the inhibitory KIRs. The loss of MHC class I on tumour cells 
should theoretically render them more susceptible to NK cell-mediated cytotoxic responses. 
Observations in colorectal cancer suggest that the prognosis is less favourable for those 
tumours which have downregulated MHC class I expression. Histological investigation of 
tumour biopsies from 336 patients with colorectal carcinoma who had not received any 
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radiotherapy showed positive correlation between loss of MHC class I and a reduced 
expression of transporters associated with antigen presentation (TAP1 and TAP2) as well as a 
reduction in infiltrating CD8+ T cells [219]. This infiltration of CD8+ T cells is an indicator of 
patient prognosis, with high infiltration correlating with a more favourable prognosis [219]. 
Also in colorectal cancer, it has been reported that downregulated, but not totally lost MHC 
class I expression [220], and the authors proposed that this could be due to the level of MHC 
class I being too low to allow efficient peptide recognition, but too high for an effective loss of 
NK cell inhibition [220].  A small observational study in 10 patients with metastatic melanoma 
who were receiving immunotherapy found that those whose tumours had high expression of 
MHC class I showed regression after treatment and those people with tumour MHC class I 
downregulation showed disease progression [221]. As the patient size is so small it is not 
possible to infer too much from the observed traits, but it would warrant further investigation 
in a larger group. One potential confounding factor to take into account is the observation that 
NK cell infiltration into tumours can be vastly reduced compared to the levels seen in 
surrounding normal tissue [222] [223].     
It is apparent that NK cells are important for tumour surveillance, as has been demonstrated 
by an 11-year follow-up study looking at NK activity in the general population in Japan which 
found that low NK cell activity correlated to increased risk of cancer development [224]. 
Furthermore, the importance of NK cells for preventing the progression of metastatic disease 
has been demonstrated using NOD/SCID mice which lack T and B lymphocytes and 
NOD/SCID/γcnull (NSG) mice which also lack NK cells [225]. Breast cancer cells (MDA-MB-231, 
MCF-7 and T47) implanted into NSG mice formed primary tumours within 3 weeks with the 
MDA-MB-231 cells also showing metastases [226]. In comparison, although primary tumours 
were present in NOD/SCID mice, they were much smaller and there were no metastases [226]. 
A greater understanding of the relationship between NK cells and metastasis might provide a 
better basis on which to develop new tumour targeted therapies.  
NK cell function is tightly controlled via a complex profile of signals that are delivered by the 
triggering of inhibitory and stimulatory receptors and ligands and evidence suggests that 
tumours and tumour-derived factors might influence the phenotype and function of NK cells.  
There is a large degree of heterogeneity in the expression of different NK cell receptors 
between individuals and there is some evidence that alterations in this might be contributing 
factor in cancer development and progression. Overall there is an increasing body of literature 
comparing the phenotype of NK cells from cancer patients to those of healthy people which 
suggests that the expression of NK activating receptors is lower in patients with cancer. 
However, data are limited across different cancers and need to be confirmed in more studies. 
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Studies from both gastric and cervical cancer patients have shown that their NK cells express 
lower levels of the activating receptor NKG2D [227, 228], with NK cells in cervical cancer 
patients also expressing lower levels of NKp30 and NKp46 [228]. In patients with acute myeloid 
leukaemia, NK cells express significantly lower levels of multiple activating receptors, namely 
NK30, NKp46, DNAM-1, CD244 (otherwise known as 2B4) and the CD94/NKG2C complex [229]. 
NK cells from patients with oesophageal squamous cell carcinoma have been found to express 
significantly lower levels of the Fc receptor CD16 than those from healthy individuals [230]. 
Investigating the effect of ex vivo incubation with IL-12 and IL-18 on NK cells derived from 
patients with non-small cell lung cancer found that they expressed lower levels of the 
activating receptors NKp46 and CD25 on the cell surface than NK cells from healthy individuals 
[231], as well as producing lower levels of IFNγ, the main NK cell stimulatory cytokine. In an 
observational study involving 677 breast cancer patients, between 50% and 99% of tumours 
expressed MIC-A, MIC-B and/or ULPB-2 [232], all of which are ligands for the NK cell activating 
receptor NKG2D, and the presence of these ligands correlates with a longer relapse free period 
(RFP) following chemotherapy or hormone therapy [232]. However, a separate study looking 
at 140 breast cancer patients found that the density of NKG2D expression, as well as other NK 
cell activating receptors NKp30, DNAM-1, CD16 and 2B4, were lower in patients with invasive 
breast cancer compared to those with in situ disease or healthy volunteers [233]. This 
apparent down regulation of activation receptors may be due to modulation of NK cells by 
tumour-associated factors, or may be indicative of a naturally occurring phenotypic profile that 
is more likely to allow tumour escape. Investigation into the effect of administering oestrogen 
on the phenotype of mouse NK cells showed that the activating receptors CD69, NKp46, 
NKG2D and 2B4 were all down regulated in response to oestrogen [234]. Since oestrogen is 
important for a large proportion of breast cancers, this finding offers one possible explanation 
for the observed down regulation in receptor expression.  
Far fewer studies have commented on the expression of inhibitory receptors on NK cell 
populations in patients with cancer, other than to discuss the genetic distribution of the many 
different KIRs through different populations. One study has reported that NK cells in patients 
with lung cancer express significantly higher levels of two inhibitory KIRs, CD158b and CD158e, 
than healthy individuals [231]. Although other publications have made direct comments on the 
ex vivo cytotoxicity of the NK cells, these have almost always assessed cytotoxicity on the basis 
of the capacity of NK cells to kill the highly NK-sensitive erythroleukaemic cell line K562.  
Target cell death can be measured via different methods. These include analysing the viability 
of target cell populations by flow cytometry using viability stains such as 7-AAD and propidium 
iodide, the release of 51chromium or by measuring the release of cytotoxic granules from NK 
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cells on the basis of surface expression of LAMP-1 (lysosome associated membrane protein 1) 
as a proxy, or using ELISPOT assays which measure the release of the serine protease 
granzyme B. NK cells from patients with lung [231], gastric [227] and breast [235] cancer all 
exhibit lower cytotoxicity than NK cells from corresponding healthy individuals. Dewan et al 
further characterised the breast tumours from the patients, and showed that NK cytotoxic 
activity was higher in patients with HER2+ tumours than those with HER- (correlating with the 
more favourable prognosis of HER2+ over HER2-). They also found that NK cytotoxicity in 
patients exhibiting only a primary tumour was higher than that in patients with metastatic 
disease [235]. It remains unclear whether individuals that express NK cells with lower levels of 
activating receptors and/or higher levels of inhibitory receptors are more predisposed to the 
development of cancer, or whether something about a tumour (the microenvironment, 
soluble factors released from the tumour, or even an indirect factor such as the resulting 
treatment) modifies NK cell receptor expression towards a more pro-tumourogenic 
environment. 
Using the NK cell line NKL and several cervical cancer lines (C33A, SiHa, HeLa), Jimenez-Perez et 
al have showed that co-culturing NK cells with tumour cells for only 4 hours leads to a 
reduction in the expression of the stimulatory receptor NKG2D [236]. In the case of SiHa and 
HeLa cell lines, this translated into a reduced cytotoxicity against K562 cells. Further 
investigations revealed different profiles of NKG2D ligand expression on the cell lines which 
correlated to the observed functional changes [236]. NK cytotoxicity was inhibited when co-
cultured with the lines expressing higher levels of the NK cell activating ligands MHC class I 
polypeptide-related sequence A (MIC-A) and UL binding protein 2 (ULBP2), both of which bind 
to the NK cell surface receptor NKG2D [236]. No cytotoxic change was observed after 
incubation with the cell line expressing high levels of another NKG2D ligand MHC class I 
polypeptide-related sequence B (MIC-B) [236]. Further investigations are required in order to 
clarify the potential modulating effect of tumours, or the significance of individual NK receptor 
expression on the development, progression and clearance of tumours. 
Whilst these are interesting observations, the evidence for tumours directly modulating the 
expressed receptor repertoires of NK cells is not conclusive. Another possibility (which could 
also occur in parallel with any potential tumour-mediated changes and is not necessarily an 
alternative explanation) is that the heterogeneity of the NK receptor and cytotoxicity profile 
between individuals could mean that some people are naturally pre-disposed to more easily 
allow the immune escape of tumours. For this to be the case, then there would need to be a 
large degree of heterogeneity in NK cell receptor repertoire profiles between individuals in 
addition to there being a stability of phenotypes within individuals. There is little published 
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evidence focusing on this potential aspect of NK cell biology, apart from that focusing on the 
Killer cell Immunoglobulin-like receptor (KIR) family [237]. There is broad diversity in KIR due to 
multiple haplotypes with allelic polymorphism, to such an extent that there is less than 1% 
chance of unrelated individuals exhibiting identical KIR profile [238]. At least one KIR gene is 
expressed by every NK cell, although during cell development different numbers and 
combinations of KIR genes are expressed by individual cells, creating a diverse, heterogeneous 
repertoire within an individual [239]. The KIR profile of individual NK cells is mediated by DNA 
methylation, with the hypermethylated genes being transcribed and the receptors expressed, 
whereas hypomethylated genes are not transcribed [240, 241]. This expression within a cell is 
stable, and is maintained for numerous generations of cell division [239-242]. This diversity 
may well contribute to potential immune escape of developing tumours, and is undoubtedly 
an interesting area of study. 
Another leukocyte population which is found to infiltrate tumours, and which is the subject of 
much attention, are regulatory T cells, as these cells can potentially offer protection to the 
tumour. As detailed previously, the phenotype of nTreg cells and iTreg cells are similar in many 
ways, with both exhibiting a CD3+, CD4+, CD25high, FoxP3+ profile. In a large number of 
publications, this receptor profile has been used to identify simply ‘Treg cells’ without attempt 
to further distinguish them, and consequently it can be difficult to fully elucidate their 
infiltration into tumours. Treg cells have been shown to infiltrate a wide range of human 
tumours, including ovarian cancer [243], gastric cancer [244], renal cell carcinoma [245], 
tongue squamous cell carcinoma [246], hepatocellular carcinoma [247], pancreatic cancer 
[248], colorectal carcinoma [249], non-small cell lung carcinoma [250] and breast cancer [251]. 
Observations in ovarian, gastric and breast cancer suggest that Treg cells infiltrate the tumours 
in response to trafficking signals mediated by CCL17 and CCL22 [243, 252, 253]. A positive 
correlation between increased numbers of Treg cells infiltrating tumours and higher tumour 
grade/stage in humans was initially described in ovarian carcinoma [243], but was also 
observed in early gastric cancer [252]. The presence of tumour-infiltrating Treg cells has also 
been found to be a positive correlative factor for poor patient prognosis in colorectal cancer 
[249], pancreatic cancer [248], squamous cell carcinoma [246] and breast cancer [251]. 
One difficulty lies in determining whether the tumour is able to provide its own protection via 
the recruitment of immunosuppressive Treg cells to the area, or whether the tumour 
flourishes because it arises in an environment which is rich in Treg cells. Evidence that tumour-
derived TGF-β1 induces the formation of CD4+CD25+ iTregs supports the former proposition 
[163]. There is evidence to show that Treg cells may exhibit greater suppressive potential 
within a tumour microenvironment, as the amount of granzyme B which they possess is higher 
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than their counterparts in the peripheral circulation [254, 255]. Treg cells isolated from 
patients with colorectal cancer have been found to specifically respond to a limited number of 
tumour antigens ex vivo [256], thereby revealing another way in which tumours might 
contribute to the creation of a protective environment. As Treg cells are able to respond to 
much lower concentrations of antigen (10-100 fold) than T effector cells [257], it might be that 
tumours can drive a pro-tumourogenic environment by increasing their numbers within the 
tumour microenvironment and promoting their suppressive capacity.  
In addition to their infiltration into tumours, a significantly higher prevalence of Treg cells 
(determined as either CD4+CD25high or Foxp3+CTLA-4+) in the peripheral blood of patients with 
a wide range of cancers (pancreatic, breast, lung, colorectal, gastric, oesophageal, cervical, 
ovarian and of the gall bladder) has also been observed [258-260]. This also appears to be the 
case in patients with early stage/low grade non-metastatic tumours [260]. This evidence 
suggests that targeting Treg cells and/or inhibiting their function might enhance protective 
anti-tumour immunity and the efficacy of immunotherapeutic strategies.   
1.1.2 Influence of cancer therapies on anti-tumour immunity 
The use of cytotoxic anti-neoplastic drugs (chemotherapy) is one of the main lines of defence 
in the treatment of cancer, particularly in the case of metastases. These treatments target 
proliferating cells and cause DNA/RNA damage, thereby resulting in the inhibition of mitosis 
and induction of apoptosis. They can affect both tumour and healthy cells, and one side-effect 
is leukocyte depletion which results in immunosuppressive consequences. Compromising the 
immune system in this way therefore poses a risk to patients. Cancer patients undergoing 
chemotherapeutic treatment often experience increased susceptibility not only to bacterial 
infection as a result of drug-induced neutropenia, but also to viral, fungal and parasitic 
infection as a consequence of lymphopenia. Cell depletion can be rapid - in the case of the 
commonly used drug cyclophosphamide, a single dose can lead to significant T and B cell 
depletion [261, 262]. The cell populations do recover once the treatment regimen is complete, 
albeit slowly. NK and B cell populations return to pre-clinical levels within 3 months of 
treatment cessation [263]. T cell populations have the longest recovery time, with CD8+ 
populations returning 3-6 months after treatment and CD4+ populations taking even longer 
[263]. In addition to reducing immune cell numbers, chemotherapeutic drugs can impair their 
mechanisms of action. The effect on NK cells includes impaired tumour recognition due to 
ligand shedding, as well as a reduction to NK cytotoxicity, and has been reviewed by Rosental 
et al [264]. 
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Despite the immunosuppressive properties of chemotherapeutic drugs, evidence suggests that 
they could boost the anti-tumourogenic immune response under certain conditions (reviewed 
by [265]), particularly through the removal of immunosuppressive cell populations such as 
Treg cells. Although observations as to the potential capacity of cyclophosphamide to promote 
immune responses were recorded in guinea pigs 50 years ago [266], at the time the 
immunosuppressive mechanistics of Treg cells were not understood. A single dose of 
cyclophosphamide has been shown to induce a marked reduction in the prevalence of 
CD4+CD25+ T cells in mice [267] and humans [268], and appears to correlate with an increase in 
anti-tumour immune activity. Although the authors refer to the CD4+CD25+ T cell population as 
‘regulatory’ cells this is not entirely accurate. CD25 is not a definitive marker for Treg cells, as it 
is also expressed on activated T cells. However, the authors do state that the depletion of 
these CD4+ cells is followed by an increase in macrophage cytotoxic activity. As Treg cells are 
capable of suppressing multiple cell types, the removal of additional T cell populations does 
not seem to be as important as the loss of suppression acting on other cell types. A reduction 
in Treg cell numbers (identified as CD45+ CD4+ CD25high Foxp3+) as a result of a single dose of 
cyclophosphamide has been shown in a phase I/II trial of renal cell cancer patients with 
IMA901, a cancer vaccine developed from a combination of multiple tumour-associated 
peptides [269]. Patients receiving this combination of a single dose of cyclophosphamide with 
the vaccine also had significantly longer survival times [269]. The use of cancer therapies also 
boosting the immune system of patients is an interesting idea, although as yet our 
understanding is insufficient to allow for this to be effectively manipulated in the clinical 
setting.  
Radiotherapy is a commonly used, standard-care treatment which involves the localised 
administration of ionising radiation in an effort to induce apoptosis through DNA damage. As 
well as directly affecting tumour cells, other cells within the tumour microenvironment will 
also receive a radiation dose [270, 271]. The outcome of this is somewhat of a double-edged 
sword, with radiation inducing both pro- and anti-tumour immune effects [272], as both 
effector and regulatory cell populations will be affected and whilst the loss of a regulatory 
population may allow increased anti-tumourogenic responses from local effector cells, they 
themselves could be reduced in number as a direct effect of induced cell death caused by 
ionising radiation.  As well as directly induced death, another effect seen after irradiating solid 
tumours is for them to release pro-inflammatory cytokines such as TNF-α [273] and IL-1 [274], 
which will promote the infiltration of leukocytes (both effector and regulatory populations) 
into the tumour microenvironment. In a mouse model examining the effect of ionising 
radiation on macrophages, the authors demonstrated that whole body irradiation with as little 
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as 0.075 Gy was sufficient to produce a 50% increase in the concentrations of the pro-
inflammatory cytokines IL-12 and IL-18 within 30 minutes [275].  
As well as the direct effects on immune cells, radiotherapy may also have a number of indirect 
immunomodualtory effects. One of these is via the promotion of leukocyte infiltration into the 
tumour microenvironment.  Irradiation (2 doses of 12Gy) of 4T1 breast cancer cell-derived 
tumours in BALB/c mice has been shown to upregulate the expression of the chemokine 
CXCL16 on the tumour, as well as trigger the release of soluble CXCL16 [276]. The consequence 
of this is an increase in the infiltration of CXCR6+ CD8+ T cells (as confirmed by a reduced level 
of infiltration following CXCL16 blocking) which correlates with tumour regression. Although 
the authors primarily focussed on CD8+ T cells, other leukocytes including CD4+ T cells, NK cells 
and NKT cells can express CXCR6 and could therefore be induced to infiltrate an irradiated 
tumour microenvironment as a consequence of CXCL16. With there being no specificity for 
either anti-tumoural or immunosuppressive populations the consequence of CXCL16 
expression following irradiation may prove to be either pro- or anti-tumoural. The 
upregulation of surface expression of CXCL16 occurs in other cancer cell lines in response to 
ionising radiation, including in the prostate carcinoma TRAMP-C1, the fibrosarcoma MC57, the 
colon carcinoma MCA38 and the mouse melanoma B16/F10. The release of CXCL16 from the 
majority of cell lines suggests that this could be a common consequence of radiotherapy.    
Irradiation can also influence the infiltration of leukocytes by modifying the tumour 
vasculature, specifically by increasing the presence of adhesion molecules (including ICAM and 
P-/E-selectins) that bind integrins and P-selectin glycoprotein ligand 1 which is expressed on 
the surface of leukocytes. These interactions facilitate the extravasation of these leukocytes 
into the tumour microenvironment [277]. A similar issue relating to the possibility that such 
effects on leukocyte infiltration could result in anti-tumoural effects that are mediated by 
effector populations, or immunosuppressive effects that are mediated by the selective 
infiltration of regulatory immune populations.  
Irradiation can also influence tumour target recognition by way of tumour antigens. Tumour 
cell death following irradiation results in the release of soluble tumour antigens which can 
result in a boost to anti-tumour immunity, via the presentation of these antigens to immune 
effector cells by APCs. Endogenous proteins that are released upon cell damage are termed 
‘alarmins’ [278]; a prevalent human alarmin is high mobility group box protein 1 (HMGB1). 
Tumour-derived HMGB1 binds to TLR-4 on the surface of DCs and is necessary to trigger the 
processing of soluble tumour antigens by DCs. This is exemplified by the observation of early 
relapse in breast cancer patients who exhibit a TLR4 polymorphism which impairs HMGB1 
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binding [279]. One class of molecules with particular interest as tumour antigens are heat 
shock (stress) proteins. Despite them historically being considered as purely intracellular 
molecules, there is increasing evidence for these proteins to be found as soluble factors 
released in the periphery [280], and that the circulating heat shock proteins might serve as 
biomarkers for a range of diseases, including cancer [281]. Extracellular heat shock proteins 
also have the potential to act as intercellular signalling molecules, an example of which is the 
fact that Hsp70 is capable of interacting with APCs through a number of cell surface receptors 
including LOX-1 [282], and Toll-like receptors [283]. It is also of note that released heat shock 
proteins have been shown to activate Treg cells through TLR-4, thus triggering an immune-
suppressive response [284]. As well as being released, a proportion of tumours present Hsp70 
within the plasma membrane [285-289], and this expression can be up-regulated by certain 
chemotherapeutic agents and also following irradiation [290]. This membrane form of Hsp70 
has been shown to act as a target recognition structure for activated NK cells, and hence the 
therapy (chemotherapy, radiation)-induced increase in membrane Hsp70 expression on 
tumours has the potential to increase their vulnerability to NK cell-mediated cytotoxicity. The 
membrane expression of Hsp70 on tumour cells and its implications for tumour targeting 
possibilities will be further discussed in section 1.3. 
As both effector and regulatory lymphocytes are capable of being influenced by factors 
resulting from tumours following therapy, it is difficult to predict whether such therapies will 
lead to a more pro- or more anti-tumourogenic environment. However, if it could be possible 
to harness irradiation that also provides an anti-tumourogenic immune environment, then 
patients could gain an additional benefit. 
With the various immunosuppressive or evasive mechanisms employed by tumour cells, any 
immunotherapy-based treatment must be able to overcome tumour-mediated endogenous 
immunoregulatory mechanisms and also the immunosuppressive effects of currently available 
chemo- and radio-therapies. A favourable approach could be the development of a highly 
specific tumour-targeted therapy which is able to act independently of the patient’s immune 
system.   
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1.2 Breast Cancer 
Breast cancer remains one of the greatest health burdens in the world, with 1 in 8 women 
developing breast cancer at some point in their lifetime. Data published by the World Health 
Organisation in 2008 showed that in the UK alone, female breast cancer was responsible for 
more than 14,300 deaths per year with around 44,000 women diagnosed with the disease in 
the same time frame (WHO data, 2008). However data from the United Kingdom and Ireland 
Association of Cancer Registries published in 2011 suggest that although the incidence of 
breast cancer is rising (almost 50,000 new cases of female breast cancer in 2010), mortality is 
falling (~11,500 in 2010). This could be attributable to the recent advances in therapies that 
target the primary tumour which are discussed below. The majority of breast cancers are of 
epithelial origin (carcinomas) and glandular (adenocarcinoma). Cancers remaining within the 
tissue in which it originated is described as in situ or non-invasive.  
A major barrier to the successful management of breast cancer is the development of 
metastasis - roughly 44% of women who are diagnosed with breast cancer will go on to 
develop some form of metastatic disease [291]. Although the disease remains classified as 
‘treatable’ under such circumstances, it is no longer deemed ‘curable’ [292, 293]. The 5-year 
survival for all breast cancer is approximately 85%, however this drops to below 20% for 
patients with metastatic disease (Cancer Research UK, 2010). Furthermore, the median 
survival of patients after diagnosis for metastatic disease is only 31 months [294, 295]. This 
clearly highlights the fact that metastatic disease is more aggressive and resistant to current 
treatments and that there is an urgent need for better understanding and treating metastatic 
disease.  
Over one hundred years ago, Paget published the ‘seed and soil’ hypothesis [296]  which 
proposed that metastatic cancer cells (which he likened to seeds) grow best in certain organs 
(soils), and he based his proposition on observations that the location of metastatic disease 
from different primary tumours did not match that expected from a truly random occurrence 
from over 900 autopsy records.  
A number of publications have revisited this hypothesis, and the general principle continues to 
be applicable [297]. The suggestions from these are that effective clearance of metastasis will 
come from targeting both the cancer cells themselves, as well as disrupting the favourable, or 
preferred, environmental features of the target organ. The most likely sites of metastasis from 
primary tumours are well characterised - for breast cancer these are the brain, bone, liver and 
lung (National Cancer Institute data, 2013). Targeting brain metastases with therapy poses its 
own difficulties, as the blood-brain barrier prevents accumulation of many molecules in the 
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brain. Another avenue of study has been to better elucidate the mechanism of metastasis 
formation from the primary tumour in order to attempt to find appropriate points at which to 
apply targeted therapy. 
Unfortunately, many of the specific mechanisms that underlie the establishment of metastatic 
disease remain elusive. The general process has been described as involving the release of 
tumour cell(s) from the primary tumour, followed by invasion of the vasculature and their 
circulation in the body. After some time, the tumour cell(s) adheres to vessel walls and 
extravasate into nearby tissue. This establishes as a new tumour site via the proliferation and 
expansion of tumour cells, and also encourages the formation of new blood vessels 
(angiogenesis). We do not yet know the timescale of these stages, exactly how the decision is 
taken for a cell/cells to disassociate from the primary or what causes the cells to stop 
circulating and extravasate where they do.  
Tumours are known to be formed of heterogeneous populations of cells, with only a small 
subset of the cells having the capacity to initiate tumour growth. In addition these are able to 
self-replicate and self-renew and consequently these cells have been called cancer stem or 
tumour initiating cells (or cancer stem-like cells, CSCs). This concept was first described in 
acute myeloid leukaemia (AML) following the observations that only a minority subset of 
human AML cells that expressed a CD34+ CD38- phenotype (<1%) were capable of initiating 
AML in NOD/SCID mice [298]. The first CSCs in solid tumours were found six years later in 
breast cancer [299]. As with AML, this discovery was made following in vivo implantation of 
human tumour samples into NOD/SCID mice. For these studies, human breast carcinoma 
samples were digested to provide single cell suspensions, which were then stained for the 
expression of cellular adhesion molecules and sorted into purified populations using flow 
cytometry, before being injected into the mammary fat pad of NOD/SCID mice. All 
implantations with CD44+CD24-/low breast tumour cells were capable of initiating tumour 
growth. Although a small proportion of CD24+ cell implantations (2 of 12) were also observed 
to give rise to growths, these were much smaller in size than those from CD24-/low 
implantations. The authors suggested that this might have resulted from limitations of the 
sorting process and an incomplete depletion of CD24-/low cells [299].      
Three hypotheses for the emergence of CSCs have been proposed [300]. Firstly, that mutations 
arising in existing stem cells could give rise to tumourigenic progeny [301]. The long life span 
and self-renewing capability of stem cells could result in increased accumulation of mutations 
and their pluripotent capacity could offer a mechanism via which tumour heterogeneity could 
be generated and maintained [302]. A second proposition is that CSCs are an intermediate cell 
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type between progenitor cells and fully differentiated progeny which retain self-renewing 
capacities of stem cells [303]. Finally, it has been suggested that cancer cells arise from mature 
fully-differentiated cells, but that a proportion of these cells can de-differentiate and re-
acquire stem cell-like properties [304]. The addition of four transcription factors (SOX2, 
NANOG, LIN28 and OCT4) to human somatic cells in vitro has been shown to be sufficient to 
induce them to mimic embryonic stem cells in both surface marker and gene expression, as 
well as confer an ability to differentiate pluripotently [304]. 
Although the existence of breast CSCs is widely accepted, studying them has been hampered 
by the failure to find unique surface markers. They have been described in terms of adhesion 
molecule expression (being CD44+ while lacking CD24) [299], an overexpression of aldehyde 
dehydrogenase 1 (ALDH1) [305], and also by their ability to pump out Hoechst 33342 stain 
[306]. An in vitro method of culturing breast cancer stem cells which has been successfully 
used for cell lines as well as primary tumour tissue was described by Ponti et al [307]. The 
authors found that culturing cells in serum-free DMEM-F12 growth medium containing 
fibroblast growth factor, epidermal growth factor, insulin and bovine serum albumin (BSA) led 
to a proportion of cells developing into non-adherent clusters (termed ‘mammospheres’). 
These mammospheres were found to exhibit the phenotype of breast CSCs (CD44+CD24-) and 
could initiate tumour growth in immunedeficient SCID mice following the implantation of as 
few as 103 cells into the mammary fat pad.  
Despite the marked advances in breast cancer treatments and improving survival rates, 30-
50% of patients who are diagnosed with early stage disease go on to develop metastatic 
disease despite receiving treatment. Furthermore, around 40% of patients relapse at some 
point after previously successful therapy [308]. The resistance of disease to current 
therapeutic strategies could possibility be due to the persistence of small numbers of breast 
CSCs. Indeed, breast CSCs have been shown to possess increased resistance to the classical 
first-line treatments of chemo- [309, 310] and radio-therapies [311, 312]. If treatments were 
able to specifically target breast CSCs, then it may be possible to reduce tumour recurrence 
rates. The rapid increase in understanding of CSCs and their biology within the last 10 years is 
likely to underpin improved treatments and outcomes over the next 10-20 years.  
1.2.1 Characterising tumours 
It has long been established that breast cancer is not a homogeneous disease, with differences 
in disease phenotype contributing to treatment responsiveness [313, 314] and patient survival 
[315-317]. High throughput gene expression analysis has been used to categorise tumours into 
groups [315]. This approach was subsequently expanded to define tumours into one of five 
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intrinsic molecular subtypes; Luminal A, Luminal B, HER2+, Triple Negative or normal-like [315, 
316, 318], on the basis of their hormone and tyrosine kinase receptor expression, tumour 
stage and grade. Discussion  surrounding the true existence of normal-like breast cancer 
subtype (so called due to the morphological similarity with normal breast tissue) resulted in a 
revised description of these entities simply having a large contamination of normal tissue 
[318], and consequently this subtype has been lost from the literature. Characteristics of the 





Table 1.2 Receptor expression on breast cancer subtypes 
Breast cancers subtypes exhibit differential expression of a variety of known surface markers. The presence of 
markers allows for the use of specific targeted therapies to be employed. (ER) Oestrogen receptor. (PR) 
Progesterone receptor. (HER2) Human epidermal growth factor receptor 2 
 
Having a classification system is highly important, as it is one of the current methods of 
deciding upon the clinical care strategy [292]. Luminal A and Luminal B tumours are both 
oestrogen receptor (ER) and typically progesterone receptor (PR) positive. They differ in 
prognoses, with survival rates being much more favourable for the former [319]. Around 25% 
of breast cancer is described as being HER2+ [320]; these are tumours which over-express the 
tyrosine kinase receptor human epidermal growth factor receptor 2 (HER2) while lacking the 
hormone receptors. Although the prognosis of HER2+ breast cancer is typically worse than with 
Luminal A or Luminal B tumours [321, 322], with a median survival of 4 years, the survival of 
patients bearing such tumours has been improved with the advent of HER2 targeting strategies 
such as trastuzumab and pertuzumab. 
 
Triple negative breast cancers (TNBC) account for up to 20% of breast cancers and do not 
express oestrogen or progesterone receptors, nor do they overexpress HER2. With their 
definition arising from the lack of expression/overexpression of a range of markers, there are 
no current targeted therapies that can specifically act on TNBCs, and consequently the only 
available treatment options are surgery, chemotherapy and radiotherapy. The prognosis for 
patients with these tumours is poor, even those who do respond to therapy typically relapse 
within months and the median survival after diagnosis of distant metastasis is only 13 months 
 ER PR HER2  
Luminal A ++ ++ +/- 
Luminal B ++ ++ +/- 
HER2+ + + ++ 
Triple negative -- -- -- 
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[323]. Triple negative breast cancers are of great interest in terms of developing novel 
therapies, as there are currently very limited treatment options.  
Breast cancers which resemble normal breast basal tissue (tissue in the outer layer of breast 
ducts), by way of expression of the filament protein vimentin, the cell-cell adhesion molecule 
p-cadherin, the small heat shock protein αβ-crystallin, the integral membrane proteins 
caveolin 1 and 2, basal cytokeratins (CK5/6, CK17 and CK14) and epidermal growth factor 
receptor (EGFR) are described as basal-like tumours. There is a large overlap between those 
tumours classified as triple negative and those which are basal-like (~75%, [324, 325] however 
there is not perfect concordance between these classifications. Around 20% of TNBCs do not 
express any basal-like markers [319, 326], and up to 30% of basal-like breast cancers are not 
triple-negative [327]. Despite this, the presence of basal-like markers being entirely 
synonymous with a triple-negative phenotype continues to be discussed in the literature [328, 
329], thereby leading to difficulties in interpreting some published data.  
Another subtype of breast cancer - Claudin-low - has also been proposed [319, 330], however 
this has not yet been adopted for clinical diagnosis. In a study published in 2012, genetic copy 
number aberration (CNA) information was used to cluster 2000 tumour biopsies into similar 
groups, resulting in the description of 10 different subgroups of disease [331]. Although the 
prognosis for patients in the different subgroups is different, further studies are required in 
order to better understand how these genetic differences might influence treatment strategies 
and outcomes.   
Patients are also assessed for their expression of mutations within the BRCA1 and BRCA2 
genes, as these account for the vast majority of familial breast cancer. Historically, although 
this meant that genetic profile was used to assess the risk of developing the disease, treatment 
strategies continued to be based on the receptor expression of the tumour. However, this 
concept is changing and genetics is increasingly being used to assist the shaping of treatments 
that are offered to patients (reviewed by [332]). Tumours with BRCA mutations express higher 
levels of the DNA repair molecule polyadenosine diphosphate ribose polymerase (PARP), 
leading to speculation that this might make them more susceptible to PARP inhibitors. 
However, this possibility requires further investigation [333, 334]. Using phosphoinositide 3-
kinase (PI3K) inhibitors in combination with PARP inhibitors could improve the effectiveness of 
the latter, since BRCA mutations often correlate with loss of phosphatase and the tensin 
homolog (PTEN) which promotes cell survival by conferring resistance to apoptosis which is 
triggered via PI3K/AKT signalling [335].  
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Bioinformatic approaches have also lead to the proposition of a further classification of breast 
cancer patients. The Nottingham Prognostic Index Plus (NPI+) [336] is enables the stratification 
of patients with breast cancer into one of seven classes of predicted survival prognosis. This 
was based initially on the expression levels of a combination of 25 biomarkers [337] although 
the classification was also found to remain true for a reduced selection of 10 of the most 
significantly influential markers [338]. This index has evolved out of a desire to improve on the 
previously published Nottingham Prognostic Index [339], in which data from 387 patients were 
used to produce an algorithm for stratifying patients in terms of survival prognosis based on 
data from only three factors; tumour size, lymph node stage and histological tumour grade. 
This was subsequently verified by a prospective long-term followup of separate patient 
cohorts, one comprising 320 patients and another 1629 patients [340] and has since been 
implemented as a clinical tool for aided the decision-making surrounding adjuvant treatment 
application. 
1.2.2 Targeted therapies 
The strategy employed for the treatment of breast cancer will depend on the characteristics of 
the tumour, its stage and grade of the tumour and the medical history of the patient. Surgery 
is typically the first treatment, often in conjunction with chemotherapy and/or radiotherapy. 
Those tumours which express oestrogen receptor can also be targeted using endocrine 
therapy, either preceding surgery or as a follow up. Over-expression of HER2 has allowed the 
development of monoclonal antibody-based therapies and small molecule tyrosine kinase 
inhibitors for the treatment of HER2+ breast tumours [341, 342].  
1.2.2.1 Endocrine therapies 
Approximately 80% of breast tumours express the oestrogen receptor (ER+ tumours) [343] and 
the vast majority of breast cancers depend on oestrogen for growth. Two endocrine therapy 
approaches are available; inhibiting the synthesis of oestrogen using aromatase inhibitors (e.g. 
amastrozole and letrozole) and blocking the binding of oestrogen to the oestrogen receptor 
using tamoxifen (reviewed in [344]). In general, tamoxifen is the first line treatment for pre-
menopausal women and aromatase inhibitors are used for the treatment of post-menopausal 
women. The latter is often given in the form of ‘neo-adjuvant’ therapy (therapy given as a 
precursor to the primary therapy, for example with the view to shrinking a tumour to an 
operable size). However, if a patient presents with a particularly aggressive tumour, then 
chemotherapy, and not endocrine therapy, will be first choice. Although no clinical trial has yet 
assessed the possibility of using a combination of chemotherapy and endocrine therapy, it is 
possible to follow a course of chemotherapy with an endocrine therapy.  
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As ER+ tumours depend on oestrogen for growth, a link between the use of hormone 
replacement therapies (HRT) and the incidence of breast cancer incidence has been proposed. 
Indeed, since 2002, the use of HRT has declined by 75% and the incidence of breast cancer has 
fallen by approximately 18% [343]. Although there may be a link, as yet there is insufficient 
evidence to show causality. Improved screening by mammography has also been cited as being 
a possible contributor to this falling incidence of disease [343]. There is also a good correlation 
between the presence of oestrogen receptors and much higher survival rates, which indicates 
the overall success of treatments that specifically target the primary tumour [345]. 
Around 50% of ER+ breast tumours also express the progesterone receptor (PR+) and are 
dependent on progesterone for growth [346]. This area is less well studied than that relating 
to oestrogen receptor expression, and is consequently less well understood. Approaches for 
specifically treating PR+ tumours are therefore not as advanced. Clinical trials in the 1990s 
investigated the possibility of using progesterone receptor antagonists as a therapy for breast 
cancer, but the results were not encouraging. In a group of 28 women with PR+ breast cancer 
given mifepristone, only 3 exhibited a partial response [347]. Although another Phase II study 
using onapristone showed better response rates (56% having partial response, 11% with static 
disease), recruitment had to be halted due to abnormal liver function tests [348]. Although 
focus therefore moved away from progesterone receptor targeting, interest is once more 
growing with the advent of new generation anti-progestins. A Phase I/II clinical trial involving 
lonaprisan is currently underway [349]. Although early in vitro investigations have been 
conducted on two more anti-progestin compounds [350] the lack of any follow-up publications 
suggest that little progress was made. 
1.2.2.2 Monoclonal antibody therapy 
The development of monoclonal antibody (mAb) therapies relies on the discovery of a suitable 
candidate marker for targeting - one that is uniquely or overexpressed on a tumour surface. 
The main focus of mAb therapy in breast cancer has been targeting the epidermal growth 
factor receptor HER2/neu, which is overexpressed in around 25% of patients. The first mAb 
against HER2 was the humanised murine antibody trastuzumab (also known as Herceptin®), 
and this was approved for use in 1998. Trastuzumab treatment has significantly improved the 
prognosis for patients with HER2+ breast cancer, with reports of 50% reduction in disease 
recurrence in patients treated with trastuzumab for one year post-surgery [351], and a 44% 
reduction in risk of death when including those patients who also received trastuzumab as a 
first line treatment [352]. Trastuzumab exerts multiple anti-tumour mechanisms of actions. 
One is the direct effect of reducing tumour proliferation via G1 cell cycle arrest, in that binding 
of trastuzumab to extracellular HER2/neu leads to disruption of HER2/HER3 interactions 
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resulting in uncoupling of PI3K-AKT signalling [353] as well as accumulation of the cyclin-
dependent kinase inhibitor p27Kip1 [354]. This significantly increases in association with cyclin-
dependent kinase 2 (CDK2), but not other CDKs [355]. Secondly, given that trastuzumab is a 
humanised IgG1 antibody, its binding to HER2/neu facilitates ADCC [356] via coupling of the Fc 
region of the antibody to FcγRIII on NK cells [357, 358]. However, resistance to trastuzumab 
can develop over time, as demonstrated by the observations that there is a significant 
reduction in response rates in those patients who had previously been treated (39%) 
compared to patients naïve for trastuzumab (71%), despite overexpressing HER2. One possible 
strategy to help with the appearance of resistance is to target the tumour with several 
therapies in tandem at the start of treatment. Already the use of trastuzumab administered as 
neoadjuvant therapy to chemotherapy and then again as adjuvant follow up has shown to be 
superior to chemotherapy alone (5 year event free survival being 43% for patients receiving  
chemotherapy but 58% for those who also received trastuzumab) [359].  
However, trastuzumab treatment is associated with significant cardiotoxicity and congestive 
heart failure in around 1% of patients [360]. Furthermore, around 50% of patients with HER2+ 
breast tumours fail to respond to, or become resistant to trastuzumab treatment [361]. With 
this in mind, other HER2 targeting therapies are arriving to the market. The recombinant 
humanised mAb pertuzumab has been approved for use in patients with HER2+ metastatic or 
locally advanced breast cancer in patients who have not received either chemotherapy or anti-
HER2 targeted therapies [362]. Pertuzumab binds to HER2, but at a different epitope than 
trastuzumab. Similar to trastuzumab, binding of pertuzumab induces ADCC [363] and prevents 
the dimerization of HER2 with other EGFRs. Due to the different binding sites of pertuzumab 
and trastuzumab, combination therapy is possible [364].  The pivotal Phase III trial which led to 
the clinical approval of pertuzumab compared the outcome of 806 patients with locally 
recurrent or metastatic breast cancer when given trastuzumab plus docetaxel plus either 
pertuzumab or placebo [364]. The addition of pertuzumab into the treatment regime 
increased the proportion of patients achieving a response (80.2% compared to 69.3%), and 
those patients who exhibited progression-free survival maintained this status for longer 
(median of 18.5 months compared to 12.4 months). As yet there is insufficient data available 
yet to comment on whether, as with trastuzumab, eventual pertuzumab resistance will occur.  
Recently approved for use as a single agent therapy against HER2+ breast cancer is the 
antibody-drug conjugate trastuzumab emtansine (also referred to as T-DM1 or Kadcyla©) 
[365]. This preparation of trastuzumab is conjugated to the cytotoxic, microtubule disrupting 
drug DM1 (a derivative of maytansinoid) using a non-reducible thioether linker [366]. 
Investigations in vitro confirm that T-DM1 retains the mechanisms of unconjugated 
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trastuzumab (the induction of ADCC and disrupting HER2/HER3 interactions leading to reduced 
cell proliferation [367]. A Phase III trial comparing the effect of giving patients lapatinib 
alongside capecitabine or giving T-DM1 has demonstrated a significant benefit to receiving T-
DM1, in terms of the proportion of patients having a partial or complete response (30.8% 
compared to 43.6%) and in the median duration of the response (6.5 months compared to 
12.6 months) [368]. This trial enrolled only those patients whose disease had progressed after 
having previously received treatment with trastuzumab. A later Phase II trial compared the 
effect of trastuzumab plus docetaxel compared to T-DM1 in patients with previously 
untreated, locally advanced breast cancer [369]. There was a statistically significant benefit to 
receiving T-DM1, in terms of median duration of progression-free survival (14.2 months 
compared to 9.2 months) and the proportion of patients responding to treatment (64.2% 
compared to 58.0%). This is a promising new development for patients with HER2+ breast 
cancer. 
1.2.2.3 Small molecule tyrosine kinase inhibitor 
An additional approach for the selective therapy of HER2+ breast cancer is to use the small 
molecule tyrosine kinase inhibitor lapatinib. Lapatinib is a dual HER2/EGFR tyrosine kinase 
inhibitor, inhibiting phosphorylation of the intracellular C-terminus kinase domain which leads 
to inhibition of both PI3K-AKT and MAPK-ERK1/2 pathways and a reduction in cell proliferation 
due to G1-phase cell cycle arrest [370, 371], and the downstream effects of lapatinib are 
similar to those seen following binding of anti-HER2 mAbs. A Phase II clinical trial of patients 
with advanced breast cancer, who had previously been treated with chemotherapy and 
trastuzumab regimes, has shown that lapatinib provides a clinical benefit (partial response or 
stable disease) to 64% of patients [372].  A Phase III clinical trial randomised patients with 
metastatic breast cancer who had previously received anthracyclines, taxanes and/or 
trastuzumab to receive capecitabine chemotherapy alone or in combination with lapatinib 
[373]. The addition of lapatinib into the regime increased median overall survival from 64.7 to 
75.0 weeks. Another similarity with anti-HER2 mAb therapies is that disease resistance occurs, 
typically around 1 year after starting treatment, and from this point the disease progresses 
rapidly [374]. Clinical trials have been conducted to assess the potential benefit of combination 
treatments targeting HER2. A randomised, Phase III trial compared the outcome of receiving 
lapatinib and trastuzumab alone or in combination in 455 patients with HER2+ breast tumours, 
who had no evidence of metastases and had received no prior treatment, who were 
undergoing surgical resection with adjuvant chemotherapy [375]. A significantly higher 
proportion of patients who received the trastuzumab/lapatinib combination were observed to 
undergo a complete response (51.3% compared to 29.5% of those who received only 
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trastuzumab and 24.7% who received lapatinib). The benefit was slightly more pronounced if 
the data from only those patients with small tumours (≤5cm) was compared (55.2% vs 28.4% 
vs 26.1%), thereby  suggesting that this may be of particular benefit as a first-line therapy 
option. 
1.2.2.4 Vaccination therapy 
The idea of developing a vaccine to boost a patient’s own immune response to a tumour has 
been a focus of study for many years. Despite much on-going research in this field, there are as 
yet no clinical vaccines for breast cancer available [376]. In fact, there is only one vaccine 
approved by the US Food and Drug Administration (FDA) for any cancer therapy; Sipuleucel-T 
for use in prostate cancer patients [377]).  
There are different strategies for delivering cancer vaccines [378], with possibilities being 
employing the use of: 
• a peptide or protein (typically with an adjuvant) 
• a recombinant virus, or other recombinant microorganism 
• tumour lysate, or dead tumour cells 
• DCs activated using peptide or protein 
• DNA plus a vector - the sequence for the peptide of interest is included in 
a delivery vector, and the peptide is produced and then processed within 
APCs 
The majority of current breast cancer vaccine trials are conducted using peptides, or DCs 
pulsed with peptides.  The benefits of using peptides are the relative ease and low-cost with 
which they can be produced, and the low risk of associated toxicity. One drawback is that the 
potential pool of patients for which a given peptide vaccine may be effective could be small 
due to the HLA restriction of the peptide. The majority of peptides under investigation are 
HLA-A2 restricted and so cannot be used for patients who do express this particular haplotype. 
Although it is relatively easy to induce a CD8+ T cell response with single peptide vaccines, 
these responses are typically short-lived [379, 380]. A more robust and sustained response can 
been observed if both CD8+ and CD4+ T cells are triggered [381]. To this end, vaccinating with 
longer peptides that can be processed via both MHC class I and MHC class II pathways, or with 
combinations of peptides that are specific for CD4+ and CD8+ T cells is considered as being a 
more viable strategy [382, 383]. 
The success of a vaccine therapy depends on finding a suitable tumour antigen which is 
selectively expressed or over-expressed by tumours, is absent (or expressed at very low levels) 
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in normal tissue, is immunogenic and, ideally, is prevalent in different patient groups and sub-
groups. Current molecules under consideration for use against breast cancer include mucin-1 
(MUC-1) [384, 385], HER2/neu [379, 386, 387], carcinoembryonic antigen (CEA) [388] and 
telomerase reverse transcriptase (hTERT). Vaccinating against MUC-1 has progressed as far as 
Phase III, with a trial involved over 1000 women with metastatic breast cancer being recently 
completed. However, the results were disappointing with no patient benefit derived from 
vaccination in terms of disease progression or overall survival [389]. Another cancer vaccine 
currently under investigation is PANVAC™, which provides antigens to both MUC-1 and CEA 
[390]. So far it has just been used in pilot studies to confirm vaccine safety, and has only been 
used in patients with metastatic carcinoma [391] [392]. There were encouraging observations 
with a proportion of patients showing partial responses and others having stable disease so 
the outcome of future larger trials will be interesting. Multiple peptides are being considered 
as the basis for vaccinating against HER-2 tumours, with the best studied being E75, AE37 and 
GP2. E75 has been used in a Phase II trial which involved 195 women with HER-2+ breast 
cancer who had already completed the standard treatments of surgery, chemotherapy and 
radiotherapy [393, 394]. Although there was a trend for vaccinated patients to have better 5-
year disease-free survival rates (89.7% compared to 80.2%), this result was not significant. 
There was, however, a correlation between vaccination and risk of recurrence, with a 48% 
reduction in vaccinated patients [395]. As yet, AE37 has only been investigated in a pilot study 
involving 15 breast cancer patients, however it did elicit a specific response and this would be 
interesting to follow up on. GP2 has also been looked at in a Phase II trial of 172 women with 
newly diagnosed breast cancer. There was a strong specific cell response which also showed a 
trend (albeit non-significant) towards a reduced risk of disease recurrence [396]. There has 
been relatively little published data regarding the use of hTERT. A small study involving 19 
patients with metastatic breast cancer found that hTERT vaccination resulted in a CD8+ T cell 
response (but no CD4+ T cell response) in just over 50% of patients, and that this correlated 
with an increase to overall survival (from 17.5 months in non-responders to 32.2 months in 
those with a high CD8+ T cell response) [397]. The development of cancer vaccines is an 
exciting area of research, in which interest has been renewed and developed over the last few 
years. However, a number of significant challenges exist and it will be interesting to see what 
arises in the near future.  
1.2.2.5 Targeting the tumour vasculature  
A common feature which is crucial for the establishment and proliferation of both primary 
tumours and distant metastases is the creation of a vascular network. Tumours are prolific 
producers of pro-angiogenic factors such as Vascular Endothelial Growth Factor (VEGF) [398]. 
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Tumours can overexpress receptors for pro-angiogenic growth factors (8-15% of breast 
cancers express amplified Fibroblast Growth Factor receptor (FGFR) [399, 400] and 
consequently promote the development of their own vascular network. The development of 
large metastases also requires the establishment of vasculature. This dependence on adequate 
vascularisation has promoted interest into the potential for a new family of cancer therapies. 
There are two classes of agents which can target the tumour vasculature; anti-angiogenic 
drugs which prevent the formation of new vessels and vascular disrupting agents (VDAs) which 
destroy previously formed vessels. VDAs can be further classified into two groups, with respect 
to their mechanism of action; ligand-based agents (targeted delivery of toxins or pro-apoptotic 
factors via ligands specifically expressed in tumour vessels) or small molecule VDAs (which 
themselves fall into two categories; flavonoids and tubulin binding). 
The most widely reported VDA in the literature is the small-molecule combretastatin A-4 
disodium phosphate (CA4P), which acts through inhibition of tubulin polymerisation [401, 
402]. Although the most commonly investigated tumours are NSCLC (non-small cell lung 
cancer), some trials of VDAs have been undertaken in patients with breast cancer. CA4P 
analogues are also under investigation and have been shown to induce apoptosis in MCF7 
breast cancer models [403]. As the outer rim of tumours is able to diffuse oxygen and nutrients 
from the surrounding environment, VDA treatment is thought to be best administered in 
combination with other therapy. Promising in vivo data (specifically detail and reference some 
of this promising data) has not translated as well as hoped. Phase II trials of the flavonoid small 
molecule VDA ASA404 administered in conjunction with standard chemotherapy of 175mg/m2 
paclitaxel plus 6mg/mL/min carboplatin to patients with NSCLC did result in a modest increase 
in patients showing a partial response (from just over 22% in those receiving standard 
chemotherapy alone, to almost 38%in those also receiving the highest dose of ASA404 [404, 
405], as well as an increase to median survival time from 9 to almost 15 months.  Early 
investigations using an in vivo SKBR3 breast cancer model have shown that CA4P received in 
conjunction with chemotherapeutic drugs (cisplatin and cyclophosphamide) induced a 10-fold 
increase in tumour cell death than chemotherapy only [406]. The lack of follow up from this 
into human clinical trials suggests that attempts to translate this therapy for breast cancer 
have been unsuccessful   
The concept of using inhibitors of angiogenesis and/or vascular disrupting agents is an 
attractive one, as it targets a feature which is common to all malignancies and could therefore 
be developed for a large number of patients. It could be used against both primary and 
secondary malignancies, and it has particular promise for those tumours for which no 
specifically targeted treatments exist, such as TNBC [407]. Indeed, current trials have 
39 | P a g e  
 
predominantly focussed on TNBC due to the current lack of any other targeted therapies for 
these patients. However, the angiogenesis inhibitors bevacizumab or polyadenosine 
diphosphate ribose polymerase inhibitors have not improved disease-free survival in patients 
with TNBC [329].    
 Current progress has been hampered by a variety of issues. There is a large interspecies 
variation in tolerance [408] necessitates intensive and time-consuming toxicity investigations 
for the translation of findings from rodent models to human trials [409]. There are also reports 
of toxicity in patients which occurs either as a result of effects on the non-tumour vasculature 
(through a lack of specificity to that within the tumour) or due to downstream effects from the 
release of cytokines [410]. VDAs including CA4P and other tubulin-binding drugs AVE8062 and 
ZD6126, as well as the flavonoid-based VDA ASA404 have all been  found to cause cardiac  
toxicities including ischaemia (oxygen restriction), dyspnea (shortness of breath) and 
hypertension in patients [410-413], as well as pain at the infusion and tumour sites and motor-
, sensory and visual neurotoxicity [412, 414].  
Promising data arising from Phase I and Phase II clinical trials using inhibitors of poly(ADP-
ribose) polymerase (PARP, a DNA repair molecule found in the nucleus) has since been 
followed up by failings at Phase III, in which no significant improvements in disease 
progression or patient survival have been observed. However, it was subsequently discovered 
that the drug used, iniparib, could not inhibit PARP when used as at the doses used [415]. 
Trials are ongoing with other drugs. 
1.2.2.6 Checkpoint Inhibitors 
A popular avenue of current investigation is the potential for boosting patients’ anti-tumour 
immune responses by removing ‘checkpoint inhibition’. T cells require both antigen 
recognition and co-stimulation in order to respond; however responses can also be hindered if 
T cells receive a co-inhibitory signal, referred to as checkpoint inhibition. Evidence now 
suggests that tumours have the capacity to trigger these inhibitory events and so that concept 
underlying checkpoint inhibition as a therapeutic strategy is that its ‘removal’ promote a more 
robust T cell response and anti-tumour immunity. The two mechanisms of checkpoint 
inhibition that have been most well studied are signalling through the T cell surface receptors 
CTLA-4 (cytotoxic T lymphocyte-associated molecule 4) and PD-1 (programmed death 1).    
CTLA-4 expression is induced on the surface of both CD4+ and CD8+ T cells after stimulation 
with MHC-presented antigen peptide, and it is constitutively expressed on the surface of Treg 
cells [416]. There is high sequence homology between CTLA-4 and the co-stimulatory receptor 
CD28 [417-419], and consequently it is of little surprise that CTLA-4 is capable of binding to the 
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same ligands (CD80 and CD86) [420, 421]. It is interesting to note that CTLA-4 binds with 
higher avidity than CD28 [422], highlighting that competitive binding could favour T cell 
inhibition. Interestingly, soluble CTLA-4, which could block available CD80 and CD86 and thus 
prevent T cell co-stimulation through CD28 has been found in the plasma of patients with 
breast cancer [260]. 
PD-1 (also referred to as B7-H1) is expressed on T cells and binding to its ligand PD-L1 results in 
signalling which inhibits T cell activation. PD-L1 has been found to be highly expressed in a 
large proportion of breast cancers and breast cancer cell lines [416]. Furthermore, there is a 
correlation between the expression of PD-L1 and tumour grade [423] The expression of PD-L1 
has also been shown to be increased in those patients undergoing chemotherapy (including 
regimes of paclitaxel, etoposide and fluorouracil) [424, 425], indicating that whilst these 
treatments have direct anti-tumour effects there could be indirect pro-tumour effects due to 
an increased potential for T cell inhibition.    
Current therapy for blocking CTLA-4 binding involves the administration of an anti-CTLA-4 
blocking mAb. Promising results with a mouse model of breast cancer in which animals treated 
with anti-CTLA-4 therapy were able to reject tumours that are derived from implanted SM1 
mammary carcinoma cells, and even reject subsequent tumour challenges despite receiving no 
further antibody therapy were obtained over 15 years ago [426]. However, Phase I and Phase II 
trials assessing anti-CTLA-4 treatments in humans have not been so effective. At Phase I, 
approximately 40% of patients were observed to maintain stable disease [427], whereas no 
observed benefit to receiving the anti-CTLA-4 treatment was observed at Phase II (clinical 
trials.gov NCT0083278). It is worth noting that these trials were considering the use of anti-
CTLA-4 therapy alone. As this does not appear to be effective in this setting, there could be 
benefit in combining anti-CTLA-4 treatments with other, conventional therapeutics. Therapies 
to block the PD-1 pathway also rely on the administration of a blocking antibody and the safety 
of anti-PD-1 mAb therapy has so far been assessed in Phase I trials. The therapy was found to 
be well tolerated with the maximum tolerated dose not reached in almost 300 patients 
suffering from a range of solid tumours, and 36% of patients with PD-L1+ tumours 
demonstrated some response [428]. A second Phase I trial involving 207 patients also found 
the treatment well tolerated, but a reduced observed response in patients, with 6-17% 
showing some response depending on tumour entity [429]. As these trials involved patients 
with a range of tumours, it is difficult to comment on the potential effectiveness of approach 
in breast cancer, and further studies to confirm whether they will prove clinically effective, be 
it alone or in combination with existing therapies are required.  
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1.2.2.7 Future considerations 
As metastases currently pose the biggest threat to overall patient survival, strategies that can 
more effectively target the establishment and progression of metastatic disease are of the 
highest priority. This could occur at any stage in the process of metastatic growth, be it after 
cells have disseminated from the primary tumour and are circulating in the vasculature, or 
once they are establishing in distant tissues. Targeted therapies, such as mAb treatments and / 
or the induction of protective adaptive and innate anti-tumour immunity, have the potential to 
effectively eradicate primary and metastatic disease and establish long-term protection 
against disease recurrence. 
The development of new immunotherapeutic or other targeting strategies for cancer would be 
greatly enhanced by the identification of features that are common to tumours, as this would 
reduce the profile of therapeutics which needs to be developed and tested. One such molecule 
might be a unique membrane form of the 70kDa heat shock (stress) protein family, Hsp70, 
which was discovered by Professor Gabriele Multhoff [285-289]. 
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1.3 Heat Shock (Stress) Proteins 
The discovery of heat shock (stress) proteins can be attributed to a serendipitous moment in 
1962, when an incubator containing Drosophila melanogaster larva was inadvertently left at an 
above optimal temperature overnight. The resulting unusual puffing patterns in gene 
expression were noticed by Professor Ferruccio Ritossa (25 February 1936 – 9 January 2014) 
[430]. However, it was not until 1974 that the products of these genes were identified and the 
term ‘heat shock protein’ was attributed to them [431]. It is now known that this term is 
somewhat of a misnomer, as intracellular levels of such proteins are upregulated in response 
to a variety of cell stresses in addition to heat shock, including, but not limited to, oxidative 
stress [432, 433], nutritional stress [434], infection [435], UV irradiation [436] and 
chemotherapeutic drugs [437]. Consequently, some of the literature has begun to refer to 
these as ‘stress proteins’, although the vast majority still retain the original ‘heat shock’ 
nomenclature. 
1.3.1 The 70kDa Family of Stress (Heat Shock) Proteins 
Heat shock proteins (Hsps) are highly conserved across species, and are found in all 
prokaryotes and eukaryotes. There are over 30 mammalian heat shock proteins, and these are 
divided into six families based on their molecular weight. The 70kDa family currently has 13 
known members. The term ‘Hsp70’ has been used to describe multiple members of the 70kDa 
family, making it difficult to fully interpret and compare some of the literature. The 
nomenclature of heat shock protein families is complex, with multiple terms given to individual 
molecules. Although a standard nomenclature has been suggested [438], inconsistencies and 
confusion in the literature remain. This study concerns the most widely studied of the 70kDa 
family, which will be referred to here as Hsp70, but is also referred to in the literature as 
HSP1A1.    
1.3.2 Intracellular Role of Hsp70 
Hsp70 is constitutively expressed at relatively low levels and acts as an ATP-dependent 
intracellular molecular chaperone [439-443] which promotes the folding and trafficking of 
nascent polypeptides and proteins [444]. In times of cellular stress, Hsp70 expression can be 
increased to much higher levels via the activation of heat shock factors (HSF) in the cytoplasm, 
their trimerisation and relocation to the nucleus, and their binding to heat shock protein gene 
promoter regions. This upregulation of expression helps to confer some transient resistance to 
apoptosis by stabilising and refolding proteins [445-447]. It can also block intracellular 
apoptotic pathways by inhibiting Bax on mitochondrial membranes [448], inhibit the 
production of the apoptosome by binding Apaf-1 [449] or by inhibiting JNK activation by 
binding to JNK-1 [450]). Hsp70 also plays a role in cell proliferation, with healthy cells 
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expressing Hsp70 during G1/S and S phase [451, 452]. Hsp70 expression can be induced by a 
number of oncogenes, including p53 [453], c-myc [454] and adenovirus E1A [455]. Intracellular 
Hsp70 is therefore over-expressed in many cancers, and this reduces the cell growth doubling 
time. The influence of Hsp70 on cell growth has been confirmed by the observation that MCF7 
cells that have been transfected to further increase intracellular Hsp70 expression exhibit a 
significantly shorter doubling time (39 hours) than those with lower expression (54 hours) 
[456].   
Many tumour cell lines express constitutively high intracellular Hsp70 and this could therefore 
contribute to their survival ability [457].  The Hsp70 expression in tumours can have 
implications for disease prognosis, and there is a general agreement that an increased 
expression of Hsp70 correlates with a less favourable prognosis [458]. Examination of primary 
human breast cancer samples has revealed that an overexpression of intracellular Hsp70 is 
correlated to both the expression of oestrogen receptor [459] and an increased rate of cellular 
proliferation [460], both of which are features of invasive breast cancer. Intracellular Hsp70 
may also be useful as a prognostic factor in human breast cancer, with the overexpression of 
Hsp70 inversely correlating with both disease-free survival [461] and overall survival [462]. 
However, other proteins within the Hsp70 family are not so clearly correlated with disease 
status. For example, although Hsp70-2 overexpression positively correlates with overall 
survival, its expression shows no association with disease-free survival [463].  
1.3.3 Extracellular Hsp70 
Although widely considered as being an intracellular protein, Hsp70 can be released from cells 
and the presence of Hsp70 in the blood of healthy humans was first reported in 1998 [280]. 
Other studies have subsequently shown that a variety of different cell types and isolated 
peripheral blood mononuclear cells (PBMCs) grown in culture medium can also release Hsp70 
[464, 465]. Cells undergoing stress have been shown to upregulate Hsp70 release, with 
extracellular levels positively correlating with increasing temperature/heat stress [465] and 
mycobacteria infection status [466]. Disease states can also be linked to increased levels of 
soluble Hsp70, in particular patients with vasculature disease. Increased levels of soluble 
Hsp70 have been observed in patients with peripheral and renal vascular disease [467]. In 
addition, levels of soluble Hsp70 could potentially be used as a biomarker for disease severity 
in atherosclerosis patients, as circulating Hsp70 levels have been shown to positively correlate 
with calcification score [468]. Circulating Hsp70 levels are also elevated in patients with 
colorectal cancer [469], prostate cancer [470] and leukaemia [471, 472]. The finding that there 
is a correlation between higher levels of Hsp70 in the circulation and poor prognosis in 
patients with leukaemia has prompted speculation as to the possible use of soluble Hsp70 
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levels as a biomarker for tumour progression [471, 472]. Further evidence as to the potential 
of circulating Hsp70 as a cancer biomarker has been provided from a mouse model head and 
neck cancer [473], in which tumours increasing levels of circulating Hsp70 positively correlated 
with the size of FaDu spheroid-derived tumours. Furthermore, a radiation-induced reduction in 
tumour size correlated with decreases in circulating levels of Hsp70, and complete tumour 
regression was associated with the return of circulating Hsp70 levels to those in control 
animals [473].  
1.3.3.1 Mechanism of Release 
Despite numerous reports of Hsp70 being found in the extracellular compartment, the 
mechanism for the release of Hsp70 from cells is still not fully understood. Hsp70 release has 
been suggested to be the result of a non-classical pathway [474], due the fact that Hsp70 lacks 
an inherent secretory leader sequence [475] and that its release is not prevented by treatment 
with Brefeldin A [464] which prevents transport of proteins from the Endoplasmic Reticulum to 
Golgi. Prior to its release, Hsp70 is found to translocate to the plasma membrane where it 
integrates into the lipid bilayer within ion channel openings [286]. This concurs with previous 
research which demonstrated an affiliation between Hsp70 and lipids in the membrane [476], 
particularly phosphatidylserine [477].  The actual release of Hsp70 may be via inverse 
evagination of the membrane, exocytosis or membrane shedding [286]. The observation that 
Hsp70 release correlates with the cell surface expression of LAMP1 [475] is further evidence of 
release via exosomes/exolysosomes and therefore exocytosis, as is the observations that 
exosomes collected from both heat stressed and mycobacteria infected cells contain 
significantly higher levels of Hsp70 than those from normal cells [465, 466]. 
1.3.3.2 Extracellular Hsp70 can bind to cells 
Evidence is also growing to support the idea that Hsp70 can bind to cells and thereby act as an 
intercellular signalling molecule. In vivo experiments in which monocytes were cultured in the 
presence of Hsp70 showed that Hsp70 could bind via Toll-like receptors (TLR) 2 and 4, the 
result of which was the release of the pro-inflammatory cytokine IL-6 [283]. To date, the seven 
cell surface receptors which have been identified as probable candidates for binding heat 
shock proteins are CD91, CD40, LOX-1, TLR-2, TLR-4 and SR-A, with all but SR-A proposed to 
bind recombinant Hsp70, as reviewed by Binder [478]. Other groups have also shown that 
Hsp70 can bind to DCs via CD91 [479] or TLR4 [480] and human endothelial cells (HDMECs) 
[481], possibly via LOX-1 [282]. A study which isolated both the ATPase domain and the 
substrate binding domain of Hsp70 has shown that although both could bind to DCs, they did 
so via distinct binding sites [482].  
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1.3.4 Immunological properties of extracellular Hsp70  
1.3.4.1 Inducing immunity to tumours  
Over two decades ago, Pramod Srivastava and colleagues showed that mice could be 
protected against tumour challenge if they had previously been injected / immunised with 
proteins that had been isolated from those same tumour cells [483]. The proteins conferring 
protection against tumours were isolated and found to include the heat shock proteins Hsp70, 
Hsp90 and gp96. Subsequent work showed that it was not actually the heat shock proteins 
themselves, but peptides bound to the heat shock proteins that were inducing the immunity, 
as peptide-free heat shock proteins conferred no protective effect [484, 485]. As indicated 
above, although heat shock proteins are primarily found intracellularly, they are also 
frequently released from tumours and this might offer a mechanism via which tumour-specific 
T cell responses can be generated [486, 487]. 
As a molecular chaperone, Hsp70 possesses the ability to bind a plethora of peptides from the 
original host cell. Hsp70-peptide complexes formed in vitro are able to elicit an immune 
response in vivo via the induction of peptide-specific CD8+ cytotoxic T cells [488]. For this, 
Hsp70-peptide complexes bind to APCs such as DCs and are internalised via endocytosis [489]. 
The Hsp70-peptide complex is trafficked within different compartments of the APC and the 
peptide is transferred to MHC class I molecules and expressed by these on the cell surface. This 
process is known as ‘cross-presentation’ and has been reviewed by Berwin [490]. Antigen 
specific activation of CD8+ T cells occurs via the recognition of peptide-MHC class I complexes 
on the APC by appropriate T cell receptors on the surface of the responding CD8+ T cell, 
concomitant with the delivery of essential co-stimulatory signals by the APC.  
Evidence also links extracellular Hsp70 to CD4+ T effector cell mediated immunity. Findings 
published in 2009 show that Hsp70 binding to DCs causes upregulation of IL-15 production and 
release, which consequently, indirectly, leads to enhanced proliferation of CD4+ T effector cells 
[480]. Work from a different group found a direct link, with Hsp70-peptide complexes being 
used in not only the MHC class I pathway, but also the MHC class II pathway, thereby 
enhancing antigen-specific CD4+ T effector cell responses [491]. 
This strategy has been employed in a number of studies that were focussed on the creation of 
personalised vaccines for cancer patients which used heat shock proteins derived from a 
patient’s own tumour to elicit an immune response against the tumour [492, 493]. A 
significant step forward has been made with another of the heat shock proteins, gp96. 
However, Phase III clinical trials in patients with melanoma, colorectal cancer or renal cell 
carcinoma, have not been as conclusive as early in vitro and experimental in vivo studies might 
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have suggested [494-496]. One potential issue relating to the use of tumour-derived gp96 as 
an anti-cancer vaccine is that there is a dose-dependent switch in the elicited immune 
response, in that low doses induce protective anti-tumour immunity, whereas high doses do 
not [497].  These findings have been confirmed using in vivo models of cardiac allograft 
transplantation (in Lewis and Wistar rats) [498] and skin grafts (in C57BL/6 mice) [499] which 
have demonstrated that high doses (100μg) administered intradermally can be anti-
inflammatory and reduce rejection responses. It might therefore be difficult to identify the 
correct dosage to be used in the clinical setting. 
In an effort to produce more effective Hsp70-based vaccines, the possibility of using Hsp70 
derived from DC-tumour fusions has been considered. Following on from studies that used the 
colon adenocarcinoma cell line MC38 fused to bone marrow-derived DCs in a murine model 
[500], the same group translated findings into the clinical setting [501]. For this, Hsp70-peptide 
complexes extracted from fusions generated from DCs isolated from healthy donor blood 
packs and tumour cells (either patient-derived ovarian cancer cells or breast cancer cell lines 
MCF7, BT20, ZR75 or SKBR3) were used to stimulate healthy donor T cells in vitro and were 
found to result in higher levels of cytotoxicity against specific targets than when T cells were 
stimulated with Hsp70 from the cells alone [501].  
One point open for discussion is the effect that internalisation of the Hsp70-peptide complex 
has on the APC. Studies have shown that DCs mature, both phenotypically and functionally, in 
response to internalising Hsp70-peptide complexes [502]. Much of the work in this area has 
made use of recombinant Hsp70 derived from E. coli systems, which can carry 
lipopolysaccharide (LPS) contamination. LPS is known for its ability to activate APCs via the 
CD14 surface receptor and Bausinger and colleagues argue that it is high levels of LPS 
contamination that result in APC maturation [503]. Their data show that Hsp70 with no LPS 
contamination, or with very low levels (<10IU/mg) do not show any capacity to induce the 
maturation of APCs. The issue of LPS contamination was addressed in a review published in 
2010, in which the authors discussed not only Hsp70, but also other stress proteins including 
Hsp60 and gp96 [504]. This review of the growing body of evidence which supports the theory 
of heat shock proteins and not LPS contamination being responsible for various immunological 
effects showed that support far outweighs the criticism. That is not to say that LPS is not an 
issue, however it does highlight the necessity of taking steps to ensure LPS contamination is 
minimal and that experiments are adequately controlled in order to ensure that effects are 
attributable to Hsp70. 
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1.3.4.2. Immunity to pathogens  
Evidence also suggests that a similar Hsp70-peptide complex-mediated mechanism can induce 
immunity to infectious agents [489, 505]. Ciupitu and colleagues showed that mice immunised 
with Hsp70 complexes formed with peptides from lymphocytic choriomeningitis virus (LCMV) 
withstood later challenge with LCMV, and exhibited reduced virus titres and the presence of 
peptide-specific cytotoxic T cells [506]. Similarly, other stress proteins can form peptide 
complexes that are capable of eliciting immune responses to infectious agents. Mice 
immunised with gp96-peptide complexes from Mycobacterium tuberculosis or Listeria have 
been shown to exhibit a significant expansion of cytotoxic T lymphocytes when compared to 
control mice [507]. Mycobacterial Hsp70 fused with proteins can also elicit an immune 
response, with mice immunised with HIV-1 p24 expressing anti-p24 IgG1 antibodies for over a 
year [508].  
1.3.4.3. Autoimmunity 
As Hsp70 is highly conserved between species, and immune responses can be directed against 
pathogen-derived Hsp70, is it also possible to see a response against self-Hsp70?  Healthy 
individuals have anti-Hsp70 antibodies in their serum [280] and although immune reactivity 
towards Hsp60 has been implicated in the progression of arthritis [509], multiple sclerosis and 
diabetes mellitus [510], there is evidence that immune reactivity against self-Hsp can be 
immunoregulatory and control inflammatory responses [511]. Ex vivo observations of BALB/c 
mice that received various doses of the heat shock protein gp96 (between 0.5 and 200 μg) 
found that inhibition in the T cell response increased with increasing dose of gp96, and that 
this inhibition was mediated via an increased activation of Treg cells [512]. Using isolated CD4+ 
T cells and Treg cells from healthy human donors, in vitro investigations have demonstrated 
that treating Treg cells with 10μg/mL can enhance their suppressive capabilities on CD4+ T cells 
by increasing the secretion of the suppressive cytokines IL-10 and TGF-β [513]. In a rat model 
of breast cancer, tumour radiofrequency ablation has been shown to increase the levels of 
circulating heat shock proteins, thereby leading to speculation that a bystander effect may be 
enhanced immunosuppression [514]. The clinical implication of the immunomodulation which 
is mediated by heat shock proteins is clearly an important point for consideration.  
1.3.5 Membrane Hsp70 (memHp70) 
In addition to being an intracellular and extracellular protein, studies in the mid-1990s by 
Gabriele Multhoff and Claus Botzler demonstrated the selective localisation of Hsp70 within 
the plasma membrane of tumour cells [285-289]. These studies revealed that Hsp70 can be 
integrated into the membrane, with only a small sequence of the substrate binding domain 
being exposed on the cell surface.  
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Figure 1.2 Structure of Hsp70 
Diagram showing the structure of Hsp70. The N-terminal or ATP-binding domain is shown in red, and the C-terminal 
or substrate binding domain is shown in blue. The substrate binding domain is comprised of two parts, a two 
layered twisted β sheet (dark blue) which can actually bind substrate and an α helical subdomain (light blue) which 
acts as a lid closing over any bound substrate.   
Imaged adapted from hsp70.com/structure 
The definitive distinction of the membrane form of Hsp70 from Hsp70 which has bound to the 
cell surface either via plasma membrane- or receptor-mediated interactions is only possible 
using a specific mAb [289]. The cmHsp70.1 mAb has been generated using hybridoma cells by 
multimmune GmbH (Munich, Germany), with specificity confirmed by way of 
immunoprecipitation using Hsp70 protein from heat shocked cells. The antibody epitope was 
determined using perspot membrane epitope mapping analysis, utilising 13-mer peptides of 
the C-terminal domain set up with 11-mer overlaps; the epitope of the cmHsp70.1 mAb is 
amino acid residues 453-461 within the β-sheet of the substrate binding domain [285]. When 
Hsp70 is held within the membrane, only a portion of the substrate-binding domian of the 
protein is exposed on the cell surface and is therefore accessible to the cmHsp70.1 mAb. All 
other commercial antibodies to Hsp70, including a mAb supplied by StressMarq Biosciences 
(clone C92F3A-5, Victoria, Canada) recognise epitopes that are outside of this region and do 
not, therefore, recognise the membrane form of Hsp70. Binding of the cmHsp70.1 mAb, but 
not the C92F3A-5 antibody therefore definitively distinguishes the membrane form of Hsp70 
from extracellular Hsp70 which has bound to the cell surface. This is an important control of 
which to be aware, as there are reports of membrane Hsp70 expression in the literature by 
other investigators which, as they have not used the cmHsp70.1 mAb, reflects Hsp70 which 
has bound to the membrane, and not the membrane form of the molecule which was first 
described by Multhoff and Botzler. 
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1.3.5.1 Membrane Hsp70 expression on Tumour Cells 
Ongoing screening of tumour biopsies taken from a variety of primary tumours including 
breast, colon, gastric, lung, prostate, head and neck, ovarian, pancreatic and haematological 
malignancies (currently standing at over 1,300 samples) indicates that around 40-60% of the 
tumours are positive for the membrane form of Hsp70, whereas corresponding normal tissue 
is membrane Hsp70 negative [285]. The potential relationship between membrane Hsp70 
expression and the prognosis of patients was investigated by Pfister et al [515]. In total, 150 
patients suffering from colon cancer, gastric cancer, lower rectal carcinoma or squamous cell 
carcinoma were assessed for memHsp70 expression and followed up for 5 years. Despite a 
similar proportion of patients with each cancer type expressing memHsp70 (37-43%), there 
were clear differences in disease prognosis; the memHsp70 status of tumours correlated with 
a significantly improved survival of patients with colon or gastric cancer, but to a significantly 
reduced survival of patients with lower rectal or squamous cell carcinoma. The authors 
hypothesise that this difference stems from different patterns of metastatic spread. Both colon 
and gastric cancers preferentially metastasise through the liver, thus exposing them to hepatic 
NK cells. Having previously demonstrated the ability of activated NK cells to recognise and kill 
memHsp70+ tumour cells (see below) [516], the authors suggest that a hepatic NK response to 
memHsp70+ metastases leads to tumour cell death and subsequent improvement in patient 
survival.  
The mechanism via which Hsp70 is selectively integrated into the plasma membranes of 
tumour cells is currently unclear. However, evidence suggests that membrane lipid 
composition might be involved, at least for some cancer cells. Release of Hsp70 from Caco-2 
epithelial cells is reduced by treatment with methyl-β-cyclodextrin, a drug which disrupts lipid 
rafts (now more commonly termed cholesterol rich microdomains or CRM) [517]. If CRMs are 
involved in Hsp70 release, then perhaps they also play a role in anchoring Hsp70 into the 
membrane. Gehrmann et al profiled lipids from plasma membranes of two human cancer cell 
lines (colon-derived CX2 and pancreas-derived Colo357) and they found significantly higher 
expression of the glycosphingolipid Gb3 in membrane Hsp70 positive cells, along with co-
localisation of the Hsp70 with Gb3 [518].  
Given that the vast majority of normal tissue is Gb3 negative, the authors suggested that this 
could help explain the high incidence of membrane bound Hsp70 in tumour cells. However, it 
appears that Gb3 is not an absolute requirement for memHsp70 expression, as recent studies 
involving breast cancer cell lines (MCF7, MDA-MB-436 and T47D) have shown high expression 
of membrane Hsp70, despite none of the cell lines being positive for Gb3 (unpublished data). 
The mechanisms by which Hsp70 locates and anchors into the plasma membrane are not yet 
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fully elucidated and it could be that the involvement of Gb3 is cell type dependent. Another 
interesting point to note is that memHsp70 expression is increased in response to gamma 
irradiation, as well as a number of chemotherapeutic agents [290, 519, 520]. The fact that 
membrane Hsp70 appears to be selectively expressed on a large proportion of tumours 
suggests that it might act as a useful and widely applicable structure and target for 
immunotherapies. Furthermore, the potential of this molecule as a targeting structure is 
further enhanced by the observations that its expression can be increased following 
conventional therapies.  
1.3.5.2 MemHsp70 as a target recognition structure for NK cells 
A key discovery by the Multhoff laboratory [289] has been that membrane Hsp70 acts as a 
target recognition structure for activated NK cells. Their studies have shown that NK cells 
which have been activated ex vivo with low dose IL-2 (100 U/ml over 3-4 days) recognise 
membrane Hsp70 positive tumour cells via CD94 molecule.  
Focusing around the 8-mer epitope of the cmHsp70.1 mAb (as this is the region which is 
available on the surface of memHsp70+ tumour cells and therefore the part available for 
recognition by NK cells), the Multhoff laboratory trialled a variety of Hsp70-derived peptides 
for their ability to activate NK cells. Using peptides from 8 to 14-mer, that match the 
cmHsp70.1 mAb epitope or that were extended towards the N-terminal, the C-terminal or 
both, as well as peptides matching equivalent regions in Hsp70hom, Hsc70 and DnaK, the 
authors found that whilst most failed to elicit NK activity, the 14-mer peptide 
TKDNNLLGRFELSG (abbreviated to TKD peptide) was able to stimulate both cytolytic and 
proliferative activity of NK cells [523]. The effect was confirmed using anti-Hsp70 mAbs to 
block the interaction [522]. The Multhoff group also showed that an increased expression of 
the membrane form of Hsp70 on tumour cells correlates to the cell having an increased 
sensitivity to killing by IL-2/TKD-activated NK cells [522]. Another interesting point to note is 
that NK cells which have been activated by Hsp70 or TKD peptide show increased expression of 
granzyme B, thereby leading to enhanced cytotoxic potential of NK cells [524].  
Investigation of human NK cells in vitro showed that stimulation with TKD peptide increases 
their migration towards, as well as cytolytic activity against, memHsp70+ cancer cells [525]. The 
action of NK cells on memHsp70 tumour cells has also been studied in vivo, using a pancreatic 
cancer model, in which Colo357 cells injected into SCID/beige mice (which lack T lymphocytes 
and NK cells). NK cells which had been incubated with low dose IL-2 (100IU/mL) and TKD 
peptide (2µg/mL) for 4 days were administered to the mice, with the result being a decrease to 
tumour burden, delayed appearance of metastases and an increase to life expectancy [526].  
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Other studies have reported on the capacity of NK cells purified from peripheral blood samples 
of both healthy donors and patients with leukaemia that had been stimulated ex vivo with a 
14-mer peptide matching the sequence of the NK cell recognition site on Hsp70 (2µg/mL), 
together with a low dose of IL-15 (10µg/mL) for 5 days (or with one or neither stimulant as a 
control) to increased density of CD56 and CD94 on the NK cells’ surface and boosted the 
cytolytic activity against memHsp70+ K562 cells or autologous/allogenic leukaemic blasts in 
vitro on the basis of their release of granzyme B using an ELISpot [527]. 
1.3.6 Clinical Application of Membrane Hsp70 targeted tumour immunotherapy  
As a large proportion of tumours express memHsp70, it is plausible to attempt to exploit this 
unique and selective expression for the therapeutic targeting of tumours. This could be 
achieved via a variety of approaches. 
1.3.6.1 Tumour targeting with NK cells 
A phase I clinical trial looking at the feasibility and safety of infusing cancer patients’ own ex 
vivo IL2/TKD-stimulated NK cells in an effort to increase cytolytic activity against tumour cells 
has been conducted [528]. The patients involved were suffering from either non-small lung cell 
carcinoma or metastasised colorectal cancer. NK cells from the majority of the patients (10 out 
of 12) exhibited an increased surface density of CD94 expression and an upregulation of NK 
cell cytolytic activity directed against membrane Hsp70 positive tumour cells following ex vivo 
stimulation. Of the 5 patients who received more than four cycles of treatment, two showed 
clinically measurable improvement.  
Following the Phase I trial, the same group also published a case report of a male patient with 
colorectal carcinoma who was given similar treatment. Peripheral blood mononuclear cells 
obtained using leukapheresis were activated ex vivo with a combination of IL-2 and TKD 
peptide for four days before being re-infused to the patient [529]. This patient received 
monthly treatment for six months, was given a three month break, then returned for a further 
three months. After treatment, there was an infiltration of NK cells to metastatic sites, and a 
reduction in expression of the colon carcinoma marker carcino-embryogenic antigen (CEA). 
These are encouraging results, as both scenarios correlate with better prognosis. Cytotoxicity 
of the NK cells was assessed in vitro which had been generated from the patient’s own tumour 
as the target [529]. 
Multiple infusion treatments resulted in increased NK cytotoxicity, and although this abated 
during the break from treatment, once the infusions recommenced NK cytotoxicity quickly 
returned to the previous level. Overall, the findings of these studies are very encouraging and 
this avenue potentially offers a novel treatment in cancer therapy. A multi-centre randomised 
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control Phase II trial in patients with non-small cell lung carcinoma commenced in Germany in 
early 2015 (Gabriele Multhoff, personal communication). 
1.3.6.2 Tumour targeting with granzyme B 
An affinity column conjugated with a 14-mer peptide corresponding to a region within the 
extracellular portion of memHsp70 was used to determine which component(s) of NK cell 
lysates bound to the solid phase. This approach identified that a 32kDa protein bound to the 
Hsp70-derived peptide, and this was identified as being granzyme B. The discovery that 
memHsp70 could act as a conduit for the internalisation of the serine protease granzyme B 
was highly significant, as this suggested another approach for the therapeutic targeting of 
tumours expressing membrane Hsp70 [530]. To confirm whether granzyme B could also bind 
to the membrane form of Hsp70 on tumour cells, the ability of memHsp70+ CX-2 (colon 
carcinoma) and Colo357 (pancreas carcinoma) cell lines to bind and take up granzyme B was 
examined. Both cells lines took up granzyme B and it was shown that granzyme B uptake 
resulted in apoptosis, despite the absence of perforin in the system [530].  
Investigations into the effect of a human recombinant form of granzyme B on a mouse 
colorectal cancer model using the CT26 cell line have showed similar results [531]. The 
treatment of cells grown in a monolayer and as spheroids with granzyme B results in caspase-3 
activation, the killing of cultured cells and a reduction in the size of spheroids [532]. Granzyme 
B has also been shown to significantly reduce the size of implanted CT26 tumours expressing 
memHsp70 in BALB/c mice [532]. No adverse side effects were recorded, nor was there any 
accumulation of granzyme B in healthy organs. The treatment therefore appears to be well 
tolerated. Further studies are now required in order to assess the feasibility of this potential 
treatment in humans.  
Whether memHsp70 expressed on breast cancer cells allows this internalisation of granzyme 
B, and if so whether knowledge pertaining to the internalisation pathway can give information 
about the ability to induce apoptosis, will be the subject of this thesis. The ability to directly 
target tumour cells on the basis of their memHsp70 expression could prove to be a valuable 
clinical tool. With around 50% of tumours expressing this molecule to some degree [285], and 
with metastatic disease expressing even higher levels than their memHsp70 expressing 
primary tumour counterparts [532], granzyme B has great potential as a therapeutic molecule 
which would be a highly specific and effective in a large proportion of patients with cancer. 
Theoretically, granzyme B could be an excellent combination treatment for cancer patients, as 
its targeting molecule (memHsp70) is widely expressed, induced by radio(chemo)therapy and 
would continue to be effective in individuals that have been rendered as being 
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immunosuppressed either as a consequence of disease or the treatments that they have 
received. Furthermore, the in situ killing of tumours is likely to induce the release of tumour 
specific antigens which might promote the development of protective anti-tumour immunity 
either alone, or in combination with an appropriately configured vaccination strategy. 
1.3.6.3 Tumour targeting with the cmHsp70.1 monoclonal antibody 
Stangl and colleagues have demonstrated that the cmHsp70.1 mAb can also be used in vivo to 
target tumours derived from the CT26 memHsp70 positive murine colorectal cancer cell line 
[533]. Three doses of the cmHsp70.1 mAb has been shown to significantly reduce tumour 
volume and increase the survival of BALB/c mice bearing subcutaneous CT26 cells. The 
cmHsp70.1 mAb binds to memHsp70 on tumour cells and promotes ADCC by NK cells. That the 
targeting is specific for memHsp70 and involves the induction of ADCC has been confirmed 
using a memHsp70- cell line (small cell lung carcinoma 1048) and treatment with C92F3A-5 
mAb (specific for an epitope unavailable in the membrane form of Hsp70) or a Fab fragment of 
cmHsp70.1 (cannot induce ADCC), none of which had any effect on tumour progression. 
The possibility of using the cmHsp70.1 mAb to better image tumours has also been considered, 
and investigated by Stangl and colleagues, again using CT26 tumours in BALB/c mice [534]. For 
these studies, mice were injected with Cy5.5-labelled cmHsp70.1 mAb 14 days after receiving 
the tumour cells. Using intraoperative fluorescent imaging it was possible to detect localisation 
of the antibody to the tumour within 30 minutes. This localisation was highly selective, as a 
similarly labelled isotype control was not detected in the tumour, and nor was the cmHsp70.1 
mAb detected in healthy surrounding tissue. By overlaying a standard optical image of the 
tumour region with the fluorescent image, the authors showed that cmHsp70.1 mAb  binding 
was restricted to an area with the tumour boundary. The antibody was endocytosed via 
mechanisms which the authors suggest involves the rapid turnover of membrane Hsp70, and 
accumulated within the tumour whilst retaining fluorescence. The fluorescence intensity 
remained at a detectable level for up to 96 hours. The implications of this study to future 
treatment possibilities are exciting. As well as offering improvements to tumour imaging, this 
specific tumour targeting and subsequent internalisation of the cmHsp70.1 mAb could enable 
the selective delivery of chemotherapeutic drugs or radio-nuclides to tumours, whilst avoiding 
damage to healthy tissue. 
Although it is clear that memHsp70 positive CT26 cells are capable of internalising 
fluorescently-labelled cmHsp70.1 mAb, the precise intracellular trafficking pathway has yet to 
be elucidated. In order to be able to exploit this effect for drug delivery it is essential to fully 
understand the subsequent intracellular movements of internalised antibody. The most 
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effective way to do this would be to undertake microscopical analysis of cells after cmHsp70.1 
mAb internalisation. The selectivity, kinetics and route(s) of cmHsp70.1 mAb internalisation 
into tumour cells will be investigated in this thesis. 
1.3.6.4 Tumour targeting with the TKDNNLLGRFELSG 14-mer peptide 
The NK cell recognition site of Hsp70 is a 14 amino acid sequence within the substrate binding 
domain (aa 450-463) [523, 525], which is within the region that is exposed extracellularly when 
Hsp70 is in the cell membrane.  Although the use of the peptide to direct and boost NK cell 
mediated cytotoxicity towards memHsp70+ tumours could prove to be a powerful tool in 
tumour therapeutics, it might also have value for tumour imaging and targeting. 
Peptides have many advantages over antibodies as targeted imaging and therapeutic agents 
[535]. They are relatively easy and quick to generate in large quantities and typically have low 
associated toxicities. They are stable, exhibit better distribution than antibodies and being 
small molecules have an enhanced ability to penetrate tissues. Peptides are already under 
investigation for targeting HER2+ breast cancer in pre-clinical mouse models. A combination of 
two peptides, one derived from the B cell epitope of HER2 and the other as a VEGF mimic, 
have been shown to inhibit the in vivo growth of TUBO tumours in BALB/c mice [536]. The 
expression of membrane Hsp70 on a large proportion of tumour entities opens up a 
potentially powerful small molecule targeting strategy. The 14-mer peptide derived from the 
C-terminal substrate binding domain of Hsp70 which is capable of binding to membrane 
Hsp70, both in vitro and in vivo, could offer an avenue to provide greater tumour imaging 
potential [535].  
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1.4 Hypotheses  
• Membrane Hsp70 on breast cancer cell lines offers a route of specific tumour 
targeting.  
• Granzyme B internalised via memHsp70 leads to apoptosis in human breast tumour 
cells. 
 
1.5 Aims and Objectives  
The aim of the proposed study is to use multi-parameter flow cytometry and fluorescent 
confocal microscopy imaging technology to define the kinetics and pathway of internalisation 
of three potential theranostics (cmHsp70.1 mAb, TKDNNLLGRFELSG 14-mer peptide and 
granzyme B) into breast cancer cell lines expressing the membrane form of Hsp70, with a view 
to better understanding their targeting and imaging potential. Specifically, this study will  
• Use imaging technology platforms to determine the uptake of cmHsp70.1 mAb, 
TKDNNLLGRFELSG 14-mer peptide and granzyme B and elucidate the pathways that 
are involved and utilised. 
• Use different imaging platforms to compare uptake pathways and kinetics in relation 
to membrane Hsp70 expression.  
• Develop novel analytical approaches that better enable uptake kinetics and co-
localisation to be interrogated from fluorescent images.   
As a secondary aim, the project will also use flow cytometry to determine whether lymphocyte 
populations express memHsp70 and whether any expression can be upregulated in response 
to factors consistent with a tumour microenvironment. 
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CHAPTER 2 Materials and Methods 
2.1 Background 
The primary aim of this study is to use imaging technology (multi-parameter flow cytometry 
and confocal microscopy) to characterise and quantify the selective internalisation of 
cmHsp70.1 mAb, granzyme B and an Hsp70-derived peptide (TKDNNLLGRFELSG) by breast 
cancer cells expressing membrane Hsp70. 
Although flow cytometry can give high-throughput results and can be used to acquire and 
analyse many different fluorescent signals in a single cell, it cannot provide any insight into the 
localisation of the signal, nor can it provide a definitive insight into the surface binding, 
internalisation and intracellular localisation of given molecules. In contrast, confocal 
microscopy provides information on localisation of target molecules on and within cells. 
Combining these two techniques permits a comprehensive analysis of cell-molecule 
interactions and their dynamic relationship(s).  
2.2 Tumour Cell Lines 
Five cancer cell lines were used in this work. Three are derived from human breast cancer 
metastasis (MDA-MB-231, MCF7, T47D), whereas the other two are derived from murine 
mammary carcinoma (4T1) and murine colon carcinoma (CT26). MDA-MB-231, MCF7, T47D 
and 4T1 cells were purchased from the European Collection of Cell Cultures (ECACC) whereas 
the CT26 cells were provided by Professor Gabriele Multhoff (Technische Universität München, 
Munich).  The three human lines were selected, as they represent a range of disease states and 
severity. 4T1 cells were used to assess whether a mouse model behaved in the same way as 
human cells. The CT26 cells were used as a comparison to previously published data which 
have demonstrated that the cmHsp70.1 mAb can specifically bind, in vivo, to tumours derived 
from colorectal cancer cells expressing memHsp70. 
 
Cell Line HER2 ER PR Classification Disease severity 
represented 
MDA-MB-231 - - - TNBC +++ 
MCF7 - + Low Luminal A ++ 
T47D - + High Luminal A + 
 
Table 2.1 Characteristics of the human breast cancer cell lines selected 
A summary of the key differences between the three human-derived breast cancer cell lines used in this study, in 
terms of receptors expressed and disease severity represented. HER2 (also HER2/neu) = Human epidermal growth 
factor receptor 2. ER = Oestrogen receptor. PR = Progesterone receptor. 
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MDA-MB-231: This epithelial cell line was derived from pleural effusion of a 51-year old 
Caucasian female with mammary adenocarcinoma [537]. It expresses receptors for both 
epidermal growth factor and transforming growth factor alpha (TGFα). These cells are 
adherent, and have a doubling time of less than 24 hours.  
 
MCF7: This epithelial cell line was also originally derived from the pleural effusion of a 69-year 
old Caucasian female patient with a mammary carcinoma [538]. The cell line differs from the 
MDA-MB-231, in that cells express the oestrogen receptor [539], and cell growth is inhibited 
by exogenous TNFα. 
 
T47D: This epithelial cell line was originally isolated from the pleural effusion of a 54-year old 
female with a ductal carcinoma and expresses a range of hormone receptors, including those 
for androgen, oestrogen, progesterone and prolactin [540]. 
 
4T1 is a tumourogenic cell line derived from the mammary gland of BALB/c mice [541]. It is a 
commonly used cell line for studying metastatic breast cancer in vivo and is an animal model 
for stage IV human breast cancer. After implantation, the primary tumour quickly and 
spontaneously metastasises to many sites, including the lung, liver, brain and lymph nodes. 
 
CT26 is a tumourogenic cell line derived from a transplantable colon carcinoma in BALB/c mice 
[542]. Although not a breast tumour model, this line was included, as the cmHsp70.1 mAb has 
previously been shown to bind to memHsp70+ tumours in vivo [534].   
 
2.2.1. Cell Culture – Maintenance 
All tumour cell lines were grown in RPMI 1640 growth medium, supplemented with foetal 
bovine serum (5% v/v in the case of the CT26 cells, 10% v/v for all the others), 6mM glutamine, 
100IU/mL penicillin and 100μg/mL streptomycin (termed RPMIcomplete) (all reagents supplied by 
Lonza). 
 
All of the cell lines are adherent and therefore require trypsin-EDTA (Lonza) treatment in order 
to passage. The growth medium was decanted from the flask and cells were washed twice with 
8-10 mL PBS (Lonza), taking care to gently bathe the PBS over the whole surface of the flask 
before decanting. This is important, as it ensures removal of as much of the remaining 
RPMIcomplete as possible. This has a high content of protein which can block the action of the 
trypsin-EDTA. After washing, 2.5 mL trypsin-EDTA was added to the flask and bathed over the 
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cells before removing with a pipette. The flask was replaced in the incubator for an 
appropriate duration for the particular cell line (see Table 2.2). Once completed, the cells were 
checked for rounded edges (to show they were beginning to detach) and the flask was gently 
tapped to dislodge cells, after which the activity of the trypsin-EDTA was neutralised by adding 
5 mL of fresh RPMIcomplete. This medium was gently pipetted a few times over the bottom of the 
flask to ensure collection of all cells, and to encourage cells into a single cell suspension rather 
than aggregating. Usually, those cell lines which require longer incubation times with trypsin-
EDTA are also more prone to cellular aggregation. A proportion of the cells was added to fresh 
RPMIcomplete in a new T75 flask, making a total volume of 10 mL. The proportion of cells added 
was dependent on cell line (see Table 2.2). 
 
 
Table 2.2 Cell culture - maintenance 
Whilst trypsin-based cellular detachment is highly effective, its action is to cleave at any lysine or arginine sites and 
therefore it is not specific for surface adherins. The cells need sufficient incubation time for the adherence to be 
disrupted, but not so long that all other surface antigens are also cleaved. This Table list the incubation times that 
are required for effective cell detachment using trypsin-EDTA incubation, as well as the proportion of cells that were 
used to seed T75 flask at each passage.  
2.3 Determining memHsp70 status of tumour cells 
The expression of membrane Hsp70 by the cell lines that were used in the study was 
determined by flow cytometry using fluorescently-labelled antibodies specific for different 
Hsp70 epitopes. For this, cells were first passaged and reseeded at cell numbers that would 
produce confluent cultures after 48 hours. 
2.3.1 Cell Culture – Experimental Set Up  
Trypsinised cells were harvested and cells were counted on a haemocytometer using trypan 
blue (Sigma Aldrich) exclusion to determine viability. One grid block from each side was 
counted, the counts were averaged and then converted to χ*106 cells/mL format.  The 
appropriate number of cells that would result in confluent cultures after 48 hours (Table 2.3) 
were suspended in 10 ml of RPMIcomplete and cultured in T75 flasks until being harvested, 
stained and analysed by flow cytometry, as described below. 
 
 Incubation time with  
trypsin-EDTA 
Passage Proportion 
MDA-MB-231 >30 seconds 1/10 
MCF7 >90 minute 1/6 
T47D >3 minutes 1/5 
4T1 >3 minutes 1/10 
CT26 >30 seconds 1/20 









Table 2.3 Seeding densities into T75 flasks 
To compensate for different growth rates, cell lines were seeded into T75 flasks at different densities which allow 
for comparable levels of confluency after 48 hours. This table details the starting number of each cell line.  
 
2.3.2 Staining of tumour cells 
The expression of memHsp70 by cultured cells was determined every 24 hours for up to four 
days, or until the cells had reached confluency. MemHsp70 was determined using the 
cmHsp70.1 mAb (multimmune GmbH, Germany) which is specific to an epitope within the 
substrate binding domain of Hsp70 which is exposed when in the membrane form [289]. The 
cmHsp70.1 mAb is the only antibody which can recognise this unique membrane form of 
Hsp70. The specificity of the staining for membrane Hsp70 expression was confirmed using a 
second anti-Hsp70 mAb (clone C92F3A-5 clone, Stressgen via Enzo Life Sciences) which is 
specific for an epitope towards the N terminus of the molecule which is inaccessible on viable, 
membrane Hsp70 positive cells. As a consequence, if cells are positive for cmHsp70.1 mAb 
staining, but not for C92F3A-5 mAb staining, then Hsp70 is present in the membrane form. 
Positivity for both antibodies indicates that the entire Hsp70 molecule is present on the cell 
surface, and this is not reflective of the presence of the unique membrane form.  This is an 
essential control for such experiments, as many cells and cell lines can release Hsp70 into the 
extracellular environment. This could then bind to the cell surface and give a false positive 
indication as to the memHsp70 status.  
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Figure 2.1 Different specificities of the cmHsp70.1 and C92F3A-5 anti-Hsp70 mMAb clones 
(A) When Hsp70 only expressed intracellularly neither antibody (cmHsp70.1 in purple; C92F3A-5 in red) can bind. If 
Hsp70 is bound to the cell membrane (B) then both antibodies are capable of binding the molecule, but when the 
membrane form of Hsp70 is present, (C) then only the cmHsp70.1 can bind.  
 
At the appropriate time, cells were harvested using Trypsin-EDTA as described above and 
viable cells counted. Cells were rested for 15 minutes before starting the staining in order to 
allow for the recovery of any memHsp70 that has been potentially cleaved during the 
trypsinisation process (Gabriele Multhoff, personal communication), after which 1x105 cells 
were transferred into 1.5 ml microfuge tubes and washed with 1 ml staining buffer (phosphate 
buffered saline (PBS) containing 10% v/v FCS). After centrifugation (300g, 4oC, 5 minutes), the 
supernatant was removed using a vacuum aspirator and cells were resuspended being placed 
on ice. Cells were resuspended in 15 µL staining buffer containing 0.2μg of either FITC-
conjugated cmHsp70.1 mAb (provided pre-conjugated by multimmune GmbH), FITC-
conjugated C92F3A-5 mAb (Stressgen via Enzo Life Sciences) or an appropriate FITC-conjugated 
IgG1 isotype control (Biolegend). The concentration of the cmHsp70.1 mAb was as 
recommended by the supplier, and the other reagents were used at the same concentration. 
Unstained cells were included as a further negative control in all assays. 
 
Samples were vortex mixed and incubated at 4oC protected from light for 30 minutes, after 
which cells were washed with 1mL staining buffer, the supernatant aspirated and cells 
resuspended in staining buffer. Cells were then transferred into 12x75 mm tubes and stored 
on ice protected from light until they could be analysed by flow cytometry, but this was always 
conducted within 1 hour. Propidium iodide (Sigma Aldrich, used at 0.5 µg in 10μL) was added 
to each sample no more than 5 minutes prior to flow cytometric data acquisition, in order to 
enable the exclusion of non-viable cells from all of the analyses. In some of the cell lines, there 
was some variation in the expression of memHsp70 over time after cell seeding (Fig. 2.2). As 
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the highest intensity expression was observed 48 hours after seeding this was the time-point 
selected for experimental use.  
 
 
Figure 2.2 Membrane Hsp70 expression of cell lines over time  
Cells were seeded into T75 flasks and their expression of memHsp70 was monitored over a period of 72 hours. The 
solid lines show the staining intensity with cmHsp70.1 (and therefore the expression of membrane Hsp70), whilst 
the dashed lines show staining intensity with the control C92F3A-5 antibody. The maximal intensity of expression 
was observed 48 hours after seeding, so this time-point was used for subsequent experiments. Data shown are the 
mean (±SEM) of at least three independent experiments.  
 
2.4 Flow Cytometry 
2.4.1 Introduction to Flow Cytometry 
Flow cytometry is a technique for analysing the size, intracellular granularity and the 
fluorescent characteristics of cells in a single cell suspension using lasers and optics. Individual 
cells pass through the laser beams, with the subsequent scattered and emitted light being 
collected by detectors which convert the light into quantifiable electrical signals.  
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This study used a BD™ LSRII flow cytometer equipped with four excitation lasers (355nm, 
405nm, 488nm, 633nm) and FACSDiva™ acquisition and data analysis software (BD 
Biosciences). Theoretically, it is possible to measure 13 fluorescent parameters, although in 
reality fewer are possible due to spectral overlap which is caused by the emission of one 
fluorophore ‘leaking’ into the detection channel for a second fluorophore. Although some 
degree of spectral overlap can be corrected by compensation (see below), this can reduce the 
sensitivity of detection. It is therefore essential that an appropriate panel of conjugated 
antibodies is selected in order to minimise spectral overlap issues. In addition, detectors 
measure the light which is scattered in line with the 488nm laser (Forward Light Scatter, FSC) 
and light which is scatted to the side of the laser (Side Light Scatter, SSC). These parameters 
provide information about the size and intracellular complexity/granularity respectively, 
thereby providing information which allows cell populations to be visualised (Fig 2.3). Three 
size and three granularity measurements can be taken, relating to the area, height and width 
of a cell, denoted by –A, –H or –W following the description at acquisition. The acquisition of at 
least the area and one other parameter enables additional analyses to be conducted 
subsequently. 
 
Figure 2.3 Visualising cell populations by flow cytometry  
The extent of forward and side scattered light provides information about the size and granularity of cells 
respectively.  In this instance MCF7 cells are shown as a distinct population in the centre of the dot plot (circled in 
red).  
2.4.2 Isotype controls  
In addition to excluding background auto-fluorescence from the analysis by including 
unstained cells in all experiments, appropriate isotype controls were also included. It is 
essential to confirm that mAbs are binding to cells via the specific receptor/marker of interest, 
and not non-specifically (e.g. via Fc receptors). In humans, antibodies fall into one of five 
classes (IgG, IgM, IgA, IgD, IgE). The inclusion of non-reactive isotype-matched controls (the 
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same class of antibody as the one of interest labelled with same fluorescent marker) in all 
experiments and the setting of analysis gates that are defined on the basis of the isotype 
control samples allows any non-specific, background binding to be excluded. In this study, such 
binding was minimised by incubating samples with normal mouse serum prior to the mAbs of 
interest. Isotype controls were included, as the expression of memHsp70 is typically 
represented as a shift in the fluorescence histogram rather than a defined separate population 
of cells. Further details on the approaches that were used for analysing the data are presented 
below. 
2.4.3 Compensation  
As indicated above, one of the difficulties that can be encountered when undertaking multi-
colour flow cytometry is the issue of spectral overlap (spillover) between the emission spectra 
of different fluorochromes. Spectral overlap occurs when the emission of one fluorophore 
‘leaks’ into the detection channel for a second fluorophore (Fig 2.4). The potential for spectral 
overlap can be minimised with careful selection of fluorochromes; i.e. selecting those which 
require different excitation sources and/or have distinct and non-overlapping emission 
spectra. However, fluorochrome options can be limited, and so in very large experiments some 
degree of spectral overlap is always unavoidable. The only approach to consider and avoid 
erroneous data is to apply ‘compensation’, the aim of which is to ‘remove’ the spectral overlap 
signal from the detection channel for the second fluorophore.  
 
The principle behind setting up compensation is to run through single colour samples for each 
fluorochrome in the panel, check the output into all of the other channels and adjust the 
percentage deductions until data are only received into the correct channel. The figures for 
compensation are quoted as percentages, and there is one for every possible pair of 
fluorochromes. It is worth noting that compensation ceases to be as effective over 50%, as the 
consequence could be an increase in false negative signals, and any fluorochrome pairs that 
produce such a high compensation requirement should not be used together in the same 
experiment.  
Applying compensation manually is difficult, especially when more than two fluorochromes are 
involved. To simplify the process some acquisition software, including BD FACSDiva, allows 
users to apply compensation calculations automatically. FACSDiva allows this to be done at 
any time, although with some software it is only possible to apply compensation at the time of 
acquisition. 
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Figure 2.4 Spectral overlap  
Spectral overlap is caused by the emission from different fluorochromes being detected in the same channel and 
can be illustrated with the emission spectra from two of the most commonly used fluorochromes; FITC and R-PE. 
The maximum emission of R-PE occurs at 576nm which is perfectly captured using a band pass (BP) 575/26 filter (a 
range of 26nm around a mid-point of 575nm). Whilst the emission peak of FITC is at 518nm, 15-30% emission still 
occurs at the longer wavelength region covered by the BP575/26 filter. Therefore, if these two fluorochromes are 
used in conjunction, a proportion of data recorded as R-PE emission will actually be from FITC emission. A process 
of compensation can be applied. This involves removing an appropriate percentage of acquired data from any 
detector channel, and is dependent on the fluorochrome combination and individual instrument voltages. 
Compensation values must be calculated for every analysis conducted. Emission curves were generated using 
CurvoMatic software (Omega Optical, Inc (USA):  www.omegsfilters.com/Products/Curvomatic). 
 
Compensation was set up using the BD CompBeads system (BD Biosciences). This comprises 
polystyrene microparticles, half of which have been coated in an anti-mouse Ig antibody and 
the other half uncoated. When antibody and beads are incubated together, coated beads can 
bind the antibody non-specifically through the Fc region whilst the uncoated beads cannot. This 
provides a sample with both positive and negative signals for the given fluorochrome. The 
benefits for using this bead system are twofold. Firstly, cell samples can be used for the 
experimental analyses rather than for the instrument set up procedures, thereby maximising 
data from a single experiment. Secondly, accurate compensation relies on having a reasonably 
sized positive population for each fluorochrome in question. Therefore, using cells with rare 
populations and/or inducible markers can make compensation very difficult. Although the 
acquisition software is used to calculate the actual compensation settings, it is important to 
know how correctly compensated data appear on screen (Fig 2.5), and also to check every 
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possible pair of fluorochromes in each experiment to ensure that the compensation has been 
applied appropriately.  
 
Figure 2.5 Applying compensation  
Although the actual compensation calculations are applied by the acquisition software, it is important to be aware 
of how this appears on screen in order to see whether it has been applied correctly. The left hand plot shows data 
before compensation, with the cell populations exhibiting a dragging, diagonal shape across the plot and seeming to 
converge in the top left corner. After compensation has been applied (right) the populations follow a more regular 
formation clearly separated from each other.  
2.4.4 Data acquisition 
To minimise the effect of photo-bleaching on the fluorochromes, cells were kept on ice and in 
the dark until the time to acquire data. Data acquisition took place as soon as possible, and 
always within 1 hour of staining the cells. To enable exclusion of non-viable cells, propidium 
iodide was added to the cells, but not more than 5 minutes before running the acquisition. For 
these particular experiments, all acquisitions took place on a BD LSRII using the 488nm 
excitation laser and acquiring through the 530/30, 575/26 and/or 610/20 nm band pass filter 
channels, depending on the specific requirements of each experiment. Data acquisition was 
automatically stopped when data on 10,000 tumour cells (or as many cells as possible) were 
collected. 
2.4.5 Post acquisition analysis  
All analysis was undertaken using FACSDiva software by creating a hierarchy of regions of 
interest around cells (Fig 2.6). It always began with setting up plots to first choose the 
population of interest, using forward (FSc) and side (SSc) light scatter profiles to define the 
relevant population. The population often appears as a dragged diagonal shape towards the 
top right corner.  Generally a “population” is also seen in the lower left hand corner of the 
display, but this is in fact cellular debris and is excluded from the analysis. Drawing a gate 
around the lymphocyte population enables only these cells to be carried onto the next level of 
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the analytical hierarchy, in which any aggregated cells (doublets) are excluded. To this end, 
area and height measurements from the forward light scatter parameter are compared. Area 
and width, or the same pairings using the side scatter data would also provide an equivalent 
output. Keeping the area measurement on the x-axis ensures that single cells are shown as the 
top diagonal population, and any aggregates will appear as a ghost population below. It is 
essential to exclude any aggregated cells, as they can give false results. A gate drawn around 
the single cells enables only these to be taken onto the next step in the hierarchy, which is the 
selection of viable cells. As with aggregates, non-viable cells can give false results during 
fluorescence analysis. The viability assessment is conducted using propidium iodide (or other 
stains such as 7-AAD), with any dead cells becoming positive for the stain and viable cells 
remaining negative. Those viable cells can be gated and carried onto the analysis of the 
markers of interest.  
 
Figure 2.6 Identification of viable tumour cells for analysis 
It is essential that flow cytometric analysis is only conducted on viable, single cell populations, as debris, cell 
aggregates and non-viable cells can all provide false positive data. Tumour cells can be seen on a forward scatter vs 
side scatter plot (A) and a region to exclude the debris which is found in the lower left corner was applied. By 
comparing cell height and area (B) single cells (red) can be separated from cell aggregates (black). Finally, the cells 
are checked for propidium iodide (PI) staining (C). Any non-viable (PI positive) cells appear on the right of the plot.  
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Once the single, viable cell population has been confirmed, then it is possible to begin analysis 
of the surface markers of interest, although the analytical approach is very much dependent 
on the expression profile of the marker. Traditionally, a gate is applied using either an 
unstained or isotype control sample as a guide then by recording the proportion of cells which 
have sufficiently high expression intensities to fall outside of the control region. A median 
value for the intensity of these positive cells is also usually recorded. However, depending on 
the profile of marker expression, this approach might not be the most appropriate. There are 
some markers for which cells are definitely either positive or negative, and in these instances it 
is perfectly reasonable to assess the percentage of cells in the population which are positive 
for marker expression. Markers for which this approach is not suited are those which result in 
a shift of the entire population, rather than the identification of two distinct populations. 
Staining cells for memHsp70 expression using the cmHsp70.1 mAb results in a single 
fluorescence peak which does not fully separate away from fluorescence profile of the 
corresponding isotype control (Fig. 2.7). When cells are exhibited as a single fluorescence 
population they are essentially all behaving in the same way, in that they might all be 
considered as being positive, but to varying degrees. In such instances, it is might be better to 
quantify results in the context of the median fluorescent intensity of the whole cell population. 
 
 
Figure 2.7 Flow cytometric analysis of cell surface marker expression 
Representative staining patterns for two different surface molecules (solid histograms) and their appropriate 
isotype control staining (open histograms) Left panel: PBMCs stained for CD4 expression. CD4 is expressed to a high 
degree on a subset of T cells, but is absent from other PBMC populations, creating a clear bi-population expression 
pattern that is easily gated for those cells which are positive. Right panel: 4T1 cells stained with cmHsp70.1 mAb do 
not exhibit a clear positive/negative divide, but rather show an overall increase in fluorescence intensity to the 
whole population. If the same gating strategy were employed here as for the staining for CD4 expression, then the 
population would be effectively cut in two by the gate.  A median fluorescence intensity of the entire population is 
therefore recorded. 
 
A higher median intensity equates to greater expression of the marker on question, whereas 
fluorescent values close to those of the isotype (or unstained) control indicate very low to no 
expression. Variations in isotype between experiments must be accounted for, and the easiest 
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way to do this to divide the median fluorescence intensity of staining which is generated 
following staining with the cmHsp70.1 mAb by the median fluorescence intensity of the 
isotype. The closer this number is to 1, the less memHsp70 is present. The data for C92F3A-5 
were analysed in the same way, and this would typically be expected to result in a 
measurement close to 1, as this antibody does not bind to memHsp70 positive tumour cells 
(Fig. 2.1).   
2.4.6 Limitations of flow cytometry 
Although flow cytometry is an excellent technique for high-throughput analysis of overall 
intensity of antigen expression, and enables effective comparison of treatments in a range of 
populations, it cannot be used to determine the localisation and / or co-localisation of labelled 
molecules. 
2.5 Membrane Hsp70-mediated uptake of cmHsp70.1 mAb, 
recombinant human granzyme B and TKDNNLLGRFELSG peptide into 
tumour cells 
Although tumour cells have been found to express memHsp70 [287, 543, 544], relatively little 
is known about the mechanism of its appearance, why it is expressed in this form, or indeed its 
functional role (if any). However, the selective expression of memHsp70 has the potential to 
provide a tumour-specific targeting structure that can be exploited for the imaging and 
potentially the delivery of therapeutics [533]. Previous evidence has shown that memHsp70 
can act as a target recognition structure for activated NK cells, and also that a monoclonal 
antibody which is specific for the Hsp70 epitope which is expressed on the plasma membrane 
(cmHsp70.1 mAb) can be used to detect and target cancer cells in vitro and in vivo tumours 
[287]. Out of these latter studies came the evidence that NK cell-mediated killing involved the 
release of granzyme B, and its interaction with, and internalisation by, this membrane form of 
Hsp70 [516]. Cancer cells expressing memHsp70 are therefore susceptible to granzyme B 
mediated cell lysis, even in the absence of perforin [530-532]. Furthermore, data obtained 
using the mouse colorectal cell line CT26, which expresses memHsp70, has demonstrated that 
granzyme B is internalised into, and kills, these cells in vitro and in vivo [531]. 
 
The goal of the present study is to use flow cytometry and confocal microscopy to further 
investigate the interaction of the cmHsp70.1 mAb, a recombinant form of human granzyme B 
and a 14-mer peptide (TKDNNLLGRFELSG) having a sequence which is derived from the 
oligomerisation domain of Hsp70 which is expressed on the cell surface of tumor cells with 
cancer cells that express memHsp70. 
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For these studies, purified cmHsp70.1 mAb was obtained from Professor Multhoff’s laboratory 
at the Technische Universität München. Recombinant human granzyme B was generated 
following a protocol developed by Professor Multhoff’s group at Technische Universität 
München [531]. Carboxyfluorescein (CF-) labelled 14-mer peptides TKDNNLLGRFELSG and a 
‘scrambled’ peptide having an identical amino acid composition, but different sequence 
(NGLTLKNDFSRLEG) at a purity >97% were obtained from EMC microcollections (Tübingen, 
Germany). Lyophilized peptides were reconstituted to a stock concentration of 1 mg/ml using 
distilled water and stored at 4°C for a period of no more than two weeks following 
reconstitution.  
2.5.1 Production of granzyme B 
Recombinant human granzyme B was generated in Professor Multhoff’s laboratory at the 
Technische Universität München following an established protocol [531], as follows. 
2.5.1.1 Transfection of HEK293 cells 
A vector construct of His-tag joined to the human granzyme B gene via an enterokinase 
domain was developed and transfected into Human Embryonic Kidney 293 (HEK293) cells. The 
transcript also included the Sh ble gene which confers resistance to zeocin, a copper-chelated 
glycopeptide antibiotic (InvivoGen, USA) [545, 546], to act as a selection marker for those cells 
successfully transfected. Cells were frozen in FCS containing 10% v/v DMSO and stored under 
liquid nitrogen until required. Although these details are provided for completeness of the 
method, the transfection procedure was actually undertaken by members of Professor 
Multhoff’s laboratory at Technische Universität München.  
2.5.1.2 Defrosting and cellular expansion 
The transfected HEK293 cells were defrosted quickly and washed in 50mL ice cold growth 
medium (RPMI 1640 containing 5% v/v FCS, 6mM ι-glutamine, 1mM sodium pyruvate, 
100IU/mL penicillin and 100μg/mL streptomycin) by centrifugation at 300g for 5 minutes then 
resuspended in growth medium containing 300μg/mL zeocin. Successful transfection means 
that cells possess the Sh ble gene which confers zeocin resistance, therefore the addition of 
zeocin into the growth medium allows for selection of transfected cells. All cells were added to 
one T75 flask and allowed to rest until confluent (typically around 3 days). After this time, cells 
were harvested with trypsin and all cells were reseeded into 2 x T162 flasks, again in growth 
medium supplemented with 300μg/mL zeocin. Cells were left until confluent (typically another 
3-4 days), at which time they underwent another expansion, this time into 5 x T162 flasks. 
From this point onwards, cells were left in growth medium without the addition of zeocin. 
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After 3-4 days, when cells have once again reached full confluency, they were expanded for 
the final time into 20 x T162 flasks. Once they were approximately 80% confluent (after 2 
days), the medium was removed and cells were washed once gently with 10mL PBS. From this 
point onwards, only unsupplemented OptiMEM medium (Life Technologies) was used. Each 
flask received 25ml of OptiMEM medium and was returned to the incubator. The supernatant 
was harvested for processing as described below every 3-4 days, with the flasks being 
replenished with fresh OptiMEM on each occasion. The harvesting of supernatants could be 
conducted up to four times before the cells began to detach in sufficient numbers to 
negatively impact on the production of granzyme B. 
2.5.1.3 Processing the supernatant 
Twenty T162 flasks typically generated 500mL of supernatant and this had to be processed 
immediately. Supernatant was decanted into 250mL Falcon tubes (BD Biosciences) and 
centrifuged at 500g for 7 minutes in order to ensure removal of cellular debris. Supernatants 
from all tubes were combined for use in the next stage of the purification process. A small 
aliquot (1mL) was taken and stored at 4oC to allow later analysis as to the presence and 
activation status of granzyme B. Imidazole (Sigma Aldrich) was added to the supernatant, to a 
final concentration of 20mM. Supernatant was then sterile filtered using a Surfactant-Free 
Cellulose Acetate (SFCA) filter (Nalgene) and another small aliquot (1mL) was saved for use 
later in protein determination and granzyme B activation assays.  
 
The granzyme B was purified using an Äkta-prime automated liquid chromatography system 
(GE Healthcare Life Sciences). After the system has been washed with 20% v/v ethanol 
followed by distilled water, a HisTrap™ FF Nickel column (GE Healthcare Life Sciences) was put 
in place and prepared with Nickel Column binding buffer (20mM TRIS, 20mM imidazole, 
500mM NaCl; pH 8.0, 4oC). An aliquot was saved (time point C, 1mL) then the supernatant was 
applied through the column. Granzyme B binds to the column via the his-tag, whilst other 
proteins pass through to the waste. Although other proteins which contain available histamine 
residues may also bind, these are removed in a subsequent purification (see later). Once the 
supernatant had been processed, 35mL of NC binding buffer was also applied to the system in 
order to ensure that all of the supernatant has passed through the column. To elute the 
granzyme B an increasing concentration of Nickel Colum elution buffer (20mM TRIS, 500mM 
imidazole, 500mM NaCl; pH 8.0, 4oC) was applied to the column, by way of a linear gradient 
beginning with 100% Nickel Column binding buffer: 0% Nickel Column Elution Buffer and 
finishing with 0% Nickel Column binding buffer: 100% Nickel Column Elution buffer after 80ml. 
The gradient was eluted into 4ml fractions (i.e. 20 fractions in total). Previous experiments 
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have found the granzyme B to be eluted in fractions 8-15. After elution, the system was 
washed first with distilled water and then with 20% v/v ethanol. The eluted fractions are stable 
at 4oC and were stored until all supernatant harvests were complete (typically two-four 
weeks). 
2.5.1.4 Determination of granzyme B content in eluted fractions 
Multiple assays were used to determine the overall protein content of the fractions, as well as 
confirm which fractions contained granzyme B.  
2.5.1.4.1 Bicinchoninic Acid  
A Bicinchininic Acid (BCA) Protein Assay kit (Pierce) was used to determine the total protein 
content of each eluted fraction, and the assay was set up in accordance with the 
manufacturer’s protocol. From the kit, solutions A and B were diluted 49 parts A and 1 part B 
and then pipetted into a flat-bottomed 96 well plate (200µL per well). A standard curve was 
created by diluting bovine serum albumin (BSA) in distilled water. The standards, blank 
(distilled water) and samples were added to the plate, 25µL to each well as appropriate. The 
plate was incubated for 30 minutes at 37oC then analysed using a BioTek EL808 Plate Reader 
set to 533nm. The protein content of samples was calculated by reference to the standard 
curve. 
2.5.1.4.2 Bradford Assay  
The total protein content of the eluted fractions was also determined using a Bradford Assay. 
For this, Bradford Solution (Sigma Aldrich) was prepared by diluting 1 part of the stock solution 
in 4 parts distilled water. Any remaining working solution was stored at 4oC for up to two 
weeks. A standard curve was created using BSA diluted in distilled water, and water only was 
used as a blank. Bradford Solution pipetted into a flat bottomed 96 well plate (200µL per well), 
then 10µL of standards, water or elution fractions were added as appropriate. In the presence 
of proteins, the Bradford Solution turns from brown to blue. The colour change is immediate 
and the plate was read on a BioTek EL808 Plate Reader using 570nm wavelength. The protein 
content of each sample (µg/ml) was determined by reference to the standard curve.  
2.5.1.4.3 SDS-PAGE 
Polyacrylamide gels (5% w/v) were stored at 4oC for up to two weeks until required. To 
prevent the gels from drying out, they were wrapped in running buffer (25mM Tris, 192mM 
glycine, 0.1% v/v sodium dodecyl sulphate (SDS)) soaked paper towels inside sealed plastic 
bags. When ready to use, the gel was unpacked and loaded into the electrophoresis chamber. 
Running buffer was poured into the space behind the gel and into the base compartment, and 
the whole unit was cooled with flowing tap water. Based on the results from the BCA or 
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Bradford assay, only those fractions containing proteins were analysed by SDS-PAGE. The 
volume of each sample used provided 20μg of protein and was made up to 30µL with distilled 
water. This was mixed with 10µL bromide blue stain (Sigma Aldrich) which enables samples to 
be seen more easily when loading into the gel. Previously generated granzyme B of a known 
concentration was included as a positive control. Samples were then denatured by incubating 
on a heating block at 95oC for 10 minutes. Samples were then transferred to ice, then directly 
to a chilled centrifuge and pulsed up to 5000g twice in order to retrieve the evaporate into the 
sample. A rainbow ladder marker was used to show the position of proteins of known sizes. 
The ladder, fraction samples and positive control were pipetted into the wells and the current 
was applied to the unit. A maximum of 30mA per gel was applied, and the gel was run until the 
ladder was fully spread. It typically took 60-90 minutes and after this time the gel was used in 
either a Coomassie Blue stain or Western Blot, as detailed below. 
2.5.1.4.4 Coomassie Blue Stain  
Gels were stained using the Coomassie Blue Assay in order to provide insight into the purity of 
the preparation. For this, the stain was prepared as 30mL distilled water, plus 10mL methanol 
and 10mL Coomassie stain (5x stock, Biorad). The Coomassie stain required mixing for at least 
10 minutes prior to use, in order to ensure all of the particulates were resuspended. The gel 
was transferred into a suitable vessel, and 50ml of the prepared stain was poured to the side. 
Gentle agitation was applied to ensure the stain covered the gel, then the vessel was left on a 
plate shaker (40 rpm) overnight. Once the bands had developed then gel was transferred to a 
fresh vessel and washed twice in Coomassie Blue wash buffer (3 parts distilled water to 1 part 
methanol), by pouring 50mL into the vessel and returning to the shaker for 5 minutes. After 
washing, the gel was placed into stabilisation buffer (1.5M ammonium sulphate). In order to 
dry the gels for imaging and storage, they were placed into drying buffer (30% v/v methanol 
and 5% v/v glycerol in water) for 30 minutes then left at room temperature in a drying 
chamber made of the gel wrapping in distilled water-soaked cellophane sheets inside a plastic 
frame. Typically drying required around 48 hours. After this time the gels were removed from 
the frame, but kept in the cellophane, and stored at room temperature protected from light.  
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Figure 2.8 Coomassie Blue staining  
A Coomassie Blue stain is a visualisation tool, to determine the purity of preparations based on the number of 
visible bands. The grey box shows the expected position of granzyme B. A rainbow ladder (stock image of which 
shown in A) was used in the gels to help estimate the size of the proteins. B The gel itself was stained then dried 
before being digitally scanned. The rainbow ladder was always loaded into the first column and the image has been 
annotated with the molecular weights of each marker. Columns 2-9 contained consecutive eluted fractions, some of 
which are expected to contained granzyme B, which would be found in the area highlighted with the red box, 
between markers of 31 and 38 kDa. In this instance, columns 5-7 contained the largest amount of potential 
granzyme B. To aid with calculating the placement of proteins, a positive control was placed into column 10. This is 
a sample from a previously prepared batch of granzyme B.   
 
2.5.1.4.5 Western Blot 
Western blot analyses were used confirm the presence of granzyme B. After samples had been 
run through SDS-PAGE, the proteins were transferred to a polyvinylidene fluoride (PVDF) 
membrane (GE Healthcare Life Sciences) via a semi-dry Western blot protocol. The gel was 
removed from the SDS-PAGE unit, and soaked in PBS containing 0.1% v/v Tween for at least 5 
minutes. The PVDF membrane was cut to the same size as the gel, and four sheets of blotting 
paper were also soaked for at least 5 minutes in PBS-Tween (0.1% v/v). After this time, 
everything was placed in the semi-dry blotter with the gel placed on top of the membrane, and 
two sheets of blotting paper above and below, all carefully pressed to avoid air bubbles 
becoming trapped between any of the layers. The unit was closed and current applied (55mA, 
but limited to 50V) for 45 minutes. Next, the membrane was stained for the presence of 
granzyme B. For this, the membrane was washed in a 5% w/v solution of milk powder for 1 
hour in order to block potential non-specific staining. Next, the membrane was transferred 
into a solution of 1% w/v milk powder containing the unconjugated primary mouse anti-
human antibody recognising granzyme B (IgG2a, clone 2C5/F5 BD Biosciences, used at 1:2000) 
and left on a plate shaker overnight. The next morning, the membrane was washed three 
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times in PBS-Tween (0.1% v/v, 15 minutes, 5 minutes, 5 minutes) and then incubated in 1% 
w/v milk powder containing a horseradish peroxidase (HRP)-conjugated rabbit anti-mouse 
secondary antibody (Dako, used at 1:2000) for 1 hour at room temperature. After this time, 
the membrane was washed three times in PBS-Tween (0.1% v/v), each for 10 minutes. The 
membrane was briefly incubated in ECL (enhanced chemiluminescence) substrate (Pierce) for 
5 minutes, after which time the membrane was imaged via film exposure, conducted in a dark 
room and beginning with an exposure time of 15 seconds. After viewing the film development, 
the membrane exposure to film could be repeated with adjustments to exposure time as 
necessary. 
 
Figure 2.9 Representative Western blot for granzyme B  
A. Molecular weights and colours of each band in the ladder used. B. Western blot using aliquots from different 
steps in the granzyme B purification. The step decrease in size indicates the point at which the enterokinase 
cleavage occurs and the granzyme B is activated. 
2.5.1.5 Activation of granzyme B 
All fractions which contained granzyme B were pooled together, and an estimation as to the 
total protein content was made using the BCA and Bradford assays. Only fractions containing 
very high amounts of granzyme B, or those fractions which contained less, but were 
particularly pure, were taken forward. This meant that the total protein content could be used 
as an estimation of the total granzyme B content.  
Granzyme B is produced in an inactive form due to the attached histidine (His)6 tag,  which is 
linked via an enterokinase digestion site. By applying enterokinase and cleaving the (His)6 tag, 
the granzyme B becomes active. For this, granzyme B was transferred to a suitable buffer 
(enterokinase buffer; 50mM Tris-HCl, 1mM CaCl2, adjusted to pH 8.0) and concentrated to 
1.5mg/mL by centrifuging the pooled granzyme B fractions in Amicon Ultra tubes (Millipore) at 
14,000g for 10-12 minutes per 10mL of sample. After the granzyme B had been processed, 
enterokinase buffer was applied to the membrane and the centrifugation was repeated. This 
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ensured that all remnants of the NC Binding Buffer and NC Elution Buffer were exchanged with 
enterokinase buffer. Granzyme B was thoroughly resuspended from the membrane by 
pipetting and transferred to a 15ml Falcon tube and diluted to 1.5mg/mL with enterokinase 
buffer. Enterokinase (Life Technologies) was added at 1U per mg of granzyme B and the 
mixture was rotated for 16 hours at room temperature. 
 
The enterokinase digestion, and therefore activation of granzyme B, was confirmed using an 
activity assay. For this, 95µL of activation detection buffer (10mM HEPES, 140mM NaCl, 
2.5mM CaCl2, adjusted to pH 8.0) containing 200mM colorimetric granzyme B substrate Ac-
IEPD-ρNA (N-acetyl-Ile-Glu-Pro-Asp-ρ-nitroanilide, Merck KGaA) was added to 5µl of the 
aliquots taken at different time stages of the granzyme B purification procedure in flat-
bottomed 96 well plates. Previously generated granzyme B was included in the assay as a 
positive control, and enterokinase buffer alone was used as a blank. The plate was read in a 
BioTek EL808 plate reader, maintained at 37oC. Readings were made at 405nm every 5 
minutes to provide information regarding the kinetics of granzyme B activity. Once granzyme B 
activity was confirmed, the sample could be further purified.  
 
 
Figure 2.10 Granzyme B activity data  
Granzyme B is produced in an inactive form due to the addition of a (His)6 tag, which is joined by an enterokinase 
digest site and is only active following incubation with enterokinase, as confirmed in the increase in optical density. 
Granzyme B activity before and after incubation with enterokinase was assessed using a colorimetric activity assay. 
Five batches of granzyme B were used in this work, all exhibiting similar optical density results from the activity 
assay, showing that the activity of granzyme B generated following this method is highly conserved.  
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2.5.1.6 Heparin purification of granzyme B 
Following the activation of granzyme B it was necessary to remove the enterokinase from the 
preparation. This was achieved by conducting a second automated liquid chromatography step 
on the Äkta-prime system, this time using a HiTrap™ Heparin HP column (GE Healthcare Life 
Sciences) and exploiting the natural high affinity binding between granzyme B cationic binding 
sites and heparin. To begin, the system was primed with granzyme B Heparin Binding Buffer 
(binding buffer, 10mM Tris-HCl, 0.1M NaCl, adjusted to pH 8.0) and then the granzyme B 
preparation, diluted in binding buffer, was applied. The column was equilibrated by washing 
with 50mL binding buffer after which time granzyme B was eluted using an increasing 
concentration of granzyme B elution buffer (10mMTris-HCl, 1.5M NaCl, adjusted to pH 8.0) by 
way of a linear gradient beginning with 100% granzyme B heparin binding buffer : 0% 
granzyme B elution buffer and ending with 0% granzyme B herparin binding buffer : 100% 
granzyme B elution buffer over 20mLs and being separated into 20 elution fractions. Typically 
granzyme B is present in fractions 10-15. Fractions were assessed by protein determination 
assays (Bradford Assay and/or BCA), and those fractions containing protein further examined 
by Coomassie Blue and/or Western blot to confirm the presence of granzyme B cleaved from 
the His(6)-tag. The granzyme B activity assay was repeated in order to confirm that the heparin 
purification steps had not interfered with the granzyme B functionality. 
 
For long term storage, the granzyme B was put through a buffer exchange process. For this, 
granzyme B was centrifuged multiple times in 10kDa molecular weight cutoff Amicon Ultra 
tubes and at 14,000g, each time discarding the old buffer and resuspending the granzyme B in 
PBS. The granzyme B was resuspended at a final concentration of 1.5mg/mL and then sterilised 
by passing through a 0.22µm filter. After aliquoting into sterile microfuge tubes the granzyme 
B was stored at -80oC until required. 
 
2.5.2 Fluorescent labelling of antibodies and proteins 
The cmHsp70.1 mAb (and the alternative Hsp70 antibody clone C92F3A-5) and granzyme B 
were conjugated to the highly photo-stable fluorochrome ATTO-488 (excitation 488nm, 
emission 523nm) in house using the Lightning-Link labelling kit (Innova Biosciences) following 
the manufacturer’s instructions. BSA (as a control for granzyme B internalisation) was similarly 
conjugated. The antibody/protein to be labelled was diluted to be within the range 1-4mg/mL, 
to which was then added the Lightning-Link modifier reagent (1µL for every 10µL of 
antibody/protein). The solution was gently mixed by pipetting then transferred directly into 
the vial containing the lyophilised fluorochrome. The solution was gently mixed, after which it 
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was incubated at room temperature whilst protected from light. The minimum suggested 
incubation time is 3 hours and that was found to be suitable for both antibody and protein 
labelling. After the incubation period, Lightning-Link Quenching Solution was added (1µL for 
every 10µL of initial antibody/protein) which negates the necessity of further purification 
steps. The labelled product was stored at 4oC, protected from light.  
 
The TKDNNLLGRFELSG peptide and the scrambled NGLTLKNDFSRLEG control peptide were 
labelled with carboxyfluorescein during their synthesis. Fluorescein has relatively low 
photostability [547] and consequently is liable to photo-bleaching when exposed to extended 
periods of light (as experienced during confocal microscopy analysis). This was the reason for 
labelling the antibodies and proteins with the highly photo-stable ATTO488, and in the future 
this would be a consideration with the peptide.   
 
2.5.3 Capacity of granzyme B to kill membrane Hsp70 positive cells in vitro 
Tumour cell lines were assessed for their susceptibility to the human recombinant granzyme B. 
Previously published data have shown that granzyme B can induce apoptosis in CX-2 colon and 
Colo357 pancreatic carcinoma cell lines expressing memHsp70, even in the absence of perforin 
[530]. To investigate whether human breast cancer cell lines expressing memHsp70 at a variety 
of intensities also undergo apoptosis in response to granzyme B (both purified and 
fluorescently-labelled), cells were incubated for up to 48 hours in growth medium containing 
4µg/ml granzyme B. Cells were removed at different time points and analysed using two flow 
cytometry-based approaches for determining cellular apoptosis – the exposure of phosphatidyl 
serine on the plasma membrane (as detected on the basis of Annexin V staining) and the 
activation of caspase 3. Optimisation experiments demonstrated that the inclusion of serum 
hampered the uptake of granzyme B, and that the most efficient uptake occurred when cells 
were incubated with granzyme B in PBS (Fig 2.11). As PBS would not sufficiently maintain cells 
over a prolonged period of time the decision was made to incubate cells in PBS containing 
granzyme B for the first hour, then growth medium would be added to the cells for the 
remaining duration of the incubation.   
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Figure 2.11 Optimisation of granzyme B uptake protocol 
CT26 cells were incubated with ATTO488-granzyme B in growth medium, or beginning in PBS with the addition of 
growth medium after an hour. The uptake of granzyme B was more efficient when the incubation began in PBS. 
Cells incubated with ATTO488-BSA were used as control and did not show any uptake over time.  
 
Firstly, for Annexin V staining, cells were counted, and 1x105 cells washed in Annexin V Binding 
Buffer (PBS containing 10% v/v FCS, 1.0mM MgCl2 and 2.5mM CaCl2) before being centrifuged 
for 5 minutes at 400g. The supernatant was removed using a vacuum aspirator and cells were 
resuspended in 100μL of Annexin V Binding Buffer. Alexa Fluor 647 Annexin V (Biolegend) was 
added (5μL), and samples vortex mixed in order to ensure even distribution of the stain, after 
which samples were incubated for 15 minutes at room temperature whilst protected from 
light. Cells were then washed in Annexin V Binding Buffer and the supernatant aspirated 
before cells were resuspended in 250μL fresh buffer. Cells were transferred to 12x75 mm 
polypropylene tubes, stored on ice protected from light before being analysed by flow 
cytometry. Immediately before analysis, 10μL Propidium Iodide (diluted from stock 1:19, 
Sigma, UK) was added to allow identification, and exclusion, of any non-viable cells. Early 
apoptotic cells were defined as being Annexin V+ PI- and were calculated as a percentage of the 

























Duration of incubation (mins) 
4ug/ml grB (growth medium) 4ug/ml grB (PBS then medium)
4ug/ml BSA control
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The influence of granzyme B on the activation of caspase-3 (an instrumental molecule in 
cellular apoptotic pathways) was determined by flow cytometry using a Caspase-3 kit (BD 
Biosciences) and following the manufacturer’s protocol. For this, cells were counted and 
washed (400g, 5 minutes) in BD Cytofix/Cytoperm Fixation and Permeabilisation Solution (BD 
Biosciences), after which they were resuspended in BD Cytofix/Cytoperm Fixation and 
Permeabilisation Solution for 20 minutes to allow cell fixation. Cells were washed twice in BD 
Perm/Wash Buffer (BD Biosciences) and then resuspended in BD Perm/Wash Buffer containing 
the appropriate volume of caspase-3 antibody for the cell number and incubated for 30 
minutes at room temperature protected from light. Cells were washed in BD Perm/Wash 
Buffer again, transferred to 12x75 mm polypropylene flow cytometry tubes and put on ice 
protected from light until immediate analysis by flow cytometry. Cells expressing active 
caspase-3 are deemed to be apoptotic, and the proportion of positive cells was determined as 
a percentage of the whole population.  
 
2.5.4 Flow cytometric assessment of uptake into memHsp70+ tumour cells  
To ensure standardised practices, all cells were seeded in T75 flasks and grown for 48 hours 
prior to use in the uptake assessments. Seeding densities were selected based on the 
proliferation rate of the different cell lines and are detailed in Table 2.4. This resulted in cells 










Table 2.4 Seeding densities into T75 flasks 
To compensate for different growth rates, cell lines were seeded into T75 flasks at different densities which allow 
for a comparable level of confluency after 48 hours growth. The Table details the starting number of each cell line.  
 
After the 48 hour growth period, cells were gently washed twice with 10mL PBS then with 2mL 
trypsin-EDTA. Cells were incubated for 1-2 minutes at 37oC then 10mL of fresh growth medium 
was applied and gently pipetted over the cells in order to fully detach them from the flask 
surface. As it was necessary for the uptake assessment to be conducted in staining buffer in 
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order to block non-specific binding, cells were centrifuged (300g, 5 minutes), the supernatant 
was decanted and cells were resuspended in 1mL staining buffer. Cells were counted on a 
haemocytometer and viable cell number ascertained using trypan blue exclusion. For each 
condition (unstained, control or fluorescently-labelled molecule of interest), 0.5x106 cells were 
transferred into a 1.5mL microfuge tube. As the staining volume was required to be low, cells 
were centrifuged (300g, 5 minutes), the supernatant was vacuum aspirated, and cells 
resuspended in 20µL staining buffer containing fluoresecently labelled molecule of interest 
(cmHsp70.1 mAb, TKDNNLLGRFELSG peptide or granzyme B) or control molecule (C92F3A-5 
mAb, IgG isotype, NGLTLKNDFSRLEG peptide or BSA) as appropriate. Cells used as the 
unstained control were resuspended in 20µL staining buffer alone. Immediately after 
resuspension, a 2µL aliquot was removed as the ‘time 0’ measurement and placed into a 
12x75mm tube containing 3mL chilled staining buffer. Half of the remaining 18µL 
cell/molecule mixture was transferred into a clean, chilled 1.5mL microfuge tube and kept on 
ice and protected from light, and the original microfuge tube was incubated at 37oC. At each 
time-point (5, 15, 30 and 60  minutes), cells were gently mixed and a 2µL aliquot was 
transferred into a 12x75mm tube containing 3mL chilled staining buffer. Once transferred to 
12x75mm tubes, cells were centrifuged immediately (300g, 5 minutes, 4oC) then the 
supernatant was decanted and cells were resuspended in 250µL staining buffer. Tubes were 
kept on ice and protected from light until all time-points were completed, then analysed via 
flow cytometry. In order to exclude non-viable cells from the analysis, 10µL of 50µg/mL 
propidium iodide was added to each tube immediately prior to data acquisition. The median 
fluorescent intensity of cells was used as a measurement of the uptake of fluorescently-
labelled molecules. The use of control molecules can confirm the specificity of the uptake, 
whilst the two different temperatures allow for a comparison between binding (on ice) and 
uptake (occurs when the cells are metabolically active at 37°C).   
2.5.5 Confocal microscopic assessment of uptake of into memHsp70+ tumour cells  
For assessments involving confocal microscopy, cells were set up in 35mm glass bottom dishes 
(MatTek™ Corporation) and grown for 48 hours before staining. The seeding densities for each 
line are detailed in Table 2.5, and these were selected in order to ensure that all cell lines 












Table 2.5 Seeding densities for MatTek™ glass bottom dishes 
The total number of cells seeded into a single MatTek™ glass bottom dish is dependent on the rapidity of cell 
division, cell size and the propensity for cell aggregation/clumping. The seeding densities selected allowed for each 
line to be at approximately the same confluence after 48 hours, when cells were stained. 
  
After the cells have grown for 48 hours they were removed from the incubator, the medium 
was aspirated using a vacuum pump, after which cells were washed with 2mL chilled PBS 
which was also vacuum aspirated to ensure that no medium remained. The fluorescently-
labelled molecules (either cmHsp70.1 mAb, granzyme B protein or the TKDNNLLGRFELSG 14-
mer peptide, or the appropriate controls) were diluted in buffer and 100μL of this solution was 
added to the central well of the dish. Dishes were then replaced in the 37oC incubator for 5, 
15, 30 or 60 minutes. After this time, dishes were washed with 2mL PBS and all liquid was 
removed using a vacuum aspirator. To enable mounting onto microscopy slides, as well as 
subsequent intracellular staining when necessary, cells were fixed using 100μL of either 4% 
w/v paraformaldehyde (PFA) or ‘Solution A’ from a Fixation and Permeabilisation Kit (Life 
Technologies). Cells were incubated with the fixation solution at room temperature and 
protected from light for 15 minutes, then washed in 2mL staining buffer. If cells did not require 
further staining, then the coverslips were detached by soaking the base of the glass bottomed 
dishes in Cover Slip Removal Fluid (MatTek Corporation), by standing the dish in an inverted 
dish lid containing 750µL of the fluid. Although the manufacturer’s datasheet suggests an 
incubation time of 45 minutes, 25 minutes was found to be sufficient. The incubation was 
conducted at room temperature and the dishes were kept protected from light for the 
duration. After this time, excess fluid was removed by standing the dishes on paper towels and 
then the coverslips were removed by applying very gentle pressure with fine tipped forceps to 
the edge of the coverslip. There may be adhesive residue remaining on the coverslip which 
must be removed, as the best images will only be obtained when the coverslip lies as flat and 
close to the microscopy slide as possible. The easiest method of removing the residue is to 
scratch it carefully with a scalpel, taking care to avoid the adhered cells. Coverslips were then 
mounted onto polysine microscope slides (VWR International) that were pre-cleaned with 70% 
v/v ethanol and allowed to fully dry, using one of VECTASHIELD® Mounting Medium (Vector 
Laboratories) containing DAPI. Care was taken to minimise the creation of air bubbles, and 
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coverslips were sealed along all edges with clear nail varnish. Slides were stored at 4oC and 
protected from light until imaging could take place (not longer than 24 hours). If cells were to 
be used for further staining, this was carried out as described below. 
 
2.5.5.1 Confocal microscopic assessment – co-localisation of internalised cmHsp70.1 
mAb, granzyme B and TKDNNLLGRFELSG peptide with intracellular vesicles  
To study the pathway of uptake in more detail intracellular structures were also stained, and 
this required the cells to be fixed and permeabilised. The intracellular vesicles selected for 
examination were endosomes (early, late and recycling), lysosomes and mitochondria. As 
previous investigations have excluded the possibility of Golgi involvement, this range of 
markers was felt to provide a reasonable covering of the other possibilities.  
For this, cells were permeabilised and stained using 100µL solution B (Invitrogen 
Fix/Permeabilisation kit) containing the appropriate concentration of primary antibody for one 
intracellular structure of interest immediately after the fixation step (described in Table 2.6).  
 
 
Table 2.6 Primary antibodies used in confocal microscopy investigations 
Primary antibodies specific for a range of intracellular vesicles were used to help elucidate the intracellular 
trafficking pathway of molecules internalised through memHsp70. They were used in combination with appropriate 
secondary antibodies, specific for the species in which the primary was raised. The dilutions used were within the 
range suggested by the manufacturers.  
 
Cells were incubated at room temperature, again in the dark, for 20 minutes. After this time, 
cells were washed in 2mL PBS then stained with 100µL of an appropriate fluorescently labelled 
secondary antibody diluted in staining buffer as described in Table 2.7. Cells were incubated at 
4oC, again in the dark, for 20 minutes and then washed with 2mL staining buffer. Cells were 
then mounted onto microscopy slides as described below. 
Primary abs Raised in Specific for Dilution Supplier  
Rab4a Rabbit Early endosome 1 in 50 Santa Cruz Biotech 
Rab5a Rabbit Early endosomes 1 in 50 Santa Cruz Biotech 
Rab7 Rabbit Late endosomes 1 in 50 Santa Cruz Biotech 
Rab9 Goat Late endosomes 1 in 50 Santa Cruz Biotech 
Rab11 Goat Recycling endosomes 1 in 50 Santa Cruz Biotech 
LAMP1 Mouse Lysosomes 1 in 50 Biolegend 
LAMP2 Rabbit Lysosomes 1 in 50 Sigma Aldrich 







Table 2.7 Secondary antibodies used in confocal microscopy investigations 
The primary antibodies which required fluorescently-labelled secondary counterparts were all either raised in rabbit 
or goat. Two secondary antibodies were used, an anti-rabbit IgG polyclonal and an anti-goat IgG polyclonal both of 
which were conjugated to Cy3™. As only one intracellular vesicle was stained for at any one time, these secondary 
antibodies were never used together. 
2.5.5.2 Confocal microscopic assessment – co-localisation of internalised molecules 
with mitochondria 
Particularly when investigating the internalisation of granzyme B, another intracellular 
structure of interest was mitochondria. The co-localisation of internalised granzyme B with 
mitochondria could provide some insight into how apoptosis could be initiated. The staining of 
mitochondria was conducted in a different way as to the other intracellular structures. Instead 
of antibodies, mitochondrial-selective dyes were used. These are membrane permeable, so 
there is no need to permeabilise cells, although not all of the dyes can withstand fixation so 
the uptake and staining protocols had to be modified for these changes.  
 
However, mitochondrial staining proved to be more problematic. Fixation can affect the 
membrane potential of mitochondria, which can lead to loss of staining. Consequently, cells 
that are stained for mitochondria had to be imaged live, meaning that it was necessary to 
make some modifications to the uptake protocol. The mitochondrial staining is conducted at 
37°C, and as the cells are live they will be metabolically active during this time. It was not 
possible to conduct the molecule uptake and mitochondria staining concurrently, as different 
durations were required for each. The cells will remain metabolically active during the 
mitochondria staining, meaning that if the molecule uptake was undertaken first the cells 
could continue to traffic internalised molecules during the staining. Therefore the intracellular 
placement of internalised molecules would no longer represent that of the incubation time-
point, but a longer duration incorporating the time of the mitochondrial staining. To account 
for this, the order of the protocol was reversed, with the mitochondria staining preceding the 
incubation with the relevant fluorescently-labelled molecule (Hsp70 mAb, granzyme B, 
peptide).  
Cells were set up in 35mm MatTek™ glass bottom dishes as described previously in Table 2.5 
and grown for 48 hours. After this time the medium was aspirated and replaced with 
Secondary abs Dilution Supplier (specificity) 
Cy3 Goat anti-Rabbit 1 in 100 Jackson ImmunoResearch  
(IgG H+L) 
Cy3 Rabbit anti-Goat 1 in 100 Jackson ImmunoResearch 
(IgG H+L) 
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mitochondria stain. Two different mitochondrial stains were used, MitoTracker® Green (MTG) 
(Molecular Probes®, Life Technologies) and MitoID™® Red (Enzo Life Sciences).  
MitoTracker® Green is stored desiccated at -20oC, and reconstituted to 1mM in DMSO. The 
reconstituted preparation was stored in 15µL aliquots (to reduce the need for repeated freeze-
thaw cycles) at -20oC for up to 3 months. For cell staining, the MitoTracker® Green was diluted 
to 100nM in growth medium then 1mL was added to the dishes. Cells were incubated for 30 
minutes at 37oC then the MitoTracker® Green medium was vacuum aspirated and cells were 
washed three times with 1mL fresh growth medium.  
MitoID™® Red is supplied in the form of a kit and staining was conducted as per the 
manufacturer’s instructions. The suppliers do not provide information relating to the 
concentration of the reagent, and so the amounts used are stated in terms of dilutions. The 
MitoID™® Red dye is stored at -20oC and a working stock is prepared as a 10-fold dilution in 
DMSO. The working stock can be stored at -20oC for up to one month. For staining cells, the 
working stock is further diluted 50-fold in 1x assay buffer (prepared as a 10-fold dilution in 
deionised water of the supplied 10x assay buffer). MitoID™® Red was added to the cells, as 
500µL to the centre of the dish. Cells were incubated for 30 minutes at 37oC then cells were 
washed twice in 1x assay buffer. 
After the mitochondria staining was complete, cells were washed once with staining buffer to 
ensure removal of the mitochondrial buffer. Cells then received 100µL of the fluorescently-
labelled molecule (staining buffer containing fluorescently labelled cmHsp70.1, 
TKDNNLLGRFELSG peptide, granzyme B or one of the appropriate controls) and were 
incubated for 5, 15, 30 or 60 minutes at 37°C. After the incubation, cells were washed with 
1mL staining buffer which was vacuum aspirated to ensure complete removal. Cells were 
covered with fresh staining buffer and kept in a chilled box, to minimise any further metabolic 
activity, and protected from light, to prevent photo-bleaching of the fluorescent molecules, 
until imaging could take place.  Immediately prior to imaging the staining buffer was aspirated 
and cells were covered with PBS (to avoid background interference of the fluorescent imaging 
by serum). Cells were imaged within 1 hour of the molecule uptake incubation being 
completed. Imaging was conducted as quickly as possible as the environment within the 
chamber was not controlled and higher than the preferable 4°C.  
2.5.5.3 Confocal Microscopy Image Acquisition 
Samples were analysed using an Inverted Zeiss LSM 510 NLO, running Zeiss Browser software 
and equipped with an argon laser (capable of 458, 477, 488 or 514nm), two helium-neon lasers 
(one emitting at 543nm and the other at 633nm) and a mercury lamp for imaging DAPI staining 
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of the nucleus. A variety of objectives that are suitable for water or oil immersion were 
available, thereby allowing for the best possible imaging of cells either in PBS suspension or 
mounted in a suitable medium (such as VECTASHIELD®). The slides were laid upside-down in 
the imaging chamber, with the mounted glass coverslip closest to the objective. By altering the 
size of the pinhole situated before the photomultiplier detectors it is possible to control the 
depth of focus in the sample, essentially imaging thin slices of a single cell. The total height of 
the cell can be set into the mechanised controls and multiple scans of the same cell can be 
conducted, working from bottom to top, and these images can be reassembled in order to 
generate an overall picture of the entire cell and allowing accurate distinction as to the cellular 
localisation of the fluorescent signal. 
Multi-colour images can be obtained, although the set up works best with fluorochromes 
which are fairly well spread along the light spectrum. To minimise any potential spillover 
between markers, each laser was only used to excite up to one fluorochrome and, with the 
exception of transmitted light, every marker was detected in a separate scan of that particular 
cellular plane. The trade off with this approach was that the scan times for cells were vastly 
increased, which increased any potential for fluorochrome bleaching. The potential impact of 
this was assessed by repeating single plane images after producing full cell stacks in order to 
ensure that fluorescent intensities had not significantly dimmed or been lost. The excitation 
lasers and filters for emission data was specific to each individual experiment dependent on 
exactly which fluorochromes were in use, but followed the description in Figure 2.12 shown 
over. 
For every experiment, the images were taken by scanning full frame shots, but cycling through 
each colour individually. Using one excitation laser at a time, and an appropriate optical set up, 
removes the need for compensation. Before image analysis commenced, the laser power, 
detector gain, and amplifier offset were adjusted to fit the minimum and maximum 
measureable fluorescent intensity into the colour palette. As these measurements were set 
with each experiment, it means that the settings are not always identical, although the 
adjustments always serve to put the minimum and maximum values at the same level, 
meaning that all the images are comparable. Predominantly the confocal images are used to 
place internalisation of specific molecules through the cells and intensity is not recorded or 
analysed so any variation of actual intensities between samples is not important, however if 
the aim were to quantify the fluorescence this would need to be addressed. 
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Figure 2.12 Schematic diagram of confocal microscope set-up. 
Different combinations of optical filters and splitters are required to acquire data from different fluorescent 
markers. Each fluorescent marker is imaged on a separate track (an entire frame is scanned for the first colour only, 
then scanned again for the next colour, repeating for as many colours as necessary). This increases the time taken 
for a complete scan, but minimises the chance of any colour spillover. The filters can be switched as necessary 
between tracks, but they are set up to reduce the number of changes necessary within a scan. The set up below was 
found to work well for the imaging conducted here.  Components listed in brackets and marked with an asterix are 
required when imaging DAPI staining. These can be computer controlled so are switched automatically between 
tracks as necessary. This image has been adapted from the configuration control window screen on the LSM 510 
software (Carl Zeiss MicroImaging GmbH, Germany).  
 
Initially, cells were imaged using the 20x objective, with the pinholes fully open. This provided 
an overview and allowed those cells for closer imaging to be identified. This would be 
undertaken using the 63x objective, with the size of the pinhole being dependent on the 
specific experiment. Higher intensities of fluorescence required the use of a smaller pinhole in 
order to create clear images, whereas a larger pinhole maximised the capture of fluorescence 
signals when low levels were present. Specific information regarding pinhole sizes are provided 
in the Results. Each cell imaged with the 63x objective was imaged as a z-stack, with single 
images taken in different planes throughout the cell. When setting up, the focus was adjusted 
to find the top and bottom of the cell, these stage heights are stored in the software and the z-
stack is performed over the distance. The thickness of the plane slices is determined by the 
size of the pinhole – with a larger pinhole leading to a thicker slice and vice versa. The software 
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automatically overlaps the slices slightly in order to better enable subsequent 3D 
reconstruction of the images.  
 2.5.6 Confocal Microscopy Image Analysis 
After consideration of the other options available, ImageJ (http://imagej.nih.gov/ij/) was 
selected as being the most suitable image analysis tool for this project. ImageJ is freely 
available in the public domain, and plugins which cover a wide range of additional applications 
available are available to download. It is possible to save any changes into the lossless 
compression .tiff format (a small file size, but all information remains). Any image 
manipulations/analyses were conducted on duplicated files so that the original always 
remained intact as a backup. The false colour overlays can be adjusted with ease and there are 
many powerful analysis tools built in to the program. 
 
All images analysed were subjected to adjustment of brightness and contrast, beginning with 
the ‘auto’ suggestions for settings and fine adjustments to reduce the background noise. All 
fluorescent channels, as well as the brightfield channel, were adjusted before further analysis 
could take place. Careful consideration was taken to ensure that any manipulations only 
enhanced the clarity of the original image. 
 2.5.6.1 Making composite images 
One of the difficulties of confocal imaging is that the natural consequence of restricting the 
height of the cell from which data are obtained is that the amount of fluorescence available in 
any one frame is also restricted and images can therefore be dim. ImageJ was therefore used 
to combine multiple slices of the same z stack together in one single composite image in some 
of the images during the post-acquisition analysis in order to compensate for this. These 
composites were saved as separate .tiff files, which could be reanalysed in ImageJ if necessary. 
Where composites have been shown instead of single images, this is stated in the figure 
legend. 
2.5.6.2 Red to magenta change 
Colour blindness affects approximately 10% of a Caucasian male population, with by far the 
most frequent affliction being the difficulty to distinguish red and green. Owing to the large 
distance between these two on the light spectrum, fluorochromes that emit in these regions 
are often used in combination as they require very little or no compensation. The detectors in 
the confocal microscope record intensity of received light, rather than an actual colour, but for 
ease, and in the case of multi-colour images necessity a false colour overlay is applied to the 
results of each of the detector channels. 






Figure 2.13 Colour blind considerations for image presentation 
The vast majority of multi-colour images presented or published make use of a red/green/blue colour combination 
which leads to dichromatic and trichromatic colour blindness sufferers being unable to make distinctions between 
some of the colours. When looking for colocalisation this is highly important. However, by using a magenta overlay 
in the place of a red one, all colours are easily distinguished by sufferers and those of normal sight, as demonstrated 
by the above reconstructions of how different colours are viewed by sufferers of different conditions.  
 
Tradition dictates that the choice of false colour overlay mimics the emission wavelength of 
the fluorochrome as closely as possible, a consequence being that red and green are often 
presented – this poses a problem for people with red-green distinction difficulties. In fact, 
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three-colour microscopy images are not unusual and the typical third choice for colour overlay 
is blue. These three colours in combination means that sufferers of all forms of dichromatic 
and trichromatic colour blindness will be unable to distinguish two of the colours presented. A 
solution has been suggested – abandon the red overlay and use magenta instead. This one 
simple change to traditional practice would mean that three colour microscopy images can be 
distinguished by sufferers of all types of dichromatic and trichromatic colour blindness (Fig 
2.13). There is also monochromatic colour blindness, but as this means that the sufferer can 
distinguish no colour at all, as opposed to having a deficiency at only some point in the 
spectrum, there is no solution to presenting multicolour images for these individuals. The 
colour change from red to magenta can be easily accomplished in ImageJ by highlighting the 
colour channel of interest and selecting ‘magenta’ from the Lookup Table drop down menu. 
 
2.5.6.3 Quantification of image data 
The distinct fluorescent spots relating to the internalisation of the cmHsp70.1 mAb, granzyme 
B and the peptides were counted manually. The spotted pattern of internalisation, indicating 
vesicular association, particularly lent itself to quantification in this manner. Cells were 
quantified over each frame of the z-stack, and any fluorescent spots present in multiple frames 
were counted in the one containing the greatest intensity. All frames from the adherent 
surface to the cell’s apex were included.  
 
Although other quantification approaches would have been useful, the nature of the confocal 
microscopy images does not allow these to be applied. Without having appropriate control 
measures to standardise the fluorescence obtained on different days it was not practical to 
attempt to quantify the fluorescent intensity. Although calculating the area of the fluorescence 
relating to the internalised molecules (cmHsp70.1 mAb, granzyme B, peptide, as appropriate) 
would have been a useful measurement, the nature of the confocal data made this impractical. 
Adjusting the brightness and/or contrast of the images also resulted in modifications to the 
size of the fluorescence spots. Without the ability to standardise the fluorescence across 
images acquired on different days, it is not possible to accurately compare spot size.  
2.5.6.3.1 Quantifying molecule distribution 
On examination, the fluorescence throughout the cell appeared to be asymmetric, and this 
was examined by counting spots at different vertical levels. As the dimensions of cells varied 
within an experiment and between cell lines, relative, rather than absolute, distances from the 
adherent surface was used as a parameter. The data were examined in two different ways. 
Firstly scatter plots of spot count against percentage distance, with every cell represented as a 
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single line. Secondly, each cell was separated into quartiles of height and the total spot count 
in each quartile was calculated.    
2.5.6.3.2 Co-localisation analysis 
The co-localisation of cmHsp70.1 mAb, granzyme B, and peptides with intracellular vesicles 
was also examined. For this, cells were incubated in the presence of the fluorescently 
conjugated molecules for a range of time points, at which time cells were stained using 
antibodies specific for endosomal or lysosomal markers, or using a mitochondrial dye. 
Colocalisation analyses were then performed on the microscopy images to confirm whether 
the molecule of interest was present in the same location as the vesicular staining. There is no 
definitive method of quantitating the extent of colocalisation. Rather, there is a wide selection 
of different equations, all requiring different assumptions to be made about the data. It was 
therefore necessary to assess which statistics are the most appropriate for the dataset. 
Preferably more than one statistic should be used, as this will provide a more robust 
description of the data. 
 
Herein, both the Pearson’s coefficient and Manders’ M1 & M2 coefficients [548] were 
calculated. The Pearson’s coefficient provides a description of the correlative variance 
between two colour channels. The output value can be anywhere between -1 (a perfect 
negative correlation) and 1 (a perfect positive correlation). If there is no relationship between 
the two channels, the value will be 0. The Manders’ M1 & M2 coefficients provide a measure 
of the proportion of one channel which overlaps the other, thereby providing information 
about each channel separately (M1 describes the proportion of channel A which overlaps with 
channel B, and vice versa for M2). As the output describes a proportion, values are only 
possible between 0 and 1.  
 
All co-localisation statistics were calculated using the ‘Just Another Co-localisation Plugin 
(JACoP)’ add-on for ImageJ [549]. For this, a region of interest was drawn around additional 
cells within the frame of view and the surrounding area was cleared to match the colour of the 
background. The image was split by colour channel, brightness/contrast adjustments were 
performed and up to one noise reduction algorithm was conducted as necessary. Images were 
loaded into the JACoP program and the threshold levels were adjusted as required. One 
benefit to using this plugin is that co-localisation statistics can be calculated as a total across all 
frames within the stack, giving a more accurate description of what is occurring in the entire 
cell.  
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 2.5.7 Limitations  
In most respects, confocal microscopy provides distinctly different analytical approaches to 
flow cytometry. The data acquisition is highly labour intensive with the possibility to obtain 
data on only a small number of cells. However, the data that are obtained are highly 
informative with regards to special information and the co-localisation of the molecules of 
interest with other cellular features. For example, it can show how a specific marker is 
clustered or spread over the cell surface, or how it sits intracellularly. Especially useful is how 
co-localisation of multiple markers can be used to show, for example, in which intracellular 
compartments lays a fluorescently labelled marker of interest after a certain incubation time.  
2.6 Membrane Hsp70 expression on lymphocytes?  
The vast majority of published literature demonstrates the presence of memHsp70 on tumour 
cells but not on healthy tissue. In fact there is only one published paper that has reported any 
expression of memHsp70 on non-tumour cells, which was that peripheral blood lymphocytes 
in healthy individuals showed 10.4% expression of memHsp70 compared to a mean of 35.2% 
in three individuals with juvenile idiopathic arthritis. It is difficult to infur too much from this, 
since the authors made no use of the C92F3A-5 Hsp70 antibody and therefore the reported 
‘memHsp70’ may in fact turn out to be Hsp70 which has bound to the surface of the 
lymphocytes. If indeed, memHsp70 is expressed at all on lymphocytes then this may provide a 
mechanism for Treg-mediated suppression.  One way by which Treg cells exert suppression on 
other lymphocytes is through the release of granzyme B. Although this occurs alongside 
perforin in cytotoxic vesicles, granzyme B can also be taken up by memHsp70 so any 
expression on lymphocytes would increase the possibility of granzyme B-induced, Treg-
mediated cell death. 
In addition, the expression of memHsp70 is not static and its expression on the surface of 
cancer cells can be upregulated by a variety of chemotherapeutic agents and radiotherapy 
[290, 519, 520]. Furthermore, evolving data suggest that the tumour microenvironment can 
impact on the phenotype and function of systemic and localised immunity. As yet, no studies 
have investigated the potential influence of the tumour microenvironment on the possible 
induction and/or upregulation of memHsp70 on lymphocytes, and if this occurs whether it 
exhibits any functionality which is consistent with its expression on tumour cells. If indeed 
memHsp70 can be induced on lymphocytes, and memHsp70 serves as a conduit through which 
granzyme B can pass into cells and induce apoptosis, then employing granzyme B as a 
treatment for memHsp70 tumours could in turn lead to adverse influences on the 
development of effective, protective anti-tumour immunity. Although this is unlikely given the 
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fact that lymphocyte populations express high levels of natural inhibitors such as SerpinB9, the 
possibility should be examined. 
2.6.1 Volunteers and Ethics 
Healthy volunteers were recruited from the University of Sheffield Medical School at the Royal 
Hallamshire Hospital, Sheffield. Donors were required to be over 18, generally fit and well, and 
not to have taken any medication within the previous week. Volunteers were given an 
information sheet prior to giving blood and were given the opportunity to ask any questions 
they had regarding the study or blood taking procedure. If the volunteers were happy to 
proceed, they were asked to sign a consent form. All volunteers were aware that they could 
withdraw from the study at any time, even after having given consent. The study was granted 
ethical approval by the Sheffield University Ethics Committee (SMBRER109). 
Blood was obtained by venepuncture and blood was collected into Lithium-Heparin (Li-Hep) 
BD Vacutainer® tubes (BD Biosciences). Tubes were gently inverted twice and kept at room 
temperature until required (typically for 10 minutes and not longer than 30 minutes). 
Volunteers were observed for a few minutes after giving blood to be sure of no adverse 
effects. All volunteers were provided with contact details should they wish to discuss anything 
after their donation.  
In order to assess whether the conditions found within a tumour microenvironment could 
affect membrane expression of Hsp70 in lymphocytes, peripheral blood mononuclear cells 
(PBMCs) were isolated from whole blood and subjected to the treatments described below. 
After treatment, the PBMCs were stained with a range of fluorescently-labelled antibodies to 
allow for flow cytometric analysis of cell subset, activation status and Hsp70 expression. 
2.6.2 Expression of memHsp70 on lymphocytes in peripheral blood 
The first assessment of memHsp70 was conducted ex vivo on lymphocytes in peripheral blood 
samples. As the blood samples were generally used for multiple experimental setups time 
constraints meant that the blood could not be stained immediately. Instead, 1mL was 
aliquotted from the Li-Hep BD Vacutainers® into sterile 7mL bijous containers and kept on ice 
until staining could take place (no longer than 3 hours from the time of the blood donation).  
The phenotype and activation state of cells in whole blood and isolated PBMCs was 
determined using a panel of fluorescently labelled mAbs (Table 2.8).  
2.6.2.1 Whole blood staining  
Whole blood samples were stained directly in 12x75 mm polypropylene flow cytometry tubes, 
using 50μL whole blood per tube. Prior to staining, samples were incubated for 10 minutes at 
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room temperature with mouse serum (2% v/v) in order to prevent potential non-specific 
antibody binding. Both unstained and isotype controls were always included. The monoclonal 
antibodies and isotypes were added as described in Table 2.9 along with 10μL staining buffer 
(PBS containing 10% v/v FCS) containing Blue Live/Dead Fixable Dead Cell Stain (Molecular 
Probes, USA). Cells were vortex mixed and then incubated at 4oC protected from light for 30 
minutes. 
 
Table 2.8. Antigens of interest for the phenotypic analysis of whole blood and PBMCs. 
Cells populations were determined on the basis of CD3, CD4, CD8 and CD56 expression, and assessed with regards 
to memHsp70 and cellular activation (using CD69 and CD25). Phosphatidylserine expression enabled apoptotic cells 
to be excluded.  
Antigen Description Clone  
CD3 The TCR co-receptor, expressed by all T cell 
subpopulations. Formed of four distinct chains (CD3γ, 
CD3δ and two CD3ε). Comprises the TCR complex 
together with CD3ζ (also known as CD247) and the TCR 
which allows signal transduction and cellular activation.  
UCHT1, specific for an 
epitope with CD3ε 
 
CD4 CD4 is a member of the immunoglobulin superfamily 
and has four immunoglobulin domains, designated D1-
D4. It interacts with the β2-domain of MHC Class II 
through D2. It is found on the surface of T helper cells as 
well as regulatory T cells.  
RPA-T4, specific for 
the D2 domain  
CD8 CD8 is a transmembrane glycoprotein which acts as a 
co-receptor for the T cell receptor and binds to MHC 
Class I. It is expressed on the surface of cytotoxic T cells.   
RPA-T8 
CD56 CD56 is a single transmembrane glycoprotein known 
also as N-CAM (Neural Cell Adhesion Molecule). It is 
involved in cellular adhesion, capable of binding to itself 
(homophilic) and to heparin sulphate (heterophilic) 
binding and is expressed by NK and NK-T cells. 
MEM-188 
Hsp70 When Hsp70 is expressed within the plasma membrane, 
the bulk of the protein remains intracellular whilst the 
substrate binding domain is in an extracellular position. 
This form of Hsp70 has been documented on tumour 
cells, and its expression can be upregulated in response 
to a variety of stresses, although its expression on 
healthy lymphocytes is unknown. 
cmHsp70.1 and 
C92F3A-5 (specific for 
different epitopes 
within the substrate 
binding domain) 
CD69 CD69 is a type II transmembrane protein, sometimes 
called very early activation antigen (VEA). Presence of 
CD69 indicates cellular activation on T cells, B cells, NK 
cells, neutrophils and eosinophils. 
FN50 
CD25 CD25, also known as low affinity IL-2 receptor α chain, is 
a type I transmembrane glycoprotein, expressed on the 
surface of activated T cells, B cells, macrophages and 
monocytes. It is also constitutively expressed on 




PS is a phospholipid component of the plasma 
membrane. In viable cells it is restricted to the 
intracellular side of the membrane, but becomes 
exposed on the extracellular surface when cells become 
apoptotic.   
4B6 











Table 2.9 Fluorescently-labelled reagents used in flow cytometric analyses. 
Details of the antibodies used in flow cytometric analyses. For each antibody the antigen recognised is given, the 
fluorochoromes used (for some antibodies multiple fluorochrome conjugates were used, in order to form 
spectorally compatible multi-antibody panels depending on the staining being conducted), the laser of excitation, 
the channel for emission detection and the volumes used in each staining procedure.     
 
After this time, samples were washed with 3mL chilled staining buffer and centrifuged (300g, 5 
minutes, 4oC). The supernatants were decanted and cells resuspended by gentle agitation of 
the tubes. Erythrocytes were lysed using BD Lysis Buffer (BD Biosciences) which was diluted to 
a 1x working solution from the stock (nine parts distilled water and one part Lysis Buffer Stock 
Solution). This working solution was stored at room temperature in glass bottles for up to 1 
month. For the lysis itself, 2mL working solution lysis buffer was added to each tube and then 
well mixed by vortexing. Cells were stored at room temperature protected from light for 20 
minutes then centrifuged (300g, 5 minutes, 4oC). The supernatant was decanted and cells were 
washed twice with 3mL staining buffer and centrifuged as before. Finally, cells were 
resuspended in 250μL staining buffer before being analysed by flow cytometry.  
 2.6.2.2 Activation of lymphocytes in whole blood 
The potential influence of polyclonal activation on the expression of membrane Hsp70 by CD4+ 
T cells, CD8+ T cells and CD56+ NK cells in whole blood was determined by activating cells with 
the polyclonal mitogenic lectin Concanavalin A (ConA). For this, whole blood was diluted 1:4 
with growth medium containing ConA (5µg/ml final concentration, #C5275 Sigma) and 
cultured for 24 hours in 96-well plates (200µl/well) in a humidified incubator at 37°C. As a 
control, blood was incubated for 24 hours after being diluted with medium in the absence of 
ConA. The contents of each well were then transferred into 12x75mm polypropylene tubes 
and washed with staining buffer (PBS containing 10% v/v FCS) then centrifuged (300g, 5 
Antigen Fluorochrome Excitation laser and 
detector channel 
CD3 QDot605 
Alexa Fluor 700 
Blue 610/20 
Red 730/50 
CD4 Pacific Blue Violet 450/50 
CD8 V500 
Alexa Fluor 700 
Violet 550/50 
Red 730/50 
CD56 Phycoerythrin Blue 575/26 




CD69 PE/Cy7 Blue 780/60 
CD25 PerCp/Cy5.5 Blue 695/60 
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minutes). The supernatant was decanted to leave approximately 50µl of sample and this was 
stained for memHsp70 expression as described previously. 
 2.6.3 Expression of memHsp70 on isolated peripheral blood mononuclear cells 
(PBMCs)  
Whole blood samples were not suitable for examining all of the treatments that were used in 
order to reflect elements of the tumour microenvironment. For these experiments PBMCs 
were isolated from whole blood using density gradient separation and exposed to range of 
different conditions. The influence of these conditions on membrane Hsp70 expression was 
then determined by multi-parameter flow cytometry. 
 2.6.3.1 Isolation of PBMCs 
PBMCs were isolated by density gradient, either with NycoPrep™ 1.077 (Axis-Shield PoC AS, 
Norway) or Lymphocyte Separation Medium LSM 1077 (PAA Laboratories GmbH, Pasching, 
Austria). Blood samples were diluted 1:1 with PBS and the diluted blood carefully layered onto 
the density gradient medium of choice (3mL blood mixture onto 6mL NycoPrep™ 1.077 in 
15mL conical tubes or 8mL blood mixture on 8mL LSM 1077 in 25mL conical tubes), after which 
samples were centrifuged (400g for 30 minutes when using NycoPrep™ 1.077 and 1200g for 20 
minutes when using LSM 1077) at 4oC with no brake applied. The PBMCs at the interphase 
layer were harvested using a Pasteur pipette and transferred into 25ml tubes, with no more 
than 5mL in one tube. In order to ensure removal of platelets, and thus reduce the potential 
for cell clumping within the preparation and also the possible effects of platelet-derived 
growth factors (which can inhibit the functional capacity of PBMCs) on the responsiveness of 
PBMCs, a second density gradient isolation step was performed. For this, the density medium 
was diluted 1:3 with phosphate buffered saline (PBS) to create a relative density of 1.068. This 
was then layered underneath the cells using a 21G needle and 20ml syringe. The samples were 
then centrifuged again, this time for 15 minutes. The change in density means the PBMCs will 
form a pellet and the platelets will collect at the interphase layer. To retrieve the PBMCs, the 
supernatant was decanted and the cell pellet was resuspended in 10ml PBS. Cells were washed 
twice in PBS (300g, 5 minutes, brake on) then resuspended in 1ml of complete growth medium 
prior to undertaking a viable cell count using a haemocytometer on the basis of trypan blue 
dye exclusion. Cells were then used for staining of memHsp70 expression or to set up 
treatments to investigate the possibility of memHsp70 induction. 
 2.6.3.2 Staining of PBMCs 
The same panel of mAbs were used to stain PBMCs as were used in the whole blood samples 
(Table 2.8). PBMCs (1.5x106) were placed into microfuge tubes and washed with 1mL of 
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staining buffer (PBS + 10% v/v FCS + 1.0mM MgCl2 + 2.5mM CaCl2) by centrifugation at 300g 
for 5 minutes at 4oC. The supernatant was aspirated and the cells resuspended in 100µL 
staining buffer containing 7.5µL Alexa Fluor 647-conjugated Annexin V (Biolegend). After 
vortexing, the cells were incubated at room temperature for 20 minutes. The cells were 
washed in 1mL staining buffer and centrifuged at 300g for 5 minutes at 4oC. After aspiration of 
the supernatant, cells were resuspended in 10µL of staining buffer and 1µL mouse serum and 
incubated at 4oC for 10 minutes before the addition of fluorescently-labelled antibodies. The 
total volume of suspension was made up to 50µL with staining buffer containing Blue 
Live/Dead Fixable Dead Cell Stain (Molecular Probes, USA), and the cells were incubated at 
4oC, protected from light, for 30 minutes. Cells were then washed with 1mL staining buffer and 
centrifuged at 300g for 5 minutes at 4oC and supernatants were aspirated. 
 
If the sample was to be analysed for intracellular expression of Hsp70, then the cells were 
resuspended in 50µL Fix/Perm Solution A (Life Technologies) and incubated at 4oC for 20 
minutes. The samples were then washed in staining buffer (1mL, centrifugation at 300g for 5 
minutes) before being resuspended in 50µl Fix/Perm Solution B (Life Technologies) and the 
C92F3A-5 anti-Hsp70 mAb, and incubated at 4oC for 20 minutes. The samples were then 
washed one final time with staining buffer (1mL, centrifugation at 300g for 5 minutes). All 
samples were washed once with PBS (300g, 5 minutes) and then resuspended in 200µL PBS 
with 100µL CellFix™ (BD Biosciences), mixed well and transferred into 12x75mm polypropylene 
tubes. Cells were stored at 4oC, protected from light, until flow cytometric analysis could be 
conducted. 
2.6.3.3 Influence of non-lethal heat 
It is well documented that heat stress upregulates the expression of intracellular Hsp70 as well 
as upregulating the expression of memHsp70 on tumour cells [287]. However, it is not known 
whether heat stress can induce memHsp70 expression on lymphocytes. To investigate 
whether increased temperature can induce expression of memHsp70, isolated PBMCs were 
incubated at an above optimal temperature environment and then stained for memHsp70 
expression as described previously. To set up the incubation, 1x106 PBMCs suspended in 1mL 
growth medium were placed in 12x75mm polypropylene tubes then incubated in a 
temperature controlled water bath at 42°C for 2 hours. This duration was selected as it was 
sufficient to induce a peak in expression of intracellular Hsp70 whilst remaining non-lethal to 
the lymphocytes (see Fig 2.14). After this time, cells were centrifuged (300g, 5 minutes), the 
supernatant was decanted and cells were resuspended in 1mL fresh medium before being 
placed into the 37°C incubator to recover for a period of 2 hours (short recovery) or 22 hours 
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(long recovery). After the recovery period, cells were stained for memHsp70 expression as 
previously described. 
 
Figure 2.14 Intracellular Hsp70 response to heat stress  
Intracellular Hsp70 content is stable under optimal incubation conditions (37°C, dashed line), but is increased in 
response to incubation at 42°C (solid line). This increase peaks after 2 hours and then remains stable. For longer 
durations (18-24 hours), incubation at 42°C is lethal. Data are presented as mean ± SEM, n = 3. 
2.6.3.4 Influence of polyclonal activation 
The effect of activation on the expression of memHsp70 by lymphocytes was assessed in two 
ways, firstly using ConA and secondly using polystyrene beads coated with anti-CD3 and anti-
CD28 mAbs. These beads polyclonally activate cells by binding to the T cell receptor (via the 
anti-CD3 mAb), and the binding of the anti-CD28 mAb mimics the delivery of essential co-
stimulatory signals that are delivered by APCs. This mode of activation closely mirrors the 
physiological events that occur following cell activation by APCs.  
 
To activate using ConA, PBMCs were suspended in medium containing 5μg/mL ConA and 
placed into 12x75mm polypropylene tubes (1x106 PBMCs in 1mL). Cells were incubated for 24 
hours at 37°C before being stained for memHsp70 expression as described earlier. For the 
second method, two different activation beads were used, Dynal Expander beads (Life 
Technologies) and Suppression Inspector beads (Miltenyi Biotec). Dynal Expander beads 
deliver a more potent stimulatory signal, as they are coated with a higher concentration of 
mAbs, and so comparing the effects of both bead populations should enable any correlation 
between the degree of cell activation and membrane Hsp70 expression to be assessed. Control 
(unstimulated) samples were cultured without beads. For the culture, 1x106 PBMCs were 
placed in 12x75mm polypropylene tubes and suspended in 1ml of medium at a 1:1 ratio with 
one or other of the beads. Cells were mixed thoroughly and then incubated at 37°C for 24 
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hours. After this time the cells were agitated to aid disruption of the bead binding. The beads 
are magnetic so samples were placed into a magnetic rack and once the beads had aggregated 
the supernatant containing the cells was transferred into a fresh tube. Cells were then stained 
for memHsp70 expression as described previously.  
 2.6.3.4.1 Influence of supernatant derived from polyclonally activated cells  
To confirm whether soluble factors released during lymphocyte activation could also have any 
effect on memHsp70 expression, supernatant was collected from cells after incubation with 
the activation beads and stored in microfuge tubes at -80°C. As a control, supernatant was also 
harvested from unstimulated cells. When required, aliquots were defrosted and added to 
Isolated PBMCs (1x106 cells in polypropylene 12x75mm tubes). Cells were either set up with 
supernatant only (100% v/v) or in supernatant with growth medium (50% v/v) and then 
incubated for 24 hours at 37°C. After this time cells were stained for memHsp70 expression as 
described previously.  
2.6.3.5 Influence of hypoxia 
 Vascularisation can be inadequate when tumours grow rapidly and regions become hypoxic. 
To assess whether the hypoxia that tumour infiltrating lymphocytes could experience can 
induce memHsp70 expression, PBMCs were examined after incubation in a hypoxic chamber. 
1x106 PBMCs suspended in 1mL growth medium and placed into 12x75mm polypropylene 
tubes were incubated for 20 hours at 37°C and 0.1% v/v oxygen. After this time the cells were 
stained for memHsp70 expression as described previously. 
2.6.3.5.1 Influence of hydrogen peroxide  
Hydrogen peroxide (H2O2) served as a chemical approach to the administration of oxidative 
stress. To this end, 1x106 PBMCs n 12x75mm polypropylene tubes were suspended in medium 
containing 1000, 100, 50, 25, 10 or 1μM H2O2 (Sigma) and incubated at 37°C for 1 hour. Cells 
were then centrifuged (300g, 5 minutes) and resuspended in 1mL fresh growth medium, after 
which they were incubated for a further 22 hours at 37°C before being stained for memHsp70 
expression, as described previously. 
 2.6.4 Data acquisition 
Data from stained PBMCs were acquired on a BD LSRII flow cytometer, in the same way as 
for the tumour cell samples. The fluorochromes and the corresponding detector channels are 
summarised in Table 2.9. Samples were run until 10,000 lymphocytes had been acquired or, if 
there were insufficient cells to obtain this number, until the whole sample volume had been 
processed.  
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 2.6.5 Post Acquisition Analysis  
The analysis was conducted using FACSDiva software and follows the same principles as the 
analysis of tumour cell samples. Hierarchical plots are drawn to first enable selection of 
different cell types and then allow examination of inducible marker expression. Before 
starting, the compensation settings were applied and checked by comparing every pair of 
fluorochromes on scatter plots.   
 
The first step in the analysis was to identify the cell populations of interest, beginning with 
selection of lymphocytes. This was conducted in a similar manner to the tumour cell analysis 
using forward and side light scatter profiles (FSC vs SSC), which correlate to the size and 
granularity of cells respectively. In the whole blood samples this allowed distinction, and 
therefore exclusion, of neutrophils and monocytes from the lymphocyte population. In the 
isolated PBMC samples only mononuclear cells were present (Fig 2.15).  
 
Figure 2.15 Identification of cell populations  
A portion of the laser light hitting the cells will be scattered and this gives information about certain physical 
properties of the cell. The angle of light scattered in front of the cell (Forward Scatter) is proportional to the size of 
the cell. The angle of light scattered to the side (Side Scatter) is proportional to the granularity. These 
measurements allow distinction of multiple populations within the same sample, as long as the relative physical 
properties are known. This is illustrated by separation of cell populations in a whole blood sample (left). After 
density gradient separation of lymphocytes the profile is very different (right). The dense region in the lower left of 
both plots shows the debris in the sample.  
 
The next step was the exclusion of cell aggregates, and this was achieved as described 
previously using the FSC-area and FSC-height parameters, from which can be selected the 
viable, non-apoptotic cells (Fig 2.16). The viability of cells was determined by exclusion of the 
blue fixable live/dead stain and non-apoptotic cells by the lack of surface expression of 
phosphatidylserine (PS). Expression of PS was determined using an anti-phosphatidylserine 
antibody (whole blood samples) or Annexin V (PBMC samples).  
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Figure 2.16 Selection of viable cell populations to analyse.  
It is essential to analyse the correct cells to get accurate results.  Dead and dying cells can autofluoresce, whereas 
clumped cells can lead to multiple phenotypes being recorded for a single cell. Starting with the FSC against SSC 
plots, the population of interest is selected. From these, the cells are displayed on a plot comparing the FSC giving 
information about cell area with that of cell height. Single cells will show as a perfectly correlated line, with any 
clumped cells below. These single cells are checked for viability, using a Blue Live/Dead Fixable stain. This stain 
detects amine residues, so while viable cells will bind a small amount to the membrane the compromised 
membrane of dead cells allows the stain to permeate into the cell resulting in much brighter staining. Finally, the 
viable cells are also checked for the early signs of apoptosis using Annexin V staining. In each plot the cells that will 
be selected are highlighted in red. 
  
The next stage was separating the different lymphocyte populations of interest (T cells and NK 
cells) on the basis of phenotypic cell surface marker expression (Fig 2.17). Initially, CD3 
expression enabled the identification of T cells (CD3+) from other lymphocytes (CD3-). The T 
cells were further divided into CD4+ and CD8+ expression (predominantly helper and cytotoxic 
populations). The CD3- lymphocyte population contains the NK cells of interest, and B cells 
which must be excluded. This is achieved using the NK cell marker CD56, for which all NK cells 
will be positive, but for which B cells are negative. By comparing CD56 with CD8 it is possible to 
distinguish two NK populations, CD8+ and CD8-. 
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Figure 2.17 Selection of lymphocyte sub-populations 
Lymphocyte sub-populations can be distinguished on the basis of different surface markers. T cells can be identified 
on the basis of their expression of CD3, and the major subpopulations on the basis of CD4 (shown in green) and CD8 
(shown in blue) expression. NK cells arte CD3-, but CD56+. Although CD56+, NK cell sub-populations express low and 
high intensities of this antigen. CD3- lymphocytes do not express CD56. A proportion of NK cells were also found to 
express CD8, which was a very interesting finding as this is not found in the published literature.   
 
Once the T cell and NK cell populations had been identified, the expression of memHsp70 and 
cellular activation markers by these populations was assessed by comparing the fluorescent 
intensity of the whole population to that of the isotype. Both CD69 and CD25 exhibited a two 
peak positive/negative profile, and so assessment was conducted into the proportion of cells 
which expressed the markers (activated cells) and the intensity of the positive expression. 
2.6.6 Response to exogenous granzyme B 
Exogenous granzyme B has been shown to lead to induction of apoptosis in the memHsp70+ 
cell line CT26 [532]. To investigate whether apoptosis can also be induced in lymphocytes by 
granzyme B, lymphocytes were incubated in the presence of granzyme B in the same way as 
tumour cell lines then assessed in terms of active caspase-3 expression and apoptosis 
determined by Annexin V binding. 
 2.7 Statistical analysis 
All statistical analyses were conducted using SPSS v20. The appropriateness of parametric tests 
was assessed by comparing mean and median measurements (for small experimental 
numbers), as well as test of normality. Paired and unpaired Student’s T tests were used to 
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compare data from two groups when these were normally distributed, with the Wilcoxon 
signed-rank test and the Mann Whitney U test being used if the data were non-parametric. A 
one-way or repeated measures ANOVA was employed for the analysis of data three or more 
groups. ANOVA tests were conducted along with post hoc comparisons; the Games-Howell 
comparison if the assumption of homogeneity was violated, otherwise a Bonferroni 
comparison if all groups had equal numbers of subjects or a Gabriel comparison if the subject 
numbers varied slightly. All analyses were performed with two-tailed hypotheses, at a 0.05 
significance level and any significant results are described as * (p<0.05), ** (p<0.01) or *** 
(p<0.001). Potential correlations were assessed using two-tailed Pearson’s Correlation 
Coefficients. Power calculations to determine necessary assay sample sizes were conducted 
using the freely available G*Power software (distributed by Heinrich Heine Universität 
Düsseldorf, www,gpower.hhu.de). 
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CHAPTER 3: Results I – Internalisation of the cmHsp70.1 mAb by 
cancer cells expressing membrane Hsp70 
3.1 Introduction 
Heat shock protein 70 (Hsp70) is found in all eukaryotic cells and is primarily considered as 
being an intracellular molecule. However, it is now known that approximately 50% of all 
tumours express a membrane form of this protein (memHsp70, [285]). The presentation of an 
Hsp70-derived sequence on the plasma membrane of tumour cells can be detected by flow 
cytometry using a fluorescently labelled antibody (clone cmHsp70.1 mAb) that binds to a site 
located in the epitope which is available at the cell surface [289]. However, the cmHsp70.1 
mAb is unique, as all other commercially-available anti-Hsp70 antibodies (including clone 
C923F5-A) recognise an epitope which is not accessible on the surface of tumour cells when 
Hsp70 is in its membrane form, but which can be recognised if extracellular Hsp70 has bound 
to the surface of tumour cells. The staining of cells using clone C923F5-A has therefore been 
used as a control to define the form of Hsp70 expression throughout this study. 
 
Given that such a large proportion of tumours, but not normal tissue, selectively express 
memHsp70, then this molecule could act as a valuable targeting structure for agents and 
molecules that specifically recognise and interact with this epitope. The studies presented 
herein have investigated the interaction of 3 such molecules: the cmHsp70.1 mAb [289, 533], a 
14-mer peptide (sequence TKDNNLLGRFELSG) which has been found to exhibit binding 
potential similar to that of the cmHsp70.1 mAb [535], and a recombinant form of human 
granzyme B [530, 532]. This chapter will address the interaction of the cmHsp70.1 mAb with 
breast cancer cell lines. 
 
The cmHsp70.1 mAb (multimmune GmbH, Munich, Germany) was originally generated by 
immunising mice with the 14-mer peptide TKDNNLLGRFELSG, comprising amino acids 450–461 
(aa450–461) in the C terminus of the inducible Hsp70. Since the human and murine sequences 
only differ in one amino acid ([550]; human TKDNNLLGRFELSG; mouse TRDNNLLGRFELSG), the 
cmHsp70.1 mAb shows a cross-reactivity for human and mouse tumours [533]. The capacity of 
this antibody to selectively bind to tumour cells via memHsp70 and induce antibody-
dependent cytotoxicity (ADCC) in vitro and in vivo [533] suggests that it might have clinical 
value as a tumour targeting agent and/or an immunotherapeutic agent. The following studies 
further examine the interaction of cmHsp70 mAb with human and murine cancer cells and its 
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internalisation. These properties will then be compared to those of the TKDNNLLGRFELSG 
peptide and recombinant granzyme B which are examined subsequently. 
3.2 Membrane Hsp70 expression by human and murine cancer cell 
lines 
The expression of memHsp70 by three human breast cancer cell lines (MDA-MB-231, MCF7 
and T47D) and two murine cell lines – CT26 (colorectal cancer) and 4T1 (mammary carcinoma) 
was determined by flow cytometry using a FITC-labelled cmHsp70.1 mAb. Using the median 
fluorescence intensity of the whole cell population relative to that of the isotype provides a 
relative measurement of the expression of memHsp70 of that cell line (Fig 3.1). A second 
Hsp70 antibody clone was also used, C92F3A-5, which binds to an epitope that is inaccessible 
when the molecule is held within the cell membrane. In the absence of cell fixation and 
permeabilisation, the C92F3A-5 antibody would only be able to bind to Hsp70 that was bound 
to the surface of cells and consequently its lack of binding can be used to confirm the presence 
of memHsp70 only. In all tumour cell lines used, the fluorescence intensity of C92F3A-5 is not 
significantly different to the isotype control, demonstrating that there is no surface bound 
Hsp70 and therefore cmHsp70.1 staining is indicative of memHsp70 only. 
 
 
Figure 3.1 Binding of cmHsp70.1 mAb antibody to tumour cell lines 
A. Representative flow cytometry plots showing the fluorescent intensity of MDA-MB-231 cells incubated for 30 
minutes at 4oC in staining buffer (black line), with isotype antibody (grey line), with C92F3A-5 mAb (light green line) 
and with cmHsp70.1 mAb (dark green line). B. The binding of FITC-labelled cmHsp70.1 mAb to both human (solid 
bars) and mouse (dotted bars) cancer cell lines, expressed as the intensity of fluorescence in the whole population 
relative to cells that were unstained. A measurement of greater than 1 indicates specific binding of cmHsp70.1 mAb 
and the higher the value the more antibody is bound, indicating a greater surface density of memHsp70. Data are 
presented as mean ± SEM and are the result of 4-7 independent experiments.  
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Of the human lines examined, MDA-MB-231 cells expressed the greatest amount of 
memHsp70, with MCF7 cells only slightly lower and T47D expressing around 50% of this 
expression. Of the mouse-derived cell lines, 4T1 expressed the highest level of memHsp70. The 
availability of cell lines which express memHsp70 to varying degrees allowed the potential 
relationship between expression of memHsp70 and the binding/internalisation of memHsp70-
specific reagents to be investigated.  
3.3 Internalisation of cmHsp70.1 mAb by cancer cells expressing 
memHsp70 
To investigate the influence of memHsp70 on the internalisation of cmHsp70 mAb by the 
different cancer cell lines, cells were incubated in the presence of FITC-labelled cmHsp70.1 
mAb at 37°C (to allow metabolic activity and therefore antibody internalisation) or 4°C (to 
allow binding only). An aliquot was saved at different time points up to 60 min, and these were 
analysed by flow cytometry. In addition, cells were also incubated at 37°C with FITC-
conjugated C92F3A-5 mAb in order to confirm the specificity of any observed effects and 
responses (Fig 3.2).   
 
All cells internalised the antibody, with significant differences between the median 
fluorescence intensity (mfi) of cells incubated with cmHsp70.1 mAb at 4°C and 37°C (one-way 
ANOVA. MDA-MB-231: F = 32.918, p < 0.001; MCF7: F = 41.859, p < 0.001; T47D: F = 19.259, p 
< 0.001; CT26: F = 19.606, p < 0.001; 4T1: F = 6.828, p < 0.001). The extent of cmHsp70.1 mAb 
internalisation was related to the intensity of memHsp70 which they expressed on their 
plasma membrane, with cell lines expressing the lowest levels of memHsp70 (T47D and CT26) 
internalising the least amount of antibody (mfi at the 60 minute, 37°C incubation time-point of 
1015 ± 64 and 1346 ± 85 respectively), compared to the lines expressing higher memHsp70 
(MDA-MB-231: 3006 ± 348; MCF7: 3835 ± 204; 4T1: 2996 ± 649). The lack of 
binding/internalisation of C92F3A-5 mAb provides a baseline measure of non-specific 
fluorescence, with the difference between this and the cmHsp70.1 at 4°C again confirming the 
specific binding of the antibody clone. 
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Figure 3.2 Uptake of fluorescently-labelled cmHsp70.1 mAb antibody into human and murine cancer cell lines 
expressing differing levels of memHsp70 
A. Representative flow cytometry plots showing the fluorescent intensity of MDA-MB-231 cells incubated for 60 
minutes at 37oC in medium (black line), with isotype (grey line), C92F3A-5 (light green line) and cmHsp70.1 (dark 
green line). B. Cells were incubated in the presence of FITC-cmHsp70.1 with samples saved at different time points, 
for up to an hour. The median fluorescent intensity of the whole population was recorded by flow cytometry. The 
intensity after 4°C incubation relates to the binding of antibody to the cell surface (dashed black lines), while the 
37°C incubation allows for inclusion of antibody internalisation (solid black lines). All cell lines are capable of binding 
and internalising the cmHsp70.1 mAb, albeit to varying degrees. As a control, cells were also incubated with the 
C92F3A-5 mAb, which did not stain cell, even after incubation at 37oC (dashed grey lines). Data are presented as 
mean ± SEM of at least three independent experiments.   
 
In addition to using flow cytometry, the uptake of ATTO488-cmHsp70.1 mAB was assessed 
using fluorescent microscopy images of cells at multiple time-points after incubation with the 
fluorescently-labelled antibody (Fig 3.3 and 3.4). Tile scan images were produced by way of 
fluorescence microscopy rather than confocal microscopy in order to ensure the total 










Figure 3.3 Representative tile scan images showing antibody uptake into MDA-MB-231 cells 
Tile scan images were produced for MDA-MB-231, MCF7, T47D, 4T1 and CT26 cells, across different time-points of 
incubation with Hsp70 antibodies. Representative tile scan images of MDA-MB-231 cells incubated with cmHsp70.1 
(A) and C92F3A5 (B) antibodies for 60 minutes are shown. Antibodies are shown in green and the nucleus stained 
with DAPI is shown in blue. Scale bar represents 50µm.   
 
Using the analysis software package ImageJ, the fluorescent intensity of every imaged cell was 
determined (normalised to the background intensity). The mean fluorescent intensity of cells 
increased over time, thereby demonstrating uptake of the fluorescently-labelled mAb. The 
level of uptake varied between cell lines, but in line with memHsp70 expression, mimicking the 
flow cytometric data shown earlier and confirming that using the in-house conjugate with 
microscopy was a robust method of examining cmHsp70.1 mAb uptake.   
 
A B 
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Figure 3.4 Uptake of ATTO488-labelled cmHsp70.1 mAb into human and murine cancer cell lines expressing 
differing levels of memHsp70 
Cancer cell lines from human (A) and mouse (B) grown in MatTek™ glass bottom dishes were incubated in the 
presence of ATTO488-cmHsp70.1 mAb for up to an hour, after which cells were imaged using fluorescent 
microscopy. Mean fluorescent intensity values were calculated and normalised to the background fluorescence. All 
cell lines are capable of internalising the cmHsp70.1 mAb, but to varying degrees and in line with the memHsp70 
expression of cell lines. Data are presented as mean ± SEM of a minimum of 80 cells from at least three 
independent experiments.   
 
The internalisation of cmHsp70.1 mAb was also studied using confocal microscopy image 
analyses in order to better understand cmHsp70.1 mAb internalisation events (Fig 3.5-3.9). 
Cells were imaged at a number of time points up to 60 min, and z-stack images covering the 
entire cell generated. It is interesting to note that internalisation of the cmHsp70.1 mAb 
resulted in the appearance of distinct fluorescent ‘spots’, thereby suggesting that the 
internalised antibody was associated with intracellular vesicles, rather than being ‘free’ and 
distributed in the cytoplasm. Although the lack of inter-experimental controls relating to 
fluorescence intensity rendered it impossible to compare the intensity of images obtained at 
different times and in different experiments, the distribution of cmHsp70.1 mAb did enable 
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quantification in the form of counting the number of distinct spots. When a spot appears over 
more than one z-stack frame it was counted in the stack in which the greatest fluorescence 
intensity was apparent.  
 
The data gained using this quantification from microscopy images tracks with the flow 
cytometry quantification of the population intensity. Simply by viewing the confocal images, it 
appears that the size of the fluorescent spots varied between the different cell lines. The 
fluorescent spots reflecting cmHsp70.1 mAb internalisation in the two murine cancer cell lines 
were much smaller than those that were apparent in the human cells lines, for reasons that 
are currently unclear but may simply be indicative of smaller sized vesicles in mouse. There 
also appear to be differences in the sizes of spots between the human cell lines, again for 
reasons that are currently unclear. It was not possible to accurately quantitate the size of the 
fluorescent spots in this setting, as the area containing fluorescence is altered as 
brightness/contrast/threshold values are adjusted, thereby meaning that any size calculation is 
entirely dependent on the image settings. Without reliable methods of calibrating the settings 
when acquiring, as well as processing, images it is therefore not possible to calculate size 
values which can be compared.  
 
 
Figure 3.5 Kinetics of cmHsp70.1 mAb uptake by MDA-MB-231 cells  
A. Representative single frame images showing ATTO488-labelled cmHsp70.1 mAb internalised into MDA-MB-231 
cells. Frames were selected from the mid-point of cells (25-75% of distance from adhered surface). ATTO488- 
cmHsp70.1 mAb  (green) appears in well-defined vesicles rather than free in the cytosol. The frames depict a region 
0.88µm thick. Scale bars are 10µm. For clarity, the nucleus was stained with DAPI and is shown here in blue. B. The 
number of distinct fluorescent spots in cells after different incubation times. This is a total count including spots 
within the cell and at the membrane. Data are presented as mean ± SEM for 10-24 individual cells, from at least two 
independent experiments.  
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Figure 3.6 Kinetics of cmHsp70.1 mAb uptake by MCF7 cells  
A. Representative single frame images showing ATTO488-labelled cmHsp70.1 mAb internalised into MCF7 cells. 
Frames were selected from the mid-point of cells (25-75% of distance from adhered surface). ATTO488- cmHsp70.1 
mAb (green) appears in well-defined vesicles rather than free in the cytosol. The frames depict a region 0.88µm 
thick. Scale bars are 10µm. For clarity, the nucleus was stained with DAPI and is shown here in blue. B. The number 
of distinct fluorescent spots in cells after different incubation times. This is a total count including spots within the 
cell and at the membrane. Data are presented as mean ± SEM for 13-24 individual cells, from at least two 
independent experiments.  
 
 
Figure 3.7 Kinetics of cmHsp70.1 mAb uptake by T47D cells  
A. Representative single frame images showing ATTO488-labelled cmHsp70.1 mAb internalised into T47D cells. 
Frames were selected from the mid-point of cells (25-75% of distance from adhered surface). ATTO488- cmHsp70.1 
mAb (green) appears in well-defined vesicles rather than free in the cytosol. The frames depict a region 0.88µm 
thick. Scale bars are 10µm. For clarity, the nucleus was stained with DAPI and is shown here in blue. B. The number 
of distinct fluorescent spots in cells after different incubation times. This is a total count including spots within the 
cell and at the membrane. Data are presented as mean ± SEM for 8-19 individual cells, from at least two 
independent experiments.  
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Figure 3.8 Kinetics of cmHsp70.1 mAb uptake by 4T1 cells  
A. Representative single frame images showing ATTO488-labelled cmHsp70.1 mAb internalised into 4T1 cells. 
Frames were selected from the mid-point of cells (25-75% of distance from adhered surface). ATTO488- cmHsp70.1 
mAb (green) appears in well-defined vesicles rather than free in the cytosol. The frames depict a region 0.88µm 
thick. Scale bars are 10µm. For clarity, the nucleus was stained with DAPI and is shown here in blue. B. The number 
of distinct fluorescent spots in cells after different incubation times. This is a total count including spots within the 
cell and at the membrane. Data are presented as mean ± SEM for 7-18 individual cells, from at least two 
independent experiments.  
 
 
Figure 3.9 Kinetics of cmHsp70.1 mAb uptake by CT26 cells  
A. Representative single frame images showing ATTO488-labelled cmHsp70.1 mAb internalised into CT26 cells. 
Frames were selected from the mid-point of cells (25-75% of distance from adhered surface). ATTO488- cmHsp70.1 
mAb (green) appears in well-defined vesicles rather than free in the cytosol. The frames depict a region 0.88µm 
thick. Scale bars are 10µm. For clarity, the nucleus was stained with DAPI and is shown here in blue. B. The number 
of distinct fluorescent spots in cells after different incubation times. This is a total count including spots within the 
cell and at the membrane. Data are presented as mean ± SEM for 9-23 individual cells, from at least two 
independent experiments.  
 
 
3.3.1 Distribution of cmHsp70.1 mAb after internalisation into human and murine 
cell lines expressing memHsp70 
Utilising z-stack images and counting the cmHsp70.1 fluorescent spots per frame, allowed the 
intracellular distribution of cmHsp70.1 mAb-containing vesicles to be described through the 
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vertical axis (i.e. from the adherent surface to the apex).  A representative montage of frames 
from a z stack is shown in Fig 3.10). 
 
 
Figure 3.10 Representative montage of z-stack confocal images showing cmHsp70.1 mAb internalised into MDA-
MB-231 cells.  
Z-stack frames from the full height of a single MDA-MB-231 cell demonstrating distribution of cmHsp70.1 mAb 
following 60 minutes incubation time. Single frame images start at the adhered surface and finish at the apex of the 
cell. Brightfield imaging is included to help with orientation. Internalised cmHsp70.1 mAb is shown in green, DAPI 
staining of the nucleus is in blue. The scale bar represents 10µm.  
 
Due to the differing sizes and morphology of cells, the use of absolute distances was not 
possible. As a consequence, the percentage of the overall height from adhered surface (0%) to 
the apex of the cell (100%) was calculated. This analysis revealed that the fluorescence spots 
preferentially localised towards the adherent surface in all of the human and murine cell lines 
(Fig 3.11 and Fig 3.12). 
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Figure 3.11 Distribution of internalised cmHsp70.1 mAb in human cancer cell lines 
Line graphs of the distribution of internalised ATTO488-labelled cmHsp70.1 mAb in every cell imaged for MDA-MB-
231, MCF7 and T47D cell lines at each time point, up to 60 minutes. Although ATTO488-cmHsp70.1 mAb appears 
throughout the full height of the cells, there is a clear bias towards the antibody being present close to the adhered 
surface of the cells. This asymmetrical distribution was observed in all cell lines and at all time- points. Each line 
represents the profile of an individual cell, with a minimum of four cells per condition. 
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Figure 3.12 Distribution of internalised cmHsp70.1 mAb in murine cancer cells 
Line graphs of the distribution of internalised ATTO488-labelled cmHsp70.1 mAb in every cell imaged for 4T1 and 
CT26 cell lines at each time point, up to 60 minutes. Although ATTO488-cmHsp70.1 mAb appears throughout the 
full height of the cells, there is a clear bias towards the antibody being present close to the adhered surface of the 
cells. This asymmetrical distribution was observed in all cell lines and at all time- points. Each line represents the 
profile of an individual cell, with a minimum of four cells per condition. 
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Over time, the number of spots found closer to the apex (up to ~75% of the cell’s height) 
increased. Although these data provide some insight into the location of internalised 
cmHsp70.1 mAb at each time point, cumulative totals of fluorescent spots over quartiles of the 
cell height (0-25%, 25-50%, 50-75%, 75-100%) were calculated. These data are shown for all 
time points (Fig 3.13A-3.17A) and each cell line is presented separately. Representative images 
for each height quartile are provided for both the 5 and 60 minute time points (Fig 3.13B-
3.17B), and these are in the form of composites composed of all frames within that quartile.  
 
 
Figure 3.13 Distribution of internalised ATTO-cmHsp70.1 mAb in MDA-MB-231 cells 
A Line graph of the mean ATTO488-labelled cmHsp70.1 mAb spot counts over the full height of cells at all 
incubation time points. The quartile containing the adherent surface consistently holds the greatest number of 
ATTO-cmHsp70.1 mAb spots. As the incubation time, increases spot counts increase over the middle quartiles (25-
50% and 50-75%) whilst the spot count remains very similar in the quartile containing the apex (75-100%). Data are 
presented as mean ± SEM, n = 24. B Representative fluorescence images of the first and last quartiles (0-25% and 
75-100%) after 5 minutes and 60 minutes incubation with ATTO488-cmHsp70.1 mAb. These are composite images 
of all frames that make up the quartile. Bright-field images are included to confirm placement of cell boundaries.  




Figure 3.14 Distribution of internalised ATTO488-cmHsp70.1 mAb in MCF7 cells 
A Line graph of the mean ATTO488-labelled cmHsp70.1 mAb spot counts over the full height of cells at all 
incubation time points. The quartile containing the adherent surface consistently holds the greatest number of 
ATTO-cmHsp70.1 mAB spots. As the incubation time, increases spot counts increase over the middle quartiles (25-
50% and 50-75%) whilst the spot count remains very similar in the quartile containing the apex (75-100%). Data are 
presented as mean ± SEM, n = 29. B Representative fluorescence images of the first and last quartiles (0-25% and 
75-100%) after 5 minutes and 60 minutes incubation with ATTO488-cmHsp70.1 mAb. These are composite images 
of all frames that make up the quartile. Bright-field images are included to confirm placement of cell boundaries.  
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Figure 3.15 Distribution of internalised ATTO488-cmHsp70.1 mAb in T47D cells 
A Line graph of the mean ATTO488-labelled cmHsp70.1 mAb spot counts over the full height of cells at all 
incubation time points. The quartile containing the adherent surface consistently holds the greatest number of 
ATTO-cmHsp70.1 mAB spots. As the incubation time, increases spot counts increase over the middle quartiles (25-
50% and 50-75%) whilst the spot count remains very similar in the quartile containing the apex (75-100%). Data are 
presented as mean ± SEM, n = 19. B Representative fluorescence images of the first and last quartiles (0-25% and 
75-100%) after 5 minutes and 60 minutes incubation with ATTO488-cmHsp70.1 mAb. These are composite images 
of all frames that make up the quartile. Bright-field images are included to confirm placement of cell boundaries.  
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Figure 3.16 Distribution of internalised ATTO488-cmHsp70.1 mAb in 4T1 cell 
A Line graph of the mean ATTO488-labelled cmHsp70.1 mAb spot counts over the full height of cells at all 
incubation time points. The quartile containing the adherent surface consistently holds the greatest number of 
ATTO-cmHsp70.1 mAb spots. As the incubation time, increases spot counts increase over the middle quartiles (25-
50% and 50-75%) whilst the spot count remains very similar in the quartile containing the apex (75-100%). Data are 
presented as mean ± SEM, n = 20. B Representative fluorescence images of the first and last quartiles (0-25% and 
75-100%) after 5 minutes and 60 minutes incubation with ATTO488-cmHsp70.1 mAb. These are composite images 
of all frames that make up the quartile. Bright-field images are included to confirm placement of cell boundaries.  
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Figure 3.17 Distribution of internalised ATTO488 cmHsp70.1 mAb in CT26 cells 
A Line graph of the mean ATTO488-labelled cmHsp70.1 mAB spot counts over the full height of cells at all 
incubation time points. The quartile containing the adherent surface consistently holds the greatest number of 
ATTO-cmHsp70.1 mAb spots. As the incubation time, increases spot counts increase over the middle quartiles (25-
50% and 50-75%) whilst the spot count remains very similar in the quartile containing the apex (75-100%). Data are 
presented as mean ± SEM, n = 23. B Representative fluorescence images of the first and last quartiles (0-25% and 
75-100%) after 5 minutes and 60 minutes incubation with ATTO488-cmHsp70.1 mAb. These are composite images 
of all frames that make up the quartile. Bright-field images are included to confirm placement of cell boundaries.  
 
As the greatest number of cmHsp70.1 mAb spots are seen close to the adhered surface it could 
be proposed that this could be the region which enables the greatest amount of cmHsp70.1 
mAb internalisation. Little is known about the presentation of Hsp70 within the membrane of 
cells and one possibility could be that it is restricted to, or more abundant at, the adhered 
surface. However this would need to be further investigated to be confirmed. Another 
possibility is that adhesion can in some way promote endocytic activity. Recent data examining 
neural maturation in a C57Bl/6J mouse model has demonstrated a link, whereby the 
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expression of neural cell adhesion molecule (NCAM) is required for the maturation of 
endocytic machinery in neurons while this maturation is impossible in NCAM knockout mice 
[551].  It may also be that there is a greater abundance of vesicles in the vicinity of adherent 
surfaces. 
 
It is worth noting that these data rely on the absolute counts of fluorescent spots, uncorrected 
for cell area. This introduces difficulties in the interpretation of data, although the situation 
was unfortunately unavoidable. Without the inclusion of a membrane-specific fluorescent 
stain, the only avenue for determining cell area lies with calculating it from the bright-field 
image. As it is not possible to conduct confocal microscopy for bright-field images the only in-
focus image sits in the centre of the z-stack. All others display varying degrees of blurring and 
therefore making accurate determination of cell boundaries close to the adherent surface and 
cell apex impossible.  
3.3.2 Association of internalised cmHsp70.1 mAb with intracellular vesicles 
The pattern of internalised cmHsp70.1 mAb was highly distinctive across all of the cell lines 
that were studied, in that it was present in well-defined spots that did not overlap with the 
nucleus. The most likely explanation is that the antibody is associated with intracellular 
vesicles, and additional studies were performed in order to better define the intracellular 
location of internalised cmHsp70.1 mAb.   
For these studies, cells were incubated with ATTO488-labelled cmHsp70.1 mAb for different 
time points, up to 60 min, after which cells were formaldehyde fixed and permeabilised. They 
were stained using primary antibodies that were specific for one of a number of markers of 
intracellular vesicles, followed by staining with an appropriate secondary antibody. The 
coverslips were detached from the culture dishes and mounted onto microscopy slides with 
VECTASHIELD® Mounting Medium containing DAPI (enabling staining of the nucleus). Cover 
slips were sealed using clear nail varnish and stored at 4°C  protected from light, until such 
time as they could be imaged (and not longer than 24 hours).  
Using fluorescently labelled antibody and fluorescently stained vesicles, co-localisation of the 
two fluorescence signals can be used as confirmation of association of the antibody with that 
particular vesicle. As well as simply observing overlap of the two fluorescent signals on the 
acquired images, a more robust method of calculation is to use co-localisation algorithms. 
There is a wide variety of these, each of which have specific criteria for their use. The analyses 
conducted in the following experiments were Pearson’s coefficient and Manders’ M1 
coefficient, using the Just Another Co-localisation Program plugin on ImageJ.  
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The association of cmHsp70.1 mAb with early endosomes in the three human-derived cell 
lines, MDA-MB-231, MCF7 and T47D was determined using antibodies specific for Rab4a and 
Rab5a. Although all of the cell lines exhibited large numbers of Rab4a+ and Rab5a+ vesicles, no 
co-localisation of internalised cmHsp70 mAb with these was observed (Table 3.1, 
representative images in Fig 3.18). 
 
 
Table 3.1 Internalisation of ATTO488-cmHsp70.1 mAb into human breast cancer cell lines may not utilise an early 
endosome pathway 
A Pearson coefficient of the correlation between internalised ATTO488-cmHsp70.1 mAb and staining for the early 
endosome markers Rab4a and Rab5a in human breast cancer cell lines MDA-MB-231, MCF7 and T47D. At all time-
points there was a positive correlation suggesting some degree of co-localisation between the markers of interest.  
B Manders’ M1 measurement calculating the percentage of internalised ATTO488-cmHsp70.1 mAb which was co-
localised with staining for the early endosome markers Rab4a and Rab5a over different time-points. The proportion 
of co-localisation is low; indicating that at each time very little cmHsp70.1 mAB is within early endosomes. Data are 
presented as mean ± SEM from 5-8 imaged cells, from at least two independent experiments.  
 
A. Pearson Coefficient 5 minutes 15 minutes 30 minutes 60 minutes 
MDA-MB-231 Rab4a 0.540 ± 0.021 0.345 ± 0.167 0.393 ± 0.102 0.489 ± 0.036 
 Rab5a 0.795 ± 0.018 0.274 ± 0.126 0.159 ± 0.061 0.475 ± 0.109 
MCF7 Rab4a 0.292 ± 0.071 0.417 ±0.085 0.372 ± 0.108 0.482 ± 0.084 
 Rab5a 0.378 ± 0.027 0.387 ±0.074 0.327 ± 0.050 0.431 ± 0.055 
T47D Rab4a 0.864 ± 0.010 0.886 ± 0.019 0.777 ± 0.068 0.501 ± 0.017 
 Rab5a 0.744 ± 0.013 0.669 ± 0.011 0.664 ± 0.013 0.044 ± 0.035 
B. Manders M1 Coefficient 5 minutes 15 minutes 30 minutes 60 minutes 
MDA-MB-231 Rab4a 4.2 ± 2.1 % 1.5 ± 0.8 % 13.0 ± 4.7% 3.3 ± 2.9 % 
 Rab5a 2.1 ± 1.5 % 2.7 ± 0.9 % 21.2 ± 4.5 % 9.0 ± 2.0 % 
MCF7 Rab4a 13.7 ± 3.2 % 11.0 ± 4.0 % 8.1 ± 3.6 % 13.3 ± 2.5 % 
 Rab5a 9.7 ± 5.8 % 5.9 ± 2.0 % 8.5 ± 4.8 % 16.0 ± 3.2 % 
T47D Rab4a 1.0 ± 0.2 % 11.9 ± 4.0 % 14.9 ± 6.1 % 3.7 ± 1.4 % 
 Rab5a 5.2 ± 0.3 % 9.4 ± 2.1 % 3.7 ± 1.9 % 16.9 ± 1.1 % 
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Figure 3.18 Trafficking of internalised ATTO488-cmHsp70.1 mAb to early endosomes in human breast cancer cell 
lines 
MDA-MB-231, MCF7 and T47D cells grown in MatTek glass bottom dishes and incubated with ATTO488-cmHsp70.1 
mAb for 5, 15, 30 or 60 minutes were fixed, permeabilised and stained for the localisation of early endosomes using 
Rab4 and Rab5 as markers. Any co-localisation of ATTO488-cmHsp70.1 mAb fluorescence (green) and endosome 
staining (magenta) could be confirmation of involvement of an early endosome pathway of cmHsp70.1 mAb 
internalisation. Co-localisation was assessed using both Pearson’s and Manders’ M1 coefficients of co-localisation, 
as well as visual overlap of the intensity channels. Images shown are representative single frames taken from the 
middle region (2nd or 3rd quartile) of cells incubated with ATTO488-cmHsp70.1 mAb for 30 minutes and 
subsequently stained for the presence of Rab5. No co-localisation was found, nor using the Rab4 marker.  Scale bars 
are 10μm.   
 
Despite not finding any co-localisation between cmHsp70.1 mAb and early endosome markers, 
it is not possible to conclude a definite lack of early endosomal involvement. Previous 
knowledge of the mechanisms of early endosome trafficking would presume involvement only 
in the initial stages of internalisation. It may be that an individual early endosome was 
associated with such a small amount of cmHsp70.1 mAb that detection above the background 
level of fluorescence was not possible, or that any association is so brief that at the specific 
moment cells are fixed the proportion of cmHsp70.1 mAb which is associated with early 
endosomes is negligible. Confirmation of these suggestions would require additional 
experiments. 
The association of cmHsp70.1 mAb with late and recycling endosomes endosomes was 
examined using antibodies for Rab7, Rab9 and Rab11, and co-localisation was observed in 
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some instances (Table 3.2 and Fig 3.19-3.21). Although cmHsp70.1 mAb was not co-localised 
with Rab7+ vesicles in any of the cell lines, some co-localisation with Rab9+ endosomes was 
observed. The proportion of cmHsp70.1 mAb fluorescence which was co-localised to Rab9 was 
similar at the 30 and 60 minute time points (MDA-MB-231: 30 min 25.3 ± 4.4% and 60 min 27.0 
± 3.8%. MCF7: 30 min 28.0 ± 5.5% and 60 min 33.3 ± 5.7%) for the MDA-MB-231 and MCF7 
cells. In contrast, co-localisation with Rab9 over these times was markedly different in T47D 
cells (from 1.4 ± 0.8% to 16.5 ± 2.1%), and this difference could reflect the lower expression of 















Table 3.2 Trafficking of internalised ATTO488-cmHsp70.1 mAb to late and recycling endosomes in human breast 
cancer cell lines 
A Pearson coefficient of the correlation between internalised ATTO488-cmHsp70.1 mAb and staining for the late 
endosome markers Rab7 and Rab9 as well the recycling endosome marker Rab11, in human breast cancer cell lines 
MDA-MB-231, MCF7 and T47D. At all time-points there was a positive correlation suggesting some degree of co-
localisation between the markers of interest. B Manders’ M1 measurement calculating the percentage of 
internalised ATTO488-cmHsp70.1 mAb which was co-localised with staining for the late endosome markers Rab7 
and Rab9 as well as the recycling endosome marker Rab11 over different time-points. The proportion of co-
localisation with both Rab9 and Rab11 in all cell lines increases over time; indicating that the internalisation of 
cmHsp70.1 mAb could utilise endosomal pathways at this time. Data are presented as mean ± SEM from 4-9 imaged 
cells, from at least two independent experiments.  
A. Pearson Coefficient 30 minutes 60 minutes 
MDA-MB-231 Rab7 0.541 ± 0.025 0.483 ± 0.039 
 Rab9 0.299 ± 0.015 0.530 ± 0.023 
 Rab11 0.586 ± 0.100 0.310 ± 0.041 
MCF7 Rab7 0.352 ± 0.071 0.314 ± 0.034 
 Rab9 0.647 ± 0.049 0.518 ± 0.025 
 Rab11 0.442 ± 0.064 0.661 ± 0.077 
T47D Rab7 0.514 ±0.013 0.457 ± 0.051 
 Rab9 0.780 ± 0.021 0.568 ± 0.070 
 Rab11 0.694 ± 0.049 0.523 ± 0.017 
B. Manders M1 Coefficient 30 minutes 60 minutes 
MDA-MB-231 Rab7 7.0 ± 2.5 % 2.2 ± 0.2 % 
 Rab9 25.3 ± 4.4 % 27.0 ± 3.8 % 
 Rab11 15.2 ± 3.3 % 17.7 ± 2.4 % 
MCF7 Rab7 7.0 ± 0.9 % 3.3 ± 1.1 % 
 Rab9 28.0 ± 5.5 % 33.3 ± 5.7 % 
 Rab11 9.1 ± 2.2 % 24.5 ± 2.1 % 
T47D Rab7 5.8 ± 1.4 % 4.8 ± 2.5 % 
 Rab9 1.4 ± 0.8 % 16.5 ± 2.1 % 
 Rab11 5.3 ± 3.0 % 12.1 ± 6.3 % 
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Figure 3.19 Trafficking of internalised ATTO488-cmHsp70.1 mAb to Rab7+ late endosomes in human breast cancer 
cell lines 
MDA-MB-231, MCF7 and T47D cells grown in MatTek™ glass bottom dishes and incubated with ATTO488-
cmHsp70.1 mAb for either 30 or 60 minutes were fixed, permeabilised and stained for Rab7 to indicate late 
endosomes. Any co-localisation of ATTO488-cmHsp70.1 mAb fluorescence (green) and endosome staining 
(magenta) could be confirmation of involvement of a late endosome pathway of cmHsp70.1 mAb internalisation. 
Co-localisation was assessed using both Pearson’s and Manders’ M1 coefficients of co-localisation, as well as visual 
overlap of the intensity channels. No co-localisation was found in any of the cell lines. Images shown are 
representative single frames taken from the middle region (2nd or 3rd quartile) of cells incubated with ATTO488-
cmHsp70.1 mAb for 60 minutes. Scale bars are 10μm.   
 
Figure 3.20 Trafficking of internalised ATTO488-cmHsp70.1 mAb to Rab9+ late endosomes in human breast cancer 
cell lines 
MDA-MB-231, MCF7 and T47D cells grown in MatTek glass bottom dishes and incubated with ATTO488-cmHsp70.1 
mAb for either 30 or 60 minutes were fixed, permeabilised and stained for Rab9 to indicate late endosomes. Any co-
localisation (white) of ATTO488-cmHsp70.1 mAb fluorescence (green) and endosome staining (magenta) could be 
confirmation of involvement of a late endosome pathway of cmHsp70.1 mAB internalisation. Co-localisation was 
assessed using both Pearson’s and Manders’ M1 coefficients of co-localisation, as well as visual overlap of the 
intensity channels. Co-localisation was found in all of the cell lines, increasing over time and increasing in line with 
the expression of memHsp70. Images shown are representative single frames taken from the middle region (2nd or 
3rd quartile) of cells incubated with ATTO488-cmHsp70.1 mAb for 60 minutes.  Scale bars are 10μm.   
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The co-localisation of cmHsp70.1 mAb with Rab11+ vesicles was much the same as with Rab9+ 
in MDA-MB-231 cells. The proportion of cmHsp70.1 mAb accounted for in terms of co-
localisation remains consistent between the 30 minute and 60 minute incubation time points 
(from 15.2 ± 3.3% to 17.7 ± 2.4%). However, the accumulation of cmHsp70.1 mAb in Rab11+ 
vesicles between 30 and 60 minute time-points was slower in MCF7 and T47D cells (MCF7: 30 
min 9.1 ± 2.1%, 60 min 24.5 ± 2.1%. T47D: 30 min 5.3 ± 3.0%, 60 min 12.1 ± 6.3%). These data 
also suggest that the level of memHsp70 expression impacts on the kinetics of cmHsp70 mAb 
uptake.  
 
Figure 3.21 Trafficking of internalised ATTO488-cmHsp70.1 mAb to Rab11+ recycling endosomes in human breast 
cancer cell lines 
MDA-MB-231, MCF7 and T47D cells grown in MatTek glass bottom dishes and incubated with ATTO488-cmHsp70.1 
mAb for either 30 or 60 minutes were fixed, permeabilised and stained for Rab11 to indicate recycling endosomes. 
Any co-localisation (white) of ATTO488-cmHsp70.1 mAb fluorescence (green) and endosome staining (magenta) 
could be confirmation of involvement of a late endosome pathway of cmHsp70.1 mAb internalisation. Co-
localisation was assessed using both Pearson’s and Manders’ M1 coefficients of co-localisation, as well as visual 
overlap of the intensity channels. Co-localisation was found in all of the cell lines, increasing over time. Images 
shown are representative single frames taken from the middle region (2nd or 3rd quartile) of cells incubated with 
ATTO488-cmHsp70.1 mAb for 60 minutes.  Scale bars are 10μm.   
 
The co-localisation of cmHsp70.1 mAb with lysosomes was determined using antibodies for 
the lysosomal associated membrane protein markers, LAMP1 and LAMP2 (Table 3.3 and Fig 
3.22). These data show a remarkably different pattern to that with the other assessed 
markers. Although a gradual increase in the co-localisation of cmHsp70.1 mAb over time was 
observed in MCF7 and T47D cells (LAMP2 co-localisation; MCF: 5 min 2.8 ± 1.2%, 15 min 12.9 ± 
2.3%, 30 min 29.4 ± 6.5 %, 60 min 35.1 ± 5.9%. T47D: 15 min 12.1 ± 2.0%, 30 min 16.1 ± 4.5%, 
60 min 24.3 ± 6.2%), there was a negligible co-localisation of cmHsp70.1 mAb with LAMP1+ or 
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LAMP2+ vesicles in MDA-MB-231 cells (LAMP2 co-localisation; 5 min 6.3 ± 4.1%, 15 min 5.9 ± 






Table 3.3 Trafficking of internalised ATTO488-cmHsp70.1 mAb to lysosomes in human breast cancer cell lines 
A Pearson coefficient of the correlation between internalised ATTO488-cmHsp70.1 mAb and staining for the 
lysosome markers LAMP1 and LAMP2, in human breast cancer cell lines MDA-MB-231, MCF7 and T47D after 5, 15, 
30 and 60 minutes incubation with cmHsp70.1 mAb. At all time-points there was a positive correlation suggesting 
some degree of co-localisation between the markers of interest. B Manders’ M1 measurement calculating the 
percentage of internalised ATTO488-cmHsp70.1 mAb which was co-localised with staining for the lysosome markers 
LAMP1 and LAMP2 over different time-points. In general, the proportion of ATTO488-cmHsp70.1 mAb co-
localisation with both LAMP1 and LAMP2 increases over time in all cell lines, indicating an accumulation of 
cmHsp70.1 mAb in lysosomes, and that this appears to inversely follow the expression of memHsp70. Data are 




A. Pearson Coefficient 5 minutes 15 minutes 30 minutes 60 minutes 
MDA-MB-231 LAMP1 0.329 ± 0.044 0.402 ± 0.107 0.465 ± 0.065 0.310 ± 0.041 
 LAMP2 0.560 ± 0.051 0.459 ± 0.039 0.590 ± 0.038 0.346 ± 0.083 
MCF7 LAMP1 0.449 ± 0.075 0.760 ± 0.113 0.858 ± 0.060 0.113 ± 0.013 
 LAMP2 0.450 ± 0.044 0.594 ± 0.112 0.682 ± 0.061 0.283 ± 0.029 
T47D LAMP1 - 0.361 ± 0.021 0.443 ± 0.050 0.109 ± 0.027 
 LAMP2 - 0.414 ± 0.046 0.445 ± 0.076 0.392 ± 0.030 
B. Manders M1 Coefficient 5 minutes 15 minutes 30 minutes 60 minutes 
MDA-MB-231 LAMP1 2.4 + 1.5 % 1.0 ± 0.7 % 3.8 ± 1.4 % 2.6 ± 1.7 % 
      
 LAMP2 6.3 + 4.1 % 5.9 + 3.2 % 7.7 ± 3.2 % 5.3 ± 3.2 % 
MCF7 LAMP1 1.9 ± 1.6 % 8.9 ± 4.2 % 13.8 ± 4.7 % 21.2 ± 5.2 % 
 LAMP2 2.8 ± 1.2 % 12.9 ± 2.3 % 29.4 ± 6.5 % 35.1 ± 5.9 % 
T47D LAMP1 - 30.2 ± 7.7 % 11.2 ± 5.5 % 13.5 ± 3.6 % 
 LAMP2 - 12.1 ± 2.0 % 16.1 ± 4.5 % 24.3 ± 6.2 % 
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Figure 3.22 Trafficking of internalised ATTO488-cmHsp70.1 mAb to lysosomes in human breast cancer cell lines 
MDA-MB-231, MCF7 and T47D cells grown in MatTek glass bottom dishes and incubated with ATTO488-cmHsp70.1 
mAb for 5, 15, 30 or 60 minutes were fixed, permeabilised and stained for LAMP1 and LAMP2 to indicate lysosomes 
endosomes. Any co-localisation (white) of ATTO488-cmHsp70.1 mAb fluorescence (green) and lysosome staining 
(magenta) could be confirmation of involvement of a late endosome pathway of cmHsp70.1 mAb internalisation. 
Co-localisation was assessed using both Pearson’s and Manders’ M1 coefficients of co-localisation, as well as visual 
overlap of the intensity channels. Co-localisation was found in all of the cell lines, increasing over time. Images 
shown are representative single frames taken from the middle region (2nd or 3rd quartile) of cells incubated with 
ATTO488-cmHsp70.1 mAb for 60 minutes and stained for LAMP2 expression.  Scale bars are 10μm.   
 
The co-localisation of cmHsp70.1 mAb with mitochondria was determined using a 
mitochondrial dye which diffuses into live cells. This approach required a different 
experimental protocol, as cells cannot be fixed. A preliminary optimisation of the staining 
protocol showed that the most reliable mitochondria staining occurred when conducted after 
the cmHsp70.1 mAb incubation period. However, since the mitochondria staining must be 
conducted at 37°C, cells will remain metabolically active and could therefore continue to 
internalise and traffic the cmHsp70.1 mAb. Care must therefore be taken when interpreting 
the mitochondria data in comparison with other co-localisation data. The time points for 
assessing mitochondria co-localisation are 30 minutes with cmHsp70.1 mAb followed by 30 
minutes with the mitochondria dye (denoted as 30+30) and 60 minutes with cmHsp70.1 mAb 
followed by 30 minutes with the dye (60+30) (Table 3.4 and Fig 3.23). All of the human-derived 
cell lines exhibited a progressive co-localisation of cmHsp70.1 mAb with mitochondria (MDA-
MB-231: 30+30 min 28.8 ± 8.9%, 60+30 min 41.1 ± 7.6%. MCF7: 30+30 min 22.3 ± 1.7 %, 60+30 












Table 3.4 Trafficking of internalised ATTO488-cmHsp70.1 mAb to mitochondria in human breast cancer cell lines 
A Pearson coefficient of the correlation between internalised ATTO488-cmHsp70.1 mAb and staining for the 
mitochondria in breast cancer cell lines MDA-MB-231, MCF7 and T47D after 30 and 60 minutes incubation with 
cmHsp70.1 mAb. At all time-points there was a positive correlation suggesting some degree of co-localisation 
between the markers of interest. B Manders’ M1 measurement calculating the percentage of internalised ATTO488-
cmHsp70.1 mAb which was co-localised with staining for the mitochondria over different time-points. The 
proportion of ATTO488-cmHsp70.1 mAb co-localisation with the mitochondria increases over time in all cell lines, 
and positively correlates to the expression of memHsp70. Data are presented as mean ± SEM from 5-10 imaged 
cells, from two independent experiments. 
 
 
Figure 3.23 Trafficking of internalised ATTO488-cmHsp70.1 mAb to mitochondria in human breast cancer cell lines 
MDA-MB-231, MCF7 and T47D cells grown in MatTek™ glass bottom dishes and incubated with ATTO488-
cmHsp70.1 mAb for 30 or 60 minutes were stained with MitoID™ red to show the mitochondria. Any co-localisation 
(white) of ATTO488-cmHsp70.1 mAB fluorescence (green) and mitochondrial staining (magenta) could be 
confirmation of trafficking of cmHsp70.1 mAB to mitochondria. Co-localisation was assessed using both Pearson’s 
and Manders’ M1 coefficients of co-localisation, as well as visual overlap of the intensity channels. Co-localisation 
was found in all of the cell lines, increasing over time. Images shown are representative single frames taken from 
the middle region (2nd or 3rd quartile) of cells incubated with ATTO488-cmHsp70.1 mAb for 60 minutes.  Scale bars 
are 10μm.   
A. Pearson Coefficient 30+30 minutes 60+30 minutes 
MDA-MB-231 0.775 ± 0.072 0.788 ± 0.018 
MCF7 0.840 ± 0.034 0.833 ± 0.048 
T47D 0.731 ± 0.032 0.735 ± 0.028 
B. Manders M1 Coefficient 30+30 minutes 60+30 minutes 
MDA-MB-231 28.8 ± 8.9 % 41.1 ± 7.6 % 
MCF7 22.3 ± 1.7 % 41.1 ± 7.7 % 
T47D 16.3 ± 2.9 % 28.0 ± 5.1 % 





Table 3.5 Trafficking of internalised ATTO488-cmHsp70.1 mAb to early endosomes in murine cancer cell lines 
A Pearson coefficient of the correlation between internalised ATTO488-cmHsp70.1 mAb and staining for the early 
endosome markers Rab4a and Rab5a, in mouse cancer cell lines 4T1 and CT26. At all time-points there was a 
positive correlation suggesting some degree of co-localisation between the markers of interest. B Manders’ M1 
measurement calculating the percentage of internalised ATTO488-cmHsp70.1 mAb which was co-localised with 
staining for the early endosome markers Rab4a and Rab5a over different time-points. The proportion of co-
localisation is low; indicating that at each time very little cmHsp70.1 mAb is within early endosomes. Data are 
presented as mean ± SEM from 7-13 imaged cells, from at least two independent experiments.  
 
 
Figure 3.24 Trafficking of internalised ATTO488-cmHsp70.1 mAb to early endosomes in murine cancer cell lines 
Murine 4T1 and CT26 cells grown in MatTek glass bottom dishes and incubated with ATTO488-cmHsp70.1 mAb for 
5, 15, 30 or 60 minutes were fixed, permeabilised and stained for the localisation of early endosomes using Rab4 
and Rab5 as markers. Any co-localisation of ATTO488-cmHsp70.1 mAb fluorescence (green) and endosome staining 
(magenta) could be confirmation of involvement of an early endosome pathway of cmHsp70.1 mAb internalisation. 
Co-localisation was assessed using both Pearson’s and Manders’ M1 coefficients of co-localisation, as well as visual 
overlap of the intensity channels. Images shown are representative single frames taken from the middle region (2nd 
or 3rd quartile) of cells incubated with ATTO488-cmHsp70.1 mAb for 30 minutes and subsequently stained for the 
presence of Rab5. No co-localisation was found, nor using the Rab4 marker.  Scale bars are 10μm.   
 
A. Pearson Coefficient 5 minutes 15 minutes 30 minutes 60 minutes 
4T1 Rab4a 0.516 ± 0.006 0.635 ±0.092 0.588 ± 0.038 0.654 ± 0.046 
 Rab5a 0.471 ± 0.080 0.671 ± 0.011 0.490 ± 0.025 0.629 ± 0.015 
CT26 Rab4a 0.213 ± 0.086 0.195 ± 0.074 0.465 ± 0.093 0.654 ± 0.011 
 Rab5a 0.162 ± 0.076 0.199 ± 0.041 0.490 ± 0.062 0.420 ± 0.080 
B. Manders M1 Coefficient 5 minutes 15 minutes 30 minutes 60 minutes 
4T1 Rab4a 5.1 ± 4.5 % 3.9 ± 0.5 % 4.5 ± 1.6 % 4.4 ± 3.5 % 
 Rab5a 2.6 ± 1.4 % 2.9 ± 0.5 % 1.5 ± 0.6 % 0.8 ± 0.4 % 
CT26 Rab4a 7.9 ± 4.1 % 12.2 ± 7.1 % 14.6 ± 3.7 % 7.4 ± 1.6 % 
 Rab5a 25.9 ± 10.5 % 8.9 ± 7.1 % 11.3 ± 3.4 % 8.1 ± 2.8 % 
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Similar analyses were conducted for the mouse-derived cell lines. Both Rab4a and Rab5a 
markers were used to assess the co-localisation of internalised cmHsp70.1 mAb with early 
endosomes. In both lines, at all time-points, and across both markers, there are very low levels 
of co-localisation (data for Rab4a at 5 min, similar for other marker/time combinations 4T1: 
5.1 ± 4.5%. CT26: 7.9 ± 4.1%) (Table 3.5 and Fig 3.24). As discussed with the human-derived 
lines, the lack of co-localisation observed does not allow for the conclusion that early 
















Table 3.6 Trafficking of internalised ATTO488-cmHsp70.1 mAb to late and recycling endosomes in murine cancer 
cell lines 
A Pearson coefficient of the correlation between internalised ATTO488-cmHsp70.1 mAb and staining for the late 
endosome markers Rab7 and Rab9 as well the recycling endosome marker Rab11, in mouse cancer cell lines 4T1 
and CT26. At all time-points there was a positive correlation suggesting some degree of co-localisation between the 
markers of interest. B Manders’ M1 measurement calculating the percentage of internalised ATTO488-cmHsp70.1 
mAb which was co-localised with staining for the late endosome markers Rab7 and Rab9 as well as the recycling 
endosome marker Rab11 over different time-points. The proportion of co-localisation with both Rab9 and Rab11 in 
all cell lines increases over time; indicating that the internalisation of cmHsp70.1 mAb could utilise endosomal 




A. Pearson Coefficient 30 minutes 60 minutes 
4T1 Rab7 0.438 ± 0.022 0.728 ± 0.022 
 Rab9 0.532 ± 0.031 0.550 ± 0.058 
 Rab11 0.529 ± 0.008 0.689 ± 0.016 
CT26 Rab7 0.591 ± 0.019 0.462 ± 0.020 
 Rab9 0.497 ± 0.027 0.372 ± 0.018 
 Rab11 0.582 ± 0.048 0.355 ± 0.052 
B. Manders M1 Coefficient 30 minutes 60 minutes 
4T1 Rab7 0.438 ± 0.022 0.728 ± 0.022 
 Rab9 0.532 ± 0.031 0.550 ± 0.058 
 Rab11 0.529 ± 0.008 0.689 ± 0.016 
CT26 Rab7 0.591 ± 0.019 0.462 ± 0.020 
 Rab9 0.497 ± 0.027 0.372 ± 0.018 
 Rab11 0.582 ± 0.048 0.355 ± 0.052 
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Figure 3.25 Trafficking of internalised ATTO488-cmHsp70.1 mAb to Rab7+ late endosomes in murine cancer lines 
Murine 4T1 and CT26 cells grown in MatTek™ glass bottom dishes and incubated with ATTO488-cmHsp70.1 mAb for 
either 30 or 60 minutes were fixed, permeabilised and stained for Rab7 to indicate late endosomes. Any co-
localisation of ATTO488-cmHsp70.1 mAb fluorescence (green) and endosome staining (magenta) could be 
confirmation of involvement of a late endosome pathway of cmHsp70.1 mAB internalisation. Co-localisation was 
assessed using both Pearson’s and Manders’ M1 coefficients of co-localisation, as well as visual overlap of the 
intensity channels. No co-localisation was found in any of the cell lines. Images shown are representative single 
frames taken from the middle region (2nd or 3rd quartile) of cells incubated with ATTO488-cmHsp70.1 mAb for 60 
minutes. Scale bars are 10μm.   
 
 
Figure 3.26 Trafficking of internalised ATTO488-cmHsp70.1 mAb to Rab9+ late endosomes in murine cancer lines 
Murine 4T1 and CT26 cells grown in MatTek glass bottom dishes and incubated with ATTO488-cmHsp70.1 mAb for 
either 30 or 60 minutes were fixed, permeabilised and stained for Rab9 to indicate late endosomes. Any co-
localisation (white) of ATTO488-cmHsp70.1 mAb fluorescence (green) and endosome staining (magenta) could be 
confirmation of involvement of a late endosome pathway of cmHsp70.1 internalisation. Co-localisation was 
assessed using both Pearson’s and Manders’ M1 coefficients of co-localisation, as well as visual overlap of the 
intensity channels. Co-localisation was found in all of the cell lines, increasing over time and increasing in line with 
the expression of memHsp70. Images shown are representative single frames taken from the middle region (2nd or 
3rd quartile) of cells incubated with ATTO488-cmHsp70.1 mAb for 60 minutes.  Scale bars are 10μm.   
 
In a similar result to that with the human-derived lines, there was no appreciable co-
localisation of cmHsp70.1 mAb with Rab7+ vesicles in either of the mouse-derived lines (4T1: 
30 min 1.7 ± 0.6%, 60 min 3.3 ± 1.1%. CT26 30 min 3.3 ± 1.4%, 60 min 11.7 ± 3.3%). However, 
some co-localisation with Rab9+ vesicles was apparent, in that there was a progressive increase 
in co-localisation, with the greater expressor of memHsp70 (4T1), also exhibiting the greater 
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co-localisation (4T1: 30 min 14.4 ± 6.4%, 60 min 25.8 ± 5.5%. CT26 30 min 9.3 ± 4.3%, 60 min 
21.6 ± 2.9%) (Table 3.6 and Fig 3.25-3.27). 
 
Figure 3.27 Trafficking of internalised ATTO488-cmHsp70.1 mAb to Rab11+ recycling endosomes in murine cancer 
cell lines 
Murine 4T1 and CT26 cells grown in MatTek glass bottom dishes and incubated with ATTO488-cmHsp70.1 mAb for 
either 30 or 60 minutes were fixed, permeabilised and stained for Rab11 to indicate recycling endosomes. Any co-
localisation (white) of ATTO488-cmHsp70.1 mAb fluorescence (green) and endosome staining (magenta) could be 
confirmation of involvement of a late endosome pathway of cmHsp70.1 mAb internalisation. Co-localisation was 
assessed using both Pearson’s and Manders’ M1 coefficients of co-localisation, as well as visual overlap of the 
intensity channels. Co-localisation was found in all of the cell lines, increasing over time. Images shown are 
representative single frames taken from the middle region (2nd or 3rd quartile) of cells incubated with ATTO488-
cmHsp70.1 mAb for 60 minutes.  Scale bars are 10μm.   
 
 
Table 3.7 Trafficking of internalised ATTO488-cmHsp70.1 mAb to lysosomes in murine cancer cell lines 
A Pearson coefficient of the correlation between internalised ATTO488-cmHsp70.1 mAb and staining for the 
lysosome marker LAMP2, in the mouse cancer cell line CT26 after 5, 15, 30 and 60 minutes incubation with 
cmHsp70.1 mAb. At all time-points there was a positive correlation suggesting some degree of co-localisation 
between the markers of interest. B Manders’ M1 measurement calculating the percentage of internalised ATTO488-
cmHsp70.1 mAb which was co-localised with staining for the lysosome marker LAMP2 over different time-points. In 
general, the proportion of ATTO488-cmHsp70.1 mAb co-localisation with LAMP2 increases over time, indicating an 
accumulation of cmHs70.1 mAb in lysosomes. Data are presented as mean ± SEM from 7-12 imaged cells, from two 
independent experiments. 
 
A. Pearson Coefficient 5 minutes 15 minutes 30 minutes 60 minutes 
4T1 LAMP2 - - - - 
CT26 LAMP2 0.620 ± 0.024 0.160 ± 0.094 0.604 ± 0.068 0.412 ± 0.026 
B. Manders M1 Coefficient 5 minutes 15 minutes 30 minutes 60 minutes 
4T1 LAMP2 - - - - 
CT26 LAMP2 1.4 ± 0.7 % 25.4 ± 3.2 % 26.8 ± 7.3 % 38.2 ± 3.7 % 
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The pattern of co-localisation with Rab11+ vesicles in CT26 and 4T1 cells was different, in that 
co-localisation progressively increased over time in CT26 cells, but remained constant in 4T1 
cells (4T1: 30 min 19.4 ± 5.7%, 60 min 15.1 ± 8.9%. CT26: 30 min 7.8 ± 1.1%, 60 min 20.3 ± 
2.7%). The more rapid internalisation of cmHsp70.1 mAb into 4T1 cells likely reflects their 
greater expression of memHsp70. 
For technical reasons, it was only possible to determine the co-localisation of cmHsp70 mAb 
with LAMP2+ lysosomes in CT26 cells. The cmHsp70.1 mAb was observed to be found co-
localised with LAMP2 as soon as the 15 minute incubation time point, and this progressively 
increased (5 min 1.4 ± 0.6%, 15 min 25.4 ± 3.2%, 30 min 26.8 ± 7.3%, 60 min 38.2 ± 3.7%) 
(Table 3.7). 
With regards to co-localisation with mitochondria, the co-localisation of cmHsp70.1 mAb in 
4T1 and CT26 cells different markedly. Although co-localisation at the first time point as well as 
an increased proportion at the later time point was apparent for 4T1 cells, there was only a 
negligible level of co-localisation at either time in the CT26 cells (4T1: 30+30 min 24.9 ± 7.4%, 







Table 3.8 Trafficking of internalised ATTO488-cmHsp70.1 mAb to mitochondria in murine cancer cell lines 
A. Pearson coefficient of the correlation between internalised ATTO488-cmHsp70.1 mAb and staining for the 
mitochondria in murine 4T1 and CT26 cells after 30 and 60 minutes incubation with cmHsp70.1 mAb. At all time-
points, there was a positive correlation suggesting some degree of co-localisation between the markers of interest. 
B. Manders’ M1 measurement calculating the percentage of internalised ATTO488-cmHsp70.1 mAb which was co-
localised with staining for the mitochondria over different time-points. The proportion of ATTO488-cmHsp70.1 mAB 
co-localisation with the mitochondria increases over time in all cell lines, and positively correlates to the expression 
of memHsp70. Data are presented as mean ± SEM from 5-6 imaged cells, from two independent experiments. 
 
 
A. Pearson Coefficient 60 minutes 60+30 minutes 
4T1 0.851 ± 0.029 0.847 ± 0.012 
CT26 0.195 ±0.047 0.192 ± 0.059 
B. Manders M1 Coefficient 60 minutes 60+30 minutes 
4T1 24.9 ± 7.4 % 36.9 ± 3.3 % 
CT26 2.1 ± 0.6 % 4.5 ± 1.9 % 
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Figure 3.28 Trafficking of internalised ATTO488-cmHsp70.1 mAb to mitochondria in murine cancer cell lines 
Murine 4T1 and CT26 cells grown in MatTek™ glass bottom dishes and incubated with ATTO488-cmHsp70.1 mAb for 
30 or 60 minutes were stained with MitoID™ red to show the mitochondria. Any co-localisation (white) of ATTO488-
cmHsp70.1 fluorescence (green) and mitochondrial staining (magenta) could be confirmation of trafficking of 
cmHsp70.1 to mitochondria. Co-localisation was assessed using both Pearson’s and Manders’ M1 coefficients of co-
localisation, as well as visual overlap of the intensity channels. Co-localisation was found in all of the cell lines, 
increasing over time. Images shown are representative single frames taken from the middle region (2nd or 3rd 
quartile) of cells incubated with ATTO488-cmHsp70.1 mAb for 60 minutes.  Scale bars are 10μm.   
 
3.4 Summary 
Although Hsp70 is typically considered as being a purely intracellular molecule, studies have 
shown that it can be actively released from cells as a soluble molecule, and also that it can be 
expressed on the plasma membranes of cancer cells (membrane Hsp70, memHsp70). 
Previously published data have demonstrated that the mouse colorectal cell line CT26 
expresses memHsp70 [534] and consequently it was included as a positive control in the 
studies that are described herein. Three human cell lines representing different degrees of 
disease severity (in descending order: MDA-MB-231, MCF7 and T47D) were examined, as was 
a murine mammary cancer cell line (4T1). Whilst all cell lines were found to express 
memHsp70, the expression levels increased with increasing severity of disease, from which the 
cells lines were derived.  
The cmHsp70.1 mAb was shown to be effective for the imaging of memHsp70+ cell lines using 
both flow cytometry and fluorescence microscopy.  It was possible to observe the uptake of 
fluorescently-labelled cmHsp70.1 mAb into the cell lines and see a pattern of vesicular 
involvement, as well as to observe that some of the antibody was free in the cell cytoplasm. 
Interrogation of confocal microscope image stacks showed the preferential presence of the 
cmHsp70.1 mAb towards the adhered surface, suggesting that this may be a favoured point of 
uptake. Intracellular vesicles were identified through the application of specific primary 
antibodies and fluorescently-labelled appropriate secondary antibodies, or through the use of 
localised dyes, enabling co-localisation measurements to track the movement of the 
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fluorescently-labelled cmHsp70.1 mAb through the cells over time. There was no observed co-
localisation of internalised cmHsp70.1 mAb with early endosomes, although this may be an 
artefact of time-point choice and speed of trafficking rather than confirmation of a non-
endocytic pathway. Involvement of late endosomes and recycling endosomes was found for all 
cell lines, with the amount of cmHsp70.1 mAb in these vesicles increasing in line with 
increasing memHsp70 expression on the cell lines. Although cmHsp70.1 mAb was also found in 
lysosomes, the amount was inverse to the memHsp70 expression of the cells. Some 
internalised cmHsp70.1 mAb was also found to traffic to the mitochondria, and again the 
proportion co-localised here increased in line with increasing expression of memHsp70 by the 
cell line under investigation.     
The uptake of cmHsp70.1 mAb by breast cancer cells is in line with published data for uptake 
of the antibody into the memHsp70+ cell line CT26. Employing the use of confocal imaging and 
detailed image analysis has allowed for further understanding of the trafficking of cmHsp70.1 
mAb internalised in memHsp70+ breast cancer cell lines.   
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CHAPTER 4: Results II – Internalisation of the TKDNNLLGRFELSG 
peptide by cancer cells expressing membrane Hsp70 
4.1 Introduction 
A monoclonal antibody which specifically binds to and is taken up by memHsp70+ breast 
tumour cells has potential as a therapeutic vehicle for the targeting of tumours. Indeed human 
monoclonal antibodies engineered with radio-labels to deliver therapeutic treatment in a 
highly selective and targeted manner is being investigated in a wide range of malignancies 
[552-556]. However, the use of antibodies does have drawbacks. Their production and 
purification are labour-intensive and highly expensive. In addition, when the antibodies have 
been derived in other species (very often in mice) they cannot be directly applied due being 
immunogenic in humans and consequently they are first transformed through a process of 
chimeric humanisation, after which there can be changes in the affinity, avidity or specificity.  
An alternative strategy is to use small molecules, such as peptides, as they are easier and 
cheaper to produce than antibodies, and can be generated in large quantities at high purity. In 
addition, peptides typically exhibit good stability in vivo and better biodistribution than 
antibodies, and are better at penetrating tissues. Therapeutic peptides are already in use in 
breast [557] as well as other cancers [558] and can be used as a tool to aid diagnostic imaging 
or to specifically deliver radionuclide therapy.  
In order for peptide-based therapies to be applicable to the widest number of patients it is 
necessary that their cellular recognition structure is widely expressed. Membrane Hsp70 offers 
such a structure, with around half of breast cancer patients having tumours which are positive 
for memHsp70 expression [285, 287-289, 543]. The capacity of a 14-mer peptide derived from 
Hsp70 (TKDNNLLGRFELSG) which had been identified as being capable of binding to 
memHsp70+ tumour cell lines to bind to, and be internalised by, cancer cell lines expressing 
memHsp70 was therefore investigated in this study.  
4.2 Binding of TKDNNLLGRFELSG peptide to cancer cells expressing 
memHsp70  
The binding of TKDNNLLGRFELSG peptide to memHsp70+ tumour cells was assessed by flow 
cytometry using a carboxy-fluorescein labelled preparation of the peptide (CF-
TKDNNLLGRFELSG) and a correspondingly labelled ‘scrambled’ peptide having an identical 
amino acid composition, but different sequence (NGLTLKNDFSRLEG, termed NGL). 
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Cells previously grown for 48 hours were harvested, counted and incubated with 75μg/mL CF- 
TKDNNLLGRFELSG at 4°C for 30 min. Cells were washed once with staining buffer (PBS 
containing 10% v/v FCS) then analysed on a BD LSRII flow cytometer. Cells which had been 
incubated in staining buffer without CF-TKDNNLLGRFELSG were used as a control, as well as 
cells incubated with a carboxy-fluorescein labelled scrambled version of the peptide (CF-NGL). 
The median fluorescent intensity of the whole population was used to calculate a relative 
intensity of each sample compared to the unstained control cells. Any relative value above one 
is indicative of specific binding, with greater values corresponding to more CF-
TKDNNLLGRFELSG bound to cells (Fig 4.1).  
 
Figure 4.1 Binding of CF-TKDNNLLGRFELSG and CF-NGLTLKNDFSRLEG peptides to cancer cell lines  
A. Representative flow cytometry plots showing the fluorescent intensity of MDA-MB-231 cells incubated for 30 
minutes at 4oC in staining buffer (black line), with CF-NGLTLKNDFSRLEG peptide (grey line) and with CF-
TKDNNLLGRFELSG peptide (green line). The binding of CF-TKDNNLLGRFELSG peptide (solid bars) and the scrambled 
control CF-NGLTLKNDFSRLEG peptide (slashed bars) to both human and mouse cancer cell lines, expressed as the 
intensity of fluorescence in the whole population relative to cells that were unstained. A measurement of greater 
than 1 indicates specific binding of CF-TKDNNLLGRFELSG and the higher the value the more peptide is bound. The 
cell lines which express more memHsp70 bind more CF-TKDNNLLGRFELSG, whilst binding of CF-NGLTLKNDFSRLEG 
was negligible. Data are presented as mean ± SEM and are the result of 4-7 independent experiments.  
 
CF-TKDNNLLGRFELSG bound to all of the cell lines, in a manner which was similar to that which 
was observed for the cmHsp70 mAb. Of the three human breast cancer cell lines, the lowest 
expresser of memHsp70, T47D, also showed the lowest binding of CF-TKDNNLLGRFELSG (1.42 
± 0.20 relative to unstained cells). The greatest expresser of memHsp70, MDA-MB-231, 
showed the greatest capacity to bind CF-TKDNNLLGRFELSG (2.61 ± 0.78 relative to unstained 
cells). MCF7 cells exhibited an intermediate capacity to bind CF-TKDNNLLGRFELSG (1.92 ± 
0.27). A similar situation was observed in the two mouse cancer cell lines, with the greatest 
expresser of memHsp70 (4T1), exhibiting higher relative CF-TKDNNLLGRFELSG binding (2.76 ± 
0.33) than CT26 cells (2.23 ± 0.34). Overall, there were no significant differences between the 
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CF-TKDNNLLGRFELSG binding of the cell lines (one way ANOVA F=1.749, p=0.167), although 
there was a significant difference in the binding of CF-TKDNNLLGRFELSG peptide to the highest 
and lowest binding cell lines (4T1 and T47D respectively; p=0.025 Games-Howell post hoc 
comparison).  
4.3 Internalisation of CF-TKDNNLLGRFELSG peptide by cancer cells 
expressing memHsp70 
As CF-TKDNNLLGRFELSG peptide is able to bind to memHsp70+ tumour cells, the next step was 
to confirm whether the peptide can also be internalised by these cells. For this, cells were 
grown for 48 hours then harvested, counted and incubated in staining buffer in the presence 
of 75μg/mL CF-TKDNNLLGRFELSG at 37°C (allowing cells to remain metabolically active) for up 
to 60 min. As a control, cells were also incubated with carboxyl-fluorescein labelled scrambled 
peptide (CF-NGL). Cells were washed in staining buffer and the median fluorescent intensity of 
the whole population of cells was analysed by flow cytometry. The fluorescent intensity of cells 
that had been maintained at 4°C over the same time period reflected cell surface CF-
TKDNNLLGRFELSG binding, with the additional fluorescence seen in cells incubated at 37°C 
reflecting the internalisation of CF-TKDNNLLGRFELSG (Fig 4.2).  
All cell lines were capable of internalising CF-TKDNNLLGRFELSG, as demonstrated by a 
significant difference between the mfi of cells incubated with CF-TKDNNLLGRFELSG at 37°C 
and incubated at 4°C (One-way ANOVA. MDA-MB-231: F=22.331, p<0.001; MCF7: F=11.087, 
p<0.001; T47D: F=19.146, p<0.001; CT26: F=10.905, p<0.001; 4T1: F=79.815, p<0.001). The 
greatest internalisation for each line was observed after 60 minutes, although no cell line 
appeared to have reached saturation by this time. Although the internalisation of CF-
TKDNNLLGRFELSG is mediated through memHsp70, the observed memHsp70 expression and 
CF-TKDNNLLGRFELSG internalisation was not entirely as expected. Although the MDA-MB-231, 
MCF7 and CT26 cell lines internalised more CF-TKDNNLLGRFELSG than T47D cells (the lowest 
memHsp70 expresser) after 60 minutes (mfi: 6,415 ± 733, Gabriel post-hoc comparisons: with 
MDA-MB-231 p=0.003, with MCF7 p=0.024, with 4T1 p=0.032, with CT26 p=0.0001), the MDA-
MB-231 and MCF7 cells did so in reverse of their memHsp70 expression (MDA-MB-231: 17,341 
± 2,463. MCF7: 22,305 ± 5,769. Data presented as mean ± SEM). The same was true of the 
mouse lines, with the lower memHsp70 expresser CT26 internalising more CF-
TKDNNLLGRFELSG (18,614 ± 4,299. Data presented as mean ± SEM) than the 4T1 cells which 
expressed higher levels of memHsp70 (14,317 ± 1,457. Data presented as mean ± SEM). 
However, there were no significant differences in the amount of CF-TKDNNLLGRFELSG which 
was internalised by MDA-MB-231, MCF7, 4T1 or CT26 cells. This suggests that there could be a 
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threshold level for an amount of memHsp70 required for adequate internalisation of CF-
TKDNNLLGRFELSG. T47D cells, which express less memHsp70 than any other cell line 
investigated here, were the only cells found to internalise significantly less CF-
TKDNNLLGRFELSG peptide.  
 
Figure 4.2 Flow cytometric assessment of CF-TKDNNLLGRFELSG peptide uptake into cancer cell lines 
A. Representative flow cytometry plots showing the fluorescent intensity of MDA-MB-231 cells incubated for 60 
minutes at 37oC in medium (black line), with CF-NGLTLKNDFSRLEG peptide (grey line) and with CF-
TKDNNLLGRFELSG peptide (green line). B. Cells were incubated in the presence of CF-TKDNNLLGRFELSG peptide 
with samples saved at different time points, for up to an hour. The median fluorescent intensity of the whole 
population was recorded, as a relative measure of the amount of CF-TKDNNLLGRFELSG. The intensity after 4oC 
incubation relates to the binding of peptide to the cell surface, while the 37oC incubation allows for inclusion of 
peptide internalisation. All cell lines are capable of binding and internalising CF-TKDNNLLGRFELSG peptide, although 
the internalisation was much lower in T47D cells (the line which expresses the least memHsp70).  Significantly more 
CF-TKDNNLLGRFELSG is associated with cells after incubation at 37oC (One-way ANOVA, F=11.066, p<0.001), 
thereby demonstrating that all cell lines are capable of internalising CF-TKDNNLLGRFELSG. Data are presented as 
mean ± SEM of at least three independent experiments. 
 
Cells were also imaged using fluorescent and confocal microscopy to produce wide angle tile 
scans as well as z-stack images of the full height of cells. This way it was possible to confirm the 
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presence of CF-TKDNNLLGRFELSG peptide within the cells. Initially fluorescent microscopy 
images were used to demonstrate the selective uptake of CF- TKDNNLLGRFELSG peptide over 




Figure 4.3 Representative tile scan images showing peptide uptake into MDA-MB-231 cells 
Tile scan images were produced for MDA-MB-231, MCF7, T47D, 4T1 and CT26 cells, across different time-points of 
incubation with Hsp70 antibodies. Representative tile scan images of MDA-MB-231 cells incubated with CF-
TKDNNLLGRFELSG (A) and CF-NGLTLKNDFSRLEG (B) antibodies for 60 minutes are shown. Peptides are shown in 
green and the nucleus stained with DAPI is shown in blue. Scale bar represents 50µm 
 
Fluorescent tile scan images were analysed using the software package ImageJ, in order to 
calculate the mean fluorescent intensity (normalised to the intensity of the background) of all 
imaged cells. Over time, the intensity from CF-TKDNNLLGRFELSG peptide increased in all cell 
lines, thereby confirming the flow cytometry data. Furthermore, the maximum observed 
fluorescent intensity for each cell line positively tracked to the level of memHsp70 expression 
of the cells (Fig 4.4). This was not exactly mimicked when cells were examined using flow 
cytometry, although still the cell lines expressing most memHsp70 were observed to uptake 
the most amount of antibody.  
A B 
141 | P a g e  
 
 
Figure 4.4 Uptake of CF-TKDNNLLGRFELSG peptide into human and murine cancer cell lines expressing differing 
levels of memHsp70 
Cancer cell lines from human (A) and mouse (B) grown in MatTek™ glass bottom dishes were incubated in the 
presence of CF-TKDNNLLGRFELSG peptide for up to an hour then imaged using fluorescent microscopy. Mean 
fluorescent intensity values were calculated, normalised to background fluorescence. All cell lines are capable of 
internalising the CF-TKDNNLLGRFELSG peptide, albeit to varying degrees, and the level of internalisation positively 
increased with increasing memHsp70 expression of cell lines. Data are presented as mean ± SEM of a minimum of 
80 cells from at least three independent experiments.   
 
As neither flow cytometry nor fluorescent microscopy can make any distinction between 
fluorescence on the surface of cells or inside cells, using these techniques it is not possible to 
confirm whether cells incubated at 37°C do indeed internalise the peptide or just allow for 
greater surface binding. In order to further investigate which occurs, it was necessary to use 
another imaging technique – namely confocal microscopy. 
 
4.3.1 Distribution of CF-TKDNNLLGRFELSG peptide after internalisation into 
memHsp70+ cancer cells 
The intracellular distribution of internalised CF-TKDNNLLGRFELSG was examined using confocal 
microscopy.  For this, cells were grown for 48 hours in glass-bottomed dishes before the 
growth medium was aspirated and replaced with staining buffer containing 75µg/mL CF-
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TKDNNLLGRFELSG. Cells were incubated for up to 60 minutes at 37°C to allow internalisation 
of CF-TKDNNLLGRFELSG to occur. Afterwards, cells were washed with staining buffer, 
formaldehyde fixed and mounted onto microscopy slides with VECTASHIELD® containing DAPI. 
Slides were kept cool and protected from light until imaging could be completed. Initially, 
single frame tile scan images of a large area of cells were imaged using an open pinhole 
setting, after which a minimum of four separate cells were imaged by confocal z-stack. 
Representative mid-stack, single frame images from one cell at each time point are shown (Fig 
4.5A-4.9A). Bright-field images are also provided in order to confirm the internalisation of the 
CF-TKDNNLLGRFELSG (shown in green). The number of spots was determined for every cell 
imaged and data are presented as the mean number of fluorescent spots per cell at each time 
point (Fig 4.5B – 4.9B). 
 
Figure 4.5 Kinetics of CF-TKDNNLLGRFELSG peptide uptake into MDA-MB-231 cells  
A. Representative single frame images showing CF-TKDNNLLGRFELSG peptide internalised into MDA-MB-231 cells. 
Frames were selected from the mid-point of cells (25-75% of distance from adhered surface). CF-TKDNNLLGRFELSG 
peptide (green) appears in well-defined vesicles rather than free in the cytosol. The frames depict a region 0.88µm 
thick. Scale bars are 10µm. For clarity, the nucleus was stained with DAPI and is shown here in blue. B. The number 
of distinct fluorescent spots in cells after different incubation times. This is a total count including spots within the 
cell and at the membrane. Data is presented as mean ± SEM for at least four individual cells, from two independent 
experiments.  
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Figure 4.6 Kinetics of CF-TKDNNLLGRFELSG peptide uptake into MCF7 cells 
A. Representative single frame images showing CF-TKDNNLLGRFELSG peptide internalised into MCF7 cells. Frames 
were selected from the mid-point of cells (25-75% of distance from adhered surface). CF-TKDNNLLGRFELSG peptide 
(green) appears in well-defined vesicles rather than free in the cytosol. The frames depict a region 0.88µm thick. 
Scale bars are 10µm. For clarity, the nucleus was stained with DAPI and is shown here in blue. B. The number of 
distinct fluorescent spots in cells after different incubation times. This is a total count including spots within the cell 
and at the membrane. Data is presented as mean ± SEM for at least six individual cells, from two independent 




Figure 4.7 Kinetics of CF-TKDNNLLGRFELSG peptide uptake into T47D cells 
A. Representative single frame images showing CF-TKDNNLLGRFELSG peptide internalised into T47D cells. Frames 
were selected from the mid-point of cells (25-75% of distance from adhered surface). CF-TKDNNLLGRFELSG peptide 
(green) appears in well-defined vesicles rather than free in the cytosol. The frames depict a region 0.88µm thick. 
Scale bars are 10µm. For clarity, the nucleus was stained with DAPI and is shown here in blue. B. The number of 
distinct fluorescent spots in cells after different incubation times. This is a total count including spots within the cell 
and at the membrane. Data is presented as mean ± SEM for at least six individual cells, from two independent 
experiments.  
 




Figure 4.8 Kinetics of CF-TKDNNLLGRFELSG peptide uptake into CT26 cells 
A. Representative single frame images showing CF-TKDNNLLGRFELSG peptide internalised into CT26 cells. Frames 
were selected from the mid-point of cells (25-75% of distance from adhered surface). CF-TKDNNLLGRFELSG peptide 
(green) appears in well-defined vesicles rather than free in the cytosol. The frames depict a region 0.88µm thick. 
Scale bars are 10µm. For clarity, the nucleus was stained with DAPI and is shown here in blue. B. The number of 
distinct fluorescent spots in cells after different incubation times. This is a total count including spots within the cell 





Figure 4.9 Kinetics of CF-TKDNNLLGRFELSG peptide uptake into 4T1 cells 
A. Representative single frame images showing CF-TKDNNLLGRFELSG peptide internalised into 4T1 cells. Frames 
were selected from the mid-point of cells (25-75% of distance from adhered surface). CF-TKDNNLLGRFELSG peptide 
(green) appears in well-defined vesicles rather than free in the cytosol. The frames depict a region 0.88µm thick. 
Scale bars are 10µm. For clarity, the nucleus was stained with DAPI and is shown here in blue. B. The number of 
distinct fluorescent spots in cells after different incubation times. This is a total count including spots within the cell 
and at the membrane. Data is presented as mean ± SEM for at least four individual cells.  
 
For all of the cell lines, the majority of CF-TKDNNLLGRFELSG appeared to be at the surface 
during the very early time points and intracellularly after 60 minutes incubation. CF-
TKDNNLLGRFELSG was not found to locate in the nucleus in any of the five cell lines at any of 
the time points assessed. As was observed for the cmHsp70 mAb, all cell lines investigated 
exhibited multiple clear, distinct spots of CF-TKDNNLLGRFELSG fluorescence. The number of 
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spots progressively increased in all of the cells lines, with MDA-MB-231 and MCF7 cells 
showing similar CF-TKDNNLLGRFELSG spot counts and an increase of almost four-fold from the 
5 minute to 60 minute time point (MDA-MB-231: 5 min = 26 ± 4 spots, 60 min = 87 ± 7 spots. 
MCF7: 5 min = 23 ± 2, 60 min = 80 ± 5. Data presented as mean ± SEM). There was a rapid 
increase in the spot count during the first 15 minutes in MDA-MB-231 cells, which was 
followed by a more consistent, steady increase thereafter. Almost all of the internalisation into 
MCF7 cells occurred between 15 and 30 min, with virtually no additional accumulation being 
apparent between 30 and 60 min. The internalisation of CF-TKDNNLLGRFELSG into T47D cells 
was less rapid (5 min = 18 ± 8, 60 min = 43 ± 5), but showed a similar internalisation pattern to 
MCF7 cells, with the largest increase in spot number occurring between 15 and 30 min. The 
level of CF-TKDNNLLGRFELSG internalisation appears to correlate with memHsp70 status, as 
T47D cells express the least memHsp70 and were found to present fewer spots of internalised 
CF-TKDNNLLGRFELSG, whereas the lines expressing more memHsp70 (MDA-MB-231 and 
MCF7) exhibited almost twice as many spots of internalised CF-TKDNNLLGRFELSG.  
In contrast to the human cell lines, there was little change in accumulation of CF-
TKDNNLLGRFELSG spots in the murine cells lines between the 5 minute and 60 minute 
incubation times (4T1: 5 min= 76 ± 9, 60 min = 93 ± 9. CT26: 5 min = 52 ± 3, 60 min = 79 ± 6). 
After only 5 min, both mouse cell lines exhibited CF-TKDNNLLGRFELSG spot counts that were 
at least twice that seen in any of the human breast cancer cell lines, indicating that these cells 
have an even greater and faster capability for internalising CF-TKDNNLLGRFELSG.  
As well as a total spot count per cell, CF-TKDNNLLGRFELSG spots were counted per frame of 
each cell stack, as has been described previously, making use of z-stack images (Fig 4.10). 
Across all cell lines, there was a trend for the bulk of the CF-TKDNNLLGRFELSG to be present at 
or near to the adhered surface of the cell. This holds across all time points, despite the amount 
of CF-TKDNNLLGRFELSG in other regions of the cell increasing (Fig 4.11 and 4.12).  




Figure 4.10 Representative montage of z-stack confocal images showing CF-TKDNNLLGRFELSG internalised into 
MDA-MB-231 cells.  
Z-stack frames from the full height of a single MDA-MB-231 cell demonstrating distribution of CF-TKDNNLLGRFELSG 
following 60 minutes incubation time. Single frame images start at the adhered surface and finish at the apex of the 
cell. Brightfield imaging is included to help with orientation. Internalised cmHsp70.1 mAb is shown in green, DAPI 
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Figure 4.11 Distribution of internalised CF-TKDNNLLGRFELSG in human breast cancer cell lines 
Distribution of internalised CF-TKDNNLLGRFELSG spots in every human breast cancer cell imaged at each time point 
up to 60 minutes. Although CF-TKDNNLLGRFELSG appears throughout the full height of the cells, there appears to 
be a greater accumulation towards the adhered surface of the cells. Cells which were incubated with CF-
TKDNNLLGRFELSG for the longest periods showed a greater number of spots in the middle region of cells.  Each line 
represents the profile of an individual cell, with a minimum of three cells per condition. 
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Figure 4.12 Distribution of internalised CF-TKDNNLLGRFELSG in mouse cancer cell lines 
Distribution of internalised CF-TKDNNLLGRFELSG spots in every 4T1 and CT26 cell imaged at each time point up to 
60 minutes. Although CF-TKDNNLLGRFELSG appears throughout the full height of the cells, there is a clear bias 
towards the peptide being present close to the adhered surface of the cells. This asymmetrical distribution was 
observed at all time-points. Each line represents the profile of an individual cell, with a minimum of four cells per 
condition. 
 
149 | P a g e  
 
To better allow interrogation of the CF-TKDNNLLGRFELSG distribution data, spot counts were 
totalled over quartiles of the cells’ height (Fig 4.13A–4.17A). This allowed average 
measurements to be made, rather than relying on raw data for all of the individual cells. Across 
all cell lines the quartile which contained the most CF-TKDNNLLGRFELSG spots was 0-25% from 
the adhered surface. These data confirm that CF-TKDNNLLGRFELSG is also preferentially 
internalised through the adhered surface. Represented composite stack images are displayed 
to show the number of spots in the upper most and lower most quartiles of each cell line after 
5 minutes and 60 minutes incubation with the CF-TKDNNLLGRFELSG peptide (Fig 4.13B-4.17B).   
 
Figure 4.13 Distribution of internalised CF-TKDNNLLGRFELSG in MDA-MB-231 cells 
A CF-TKDNNLLGRFELSG spot counts over the full height of cells at all incubation time points. The quartile containing 
the adherent surface consistently holds the greatest number of CF-TKDNNLLGRFELSG spots. As the incubation time 
increases spot counts increase over the middle quartiles (25-50% and 50-75%). The spot count remains very similar 
in the quartile containing the apex (75-100%). Data are presented as mean ± SEM, n = 5. B Representative 
fluorescence images of the first and last quartiles (0-25% and 75-100%) after 5 minutes and 60 minutes incubation 
with CF-TKDNNLLGRFELSG. These are composite images of all frames that make up the quartile. Bright-field images 
are included to confirm placement of cell boundaries.  




Figure 4.14 Distribution of internalised CF-TKDNNLLGRFELSG in MCF7 cells 
A CF-TKDNNLLGRFELSG spot counts over the full height of cells at all incubation time points. The quartile containing 
the adherent surface consistently holds the greatest number of CF-TKDNNLLGRFELSG spots. As the incubation time 
increases spot counts increase over the middle quartiles (25-50% and 50-75%). The spot count remains very similar 
in the quartile containing the apex (75-100%). Data are presented as mean ± SEM, n = 7. B Representative 
fluorescence images of the first and last quartiles (0-25% and 75-100%) after 5 minutes and 60 minutes incubation 
with CF-TKDNNLLGRFELSG. These are composite images of all frames that make up the quartile. Bright-field images 
are included to confirm placement of cell boundaries.  
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Figure 4.15 Distribution of internalised CF-TKDNNLLGRFELSG in T47D cells 
A CF-TKDNNLLGRFELSG spot counts over the full height of cells at all incubation time points. The quartile containing 
the adherent surface consistently holds the greatest number of CF-TTP spots. As the incubation time increases spot 
counts increase over the middle quartiles (25-50% and 50-75%). The spot count remains very similar in the quartile 
containing the apex (75-100%). Data are presented as mean ± SEM, n = 11. B Representative fluorescence images of 
the first and last quartiles (0-25% and 75-100%) after 5 minutes and 60 minutes incubation with CF-
TKDNNLLGRFELSG. These are composite images of all frames that make up the quartile. Bright-field images are 
included to confirm placement of cell boundaries.  
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Figure 4.16 Distribution of internalised CF-TKDNNLLGRFELSG in 4T1 cells 
A CF-TKDNNLLGRFELSG spot counts over the full height of cells at all incubation time points. The quartile containing 
the adherent surface consistently holds the greatest number of CF-TKDNNLLGRFELSG spots. As the incubation time 
increases spot counts increase over the middle quartiles (25-50% and 50-75%). The spot count remains very similar 
in the quartile containing the apex (75-100%). Data are presented as mean ± SEM, n = 6. B Representative 
fluorescence images of the first and last quartiles (0-25% and 75-100%) after 5 minutes and 60 minutes incubation 
with CF-TKDNNLLGRFELSG. These are composite images of all frames that make up the quartile. Bright-field images 
are included to confirm placement of cell boundaries.  
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Figure 4.17 Distribution of internalised CF-TKDNNLLGRFELSG in CT26 cells 
A CF-TKDNNLLGRFELSG spot counts over the full height of cells at all incubation time points. The quartile containing 
the adherent surface consistently holds the greatest number of CF-TKDNNLLGRFELSG spots. As the incubation time 
increases spot counts increase over the middle quartiles (25-50% and 50-75%). The spot count remains very similar 
in the quartile containing the apex (75-100%). Data are presented as mean ± SEM, n = 9. B Representative 
fluorescence images of the first and last quartiles (0-25% and 75-100%) after 5 minutes and 60 minutes incubation 
with CF-TKDNNLLGRFELSG. These are composite images of all frames that make up the quartile. Bright-field images 
are included to confirm placement of cell boundaries.  
 
In the three human cell lines, as the incubation duration increases so does the mean spot 
count of CF-TKDNNLLGRFELSG, particularly evident in the first three quartiles (0-75%) thereby 
demonstrating an accumulation of CF-TKDNNLLGRFELSG throughout the cells over time. At all 
time-points, very little CF-TKDNNLLGRFELSG is found within the apex quartile of the cells. The 
situation in the mouse cell lines differs, with the CF-TKDNNLLGRFELSG distribution through the 
cells remaining similar across the time-points, with the vast majority of CF-TKDNNLLGRFELSG 
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being found in the quartile at the adherent cell surface. This could be due to CF-
TKDNNLLGRFELSG being trafficked more slowly in the mouse cell lines, and thus the 
accumulation of CF-TKDNNLLGRFELSG takes longer than the durations examined here. The 
large number of CF-TKDNNLLGRFELSG spots in the adherent surface quartile, even after the 
shortest duration, suggests a potential preferential route of internalisation around the point of 
cell adhesion.  
4.3.2 Internalised CF-TKDNNLLGRFELSG peptide associates with mitochondria   
As was observed for cmHsp70 mAb, internalised CF-TKDNNLLGRFELSG appears as well defined, 
distinct spots throughout the cell, thereby leading to the proposition that is associated with 
intracellular vesicles. Attempts were therefore made to stain the intracellular vesicles of cells 
incubated with CF-TKDNNLLGRFELSG in order to determine co-localisation profiles. For these 
experiments, cells were grown for 48 hours in glass bottomed dishes and then incubated in 
staining buffer containing 75µg/mL CF-TKDNNLLGRFELSG. After the desired incubation period, 
cells were formaldehyde fixed, permeabilised and stained with appropriate primary and 
secondary antibodies, as described previously. However, fluorescence signals could be 
detected. In an attempt to solve this problem, different permeabilisation agents were tried 
(saponin, Triton X and methanol), but all with the same result. The conclusion is that 
permeabilisation results in the peptide being washed out from cells, however the reason for 
this is unclear. Unfortunately it was not possible to generate Biacore data relating to peptide 
binding affinity, however a peptide ELISA demonstrated that the TKDNNLLGRFELSG peptide 
bound specifically to Hsp70 in a concentration-dependent manner [535]. In the future it would 
be of interest to obtain Biacore data to establish with what affinity the peptide binds to Hsp70.  
Due to the observed peptide leaching it was not possible to fully elucidate the internalisation 
pathway of CF-TKDNNLLGRFELSG. A different protocol would need to be employed, such as 
labelling the vesicles of live cells rather than having to fix and then permeabilise cells, and this 
would be the strategy adopted in the future. There was just one intracellular structure for 
which co-localisation investigations could be conducted; the mitochondria. This is because the 
MitoID staining protocol involves using live cells, with the stain diffusing in rather than 
requiring cell permeabilisation. Co-localisation of the CF-TKDNNLLGRFELSG peptide and 
stained mitochondria was assessed following 60 minute incubation with the CF-
TKDNNLLGRFELSG peptide with subsequent 30 minute mitochondrial staining, for the human 
breast cancer cell lines MDA-MB-231, MCF7 and T47D (Table 4.1 and Fig 4.18) and the mouse 
cancer cell lines 4T1 and CT26 (Table 4.2 and Fig 4.19). 
 









Table 4.1 Trafficking of internalised CF-TKDNNLLGRFELSG peptide to mitochondria in human breast cancer cell 
lines 
A. Pearson coefficient of the correlation between internalised CF-TKDNNLLGRFELSG peptide and staining for the 
mitochondria in breast cancer cell lines MDA-MB-231, MCF7 and T47D after 60 minutes incubation with CF-
TKDNNLLGRFELSG. The positive correlation suggests some degree of co-localisation. B. Manders’ M1 measurement 
calculating the percentage of internalised CF-TKDNNLLGRFELSG which was co-localised with staining for the 
mitochondria. The proportion of CF-TKDNNLLGRFELSG co-localising with the mitochondria is increases with the 




Figure 4.18 Trafficking of internalised CF-TKDNNLLGRFELSG peptide to mitochondria in human breast cancer cell 
lines 
MDA-MB-231, MCF7 and T47D cells grown in MatTek™ glass bottom dishes and incubated with CF-
TKDNNLLGRFELSG peptide for 60 minutes were stained with MitoID™ red to show the mitochondria. Any co-
localisation (white) of CF-TKDNNLLGRFELSG fluorescence (green) and mitochondrial staining (magenta) could be 
confirmation of trafficking of CF-TKDNNLLGRFELSG to mitochondria. Co-localisation was assessed using both 
Pearson’s and Manders’ M1 coefficients of co-localisation, as well as visual overlap of the intensity channels. Co-
localisation was found in all of the cell lines, increasing in line with increased memHsp70 expression. Images shown 
are representative single frames taken from the middle region (2nd or 3rd quartile) of cells incubated CF-
TKDNNLLGRFELSG for 60 minutes.  Scale bars are 10μm.   
A. Pearson Coefficient 60+30 minutes 
MDA-MB-231 0.585 ± 0.065 
MCF7 0.855 ± 0.010 
T47D 0.813 ± 0.010 
B Manders M1 Coefficient 60+30 minutes 
MDA-MB-231 43.3 ± 7.0 % 
MCF7 40.7 ± 5.6 % 
T47D 14.1 ± 4.1 % 

















Table 4.2 Trafficking of internalised CF-TKDNNLLGRFELSG peptide to mitochondria in murine cancer cell lines 
A. Pearson coefficient of the correlation between internalised CF-TKDNNLLGRFELSG peptide and staining for the 
mitochondria in cancer cell lines 4T1 and CT26 after 60 minutes incubation with CF-TKDNNLLGRFELSG. There was a 
positive correlation suggesting some degree of co-localisation. B. Manders’ M1 measurement calculating the 
percentage of internalised CF-TKDNNLLGRFELSG which was co-localised with staining for the mitochondria. The 
proportion of CF-TKDNNLLGRFELSGco-localisation with the mitochondria positively correlates to the expression of 






Figure 4.19 Trafficking of internalised CF-TKDNNLLGRFELSG to mitochondria in murine cancer cells lines 
4T1 and CT26 cells grown in MatTek™ glass bottom dishes and incubated with CF-TTP for 60 minutes were stained 
with MitoID™ red to show the mitochondria. Any co-localisation (white) of CF-TTP fluorescence (green) and 
mitochondrial staining (magenta) could be confirmation of trafficking of TTP to mitochondria. Co-localisation was 
assessed using both Pearson’s and Manders’ M1 coefficients of co-localisation, as well as visual overlap of the 
intensity channels. Co-localisation was found in both of the cell lines. Images shown are representative single 
frames taken from the middle region (2nd or 3rd quartile) of cells incubated with ATTO488-cmHsp70.1 mAb for 60 
minutes. Although hoechst staining of the nucleus was also conducted the strength of the signal was insufficient to 
obtain images under confocal conditions.  Scale bars are 10μm.   
 
 
Some degree of co-localisation between internalised CF-TKDNNLLGRFELSG and mitochondria 
was apparent in all of the human breast cancer cell lines. Using the Manders’ M1 coefficient, it 
was possible to calculate the proportion of CF-TKDNNLLGRFELSG co-localising at the 
mitochondria. The proportion of co-localisation appears to correlate with the memHsp70 
A. Pearson Coefficient 60+30 minutes 
4T1 0.822 ± 0.011 
CT26 0.778 ± 0.011 
B. Manders M1 Coefficient 60+30 minutes 
4T1 31.2 ± 4.8 % 
CT26 4.2 ± 2.1 % 
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status, with the greatest co-localisation being apparent in MDA-MB-231 cells (43.3 ± 7.0%), 
followed by MCF7 (40.7 ± 5.6%) and T47D cells (14.1 ± 4.1%). The two mouse cancer cell lines 
exhibited vastly different degree of CF-TKDNNLLGRFELSG co-localisation with the mitochondria 
(4T1: 31.2 ± 4.8% CT26: 4.2 ± 2.1%), but this still followed in line with their memHsp70 
expression.  
4.4 Summary 
The Hsp70-derived 14-mer peptide TKDNNLLGRFELSG was found to bind to memHsp70+ breast 
cancer cell lines, in a manner which positively tracked with the expression density of 
memHsp70. When cells were incubated with the CF-TKDNNLLGRFELSG peptide at 37oC, and 
were therefore metabolically active, the peptide was rapidly internalised. The accumulated 
intracellular quantities of peptide also increased with increasing levels of memHsp70 
expression on cell lines. There is a good degree of specificity to the binding and internalisation, 
although a ‘scrambled’ version of the peptide (NGL) did exhibit a small amount of binding and 
internalisation as well. The NGL peptide comprises the same 14 amino acids, and so will have 
the same overall charge as the TKDNNLLGRFELSG peptide, and this may explain the low levels 
of binding and uptake exhibited. 
When cells were fixed and permeabilised any internalised peptide was found to leak from the 
cells, making staining of intracellular vesicles difficult. The mitochondrial stain, which passively 
diffuses into live cells, did not pose this problem and the CF-TKDNNLLGRFELSG peptide was 
found to co-localise to mitochondria in the same manner as the cmHsp70.1 mAb. Due to time 
constraints it was not possible to use other similar diffuse dyes to study co-localisation with 
other intracellular structures, however this is something which could be looked into in the 
future.  
Since TKDNNLLGRFELSG is part of the oligomerisation domain of Hsp70, it was hypothesized 
that the binding of the peptide to Hsp70 involves mechanisms that are related to the 
oligomerisation domain of Hsp70. Furthermore, it appeared that the uptake and intracellular 
transport of TKDNNLLGRFELSG follows similar pathways as those for the cmHsp70.1 mAb.  
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CHAPTER 5  
Results III – Internalisation of recombinant human Granzyme B by 
cancer cell lines expressing membrane Hsp70 
5.1 Introduction 
The serine protease granzyme B is one of the primary constituents of cytotoxic granules 
released by NK cells and cytotoxic CD8+ T cells. In this setting, granzyme B is released in 
conjunction with perforin which facilitates its delivery into target cells. Granzyme B 
preferentially cleaves substrates at aspartic acid residues [55] and acts on many components 
of the apoptotic pathway. Granzyme B is capable of activating the zymogens procaspase-3 [56, 
57] and procaspase-8 [59], as well as directly acting downstream on caspase substrates, 
including the Bcl-2 family member Bid [62], inhibitor of caspase-activated DNase (ICAD) [60, 
559], poly (ADP-ribose) polymerase (PARP) [61] and the catalytic subunit of DNA-dependent 
protein kinase (DNA-PKcs) [61]. Granzyme B therefore has great potential as a therapeutic 
agent, if strategies for effectively (and selectively) delivering it to tumour cells could be 
developed. 
Two human cell lines which express memHsp70, the colon carcinoma line CX-2 and the 
pancreas carcinoma Colo357, have been shown to bind and internalise recombinant human 
granzyme B in the absence of perforin [530]. It has also been demonstrated that 
internalisation is mediated via memHsp70, and that it leads to apoptotic cell death [530]. The 
following studies are aimed at learning more about the mechanism of memHsp70-mediated 
internalisation of granzyme B so that its potential as a cancer therapeutic can be better 
evaluated. For these experiments, the potential internalisation of exogenous recombinant 
human granzyme B by three human breast cancer cell lines and two murine cancer cell lines, 
and the biological consequences have been studied. 
5.2 Internalisation of granzyme B by cancer cells expressing 
memHsp70 
The ability of granzyme B to bind to memHsp70+ tumour cells was investigated by flow 
cytometry using ATTO488-labelled granzyme B. As a control, cells were also incubated with 
ATTO488-labelled bovine serum albumin (BSA). There is a clear difference between the results 
for cells incubated with granzyme B and those incubated with BSA, indicating specific uptake of 
granzyme B (Fig 5.1).  




Figure 5.1 Flow cytometric assessment of uptake of fluorescently-labelled granzyme B into cancer cell lines 
A. Representative flow cytometry plots showing the fluorescent intensity of MDA-MB-231 cells incubated for 60 
minutes at 37oC in medium (black line), with ATTO488-labelled BSA (grey line) and with ATTO488-labelled granzyme 
B (green line). B. Cells were incubated in the presence of ATTO488-labelled granzyme B with samples saved at 
different time points, for up to an hour. The median fluorescent intensity of the whole population was recorded, as 
a comparative measure of the amount of granzyme B (solid black line). The intensity after incubation with similarly 
ATTO488-labelled BSA serves as a control (dashed grey line). All cell lines are capable of specifically binding and 
internalising granzyme B. Data are presented as mean ± SEM of at least three independent experiments.   
 
Although there was a progressive increase in the internalisation of granzyme B by the human 
cell lines over time, the internalisation of granzyme B into the murine cells was more rapid, 
peaked earlier and declined thereafter. The reasons for this different profile remain unclear 
and further studies are required.  
The internalisation of fluorescently-labelled granzyme B into memHsp70+ tumour cells was 
also confirmed using confocal microscopy. As the flow cytometry data indicated that the 
intensity of granzyme B appeared to reduce after 30 minutes in the mouse cell lines, the 
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confocal microscopy was conducted at longer time points. Serum was shown to interfere with 
granzyme B uptake so these incubations were conducted in PBS only. Cells were grown in glass 
bottomed dishes for 48 hours then washed and incubated with PBS containing 4µg/mL 
ATTO488-labelled granzyme B for up to 60 min. Cells receiving longer incubation times were 
provided with 1mL fresh growth medium then replaced in the 37°C incubation environment for 
the remaining incubation period. As a consequence, incubation times are denoted as 60+30 
and 60+210 minute time points. After incubation, cells were formaldehyde fixed and mounted 
onto microscopy slides using VECTASHIELD® mounting medium containing DAPI to enable 
staining of the nucleus, except at the latest time point of 60+210 min. This time point was used 
to determine the co-localisation of granzyme B with mitochondria and was conducted using 
live imaging. At this time Hoechst staining was conducted, although the fluorescence was 
insufficient to be detected in the single frames of confocal microscopy.  
 
Cells were imaged using fluorescent and confocal microscopy to produce wide angle tile scans 
as well as z-stack images of the full height of cells. Fluorescent tile scan images were obtained 
demonstrating the specificity of internalisation of ATTO488-labelled granzyme B compared to 
ATTO488-labelled BSA, with images analysed using ImageJ in order to calculate the mean 
fluorescent intensity (normalised to the intensity of the background) of all imaged cells. 
Representative tile scan images are shown below (Fig 5.2) 
 
 
Figure 5.2 Representative tile scan images showing antibody uptake into MDA-MB-231 cells 
Tile scan images were produced for MDA-MB-231, MCF7, T47D, 4T1 and CT26 cells, across different time-points of 
incubation with ATTO488-labelled granzyme B and ATTO488-labelled BSA. Representative tile scan images of MDA-
MB-231 cells incubated with ATTO488-labelled granzyme B (A) and ATTO488-labelled BSA (B) for 60+30 minutes are 
shown. Granzyme B and BSA are shown in green and the nucleus stained with DAPI is shown in blue. Scale bar 
represents 50µm.   
 
 Over time, the intensity from ATTO488-granzyme B increased in all cell lines, thereby 
confirming the flow cytometric analysis, and the maximum observed fluorescent intensity for 
each cell line positively tracked with the level of memHsp70 expression of the cells (Fig 5.3).    
A B 
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Figure 5.3 Uptake of ATTO488-labelled granzyme B into human and murine cancer cell lines expressing differing 
levels of memHsp70 
Cancer cell lines from human (A) and mouse (B) grown in MatTek™ glass bottom dishes were incubated in the 
presence of ATTO488-granzyme B for up to an hour then imaged using fluorescent microscopy. Mean fluorescent 
intensity values were calculated, normalised to background fluorescence. All cell lines are capable of internalising 
the granzyme B but to varying degrees, with increasing internalisation occurring in line with increasing memHsp70 
expression in cell lines. Data are presented as mean ± SEM of a minimum of 80 cells from at least three independent 
experiments.   
 
Representative single frame images taken from around the midpoint of cells height (within 25-
75% from the adhered surface) are shown at each time point (Fig 5.4A-5.8A). Internalised 
granzyme B presents as distinct spots of fluorescence (green), indicating association with 
intracellular vesicles. Bright-field images are provided to show the placement of cell 
boundaries. In all cell lines, it is clear to see an increase in the internalised granzyme B from 30 
minutes to the other time points. 
In order to also provide some quantitative analysis of granzyme B internalisation, the 
fluorescent spots of granzyme B where counted over the full height of every z-stack imaged, to 
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produce a measure of spots per cell. If a spot was present in more than one frame, it was 
counted only in the one where the greatest fluorescent intensity was observed (Fig 5.4B-5.8B). 
When interpreting these quantifications it is very important to keep the experiment protocol 
in mind. Cells were incubated with PBS containing granzyme B for up to 60 minutes, but at this 
time cells on longer incubation times received fresh growth medium. This would have provided 
serum as well as diluting any remaining granzyme B. Both of these procedures would be 
expected to reduce the rate of uptake of granzyme B. It is then reasonable to assume that 
from 60 minutes onwards, cells were merely trafficking granzyme B that had already been 
internalised rather than continuing to increase their intracellular granzyme B content. Any 
changes to spot count after this point should only relate to the continuing trafficking of 




Figure 5.4 Kinetics of granzyme B uptake by MDA-MB-231 cells  
A. Representative single frame images showing ATTO488-labelled granzyme B internalised into MDA-MB-231 cells. 
Frames were selected from the mid-point of cells (25-75% of distance from adhered surface). After 30 minutes 
incubation time the majority of granzyme B (green) appears to be surface bound (with a ring formation following 
the edge of cell seen in the bright-field image). At longer incubations, the granzyme B can be seen within the cell 
boundary and therefore has been internalised. Granzyme B appears as well-defined spots suggesting vesicular 
association rather than being free in the cytosol. The images shown depict a region 0.88µm thick. Scale bars 
represent 10µm. For clarity, the nucleus was stained with DAPI (blue). B. The number of distinct fluorescent spots in 
cells after different incubation times. This is a total count including spots within the cell and at the membrane. Data 
is presented as mean ± SEM for 9-30 individual cells, from at least two independent experiments.  
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Figure 5.5 Kinetics of granzyme B uptake by MCF7 cells 
A. Representative single frame images showing ATTO488-labelled granzyme B internalised into MCF7 cells. Frames 
were selected from the mid-point of cells (25-75% of distance from adhered surface). After 30 minutes incubation 
time the majority of granzyme B (green) appears to be surface bound (with a ring formation following the edge of 
cell seen in the bright-field image). At longer incubations the granzyme B can be seen within the cell boundary and 
therefore has been internalised. Granzyme B appears as well-defined spots, suggesting vesicular association rather 
than being free in the cytosol. The images shown depict a region 0.88µm thick. Scale bars represent 10µm. For 
clarity, the nucleus was stained with DAPI (blue). B. The number of distinct fluorescent spots in cells after different 
incubation times. This is a total count including spots within the cell and at the membrane. Data is presented as 
mean ± SEM for 10-24 individual cells, from at least independent experiments. 
 
 
Figure 5.6 Kinetics of granzyme B uptake by T47D cells   
A. Representative single frame images showing ATTO488-labelled granzyme B internalised into T47D cells. Frames 
were selected from the mid-point of cells (25-75% of distance from adhered surface). After 30 minutes incubation 
time the majority of granzyme B (green) appears to be surface bound (with a ring formation following the edge of 
cell seen in the bright-field image). At longer incubations the granzyme B can be seen within the cell boundary and 
therefore has been internalised. Granzyme B appears as well-defined spots, suggesting vesicular association rather 
than being free in the cytosol. The images shown depict a region 0.88µm thick. Scale bars represent 10µm. For 
clarity, the nucleus was stained with DAPI (blue). B. The number of distinct fluorescent spots in cells after different 
incubation times. This is a total count including spots within the cell and at the membrane. Data is presented as 
mean ± SEM for 13-28 individual cells, from at least two independent experiments.  
 
164 | P a g e  
 
 
Figure 5.7 Kinetics of granzyme B uptake by 4T1 cells   
A. Representative single frame images showing ATTO488-labelled granzyme B internalised into 4T1 cells. Frames 
were selected from the mid-point of cells (25-75% of distance from adhered surface). After 30 minutes incubation 
time the majority of granzyme B (green) appears to be surface bound (with a ring formation following the edge of 
cell seen in the bright-field image). At longer incubations the granzyme B can be seen within the cell boundary and 
therefore has been internalised. Granzyme B appears as well-defined spots, suggesting vesicular association rather 
than being free in the cytosol. The images shown depict a region 0.88µm thick. Scale bars represent 10µm. For 
clarity, the nucleus was stained with DAPI (blue). B. The number of distinct fluorescent spots in cells after different 
incubation times. This is a total count including spots within the cell and at the membrane. Data is presented as 
mean ± SEM for 11-37 individual cells, from at least two independent experiments.  
 
 
Figure 5.8 Kinetics of granzyme B uptake by CT26 cells   
A. Representative single frame images showing ATTO488-labelled granzyme B internalised into CT26 cells. Frames 
were selected from the mid-point of cells (25-75% of distance from adhered surface). After 30 minutes incubation 
time the majority of granzyme B (green) appears to be surface bound (with a ring formation following the edge of 
cell seen in the bright-field image). At longer incubations the granzyme B can be seen within the cell boundary and 
therefore has been internalised. Granzyme B appears as well-defined spots, suggesting vesicular association rather 
than being free in the cytosol. The images shown depict a region 0.88µm thick. Scale bars represent 10µm. For 
clarity, the nucleus was stained with DAPI (blue). B. The number of distinct fluorescent spots in cells after different 
incubation times. This is a total count including spots within the cell and at the membrane. Data is presented as 
mean ± SEM for 9-28 individual cells, from at least two independent experiments.  
 




The MDA-MB-231 cells showed consistent spot counts between 60 minutes (43 ± 7) and 
60+210 minutes (46 ± 3), but the other human breast cancer cell lines behaved differently. The 
MCF7 cells showed a reduction in spot count (60 minutes = 50 ± 4, 60+210 minutes = 36 ± 3), 
which could indicate an accumulation of granzyme B from multiple intracellular vesicles. In 
contrast, there was an increase in spot count from 60 minutes (18 ± 3) to 60+30 minutes (44 ± 
2) and then a slight decline at 60+210 minutes (37 ± 2) in T47D cells. One way to explain this 
large increase in count between 60 and 60+30 minutes could be that, during trafficking, 
granzyme B from one vesicle is dispersed into many. Alternatively, granzyme B may be 
internalised in such a low concentration that the emitted fluorescence is below the confocal 
detection threshold. Perhaps only after granzyme B has been trafficked to a particular part in 
the internalisation pathway does it accumulate to such an extent for there to be a sufficient 
fluorescent signal to be distinguished from the background. Of the mouse cell lines, 4T1 cells 
show some reduction in spot number from 60 minutes (46 ± 7) to 60+210 minutes (31 ± 3), 
whereas CT26 cells were remarkably consistent (60 minutes = 35 ± 3, 60+210minutes = 38 ± 2).  
5.2.1 Distribution of internalised granzyme B 
Spots were counted for each frame of the z-stack (Fig 5.9), it was possible to examine the 
distribution of granzyme B in cells, as has been described above for the cmHsp70 mAb and the 
TKDNNLLGRFELSG peptide. As for these, the majority of the internalised granzyme B was 
localised near to the adherent surface initially, after which it appeared to be more evenly 
distributed (Figs 5.10-5.11).   
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Figure 5.9 Representative montage of z-stack confocal images showing ATTO488-grB internalised into MDA-MB-
231 cells.  
Z-stack frames from the full height of a single MDA-MB-231 cell demonstrating distribution of ATTO488-grB 
following 60 minutes incubation time. Single frame images start at the adhered surface and finish at the apex of the 
cell. Brightfield imaging is included to help with orientation. Internalised cmHsp70.1 mAb is shown in green, DAPI 
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Figure 5.10 Distribution of internalised ATTO488-granzyme B In human breast cancer cell lines 
Line graphs of the distribution of internalised ATTO488-labelled granzyme B in every cell imaged for MDA-MB-231, 
MCF7 and T47D cell lines at each time point, up to 60+210 minutes. Although ATTO488- granzyme B appears 
throughout the full height of the cells, there is a clear bias towards the antibody being present close to the adhered 
surface of the cells. This asymmetrical distribution was observed in all cell lines and at all time- points. Each line 
represents the profile of an individual cell, with a minimum of three cells per condition. 
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Figure 5.11 Distribution of internalised ATTO488-granzyme B In mouse cancer cell lines 
Line graphs of the distribution of internalised ATTO488-labelled granzyme B in every cell imaged for 4T1 and CT26 
cell lines at each time point, up to 60+210 minutes. Although ATTO488-granzyme B appears throughout the full 
height of the cells, there is a clear bias towards the antibody being present close to the adhered surface of the cells. 
This asymmetrical distribution was observed in all cell lines and at all time- points. Each line represents the profile 
of an individual cell, with a minimum of three cells per condition. 
Granzyme B spots were also quantified, not per frame, but according to their vertical position 
in the cell height. Cell lines are presented separately, with all time points indicated (Fig 5.12A-
5.16A). The amount of granzyme B in the first quartile, towards the adhered surface, was 
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always greater than in any other quartile, however within each cell line all time points gave 
very similar results. Representative images from the 60+30 minute time point are included (Fig 
5.12B-5.16B), and presented as composite images to accurate display data included in each 
quartile. A single frame brightfield image is included to allow determination of the cell 
boundary.   
 
Figure 5.12 Granzyme B is pre-dominantly internalised through the adhered surface of MDA-MB-231 cells.  
A. Using confocal microscopy z-stack images, the number of distinct fluorescent granzyme B spots was calculated 
over quartiles of the cell height. At all-time points the quartile containing the most granzyme B was the first, from 
the adhered surface to 25% of the cells height. The cross-sectional area of adhered cells is always greatest in this 
quartile and is a possible confounding factor, however due to the difficulty in calculating area accurately from 
bright-field images obtained on a confocal microscope it was not possible to normalise the results for area. Data are 
presented as mean ± SEM, n = 31. B. Representative images to highlight the difference between the first and last 
quartile (matching the adhered point and apex of the cell). It is clear to see that the first quartile contains vastly 
more granzyme B than the top of the cell. Fluorescent images shown are representative composites, formed as a 
sum of the intensity in all frames within the quartile of interests. Bright-field images are single frames from the 
middle of the cell. Scale bars are 10μm. 
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Figure 5.13 Granzyme B is pre-dominantly internalised through the adhered surface of MCF7 cells 
A. Using confocal microscopy z-stack images, the number of distinct fluorescent granzyme B spots was calculated 
over quartiles of the cell height. At all-time points the quartile containing the most granzyme B was the first, from 
the adhered surface to 25% of the cells height. The cross-sectional area of adhered cells is always greatest in this 
quartile and is a possible confounding factor, however due to the difficulty in calculating area accurately from 
bright-field images obtained on a confocal microscope it was not possible to normalise the results for area. Data are 
presented as mean ± SEM, n = 24. B. Representative images to highlight the difference between the first and last 
quartile (matching the adhered point and apex of the cell). It is clear to see that the first quartile contains vastly 
more granzyme B than the top of the cell. Fluorescent images shown are representative composites, formed as a 
sum of the intensity in all frames within the quartile of interests. Bright-field images are single frames from the 
middle of the cell. Scale bars are 10μm. 
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Figure 5.14 Granzyme B is pre-dominantly internalised through the adhered surface of T47D cells.  
A. Using confocal microscopy z-stack images, the number of distinct fluorescent granzyme B spots was calculated 
over quartiles of the cell height. At all time-points the quartile containing the most granzyme B was the first, from 
the adhered surface to 25% of the cells height. The cross-sectional area of adhered cells is always greatest in this 
quartile and is a possible confounding factor, however due to the difficulty in calculating area accurately from 
bright-field images obtained on a confocal microscope it was not possible to normalise the results for area. Data are 
presented as mean ± SEM, n = 28. B. Representative images to highlight the difference between the first and last 
quartile (matching the adhered point and apex of the cell). It is clear to see that the first quartile contains vastly 
more granzyme B than the top of the cell. Fluorescent images shown are representative composites, formed as a 
sum of the intensity in all frames within the quartile of interests. Bright-field images are single frames from the 
middle of the cell. Scale bars are 10μm. 
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Figure 5.15 Granzyme B is pre-dominantly internalised through the adhered surface of 4T1 cells.  
A. Using confocal microscopy z-stack images, the number of distinct fluorescent granzyme B spots was calculated 
over quartiles of the cell height. At all-time points the quartile containing the most granzyme B was the first, from 
the adhered surface to 25% of the cells height. The cross-sectional area of adhered cells is always greatest in this 
quartile and is a possible confounding factor, however due to the difficulty in calculating area accurately from 
bright-field images obtained on a confocal microscope it was not possible to normalise the results for area. Data are 
presented as mean ± SEM, n = 37. B. Representative images to highlight the difference between the first and last 
quartile (matching the adhered point and apex of the cell). It is clear to see that the first quartile contains vastly 
more granzyme B than the top of the cell. Fluorescent images shown are representative composites, formed as a 
sum of the intensity in all frames within the quartile of interests. Bright-field images are single frames from the 
middle of the cell. Scale bars are 10μm. 
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Figure 5.16 Granzyme B is pre-dominantly internalised through the adhered surface of CT26 cells.  
A. Using confocal microscopy z-stack images, the number of distinct fluorescent granzyme B spots was calculated 
over quartiles of the cell height. At all time-points the quartile containing the most granzyme B was the first, from 
the adhered surface to 25% of the cells height. The cross-sectional area of adhered cells is always greatest in this 
quartile and is a possible confounding factor, however due to the difficulty in calculating area accurately from 
bright-field images obtained on a confocal microscope it was not possible to normalise the results for area. Data are 
presented as mean ± SEM, n = 26. B. Representative images to highlight the difference between the first and last 
quartile (matching the adhered point and apex of the cell). It is clear to see that the first quartile contains vastly 
more granzyme B than the top of the cell. Fluorescent images shown are representative composites, formed as a 
sum of the intensity in all frames within the quartile of interests. Bright-field images are single frames from the 
middle of the cell. Scale bars are 10μm. 
 
5.3.2 Association of internalised granzyme B with intracellular vesicles 
In order to better understand the route of memHsp70-mediated granzyme B internalisation, 
cells which had been incubated with ATTO488-granzyme B were formaldehyde fixed, 
permeabilised and stained with primary antibodies specific for one of a range of markers of 
intracellular vesicles and an appropriate fluorescently-labelled secondary antibody. Co-
localisation was determined by visualising the overlap of fluorescence channels on the 
confocal images, as well as calculating Pearson’s coefficient and Manders’ M1 coefficient, as 
described above.  
There was no evidence of early endosome involvement at any time, with either of the markers 
used (Rab4a data. MDA-MB-231: 30 min 2.1 ± 0.4%, 60 min 3.9 ± 1.4%. MCF7 30 min 5.3 ± 
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2.2%, 60 min 3.7 ± 1.6%. T47D 30 min 0.7 ± 0.4%, 60 min 7.2 ± 3.6%. Similar data were 
obtained for Rab5a) (Table 5.1). The initial time point used was 30 minutes; since the flow 
cytometry data showed that there was no appreciable uptake of granzyme B prior to this time 
point (Fig 5.17). However, this is not conclusive evidence that no internalisation into early 
endosomes has occurred, as it might be that such small quantities of granzyme B are 
















Table 5.1 Trafficking of internalised ATTO488-granzyme B to early endosomes in human breast cancer cell lines  
A. Pearson coefficient of the correlation between internalised ATTO488-granzyme B and staining for the early 
endosome markers Rab4a and Rab5a, in human breast cancer cell lines MDA-MB-231, MCF7 and T47D. At all time-
points there was a positive correlation suggesting some degree of co-localisation between the markers of interest. 
B. Manders’ M1 measurement calculating the percentage of internalised ATTO488-granzyme B which was co-
localised with staining for the early endosome markers Rab4a and Rab5a over different time-points. The proportion 
of co-localisation is low; indicating that at each time very little ATTO488-granzyme B  is within early endosomes at 
any of the measured time-points. Data are presented as mean ± SEM from 5-6 imaged cells, from two independent 
experiments.  
 
A. Pearson Coefficient 30 minutes 60 minutes 
MDA-MB-231 Rab4a 0.328 ± 0.049 0.261 ± 0.043 
 Rab5a 0.119 ± 0.030 0.262 ± 0.036 
MCF7 Rab4a 0.347 ±0.069 0.385 ±0.039 
 Rab5a 0.134 ± 0.053 0.341 ± 0.013 
T47D Rab4a 0.398 ± 0.115 0.376 ± 0.050 
 Rab5a -0.124 ± 0.015 - 
B. Manders M1 Coefficient 30 minutes 60 minutes 
MDA-MB-231 Rab4a 2.1 ± 0.4 % 3.9 ± 1.4 % 
 Rab5a 3.8 ± 1.8 % 5.9 ± 3.1 % 
MCF7 Rab4a 5.3 ± 2.2 % 3.7 ± 1.5 % 
 Rab5a 3.0 ± 1.0 % 4.3 ± 1.0 % 
T47D Rab4a 0.7 ± 0.4 % 7.2 ± 3.6 % 
 Rab5a 1.9 ± 1.4 % - 
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Figure 5.17 Trafficking of internalised ATTO488-granzyme B to early endosomes in human breast cancer cell lines  
MDA-MB-231, MCF7 and T47D cells grown in MatTek glass bottom dishes and incubated with granzyme B for either 
30 or 60 minutes were fixed, permeabilised and stained for the localisation of early endosomes using Rab4 and 
Rab5 as markers. Any co-localisation of ATTO488-granzyme B fluorescence (green) and endosome staining 
(magenta) could confirm the involvement of an early endosome pathway of ATTO488-granzyme B internalisation. 
Co-localisation was assessed using both Pearson’s and Manders’ M1 coefficients of co-localisation, as well as visual 
overlap of the intensity channels. Images shown are representative single frames taken from the middle region of 
cells incubated with ATTO488-granzyme B for 60 minutes and subsequently stained for the presence of Rab5. No 
co-localisation was found, nor using the Rab4 marker. After 30 minutes the majority of ATTO488-granzyme B 
appeared bound to the cell surface and did not co-localise with either early endosome marker. Images shown are 
representative single frames selected from the middle region of the cells (2nd or 3rd quartile). Scale bars are 10μm.   
 
In contrast to the findings for early endosomes there was a clear trend between the 
proportion of granzyme B co-localised to Rab7a+ late endosomes and the memHsp70 status of 
the cell line (60+30 minute data. MDA-MB-231: 21.5 ± 6.5%. MCF7: 14.3 ± 4.6%. T47D: 4.7 ± 
1.3%) (Table 5.2 and Fig 5.18). A similar profile was also seen in the alternative late endosome 
marker of Rab9 (Table 5.3 and Fig 5.19), although the proportion of co-localisation was greater 
in all cell lines (60+30 minute data. MDA-MB-231: 79.4 ± 5.4%. MCF7: 48.4 ± 7.2%. T47D: 38.2 
± 7.8%). An almost identical profile of co-localisation was observed for Rab11+ recycling 
endosomes (Table 5.4 and Fig 5.20) (60+30 minute data. MDA-MB-231: 62.9 ± 10.7%. MCF7: 



















Table 5.2 Trafficking of internalised ATTO488-granzyme B through late and recycling endosomes in human breast 
cancer cell lines  
A. Pearson coefficient of the correlation between internalised ATTO488-granzyme B and staining for the late 
endosome markers Rab7 and Rab9 as well the recycling endosome marker Rab11, in human breast cancer cell lines 
MDA-MB-231, MCF7 and T47D. There was a positive correlation suggesting some degree of co-localisation between 
the markers of interest. B. Manders’ M1 measurement calculating the percentage of internalised ATTO488-
granzyme B which was co-localised with staining for the late endosome markers Rab7 and Rab9 as well as the 
recycling endosome marker Rab11. The proportion of co-localisation with both Rab9 and Rab11 in all cell lines 
positively correlates with the intensity of memHsp70 expression. Data are presented as mean ± SEM from 5-8 
imaged cells, from two independent experiments. 
 
A. Pearson Coefficient 60+30 minutes 
MDA-MB-231 Rab7 0.349 ± 0.046 
 Rab9 0.760 ± 0.045 
 Rab11 0.400 ± 0.066 
MCF7 Rab7 0.383 ± 0.049 
 Rab9 0.319 ± 0.124 
 Rab11 0.412 ± 0.073 
T47D Rab7 0.451 ± 0.044 
 Rab9 0.517 ± 0.028 
 Rab11 0.699 ± 0.029 
B. Manders M1 Coefficient 60+30 minutes 
MDA-MB-231 Rab7 21.5 ± 6.5 % 
 Rab9 79.4 ± 5.4 % 
 Rab11 62.9 ± 10.7 % 
MCF7 Rab7 14.3 ± 4.6 % 
 Rab9 48.4 ± 7.2 % 
 Rab11 48.0 ± 4.4 % 
T47D Rab7 4.7 ± 1.3 % 
 Rab9 38.2 ± 7.8 % 
 Rab11 39.7 ± 5.1 % 
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Figure 5.18 Trafficking of internalised ATTO488-granzyme B to Rab7+ late endosomes in human breast cancer cell 
lines  
MDA-MB-231, MCF7 and T47D cells grown in MatTek™ glass bottom dishes and incubated with ATTO488-granzyme 
B for 60 minutes followed by a further 30 minute incubation period were then fixed, permeabilised and stained for 
Rab7 to indicate late endosomes. Any co-localisation of ATTO488-granzyme B fluorescence (green) and endosome 
staining (magenta) could be confirmation of involvement of a late endosome pathway of ATTO488-granzyme B 
internalisation. Co-localisation was assessed using both Pearson’s and Manders’ M1 coefficients of co-localisation, 
as well as visual overlap of the intensity channels. No co-localisation was found in any of the cell lines. Images 
shown are representative single frames taken from the middle region (2nd or 3rd quartile) of cells. Scale bars are 
10μm.   
 
 
Figure 5.19 Trafficking of internalised ATTO488-granzyme B to Rab9+ recycling endosomes in human breast 
cancer cell lines  
MDA-MB-231, MCF7 and T47D cells grown in MatTek™ glass bottom dishes and incubated with ATTO488-granzyme 
B for 60 minutes followed by a further 30 minute incubation period were then fixed, permeabilised and stained for 
Rab9 to indicate late endosomes. Any co-localisation of ATTO488-granzyme B fluorescence (green) and endosome 
staining (magenta) could be confirmation of involvement of a late endosome pathway of ATTO488-granzyme B 
internalisation. Co-localisation was assessed using both Pearson’s and Manders’ M1 coefficients of co-localisation, 
as well as visual overlap of the intensity channels. Co-localisation was found in all of the cell lines and increased with 
increasing expression of memHsp70. Images shown are representative single frames taken from the middle region 
(2nd or 3rd quartile) of cells. Scale bars are 10μm.   




Figure 5.20 Trafficking of internalised ATTO488-granzyme B to Rab11+ recycling endosomes in human breast 
cancer cell lines  
MDA-MB-231, MCF7 and T47D cells grown in MatTek™ glass bottom dishes and incubated with ATTO488-granzyme 
B for 60 minutes followed by a further 30 minute incubation period were then fixed, permeabilised and stained for 
Rab11 to indicate late endosomes. Any co-localisation of ATTO488-granzyme B fluorescence (green) and endosome 
staining (magenta) could be confirmation of involvement of recycling endosomes in the pathway of ATTO488-
granzyme B internalisation. Co-localisation was assessed using both Pearson’s and Manders’ M1 coefficients of co-
localisation, as well as visual overlap of the intensity channels. Co-localisation was found in all of the cell lines, with 
the proportion increasing in line with the expression of memHsp70. Images shown are representative single frames 
taken from the middle region (2nd or 3rd quartile) of cells. Scale bars are 10μm.   
 
Although co-localisation with LAMP1 and LAMP2 lysosomes was similar, unlike with Rab9 and 
Rab11 there was a negative trend between co-localisation and memHsp70 status (60+30 
minute, LAMP2 data. MDA-MB-231: 9.8 ± 2.5%. MCF7: 18.9 ± 2.2%. T47D: 20.3 ± 7.6%. Similar 





















Table 5.3 Trafficking of internalised ATTO488-granzyme B to lysosomes in human breast cancer cell lines  
A. Pearson coefficient of the correlation between internalised ATTO488-granzyme B and staining for the lysosomal 
markers LAMP1 and LAMP2, in human breast cancer cell lines MDA-MB-231, MCF7 and T47D. There was a positive 
correlation suggesting some degree of co-localisation between the markers of interest. B. Manders’ M1 
measurement calculating the percentage of internalised ATTO488-granzyme B which was co-localised with staining 
for the lysosomal markers LAMP1 and LAMP2. The proportion of co-localisation with both markers negatively 
correlates with the intensity of memHsp70 expression on cell lines. Data are presented as mean ± SEM from 5-6 
imaged cells, from two independent experiments. 
 
 
A. Pearson Coefficient 60+30 minutes 
MDA-MB-231 LAMP1 0.134 ± 0.066 
 LAMP2 0.212 ± 0.048 
MCF7 LAMP1 0.425 ± 0.054 
 LAMP2 0.378 ± 0.015 
T47D LAMP1 0.408 ± 0.084 
 LAMP2 0.412 ± 0.073 
B. Manders M1 Coefficient 60+30 minutes 
MDA-MB-231 LAMP1 6.8 ± 6.2 % 
 LAMP2 9.8 ± 2.5 % 
MCF7 LAMP1 15.7 ± 3.0 % 
 LAMP2 18.9 ± 2.2 % 
T47D LAMP1 22.0 ± 7.0 % 
 LAMP2 20.3 ± 7.6 % 
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Figure 5.21 Trafficking of internalised ATTO488-granzyme B to lysosomes in human breast cancer cell lines  
MDA-MB-231, MCF7 and T47D cells grown in MatTek glass bottom dishes and incubated with ATTO488-granzyme B 
for 60 minutes followed by a further 30 minutes incubation were then fixed, permeabilised and stained for LAMP1 
and LAMP2 to indicate lysosomes endosomes. Any co-localisation (white) of ATTO488-granzyme B fluorescence 
(green) and lysosome staining (magenta) could be confirmation of involvement of a late endosome pathway of 
ATTO488-granzyme B internalisation. Co-localisation was assessed using both Pearson’s and Manders’ M1 
coefficients of co-localisation, as well as visual overlap of the intensity channels. Co-localisation was found in all of 
the cell lines, increasing over time. Images shown are representative single frames taken from the middle region 
(2nd or 3rd quartile) of cells stained for LAMP2 expression.  Scale bars are 10μm.   
 
Co-localisation of granzyme B with mitochondria was also observed, but only at a time point 
later than that when co-localisation was observed with other markers (MDA-MB-231: 60+30 
minutes 5.5 ± 1.7%, 60+210 minutes 23.0 ± 6.2%. MCF7: 60+30 minutes 3.8 ± 2.4%, 60+210 
minutes 17.8 ± 3.0%. T47D: 60+30 minutes 0.4 ± 0.2%, 60+210 minutes 15.0 ± 3.1%) (Table 5.4 
















Table 5.4 Trafficking of internalised ATTO488-granzyme B to mitochondria in human breast cancer cell lines  
A. Pearson coefficient of the correlation between internalised ATTO488-granzyme B and staining for the 
mitochondria in breast cancer cell lines MDA-MB-231, MCF7 and T47D after 60 minutes incubation with ATTO488-
granzyme B followed by a further 30 or 210 minute incubation. At both time-points there was a positive correlation 
suggesting some degree of co-localisation between the markers of interest. B. Manders’ M1 measurement 
calculating the percentage of internalised ATTO488-granzyme B which was co-localised with staining for the 
mitochondria over different time-points. The proportion of ATTO488-granzyme B co-localisation with the 
mitochondria increases over time in all cell lines, and positively correlates to the expression of memHsp70. Data are 
presented as mean ± SEM from 9-12 imaged cells, from at least two independent experiments. 
 
Figure 5.22 Trafficking of internalised ATTO488-granzyme B to mitochondria in human breast cancer cell lines  
MDA-MB-231, MCF7 and T47D cells grown in MatTek™ glass bottom dishes and incubated with ATTO488-granzyme 
B for 60 minutes followed by a further 30 or 210 minute incubation were then stained with MitoID™ red to show 
the mitochondria. Any co-localisation (white) of ATTO488-granzyme B fluorescence (green) and mitochondrial 
staining (magenta) could be confirmation of trafficking of ATTO488-granzyme B to mitochondria. Co-localisation 
was assessed using both Pearson’s and Manders’ M1 coefficients of co-localisation, as well as visual overlap of the 
intensity channels. Co-localisation was found in all of the cell lines, increasing over time. Images shown are 
representative single frames taken from the middle region (2nd or 3rd quartile) of cells incubated with ATTO488-
granzyme B for 60+210 minutes.  Scale bars are 10μm.   
Similar to the situation with the human-derived cell lines, there was negligible co-localisation 
of granzyme B with Rab4a+ and Rab5+ early endosomes at any time in 4T1 and CT26 cells (4T1: 
A. Pearson Coefficient 60+30 minutes 60+210 minutes 
MDA-MB-231 0.384 ± 0.031 0.413 ± 0.031 
MCF7 0.365 ± 0.061 0.473 ± 0.053 
T47D 0.375 ± 0.060 0.565 ± 0.029 
B. Manders M1 Coefficient 60+30 minutes 60+210 minutes 
MDA-MB-231 5.5 ± 1.7 % 23.0 ± 6.2 % 
MCF7 3.8 ± 2.4 % 17.8 ± 3.0 % 
T47D 0.4 ± 0.2 % 15.0 ± 3.1 % 
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30 minutes 2.8 ± 1.3%, 60 minutes 3.1 ± 2.2%. CT26: 30 minutes 5.0 ± 0.8%, 60 minutes 3.8 ± 










Table 5.5 Trafficking of internalised ATTO488-granzyme B to early endosomes in murine cancer cell lines  
A. Pearson coefficient of the correlation between internalised and staining for the early endosome markers Rab4a 
and Rab5a, in mouse cancer cell lines 4T1 and CT26. At both time-points there was a positive correlation suggesting 
some degree of co-localisation between the markers of interest. B. Manders’ M1 measurement calculating the 
percentage of internalised ATTO488-granzyme B which was co-localised with staining for the early endosome 
markers Rab4a and Rab5a over different time-points. The proportion of co-localisation is low; indicating that at 
each time very little ATTO488-granzyme B is within early endosomes. Data are presented as mean ± SEM from 6-9 
imaged cells, from two independent experiments.  
 
Figure 5.23 Trafficking of internalised ATTO488-granzyme B to early endosomes in murine cancer cell lines 
4T1 and CT26 cells grown in MatTek glass bottom dishes and incubated with ATTO488-granzyme B for 30 or 60 
minutes were fixed, permeabilised and stained for the localisation of early endosomes using Rab4 and Rab5 as 
markers. Any co-localisation of ATTO488-granzyme B fluorescence (green) and endosome staining (magenta) could 
be confirmation of involvement of an early endosome pathway of ATTO488-granzyme B internalisation. Co-
localisation was assessed using both Pearson’s and Manders’ M1 coefficients of co-localisation, as well as visual 
overlap of the intensity channels. Images shown are representative single frames taken from the middle region (2nd 
or 3rd quartile) of cells incubated with ATTO488-granzyme B for 30 minutes and subsequently stained for the 
presence of Rab5. No co-localisation was found, nor using the Rab4 marker.  Scale bars are 10μm.   
A. Pearson Coefficient 30 minutes 60 minutes 
4T1 Rab4a 0.237 ± 0.033 0.300 ± 0.036 
 Rab5a 0.292 ± 0.065 0.447 ± 0.092 
CT26 Rab4a 0.318 ± 0.033 0.294 ± 0.015 
 Rab5a 0.211 ± 0.016 0.220 ± 0.017 
B. Manders M1 Coefficient 30 minutes 60 minutes 
4T1 Rab4a 2.8 ± 1.3 % 3.1 ± 2.2 % 
 Rab5a 9.9 ± 3.1 % 1.9 ± 0.8 % 
CT26 Rab4a 5.0 ± 0.8 % 3.8 ± 1.6 % 
 Rab5a 3.1 ± 0.8 % 3.2 ± 1.0 % 
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As seen with the human-derived cell lines, there was a small degree of granzyme B co-
localisation with Rab7+ late endosomes which followed in line with the memHsp70 status of 
the cell lines (60+30 minute data. 4T1:26.6 ± 5.1%. CT26: 8.5 ± 1.6%) (Table 5.6 and Fig 5.24). A 
similar profile was observed with the alternative late endosomal marker, Rab9 (Table 5.6 and 
Fig 5.25), and a greater proportion of granzyme B co-localised with Rab9+ late endosomes than 
with Rab7+ late endosomes (60+30 minute data. 4T1: 31.7 ± 4.3%. CT26 26.4 ± 4.3%).  
Although granzyme B also co-localised with Rab11+ recycling endosomes the profile in the 
mouse lines was different to that seen in the human cell lines. All three human cell lines 
exhibited a smaller proportion of granzyme B co-localised to Rab11+ vesicles than those 
expressing Rab9, whereas in both mouse lines the situation was reversed, in that the greater 
proportion of co-localisation was observed in Rab11+ vesicles (60+30 minute data. 4T1: 60.9 ± 











Table 5.6 Trafficking of internalised ATTO488-granzyme B to late and recycling endosomes in murine cancer cell 
lines 
A. Pearson coefficient of the correlation between internalised ATTO488-granzyme B and staining for the late 
endosome markers Rab7 and Rab9 as well the recycling endosome marker Rab11, in mouse cancer cell lines 4T1 
and CT26. Cells were incubated with granzyme B for 60 minutes followed by a further 30 minutes incubation and 
there was a positive correlation suggesting some degree of co-localisation between the markers of interest. B. 
Manders’ M1 measurement calculating the percentage of internalised ATTO488-granzyme B which was co-localised 
with staining for the late endosome markers Rab7 and Rab9 as well as the recycling endosome marker Rab11. The 
proportion of co-localisation with both Rab9 and Rab11 in all cell lines positively correlates with the intensity of 
memHsp70 expression. Data are presented as mean ± SEM for 6-9 imaged cells, from two independent 
experiments. 
A. Pearson Coefficient 60+30 minutes 
4T1 Rab7 0.413 ± 0.027 
 Rab9 0.384 ± 0.026 
 Rab11 0.562 ± 0.092 
CT26 Rab7 0.363 ± 0.020 
 Rab9 0.373 ± 0.096 
 Rab11 0.520 ± 0.036 
B. Manders M1 Coefficient 60+30 minutes 
4T1 Rab7 26.6 ± 5.1 % 
 Rab9 31.7 ± 4.3 % 
 Rab11 60.9 ± 4.6 % 
CT26 Rab7 8.5 ± 1.6 % 
 Rab9 26.4 ± 4.3 % 
 Rab11 31.4 ± 5.5 % 




Figure 5.24 Trafficking of internalised ATTO488-granzyme B to Rab7+ late endosomes in murine cancer cell lines 
4T1 and CT26 cells grown in MatTek™ glass bottom dishes and incubated with ATTO488-granzyme B for 60 minutes 
followed by a further 30 minute incubation were fixed, permeabilised and stained for Rab7 to indicate late 
endosomes. Any co-localisation of ATTO488-granzyme B fluorescence (green) and endosome staining (magenta) 
could be confirmation of involvement of a late endosome pathway of granzyme B internalisation. Co-localisation 
was assessed using both Pearson’s and Manders’ M1 coefficients of co-localisation, as well as visual overlap of the 
intensity channels. No co-localisation was found in any of the cell lines. Images shown are representative single 
frames taken from the middle region (2nd or 3rd quartile) of cells. Scale bars are 10μm.   
 
 
Figure 5.25 Trafficking of internalised ATTO488-granzyme B to Rab9+ late endosomes in murine cancer cell lines 
4T1 and CT26 cells grown in MatTek™ glass bottom dishes and incubated with ATTO488-granzyme B for 60 minutes 
followed by a further 30 minute incubation period were then fixed, permeabilised and stained for Rab9 to indicate 
late endosomes. Any co-localisation of ATTO488-granzyme B fluorescence (green) and endosome staining 
(magenta) could be confirmation of involvement of a late endosome pathway of ATTO488-granzyme B 
internalisation. Co-localisation was assessed using both Pearson’s and Manders’ M1 coefficients of co-localisation, 
as well as visual overlap of the intensity channels. Co-localisation was found in all of the cell lines and increased in 
line with increasing expression of memHsp70. Images shown are representative single frames taken from the 
middle region (2nd or 3rd quartile) of cells. Scale bars are 10μm.   
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Figure 5.26 Trafficking of internalised ATTO488-granzyme B to Rab11+ recycling endosomes in murine cancer cell 
lines 
4T1 and CT26 cells grown in MatTek™ glass bottom dishes and incubated with ATTO488-granzyme B for 60 minutes 
followed by a further 30 minute incubation period were then fixed, permeabilised and stained for Rab11 to indicate 
late endosomes. Any co-localisation of ATTO488-granzyme B fluorescence (green) and endosome staining 
(magenta) could be confirmation of involvement of recycling endosomes in the pathway of ATTO488-granzyme B 
internalisation. Co-localisation was assessed using both Pearson’s and Manders’ M1 coefficients of co-localisation, 
as well as visual overlap of the intensity channels. Co-localisation was found in all of the cell lines and increased in 
line with increasing expression of memHsp70. Images shown are representative single frames taken from the 
middle region (2nd or 3rd quartile) of cells. Scale bars are 10μm.   
 
The two mouse cells lines were also investigated for the possibility of internalised granzyme B 
co-localising to lysosomes. Granzyme B co-localised with LAMP2+ lysosomes in both cells lines 
at almost identical percentages (60+30 minute data. 4T1: 35.4 ± 5.1%. CT26: 33.7 ± 4.8%) 






Table 5.7 Trafficking of internalised ATTO488-granzyme B to lysosomes in murine cancer cell lines 
A. Pearson coefficient of the correlation between internalised ATTO488-granzyme B and staining for the lysosome 
marker LAMP2, in the mouse cancer cell lines 4T1 and CT26 60 minutes incubation with granzyme B followed by a 
further 30 minute incubation. There was a positive correlation suggesting some degree of co-localisation between 
the markers of interest. B. Manders’ M1 measurement calculating the percentage of internalised ATTO488-
granzyme B which was co-localised with staining for the lysosome marker LAMP2. There is a similar proportion of 
internalised ATTO488-granzyme B that co-localises with LAMP2 in both cell lines. Data are presented as mean ± SEM 
from 5-6 imaged cells, from two independent experiments. 
A. Pearson Coefficient 60+30 minutes 
4T1 LAMP2 0.408 ± 0.073 
CT26 LAMP2 0.485 ± 0.030 
B. Manders M1 Coefficient 60+30 minutes 
4T1 LAMP2 35.4 ± 5.1 % 
CT26 LAMP2 33.7 ± 4.8 % 




Figure 5.27 Trafficking of internalised ATTO488-granzyme B to lysosomes in murine cancer cell lines 
4T1 and CT26 cells grown in MatTek™ glass bottom dishes and incubated with ATTO488-granzyme B for 60 minutes 
followed by a further 30 minute incubation period were then fixed, permeabilised and stained for LAMP2 to 
indicate lysosomes. Any co-localisation of ATTO488-granzyme B fluorescence (green) and lysosome staining 
(magenta) could be confirmation of involvement of lysosome in the internalisation of granzyme B. Co-localisation 
was assessed using both Pearson’s and Manders’ M1 coefficients of co-localisation, as well as visual overlap of the 
intensity channels. Co-localisation was found in both of the cell lines but seemingly independent of memHsp70 
expression. Images shown are representative single frames taken from the middle region (2nd or 3rd quartile) of 
cells. Scale bars are 10μm.   
 
The findings relating to the co-localisation of granzyme B with mitochondria in the mouse cell 
lines also differed from those that were obtained with the human cell lines. Rather than co-
localisation only being evident at the very latest time point, granzyme B co-localisation with 
mitochondria appeared earlier in both of the mouse cell lines  (Table 5.8 and Fig 5.28) (4T1: 
60+30 min 20.3 ± 2.7%, 60+210 min 33.7 ± 3.6%. CT26: 60+30 min 11.6 ± 4.2%, 60+210 min 
21.7 ± 4.7%). The observed co-localisation increased with increasing expression of memHsp70 

















Table 5.8 Trafficking of internalised ATTO488-granzyme B to mitochondria in murine cancer cell lines 
A. Pearson coefficient of the correlation between internalised ATTO488-granzyme B and staining for the 
mitochondria in cancer cell lines 4T1 and CT26 after 60 minutes incubation with granzyme B followed by a further 
30 or 210 minutes incubation. At both time-points there was a positive correlation suggesting some degree of co-
localisation between the markers of interest. B. Manders’ M1 measurement calculating the percentage of 
internalised ATTO488-granzyme B which was co-localised with staining for the mitochondria over different time-
points. The proportion of ATTO488-granzyme B co-localisation with the mitochondria increases over time in both 
cell lines, and positively correlates to the expression of memHsp70. Data are presented as mean ± SEM from 8-9 
imaged cells, from two independent experiments. 
 
 
Figure 5.28 Trafficking of internalised ATTO488-granzyme B to mitochondria in murine cancer cell lines 
4T1 and CT26 cells grown in MatTek™ glass bottom dishes and incubated with ATTO488-granzyme B for 60 minutes 
followed by a further 30 or 210 minutes incubation were stained with MitoID™ red to show the mitochondria. Any 
co-localisation (white) of ATTO488-granzyme B fluorescence (green) and mitochondrial staining (magenta) could be 
confirmation of trafficking of granzyme B to mitochondria. Co-localisation was assessed using both Pearson’s and 
Manders’ M1 coefficients of co-localisation, as well as visual overlap of the intensity channels. Co-localisation was 
found in both of the cell lines and increased over time. Images shown are representative single frames taken from 
the middle region (2nd or 3rd quartile) of cells incubated with ATTO488-granzyme B for 60+210 minutes.  Scale bars 
are 10μm.   
 
  
A. Pearson Coefficient 60+30 minutes 60+210 minutes 
4T1 0.650 ± 0.031 0.490 ± 0.022 
CT26 0.493 ± 0.071 0.461 ± 0.024 
B. Manders M1 Coefficient 60+30 minutes 60+210 minutes 
4T1 20.3 ± 2.7 % 33.7 ± 3.6 % 
CT26 11.6 ± 4.2 % 21.7 ± 4.7 % 
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5.4 Induction of apoptosis 
Granzyme B released by NK cells or cytotoxic CD8+ T cells undergoes perforin-mediated 
internalisation into target cells, after which it cleaves one of a number of substrates within the 
apoptosis pathway to induce cell death. Although it has herein been clearly demonstrated that 
memHsp70 can also mediate the internalisation of granzyme B, it is not known whether the 
subsequent intracellular trafficking route allows granzyme B access to apoptosis-inducing 
pathways and machinery. Initially, detection of both active caspase-3 and the presence of 
surface phosphatidylserine (by way of staining with Annexin V) were employed. As activation 
of caspase-3 is an intracellular process, detection is only possible after fixing and 
permeabilising the cells, whereas Annexin V staining can only be conducted on live cells.  
All cells were grown in 24 well plates and, after seeding, were allowed 48 hours to grow before 
being incubated with recombinant human granzyme B. As serum has been found to interfere 
with the binding and uptake of granzyme B, it was necessary to first aspirate the growth 
medium and wash cells once in PBS. This was also aspirated and replaced with PBS containing 
4µg/ml granzyme B. Cells were then incubated for 60 minutes at 37°C. Control cells were 
washed in the same manner, but the negative controls received PBS only and the positive 
controls PBS containing camptothecin for the incubation period. After the incubation period 
was completed, fresh growth medium was administered to all wells. If cells were already 
undergoing apoptosis during this time, it could have been possible for them to detach from the 
plate. As it was crucial to ensure that these cells were not removed from the culture, the PBS 
containing granzyme B was not removed, but the fresh medium simply added to the well. 
Although the presence of the PBS would serve to dilute the medium, there was such a large 
disparity in volumes (1 mL medium and 200µL PBS/granzyme B) it was felt that the cells would 
suffer no adverse effects. This was confirmed on the basis of observations that there was no 
viability loss in control cultures, in which cells had been incubated in PBS. 
The results of the experiments relating to the capacity of granzyme B to induce caspase-3 
activation proved to be inconclusive. There were very few significant increases to the levels of 
active caspase-3 following granzyme B treatment, and the results for the controls that had 
been incubated with camptothecin were also variable (Fig 5.29 and 5.30). There were also no 
apparent effects on Annexin V binding (data not shown).  
That the camptothecin control did not consistently induce activation of caspase-3 reduces 
confidence in the capacity of this approach to determine the induction of apoptosis. At no time 
was there significant evidence of caspase-3 activation in T47D cells in response to 
camptothecin treatment, however there was in both MDA-MB-231 and MCF7 cells. In the 
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human cell lines there was only instance of granzyme B incubation resulting in significant levels 
of caspase-3 activation, with MDA-MB-231 cells 4 hours after granzyme B introduction.  
A very similar scenario was observed with the mouse cell lines, with the only significant 
induction of caspase-3 activation being seen in CT26 cells after 4 hours treatment with 
granzyme B. Whilst the activation of caspase-3 in 4T1 cells at the same time point was 
approaching significance, it was not achieved. At the later time points of 24 and 48 hours after 
granzyme B treatment, the activation of caspase-3 was indistinguishable from the level seen in 
untreated cells. Whilst the mean activation of caspase-3 resulting from camptothecin 
incubation was always greater than in the untreated cells, the differences were not always 
significant.  
 
Of the human cell lines, the two which express the greatest amount of memHsp70 were the 
two found to exhibit significant levels of caspase-3 activation 4 hours after granzyme B 
introduction, whilst the low memHsp70 expresser T47D did not. Knowing that granzyme B is 
internalised through memHsp70, this finding is not altogether surprising. The limited 
expression of memHsp70 on T47D cells may not be capable of internalising sufficient granzyme 
B within the time frame to induce apoptosis. As earlier optimisation experiments showed, the 
addition of serum into the system interfered with the memHsp70-mediated uptake of 
granzyme B into cells. The addition of growth medium after 60 minutes would be sufficient to 
reduce the internalisation of any remaining granzyme B from this point onwards. The situation 
in the mouse cell lines does not currently ‘track’ with the memHsp70 status, as it is the lower 
memHsp70 expresser, CT26, which was found to activate caspase-3 4 hours post granzyme B 
introduction. The 4T1 cells, which express more memHsp70, showed no significant activation 
of caspase-3 at any time after granzyme B introduction. This may simply be an artefact of 
having data variation in a small sample size, and ideally this could be repeated in the future in 
order to boost n numbers. 
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Figure 5.29 Activation of caspase-3 in human breast cancer cell lines after incubation with granzyme B. 
Only the MDA-MB-231 cell line, which exhibits the highest level of memHsp70, was found to express significantly 
increased levels of activated caspase-3 when incubated with granzyme B. This significant difference was only seen 4 
hours after introduction of granzyme B, and at later time points there was no difference in activated caspase-3 
when compared to the untreated cells (Control: 1.24 ± 0.01, granzyme B: 1.52 ± 0.6. One way ANOVA F=43.844, 
p=0.001. Within subject contrast F=19.401, p=0.012). Other human cell lines (MCF7 and T47D) did not express 
activated caspase-3 in response to any duration of granzyme B incubation. Activation of caspase-3 was observed in 
both MDA-MB-231 and MCF7, however due to large variation in the results did not reach significance in MCF7 after 
48 hours. T47D cells did not exhibit significant levels of caspase-3 activation at any time, after either granzyme B or 
camptothecin incubation (MDA-MB-231: 4 hour control 1.24 ± 0.01, camptothecin 1.44 ± 0.06, 24 hour control 1.30 
± 0.03, camptothecin 1.78 ± 0.11, 48 hour control 1.50 ± 0.13, camptothecin 3.37 ± 0.27. One way ANOVA F=43.844, 
p=0.001. Within subject contrast 4hr F=15.201, p=0.018, 24hr F=25.657, p=0.007, 48hr F=169.471, p=0.0002 ; MCF7 
4 hour control 2.27 ± 0.31, camptothecin 2.60 ± 0.36, 24 hour control 2.34 ± 0.14, camptothecin 3.12 ± 0.12. One 
way ANOVA F=1.172, p=0.355. Within subject contrast 4hr F=11.486, p=0.043, 24hr F=67.094, p=0.004). Significance 
values displayed as * p<0.05, ** p<0.01. Data are presented as mean ± SEM from three independent experiments. 
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Figure 5.30 Activation of caspase-3 in mouse cancer cell lines after incubation with granzyme B. 
The greatest activation of caspase-3 resulting from granzyme B incubation appeared in both CT26 and 4T1 after 4 
hours, but only in the CT26 cells was this to a significant level (Control: 2.9 ± 0.3, granzyme B:4.6 ± 0.7. One way 
ANOVA F=3.784, p=0.005. Within subject contrast F=25.911, p=0.015). Cells that were treated with camptothecin, in 
an attempt to provide a positive control for caspase-3 activation, were found to exhibit significantly increased levels 
of caspase-3 activation at 24 hours after treatment, and in the case of 4T1 cells, also at 48 hours (CT26: control 2.9 ± 
0.1, camptothecin 5.0 ± 0.4. Within subject contrast F=36.413, p=0.009. 4T1: 24 hour control 2.4 ± 0.2, 
camptothecin 5.4 ± 0.4. One way ANOVA F=51.041, p=51.041. Within subject contrast F=151.593, p=0.007. 48 hour 
control 2.3 ± 0.1, camptothecin 10.4 ± 0.3. Within subject contrast F=304.644, p=0.003). Significance values 
displayed as * p<0.05, ** p<0.01. Data are presented as mean ± SEM from three independent experiments. 
 
The lack of clarity and inconsistency of the caspase-3 activation data were highly surprising. 
From a morphological perspective, untreated cells retained normal growth morphology, 
whereas a proportion of the human and mouse cell lines that had been treated with 
camptothecin or granzyme B were smaller and rounded in appearance. Furthermore, some 
cells had detached from the plate and were observed to be in suspension within the growth 
medium. These changes in appearance were observed in all time points, but were more 
pronounced at later time points. These are characteristics of cells having undergone apoptosis, 
so it is surprising that the activation of caspase-3, taken as a measurement of apoptosis, was 
not present. There are a number of possibilities for this discrepancy. Perhaps cells were not 
analysed at the most appropriate time-point to observe activated caspase-3. Since the 
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activation is a transient event timing is crucial, and it may be that a shorter incubation time 
was required. It may be that caspase-3 activation is an inappropriate marker of memHsp70-
mediated granzyme B-induced apoptosis, if the uptake and trafficking pathway does not allow 
for caspase-3 interaction but perhaps instead relies on an alternative method of apoptosis 
induction. Whilst harvesting the cells from the plates prior to staining it was noticed that those 
wells with cells incubated with camptothecin or granzyme B appeared to hold fewer cells, and 
with a smaller proportion adhered to the well surface, than the control wells. This sparked 
further microscopical image analysis of the cells.   
 
As the selected staining did not provide data to match the observed changes in cell 
morphology, additional experiments incubated cells in the presence of granzyme B for a 
variety of time points and then imaged the cultures on the Zeiss 510 inverted microscope. For 
this, cells were set up in glass bottomed dishes and grown for 48 hours before washing in PBS 
and applying PBS containing granzyme B for 60 min. After this time, 2 mL of fresh growth 
medium was added and cells were incubated for the remainder of their respective incubation 
durations (up to 2, 4 or 24 hours). Cells were washed and mounted onto microscopy slides 
using VECTASHIELD® containing DAPI, to stain the nucleus. This protocol necessitated the 
washing of wells before samples were mounted onto microscopy slides for imaging. This 
process would therefore remove fully detached cells. This compromise was deemed 
acceptable because even if detached cells were still present, they could not have been imaged 
easily. Single frame images of the bright-field channel (to show the cell morphology) and DAPI 
(to place the nucleus) were obtained using a 20x dry objective with representative images 
shown for human (Fig 5.31) and mouse (Fig 5.32) cell lines. The control cells show the usual 
morphology, and although all cell lines have their own typical morphology they all exhibit 
elongated structures with jagged cell edges. After 2 hours, cells begin to exhibit rounded 
qualities, with greater space between cells. After 4 hours, the spacing of cell is more 
pronounced. By 24 hours, there is a marked reduction in cell number, however those which 
remain have reverted back to a typical growth morphology, as seen in the control panel.  
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Figure 5.31 Morphology of human breast cancer cell cultures after incubation with granzyme B 
Even one hour after the introduction of granzyme B to the cells, their morphology can be seen to change. Cells 
begin to round up and by 2-4 hours there is a clear reduction in cell number due to detachment and cells being 
washed away. After 24 hours, the cell number is much reduced, however those cells which remain have returned to 




Figure 5.32 Morphology of mouse cancer cell cultures after incubation with granzyme B. 
Even one hour after the introduction of granzyme B to the cells, their morphology can be seen to change. Cells 
begin to round up and by 2-4 hours there is a clear reduction in cell number due to detachment and cells being 
washed away. After 24 hours, the cell number is much reduced, however those cells which remain have returned to 
standard adhered morphology like that of the control population. 
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As a proportion of cells which adhere and grow remain following granzyme B incubation, it 
would appear that a single dose of granzyme B is insufficient to kill all cells, or that this reflects 
the heterogeneous nature of memHsp70 expression within these cell lines. In future 
experiments it may be worth investigating the consequences of re-incubating the remaining 
cells with granzyme B again, to determine whether the residual observed cell population is due 
to some inherent degree of granzyme B resistance (due to variable memHsp70 expression for 
example) or perhaps due to exhaustion of granzyme B in the media before complete killing can 
occur.  
5.5 Involvement of sugars in the binding of granzyme B to memHsp70 
Granzyme B uptake was found to be inhibited following deglycosylation (Mathias Gehrmann 
personal communication followed by [531]) and so to investigate further whether sugars are 
involved in the binding and subsequent internalisation of granzyme B to cancer cells 
expressing memHsp70, a variety of sugars were used as potential blocking agents and the 
results analysed by both flow cytometry and confocal microscopy. To date, these experiments 
have only been conducted on a single cell line (CT26), and so they need to be repeated using 
other cell lines in order to confirm the wider applicability of the findings.  
For the experiments, CT26 cells were incubated in the presence of staining buffer containing 
either 10mM or 20mM of fucose, galactose, glucosamine, glucose, mannose, or n-acetyl 
neuraminic acid (NANA) and incubated at 37°C for 30 minutes. After this time, the buffer was 
replaced with PBS containing fluorescently-labelled granzyme B and cells were incubated at 
37°C for an additional 30 minutes. Cells were then directly analysed via flow cytometry, with 
any reduction in fluorescence compared to the control being evident of blocking of the 
granzyme B. Only one of the sugar treatments was found to significantly impair granzyme B 
uptake; 20mM of n-acetyl neuraminic acid (Fig 5.33). This treatment resulted in an almost 40% 
reduction in detected fluorescence compared to the control cells (relative fluorescence; 
control 5.2 ± 0.4, 20mM NANA 3.3 ± 0.1). 
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Figure 5.33 Internalisation of ATTO488-granzyme B by CT26 cells can be impaired by the presence of N-acetyl 
neuraminic acid. 
CT26 cells pre-incubated with 10mM or 20mM of a variety of sugars (fucose, galactose, glucosamine, glucose, 
mannose and N-acetyl neuramininc acid) for 30 minutes were subsequently incubated in the presence of 4µg/mL  
ATTO488-granzyme B for a further 30 minutes. Whilst most sugars have no effect on the binding and uptake of 
granzyme B, pre-incubation with 20mM NANA results in a significant reduction in the amount of granzyme B 
processed by CT26 cells. Data shown are mean + SEM from 3-5 independent experiments. Significance determined 
by one-way independent ANOVA (F=2.569, p=0.014) with Games-Howell post-hoc comparison (p=0.019) 
 
More information pertaining to the influence of sugars was obtained using confocal 
microscopy. For this, cells were set up on MatTek glass-bottomed dishes and grown for 48 
hours, before being treated with 10mM of one of the sugars for 30 minutes at 37°C. 
Subsequently cells were washed, and incubated with granzyme B in PBS for a further 30 
minutes at 37°C. After this time, cells were formaldehyde fixed, permeabilised and stained 
with antibodies specific for LAMP2, followed by an appropriate Cy3-labelled secondary 
antibody. LAMP2 was selected as the cells had previously exhibited a measurable co-
localisation between internalised ATTO488-granzyme B and LAMP2. If the pre-treatment of the 
cells with sugars did indeed influence the uptake of granzyme B then a quantifiable variation in 
co-localisation would be observed. Next, the glass coverslips were detached from the dishes 
and mounted on microscopy slides using VECTASHIELD® containing DAPI. Slides were stored at 
4°C protected from light until imaging could commence. Representative single frame images 
from the middle of cells treated with each sugar are shown (Fig 5.34).  
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Figure 5.34 Internalisation of ATTO488-granzyme B by CT26 cells can be impaired by the presence of N-acetyl 
neuraminic acid. 
CT26 cells pre-incubated with 10mM of a variety of sugars (fucose, galactose, glucosamine, glucose, mannose and 
N-acetyl neuramininc acid) for 30 minutes were subsequently incubated in the presence of 4µg/mL ATTO488-
granzyme B (green) for a further 30 minutes. Cells were fixed, permeabilised and stained for the presence of LAMP2 
(magenta) and mounted in VECTASHIELD containing DAPI to stain the nucleus (blue). The majority of sugars did 
not significantly alter the internalisation of ATTO488-granzyme B, however incubation with 10µM resulted in 
binding of ATTO488-granzyme B, but virtually no internalisation. Images shown are representative single frames 
taken from the middle region of the cells. Scale bars represent 10µm.  
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The profile of ATTO488-granzyme B (green) presents as spots within the cell boundary, and 
therefore has been internalised, after 5 of the sugar treatments. The cells treated with 10mM 
of n-acetyl neuraminic acid differed, as the majority of granzyme B was found instead along 
the cell boundary. These findings suggest that although granzyme B binding is unaffected, its 
internalisation has somehow been impaired by the presence of NANA. In an effort to provide 
some quantification on the reduction of internalised granzyme B, one of the vesicle stainings 
was employed. LAMP2 staining was used as it showed measureable co-localisation with 
granzyme B in CT26 cells incubated for 30 minutes.  
The inclusion of LAMP2 staining (magenta) allowed the co-localisation of granzyme B with 
LAMP2+ vesicles to be calculated. Previously internalised ATTO488-granzyme B had been 
shown to co-localise with different intracellular vesicle stainings and any of them could have 
been used at this point. The results of all treatments, including the control cells which received 
no sugar incubation, are shown (Table 5.9), and the only treatment to significantly reduce the 
co-localisation of granzyme B with LAMP2+ vesicles was 10mM n-acetyl neuraminic acid 
(Control: 33.7 ± 4.8%. NANA: 5.6 ± 3.1%). These findings confirm and extend the flow 
cytometry data.  
 
Table 5.9 Influence of incubation with sugars on the uptake of granzyme B into CT26 cells 
CT26 cells pre-treated with one of six different sugars then incubated with ATTO488-granzyme B were analysed by 
confocal microscopy to calculate the proportion of ATTO488-granzyme B co-localised to lysosomes (LAMP2+). Cells 
pre-treated with N-acetyl Neuraminic Acid showed a significant reduction in co-localisation indicating that 
significantly less ATTO488-granzyme B was internalised. One-way ANOVA F=10.002, p=0.000005, Hochberg post-hoc 
test p=0.0001. Data are presented as mean ± SEM from 4-6 imaged cells, from two independent experiments. 
Time restraints did not allow for this to be investigated with the breast cancer cell lines 
however this would be an interesting follow-up in the future. 
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5.6 Summary 
The serine protease granzyme B is a main constituent in the cytotoxic granules of natural killer 
cells and cytotoxic CD8+ T cells which acts to induce apoptosis. In this setting, granzyme B is 
able to enter the target cells by way of combined action with the pore-forming protein 
perforin, however the presence of memHsp70 on the cell surface has been shown to 
circumvent this need. Recombinant human granzyme B is able to bind directly to memHsp70, 
an action that is dependent on mammalian post-translational modifications and is not possible 
if the granzyme B is deglycosylated [531]. MemHsp70 positive breast cancer cell lines were 
shown to bind and uptake granzyme B, with the rate of uptake increased in line with increasing 
memHsp70 expression levels. Using fluorescently labelled granzyme B the trafficking of 
internalised granzyme B could be tracked and was found to involve a late endosome pathway 
with a proportion co-localising to the mitochondria and some going into lysosome 
degradation. The uptake of granzyme B occurred predominantly around the adhered surface 
of cells, suggesting a possible link between memHsp70 and cell adherence. Following on from 
the finding that mammalian post-translational modifications are required for efficient binding 
and uptake, it was shown that N-acetyl neuraminic acid could successfully block the majority of 
granzyme B uptake into CT26 murine colorectal carcinoma cells. This issue needs to be 
addressed in breast cancer cells to confirm if the same is true in different cell lines and cancer 
types.  
Once internalised, granzyme B induces apoptosis in 4 hours as measured by flow cytometry 
caspase-3 activation, in MDA-MB-231 and CT26 cells. However, when viewed using microscopy 
image analysis all memHsp70 positive cell lines were observed to show morphological features 
apoptosis such as cell rounding, blebbing and detachment. It may be that caspase-3 activation 
is not the most appropriate measure for memHsp70-mediated granzyme B-induced cell death, 
either because the granzyme B acts via a different pathway of apoptosis induction or that the 
activation is transient and the time-points investigated were not the most appropriate. 
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CHAPTER 6  
RESULTS IV – Lymphocytes and memHsp70 expression 
 
6.1 Introduction  
Although heat shock protein 70 has been traditionally viewed as being an intracellular protein, 
the selective expression of a membrane form of Hsp70 on a large proportion (~50%) of 
tumours has been reported [285]. The development of new molecules that can interact with 
this membrane form of Hsp70 could therefore provide a platform on which to develop a range 
of tumour targeting and therapeutic agents. Finding a marker which allows the imaging and/or 
targeting of primary and metastatic tumours could offer real advances in cancer treatment. 
However, for this to be the case, it is essential that healthy cells do not, and cannot be induced 
to, express membrane Hsp70. As the membrane Hsp70 status of peripheral blood immune 
cells has never been investigated before, the aim of this part of the study is to provide a 
thorough assessment of any membrane expression of Hsp70 in peripheral blood immune cells 
at rest and after stresses. If indeed memHsp70 were to be found on peripheral blood immune 
cells this could prove to be highly important. MemHsp70 has been found to mediate 
internalisation of granzyme B resulting in cellular apoptosis [530, 532], and granzyme B has 
also been proposed as one mechanism for regulatory T cells eliciting immunosuppression by 
way of removal of effector cells [167, 168]. 
Peripheral blood lymphocytes from healthy volunteers were assessed ex vivo for the presence 
of membrane Hsp70, as well as after a variety of treatments designed to reflect different 
conditions which could be experienced in a tumour environment. The expression of 
memHsp70 was assessed using flow cytometric analysis following incubation with FITC-
labelled antibodies specific for Hsp70 and appropriate isotype control antibodies. The inclusion 
of the C92F3A-5 Hsp70 mAb (which is specific for an epitope which is unavailable when the 
molecule is present on the membrane) in addition to the cmHsp70.1 mAb allows memHsp70 
to be distinguished from extracellular Hsp70 which has bound to the cell surface.  
 
6.1.1 Membrane Hsp70 expression on peripheral blood immune cells 
The presence of memHsp70 on CD4+ and CD8+ T cells, as well as CD56+ NK cells in whole blood 
and PBMC preparations was determined. For this, whole blood samples were stained 
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immediately after venepuncture in order to provide the most accurate estimation of the in 
vivo situation. Complete whole blood was not a suitable medium for the majority of treatment 
conditions, and so the impact of density gradient separation on the memHsp70 expression of 
lymphocytes was assessed by staining PBMCs immediately following the separation and also 
24 hours later. 
The expression of memHsp70 is determined on the basis of positive staining with the FITC-
labelled cmHsp70.1 mAb. Membrane Hsp70 is an inducible molecule, and consequently, rather 
than reporting the results as ‘percentage positive’ expression can be more accurately 
described in terms of ‘relative intensity’. This is calculated as the median fluorescence intensity 
(mfi) of the stained cells divided by the mfi of the isotype control. A relative intensity of 1 is 
indicative of no difference over the isotype (and therefore no memHsp70 expression). As the 
relative intensity value increases it is indicative more intense staining and therefore greater 
expression of memHsp70.     
 
Figure 6.1 Representative memHsp70 staining patterns for whole blood and PBMCs 
Representative flow cytometry histograms depicting unstained cells (black line), and cells incubated with isotype 
(grey line), C92F3A-5 mAb (light green line) and cmHsp70.1 mAb (dark green line), for viable lymphocyte 
populations in a whole blood sample and a preparation of isolated PBMCs. 
 
The relative intensity of memHsp70 on all lymphocyte subsets in whole blood analysed ex vivo 
was low (CD4+ T cells 1.28 ± 0.12, CD8+ T cells 1.37 ± 0.13, NK cells 1.33 ± 0.37; mean ± SEM, 
n=7) (Fig. 6.2). The staining with the alternative Hsp70 antibody clone C92F3A-5 had relative 
intensity measurements close to 1 for all of the lymphocytes assessed (CD4+ T cells 0.69 ± 0.13, 
CD8+ T cells 0.91 ± 0.16, NK cells 0.76 ± 0.14; mean ± SEM, n=5). These results were not 
significantly different to the isotype control (Multivariate ANOVA, F=0.703, p=0.409).  
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In contrast to whole blood, the relative intensity of cmHsp70.1 mAb binding to all cell types 
was increased following density gradient separation. (CD4+ T cells 2.21 ± 0.46, CD8+ T cells 2.67 
± 0.27, NK cells 3.38 ± 1.12; mean ± SEM, n=5, multivariate ANOVA F=11.403, p=0.002). This 
increase was maintained even after a 24 hour incubation period (CD4+ T cells 2.83 ± 0.37, CD8+ 
T cells 3.34 ± 0.39, NK cells 4.14 ± 0.80; mean ± SEM, n=5). The relative intensity of C92F3A-5 
staining was the same as the isotype control (multivariate ANOVA F=0.426, p=0.517).  There 
was no evidence that venepuncture or density gradient separation had any effect on cellular 
activation, as there was no expression of either CD69 or CD25 (data not shown). 
The level of memHsp70 staining on whole blood lymphocyte populations when examined ex 
vivo is negligible and not significantly different to the isotype control. When cells are examined 
after PBMC isolation as well as after 24 hours rest period the level of memHsp70 induction is 
to similar relative levels as on tumour cells. 
 
Figure 6.2 Relative intensities of staining with fluorescently-labelled cmHsp70.1 mAb and C92F3A-5 on 
lymphocyte subsets in whole blood and following density gradient separation 
Peripheral blood lymphocytes assessed ex vivo expressed very low levels of memHsp70 (shown by the relative 
intensities of both cmHsp70.1 mAb and C92F3A-5 binding being close to 1). PBMC isolation promoted the binding of 
the cmHsp70.1 mAb to CD4+ and CD8+ T cells, as well as NK cells. This binding was retained following a 24 hour 
period of 37°C incubation. Data are presented as mean + SEM, n = 5. * p<0.05, ** p<0.01. 
 
** 
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6.1.2 Effect of different stimuli on memHsp70 expression  
Lymphocytes are subjected to numerous different influences and undergo many responses. 
Tumours provide an immune stress and could be responsible for influences on the 
lymphocytes. The aim here was to investigate whether any of a variety of possible stimuli / 
stressors were able to induce the capacity of the cmHsp70.1 mAb to bind to lymphocytes.  
 
6.1.2.1 Heat stress 
Although the intracellular increase of Hsp70 in lymphocytes in response to heat stress has 
been well documented [560, 561] no data regarding the possible influence on the membrane 
form of the molecule is available. To investigate, isolated PBMCs were incubated at 42°C for 
two hours, and then allowed to rest at 37°C for either 2 hours or 22 hours (Fig 6.3). There was 
no significant change in cmHsp70.1 mAb binding after heat stress with either the short, 2 hour 
rest period or the longer 22 hour rest (CD4+ T cells: control 2.93 ± 1.23, 2hr rest 3.09 ± 1.26, 
22hr rest 2.79 ± 0.07, one-way ANOVA F = 0.041 p = 0.960; CD8+ T cells: control 4.04 ± 1.26, 
2hr rest 3.73 ± 1.25, 22hr rest 3.12 ± 0.07, one-way ANOVA F = 0.230 p = 0.799; NK cells: 
control 4.11 ± 2.07, 2hr rest 3.89 ± 2.31, 22hr rest 3.74 ± 0.88 one-way ANOVA F = 0.004 p = 
0.996; all data presented as mean ± SEM, n = 6).  
As the mechanism of Hsp70 appearing on the membrane is not yet known, one simple 
proposition is that memHsp70 expression is directly dependent on the intracellular Hsp70 
content. Alongside the staining for membrane Hsp70, lymphocytes were subjected to fixation/ 
permeabilisation and stained for intracellular Hsp70. In line with a wealth of published 
literature, lymphocytes were found to upregulate intracellular Hsp70 levels in response to 
increasing durations of incubation at 42oC, up to 2 hours. Incubating cells at 37oC had no effect 
on intracellular Hsp70 (Fig 6.4).  
 




Figure 6.3 Effect of heat stress on the binding of cmHsp70.1 mAb to lymphocytes 
Heat stress that was sufficient to increase intracellular expression (data not shown) did not lead to any increase in 
the binding of cmHsp70.1 mAb over that caused by density gradient isolation of PBMCs. The relative intensity of the 
binding of the C92F3A-5 clone did not significantly increase over the isotype, confirming the presence of cmHsp70.1 
mAb binding rather than the binding of extracellular Hsp70 to the cell surface. Data are presented as mean + SEM, n 
= 6. * p<0.05, ** p<0.01. 
 
 
Figure 6.4 Intracellular Hsp70 response of lymphocytes to heat stress  
Intracellular Hsp70 content of lymphocytes is stable under optimal incubation conditions (37°C, dashed line), but is 
increased in response to incubation at 42°C (solid line). This increase peaks after 2 hours and then remains stable. 
Data presented as mean ± SEM, n = 3. 
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This would indicate that rather than a simple, direct relationship between intracellular Hsp70 
content and memHsp70 expression, there is no relationship between the two. Additionally, 
none of the cell populations showed any sign of activation following heat stress, as there was 
no change in their expression of CD69 or CD25 (data not shown). 
6.1.2.2 Cellular activation 
The influence of activation (concanavalin A and incubation with CD3/CD28 mAb-coated beads) 
on the binding of cmHsp70.1 mAb to density gradient isolated PBMCs populations was 
determined (Fig 6.5).    
 
Figure 6.5 Representative CD69 staining pattern  
Representative flow cytometry histogram depicting unstained cells (black line), and cells incubated with isotype 
(grey line) and with anti-CD69 mAb (blue line), for viable lymphocyte populations in a preparation of isolated 
PBMCs. 
6.1.2.2.1 Influence of activation with Concanavalin A on cmHsp70.1 mAb binding to 
lymphocyte sub-populations  
Whole blood and PBMC preparations were stimulated with Concanavalin A (ConA) for 24 
hours, after which the activation state and capacity of CD4+ T cells, CD8+ T cells and CD56+ NK 
cells to bind FITC-cmHsp70.1 mAb were determined by flow cytometry. Although ConA 
treatment induced a significant activation of CD4+ T cells and CD56+ NK cells in whole blood 
(CD4+ T cells: control 2.5 ± 1.0 %, ConA 11.3 ± 0.5 %, Student’s Paired t test t(3) = -7.495, p = 
0.005; NK cells: control 12.5 ± 8.3 %, ConA 33.8 ± 15.5 %, Student’s Paired t test t(3) = -3.203, p 
= 0.049; data presented as mean ± SEM, n = 4). There was no effect on the activation of CD8+ T 
cells (control 10.0 ± 3.9 %, ConA 10.6 ± 3.0, Student’s Paired t test t(3) = -0.242, p = 0.825, data 
presented as mean ± SEM, n = 4) (Fig 6.6). 
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When cells were examined in the whole blood sample there was a trend for the addition of 
ConA to reduce FITC-cmHsp70.1 binding to T cells (Fig 6.7. CD4+ T cells: control 1.37 ± 0.07, 
ConA 1.21 ± 0.02; CD8+ T cells: control 1.95 ± 0.20, conA 1.49 ± 0.12, data presented as mean ± 
SEM, n = 4), however the decrease did not reach significance for either cell type (Student’s 
Paired t test: CD4+ T cells t(3) = 1.860, p = 0.160; CD8+ T cells t(3) = 2.240, p = 0.111). The ConA 
treatment did not result in any such trend in NK cells (Fig 6.7), with no change in memHsp70 
expression being observed (control 1.53 ± 0.22, ConA 1.52 ± 0.18; Student’s Paired T test t(3) = 
0.041, p = 0.970, data presented as mean ± SEM, n = 4). 
Cellular activation was achieved to a much greater extent when ConA was used to stimulate 
isolated PBMCs (Fig 6.6). In this situation, activation induced a significant increase in the 
proportion of cells expressing CD69 (CD4+ T cells: control 3.6 ± 2.4 %, ConA 76.0 ± 6.3 %, 
Student’s Paired t test t(2) = -8.543, p = 0.013; CD8+ T cells: 4.8 ± 1.9 %, ConA 68.0 ± 6.7 %, 
Student’s Paired t test t(2) = -7.394, p = 0.018; NK cells: control 11.5 ± 1.5 %, ConA 51.4 ± 6.5 
%, Student’s Paired t test t(2) = -5.154, p = 0.036, all data presented as mean ± SEM, n = 3). 
This difference in activation capability could be attributed to the ConA being ‘mopped up’ by 
elements within the blood, such as sugars and other carbohydrates, and by cells with an 
abundance of these on their surface such as monocytes. ConA is a lectin and binds to cells 
through sugars on the cell membrane, predominately α-D-mannosyl and α-D-glucosyl groups, 
both of which are abundant on the surface of monocytes.  
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Figure 6.6 Lymphocyte activation following 24 hour stimulation with ConA in whole blood and PBMC 
preparations. 
Incubation with ConA for 24 hours resulted in significant activation of T cell and NK cell populations in isolated 
PBMCs. In whole blood samples only CD4+ T cells and NK cells were significantly activated, and then to a lesser 
degree than their counterparts in the PBMC preparation. Data presented as mean + SEM, n = 4. * p<0.05, ** p<0.01. 
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Figure 6.7 The effect of ConA on FITC-cmHsp70.1 mAb binding to lymphocytes in whole blood 
A 24 hour incubation with ConA in whole blood did not result in any significant alteration to the cmHsp70.1 mAb 
binding to T cells or NK. There was no staining with the C92F3A-5 Hsp70 antibody clone over and above that of the 
isotype control. Data presented mean + SEM, n = 4. 
 
 
When ConA was used to activate PBMCs there was no obvious trend or significant differences 
in binding of cmHsp70.1 mAb observed in any cell type (Fig 6.8. CD4+ T cells: control 2.38 ± 
0.23, ConA 2.57 ± 0.18, Student’s Paired T test t(2) = -0.535, p = 0.646; CD8+ T cells: control 
3.01 ± 0.48, ConA 2.96 ± 0.47, Student’s Paired T test  t(2) = 0.325, p = 0.776; NK cells: control 
2.42 ± 0.11, ConA 2.31 ± 0.16, Student’s Paired T test t(2) = 0.429, p = 0.710; all data presented 
as mean ± SEM, n = 3).    
Even the enhanced activation levels observed when ConA was applied to PBMC preparations 
did not lead to any significant changes in FITC-cmHsp70.1 mAb binding to T cell or NK 
populations. This would suggest that there is either no link between cellular activation status 
and memHsp70 expression in lymphocytes, or that the timeframe for any downstream effects 
on memHsp70 is a result of activation is longer than that assessed here, or that there is a 
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critical threshold of activation before memHsp70 is affected that the ConA stimulation was 
insufficient to achieve. 
6.1.2.2.2 Influence of activation with CD3/CD28 mAb-coated beads on cmHsp70.1 mAb 
binding to lymphocyte sub-populations 
In order to assess another route of cellular activation, isolated PBMCs were incubated in the 
presence of polystyrene beads coated with anti-CD3/CD28 mAb. These beads mimic T cell 
receptor engagement and the concomitant delivery of co-stimulatory signals. NK cells cannot 
respond to the beads directly, but are stimulated by the cytokines released from T cells upon 
their activation. Two bead preparations which offer different levels of stiumulus due to 
different concentrations of antibodies were used. Human T-Activator CD3/CD28 Expander 
beads (Dynabeads®, Life Technologies) provide a very strong signal, whereas Treg Suppression 
Inspector beads (Inspector beads, Miltenyi Biotec) provide a weaker signal. These beads are 
unsuitable for use in whole blood samples and consequently only isolated PBMCs could be 
investigated in this way. Using the expression of CD69 as a marker of activation status, both T 
cell subsets and the NK cells were found to be activated as a result of incubation with both 
preparations of CD3/CD28 mAb beads (CD4+ T cells: control 1.8 ± 0.4 %, Inspector 28.5 ± 7.4 %, 
expander beads 86.4 ± 5.7 %; CD8+ T cells: control 3.1 ± 0.7 %, Inspector 29.9 ± 6.0 %, expander 
beads 95.9 ± 2.1 %; NK cells: control 17.2 ± 7.6 %, Inspector 56.6 ± 15.9, expander beads 97.8 ± 
1.2 %; data presented as mean ± SEM, n = 5, Fig 6.9). The activation achieved with stimulation 
using both the Inspector bead and expander bead preparations was significant for all cell 
subsets (CD4+ T cells: one-way repeated ANOVA F = 47.625, p < 0.001, Control vs Inspector p = 
0.080, Control vs expander beads p < 0.001 Bonferroni post hoc comparison; CD8+ T cells: one-
way ANOVA F = 198.799, p < 0.001, Control vs Inspector p = 0.040, Control vs expander beads 
p < 0.001, Bonferroni post hoc comparison; NK cells: one-way ANOVA F = 19.887 p = 0.002, 
Control vs Inspector p = 0.216, Control vs expander beads p = 0.005, Bonferroni post hoc 
comparisons).  
 




Figure 6.8 Effect of ConA on FITC-cmHsp70.1 mAb binding to lymphocytes in an isolated PBMC preparation 
24 hour incubation with ConA in an isolated PBMC preparation did not lead to any significant alterations in FITC-
cmHsp70.1 mAb binding to T cell and NK cell populations. There was no staining with the C92F3A-5 Hsp70 antibody 
clone over and above that of the isotype control. Data presented as mean + SEM, n = 3.   
 




Figure 6.9 Effect of incubation with anti-CD3/CD28 mAB coated beads on the activation status of lymphocyte 
subsets. 
T cells and NK cells exhibited significant activation following incubation with anti-CD3/CD28 mAb coated beads. 
Whilst the T cells are activated directly through TCR co-stimulation, the NK cells respond instead to the resulting 
cytokines released from activated T cells. Data presented as mean + SEM, n = 4/5. * p<0.05, ** p<0.01, *** p<0.001. 
 
Although there was a trend for cmHsp70.1 mAb binding to cell subsets to increase after 
cellular activation (CD4+ T cells: control 2.77 ± 0.41, Inspector 3.49 ± 0.70, expander beads 5.32 
± 1.69; CD8+ T cells: control 3.21 ± 0.37, Inspector 3.91 ± 0.58, expander beads 5.47 ± 1.48; NK 
cells: control 4.80 ± 1.64, Inspector 6.46 ± 1.92, expander beads 6.73 ± 2.77; data presented as 
mean ± SEM, n = 5, Fig 6.10), none of these effects were found to be of statistical significance 
(CD4+ T cells: one-way repeated ANOVA F = 2.719, p = 0.174; CD8+ T cells: one-way repeated 
ANOVA F = 2.195, p = 0.212; NK cells: one-way repeated ANOVA F = 1.261, p = 0.349). This lack 
of significance is most likely due to the relatively small number of subjects investigated. Using 
these data, power calculations were preformed to assess the necessary sample size required 
to detect significant effects with a one-way repeated ANOVA at the 0.05 level. The result was 
that experimental group sizes of 12 would be needed to confirm whether the trend for 
memHsp70 to increase following anti-CD3/CD28 coated bead activation of lymphocytes. 
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Increasing the subject count to this level is something that would be desirable to complete in 
the future.  
 
 
Figure 6.10 Effect of incubation with anti-CD3/CD28 mAB coated beads on cmHsp70.1 mAB binding to PBMC 
subpopulations 
Both T cell subsets and NK cells exhibited an increase of the relative intensity of FITC-cmHsp70.1 mAb binding 
following 24 hour exposure to anti-CD3/CD28 mAb stimulation. Data are presented as mean + SEM, n = 4/5.  
 
6.1.2.2.3 Supernatants from activated PBMC cultures 
To investigate whether T cell and NK cell derived cytokines can influence the binding of 
cmHsp70.1 mAb, isolated PBMCs were incubated with the supernatant of PBMCs incubated 
with Inspector or Expander beads, or with supernatants derived from control PBMCs (100% v/v 
or 50% v/v). The concern with using 100% v/v supernatant was that the medium could be 
nutrient depleted from already being used to support activated cells for 24 hours, and that it 
could lead to nutrient starvation stress rather than simply providing released factors from cell 
activation. However, cells incubated in 100% v/v supernatant exhibited good viability (>95%) 
and so nutrient deficiency did not appear to pose a problem. The addition of the 50% v/v also 
allowed for concentration-dependent effects to be observed.  
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Although CD8+ T cells showed no increase to activation after incubation with supernatants 
derived from anti-CD3/CD28 mAb activated PBMCs (control: 16.9 ± 6.4%; 50% v/v: control 15.4 
± 5.7 %, inspector 16.8 ± 5.9 %,  expander beads 24.1 ± 10.8 %; 100% v/v: control 16.8 ± 6.6 , 
inspector 15.2 ± 8.0 %, expander beads 22.1 ± 8.7; one-way ANOVA F = 0.338, p = 0.907, data 
presented as mean ± SEM, n = 4, Fig 6.11), CD4+ T cells did show activation in response to the 
supernatants, with a trend for increasing activation in a concentration-dependent manner and 
in line with the strength of activation of the beads themselves (control: 2.9 ± 1.2 %; 50% v/v: 
control 3.7 ± 0.7 %,  inspector 7.8 ± 1.8 %, expander beads 13.5 ± 3.7 %; 100% v/v: control 4.1 
± 0.7 %, inspector 10.7 ± 2.7 %, expander beads 16.4 ± 2.1 %; one-way ANOVA F = 9.027, p < 
0.001, significance differences between Control vs 50% v/v expander beads supernatant (p = 
0.004) and Control vs 100% v/v expander beads supernatant (p = 0.001) determined by Gabriel 
post hoc comparison), data presented as mean ± SEM, n = 4, Fig 6.11). NK cells were also 
activated in response to incubation with supernatants from previously activated PBMCs 
(control: 12.1 ± 5.5 %; 50% v/v: control 16.1 ± 7.9 %, inspector 62.3 ± 8.7 %, expander beads 
95.4 ± 2.1; 100% v/v: control 19.4 ± 6.1 %, 77.7 ± 4.8 %, expander beads 94.7 ± 2.5 %; one-way 
ANOVA F = 54.436, p < 0.001, significant differences between Control and all concentrations of 
both supernatants derived from beads activated lymphocytes (p < 0.001) determined by 
Gabriel post hoc comparison, data presented as mean ± SEM, n = 4, Fig 6.11). Compared to the 
control sample, none of the control supernatants were found to have any significant effect on 
cellular activation for any of the lymphocytes studied, demonstrating that there is no 
confounding factor within the supernatant that may influence activation.    
Whilst there was a concentration dependent activation in conjunction with supernatant 
derived from incubation with the less potent inspector beads, the activation levels of NK cells 
in response to supernatant derived from expander bead stimulation were consistent and 
independent of the concentration of supernatant used. The levels of activation in NK cells 
were similar to those seen when PBMCs were incubated with the beads, and this is 
unsurprising as NK cells respond to the released cytokines rather than the beads themselves.   
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Figure 6.11 Effect of the incubation with supernatants derived from CD3/CD28 mAb activated PBMCs on the 
activation status of lymphocyte subsets 
Incubating PBMCs in supernatant derived from anti-CD3/CD28 mAb activated cells did not lead to any activation of 
CD8+ T cells, although CD4+ T cells and NK cells did exhibit activation. The most pronounced activation resulted from 
incubation with the highest concentration of supernatant derived from expander bead (the more potent) 
stimulation.  Data presented as mean + SEM, n = 4. ** p<0.01, *** p<0.001. 
 
Incubation of PBMCs with supernatants had little effect on cmHsp70.1 mAb binding to T cells, 
apart from when cells were incubated with 100% v/v supernatant derived from expander bead 
stimulated PBMCs, but this effect was found not to be of statistical significance (CD4+ T cells – 
control: 2.86 ± 1.21, 50% v/v: control 2.96 ± 1.12, inspector 2.86 ± 0.85, expander beads 3.26 ± 
1.15; 100% v/v control: 2.75 ± 0.73, inspector 2.93 ± 0.81, expander beads 4.41 ± 1.71; one-
way ANOVA F = 0.263, p = 0.945. CD8+ T cells – control: 3.93 ± 1.19, 50% v/v: control 4.13 ± 
0.95, inspector 3.76 ± 0.79, expander beads 4.09 ± 0.71; 100% v/v control: 3.92 ± 0.52, 
inspector 3.71 ± 0.60, expander beads 4.73 ± 1.16; one-way ANOVA F = 0.151, p = 0.986. Data 
presented as mean ± SEM, n = 4, Fig 6.12). However, cmHsp70.1 mAb binding to NK cells was 
increased following incubation with supernatants derived from PBMCs incubated with both 
inspector and expander beads, although again these effects were not of statistical significance 
(control: 3.96 ± 1.94 %; 50% v/v: control 3.82 ± 1.72 %, inspector 4.44 ± 2.04 %, expander 
beads 6.73 ± 2.35; 100% v/v: control 3.55 ± 1.37 %, 4.41 ± 1.73 %, expander beads 8.26 ± 2.93 
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%; one-way ANOVA F = 0.737, p = 0.628) The results from the using different concentrations of 
inspector bead supernatant were similar, although the cmHsp70.1 mAb binding following 
incubation with expander beads supernatant was increased in a concentration-dependent 
manner. 
The magnitude of the relative intensity expression of cmHsp70.1 mAb binding was greater with 
100% v/v expander bead derived supernatant than when PBMCs were incubated with 
expander beads themselves. As NK cells respond to the cytokines released after activation, 
when beads are used there is a waiting period after addition of the beads and until the T cells 
begin to release IL-2 and NK cells can respond. When the supernatant is used there is no lag 
period, as released IL-2 is already present and NKs can respond immediately. If cmHsp70.1 
mAb binding is somehow linked to NK activation status, then the increased binding in response 




Figure 6.12 Effect of incubation with supernatants derived from CD3/CD28 mAb activated PBMCs on the binding 
of cmHsp70.1 mAb to lymphocyte subsets 
Incubating PBMCs in supernatant derived from bead activated cells did not lead to any change in cmHsp70.1 mAb 
binding to T cells subsets, only NK cells. The Inspector bead supernatant results in a modest increase in cmHsp70.1 
mAb binding, whilst the expander bead-derived supernatant resulted in a concentration dependent increase to the 
relative intensity of cmHsp70.1 mAb binding up to twice the level of the control. Data presented as mean + SEM, n = 
4.  
215 | P a g e  
 
6.1.2.2.4 Relationship between lymphocyte activation status and cmHsp70.1 mAb binding 
expression  
In order to further investigate the possible relationship between activation status and 
cmHsp70.1 mAb binding, correlation analyses were performed on data relating to the 
percentage of CD69 expression and the relative intensity of memHsp70 expression for CD4+ T 
cells, CD8+ T cells and NK cells (Fig 6.13). Paired data for percentage of CD69 and relative 
intensity of cmHsp70.1 mAb binding from all treatments used is presented on scatter plots 
with linear trendlines applied.  For all lymphocyte subsets, there was found to be a significant 
positive correlation between the expression of CD69 (as a measurement of cellular activation) 
and the relative intensity of cmHsp70.1 mAb staining (Pearson’s Correlation Co-efficient: CD4+ 
T cells r=0.352, p=0.002; CD8+ T cells r=0.301, p=0.008; NK cells r=0.518, p<0.001). Whilst the 
correlation is significant for all lymphocyte subsets, the value of the correlation coefficient is 
fairly low in all instances, suggesting that either activation is just one of many factors that can 
influence cmHsp70.1 mAb binding. 
 
Figure 6.13 Relationship between activation status and cmHsp70.1 mAb binding to lymphocyte subsets.  
Regression analysis was conducted to describe the relationship between activation status and cmHsp70.1 mAb 
binding. Data were combined across all lymphocyte stainings from all treatments (n = 64). Although all lymphocyte 
subsets were found to exhibit a positive correlation between activation and memHsp70 expression, the magnitude 
was low indicating that multiple factors in addition to activation could influence cmHsp70.1 mAb binding. 
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6.1.2.3 Oxidative stress 
Using density gradient isolated PBMCs, lymphocytes were assessed for their capacity to bind 
the cmHsp70.1 mAb following exposure to oxidative stress. This was conducted using two 
methods; incubation of the cells under 0.1% v/v O2 in a hypoxic chamber (mimicking the 
physiological hypoxia in the centre of a tumour) and by incubation in the presence of H2O2 (a 
chemical-induced oxidative stress to investigate whether the mechanism or end result can 
influence cmHsp70.1 mAb binding). 
 
6.1.2.3.1 Hypoxic chamber 
All lymphocyte subsets retained high viability (>85%) after the incubation at 0.1% v/v O2. 
Although there appeared to be a trend for the relative intensity of cmHsp70.1 mAb binding to 
be reduced following exposure to a hypoxic environment, this was not significant for any of 
the cell subsets (CD4+ T cells: control 2.26 ± 0.34, 0.1% O2 2.01 ± 0.24; CD8+ T cells: control 3.42 
± 0.52, 0.1% O2 3.37 ± 0.30; NK cells: control 2.91 ± 0.25, 0.1% O2 2.38 ± 0.08. Data presented 
as mean ± SEM, n = 3. Two-tailed Student’s paired T test: CD4+ T cells t(2) = 4.163, p = 0.053; 
CD8+ T cells t(2) = 0.420, p = 0.715; NK cells t(2) = 2.412, p = 0.137. Fig 6.14). Power 
calculations to compute the necessary sample size required to detect significant differences 
were calculated using G*Power software. CD4+ T cells and NK cells were found to require 
sample sizes of 31 and 9 respectively, but CD8+ T cells would require 2231. This would suggest 
that CD8+ T cells do not modulate memHsp70 expression in response to a hypoxic 
environment. In the future it would be preferable to increase the sample size to 30 to confirm 
whether memHsp70 expression in CD4+ T cells and NK cells does respond to a hypoxic 
environment. In addition, as only one time point was assessed and the cell subsets exhibited 
only a small trend for a reduction in cmHsp70.1 mAb binding following hypoxia, it could be 
that sustaining a hypoxic environment for a longer duration may result in a greater reduction 
to cmHsp70.1 mAb binding. However, it would be difficult to apply this environment whilst still 
maintaining cell viability.  
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Figure 6.14 Effect of incubation under 0.1% v/v O2 on the relative intensity of cmHsp70.1 mAb binding 
A non-lethal hypoxic environment did not have any significant impact on the relative intensity of cmHsp70.1 mAb 
binding by lymphocyte subsets, although there was a trend for a reduction. Data are presented as mean + SEM, n = 
3.  
5.1.2.3.2 Hydrogen peroxide 
Density gradient isolated PBMCs were incubated in the presence of H2O2. The biggest problem 
encountered when incubating cells was ensuring a high level of cell viability. Only a 10µM 
concentration maintained an acceptable level of viability, other concentrations attempted 
(1000, 100, 50 and 25µM) resulted in only 10-40% of cells remaining viable. To ensure that any 
results were indeed due to the treatment in question and not an artefact of other stresses 
within the environment, only the 10µM was selected for investigation. All lymphocyte subsets 
were found to exhibit a significantly reduced relative intensity of cmHsp70.1 mAb binding 
following incubation in the presence of 10µM H2O2 (CD4+ T cells: control 2.95 ± 0.34, H2O2 2.47 
± 0.33; CD8+ T cells: control 3.41 ± 0.29, H2O2 2.90 ± 0.25; NK cells: control 3.81 ± 0.29, H2O2 
3.07 ± 0.34. Data presented as mean ± SEM, n = 3. Two-tailed Student’s paired T test: CD4+ T 
cells t(2) = 7.021, p = 0.020; CD8+ T cells t(2) = 13.180, p = 0.006; NK cells t(2) = 6.712, p = 
0.021, Fig 6.15). 
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Figure 6.15 Effect of H2O2 incubation on the relative intensity of cmHsp70.1 mAb binding to lymphocyte subsets. 
Incubating PBMCs with 10µM H2O2 induces a chemical hypoxia and leads to a reduction in cmHsp70.1 mAb binding 
by T cell populations and NK cells. Due to high levels of non-viability when greater concentrations were used, it was 
not possible to demonstrate a concentration dependent curve within the results. Data presented as mean + SEM, n 
=3.   
6.2 Summary 
None of the peripheral cell populations assessed ex vivo were found to express memHsp70, 
which falls in line with other published data that healthy tissue is memHsp70- and only tumour 
tissue is positive for memHsp70. When cellular activation was performed ex vivo on whole 
blood samples then there was also no expression of memHsp70. When PBMCs were isolated 
via density gradient separation there was the appearance of cmHsp70.1 mAb binding. Whilst 
this demonstrates that cells have some capacity to exhibit Hsp70 on their membrane it is also 
worth noting that is a highly artificial scenario and that cellular separation does not have an in 
vivo analogy and it does not mean that cells would memHsp70 in the circulating periphery. 
Although some regulation of cmHsp70.1 mAb binding to lymphocyte subpopulations in 
response to certain stimuli (cell activation, hypoxia and tumour-secreted factors) was 
apparent, it is difficult to assess the relevance of these findings. Since the stimuli were applied 
to isolated PBMCs which were already binding cmHsp70.1 mAb binding in a somewhat artificial 
manner, it is unclear whether the same stimuli would have resulted in cmHsp70.1 mAb binding 
if the cells had not undergone the density gradient separation.  
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CHAPTER 7 Discussion  
 
Hsp70 is a molecular chaperone which serves a number of cytoprotective and essential 
‘housekeeping’ functions in times of internal and external stress. The upregulation of 
intracellular Hsp70 expression is a common feature of cancer cells and relates to their highly 
proliferative state. Importantly, in the context of cancer, the upregulation and elevated 
expression of heat shock proteins confers protection against the effects of many therapeutic 
interventions.  
 
The cytoprotective effect of Hsp70 in cancer cells can be deleterious to patients, as illustrated 
by the observation that the prognosis of patients whose tumours express high levels of 
intracellular Hsp70 is typically worse [562]. The occurrence of environmental stresses can 
further upregulate the expression of Hsp70, via the transcription factor heat shock factor 1 
(HSF1). HSF1 has also been found to be overexpressed in tumour cells, and is a cause of the 
constitutive overexpression of Hsp70 [563]. The association of Hsp70 and HSF1 overexpression 
with poor patient prognosis is related to an increased incidence of metastasis and an enhanced 
resistance to chemo- and radiotherapies [564]. Since knock-down of Hsp70 or HSF1 leads to 
enhanced sensitivity of cancer cells to radiotherapy [565], a similar response may be possible 
via the application of inhibitors. In this regard, the small molecular weight Hsp70/HSF1 
inhibitor NZ28 has been reported to reduce Hsp70 and HSF1 levels in vitro to such an extent 
that treated cancer cells subsequently exhibit an increased susceptibility to radiation [566].  
Another heat shock protein which has generated interest for therapeutic targeting using 
inhibitors is Hsp90. A multitude of oncogenic client proteins including HER2, mutant p53, 
mutant EGFR, surviving and HIF-1α are chaperoned by Hsp90 and consequently the effective 
inhibition of Hsp90 offers an attractive potential anti-cancer avenue. The use of Hsp90 
inhibitors can improve the radiosensitivity of tumour cell lines [567, 568], however one 
significant hurdle to overcome is that inhibition of hsp90 is one of the stresses which activates 
HSF1, consequently triggering upregulation of Hsp70 expression and the cells gain back some 
radioresistance. Experiments performed in vitro on breast and lung cancer cells lines have 
shown that the use of an Hsp90 inhibitor (NVP-AUY922) in addition to the Hsp70/HSF1 
inhibitor NZ28 results in lower concentrations of inhibitors (~20 fold) being required in order 
to see the same increase in tumour radio-sensitivity [566].    
In addition to being expressed intracellularly, a large proportion of tumours (~50-80%) have 
been found to also display Hsp70 on the surface of their plasma membrane (memHsp70) [287, 
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569]. This membrane-associated localisation of Hsp70 is restricted to tumours, with normal 
surrounding tissue and other tissues being negative for memHsp70 expression. Ongoing 
analysis of patient tumour biopsies (currently standing at over 1300 samples) confirms the 
tumour-specificity of memHsp70 and shows memHsp70-positivity occurs in 40-80% of 
tumours, depending on the tumour type. When biopsies from primary and secondary tumour 
tissue are available, the metastases maintain the memHsp70 phenotype of the primary 
tumour [532]. Analysis of a smaller cohort, comparing biopsies of 150 patients with either 
colon, gastric, lower rectal or squamous cell carcinomas found that whilst all tumour types 
expressed similar levels of memHsp70 (37-43%) there was a disparity between memHsp70 
status and patient survival. For those patients with colon and gastric carcinoma, the presence 
of memHsp70 correlated with longer overall survival, but for lower rectal and squamous cell 
carcinomas the opposite was true with memHsp70+ patients having a reduced overall survival 
[515]. The authors hypothesise that the favoured routes of metastasis may account for the 
survival differences. Both colon and gastric cancers metastasise through the liver, and the 
authors propose that hepatic natural killer (NK) cells may better recognise memHsp70+ cells 
and hence patients may gain a survival benefit [515]. This is supported by findings that 
memHsp70 serves as a target recognition and activation structure for NK cells [288, 570] as 
well as the increased abundance of NK cells in the liver [571]. 
The definitive presence of this unique membrane form of Hsp70 is confirmed by staining cells 
using an anti-Hsp70 mAb (clone C92F3A-5) which recognises an epitope which is not available 
when Hsp70 is expressed in its membrane, but is available if extracellular Hsp70 has become 
associated with the cell surface. The mechanism for the presence of memHsp70 has not yet 
been elucidated, although data from the memHsp70+ mouse colorectal carcinoma cell line 
CT26 has provided evidence for the co-localisation of memHsp70 within cholesterol-rich 
microdomains [518] [572], based on the observation that cholesterol depletion by methyl-beta 
cyclodextrin treatment led to a reduction in the membrane expression of hsp70 [518]. The 
authors observed no change in memHsp70 expression when cells were subject to 
modifications in environmental salt concentrations or pH, which would have been indicative of 
associations with proteins, leading to the assumption that memHsp70 interacts with 
membraneous lipids [518]. Profiling cell membranes of memHsp70+ and memHsp70- colon and 
pancreas carcinoma cell lines by electrospray tandem mass spectrometry found no difference 
in phosphatidylcholine, sphingomyelin, dihydrosphingomyelin, ceramide, phosphatidylserine, 
phosphatidylethanolamine or glucosylceramide, however globotriaosylceramide (Gb3/CD77) 
was found to exhibit at significantly higher levels in memHsp70+ cell lines [518]. Performing 
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vesicle copellation assays showed that Hsp70 bound to vesicles containing Gb3, but not to 
those with other, physiologically relevant lipid compositions.  
 
From a potential therapeutic perspective, studies have demonstrated that memHsp70 can act 
as a target recognition structure for NK cells that have been activated (4 days) in vitro with low 
dose IL-2 alone (100IU/mL) [523, 526] or with low-dose IL-2 in addition to a 14-mer peptide 
which includes the epitope to which the cmHsp70.1 mAb is reactive. Such activated NK cell 
populations have been shown to selectively kill memHsp70+ CT26 cells [533], as well as a range 
of other murine and human tumour cells that express the membrane form of Hsp70 in vitro 
[523, 573]. The Multhoff group translated these findings into the clinical setting by undertaking 
a Phase I clinical trial to assess the safety and tolerability of adoptively-transferred 14-mer 
peptide/IL-2 activated autologous NK cells in 11 patients with colorectal cancer and one with 
non-small cell lung cancer [528]. The trial showed the procedure to be safe, with no negative 
side effects in patients. Following the procedure, activated NK cells comprised 8-20% of 
patients’ lymphocytes, and in 10 of the 12 patients in vitro cytolytic activity of 14-mer-
peptide/IL-2 activated NK cells was enhanced. In a follow-up study of one of the patients with 
colorectal carcinoma [529], a stable cell line was generated from the patient’s own tumour to 
allow personalised cytotoxicity assays to be performed using the patients NK cells following 
repeated cycles of infusion following leukapheresis and extrinsically activated with 14-mer 
peptide and IL-2. The patient received 9 infusions, 6 of which were given monthly, and the 
remaining 3 being given monthly following a 3-month pause. NK cell responsiveness was 
increased following activation and infusion, and this was heightened with each cycle [529]. The 
pause in treatment led to a gradual decline in responsiveness, but this was recovered when 
treatment resumed. This leukapheresis/activation/re-infusion therapeutic strategy is currently 
being investigated in a randomised multicentre Phase II clinical trial in patients with non-small 
cell lung carcinoma lung cancer who have opted for chemo(radio)therapy [574].    
NK cell-mediated tumour cell lysis in vitro can be enhanced in the presence of cmHsp70.1 
mAb, due to the induction NK cell-mediated antibody-dependent cellular cytotoxicity (ADCC) 
[522]. These findings have been extended and corroborated by in vivo observations that mice 
bearing implanted CT26 tumours that received three doses of cmHsp70.1 mAb exhibited both 
a significant reduction in tumour size as well as an infiltration of NK cells into the tumour 
microenvironment [533].  
An important feature of membrane Hsp70 expression is that ‘standard’ therapeutic 
approaches such as chemotherapy and radiotherapy enhance the cell surface density of Hsp70 
on tumours [290, 519, 575, 576], thereby enhancing the potential sensitivity of tumours to 
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targeting by NK cells, the cmHsp70 mAb and granzyme B, as well as improving the potential to 
image and define the boundaries of the tumour using appropriately labelled cmHsp70.1 mAb 
and Hsp70-derived peptides.  
7.1 The cmHsp70.1 monoclonal antibody as a theranostic 
The term “theranostics” has been coined to define the pre-clinical and clinical approaches that 
are being used to develop more specific, individualised therapies for various diseases, and to 
combine diagnostic and therapeutic capabilities into a single agent. 
 
In addition to being capable of identifying the expression of memHsp70 by tumour cells and 
inducing ADCC in vitro and in vivo, the cmHsp70.1 mAb can also be selectively taken up into 
tumour cells, as demonstrated by the tumour-specific accumulation of FITC-labelled 
cmHsp70.1 mAb into memHsp70+ CT26 carcinoma cell-derived tumours [533]. These initial 
studies have been extended and expanded upon in the programme of work which constitutes 
this thesis. The cmHsp70.1 mAb therefore offers potential platform on which to develop new 
tumour imaging and targeting strategies, either as a sole reagent, or as part of an imaging / 
therapeutic complex in the clinical setting. These could be particularly valuable for the 
visualisation and targeting of metastatic disease, since it would allow for a specific way to 
pinpoint or treat even small, distant metastases.   
With breast cancer being one of the most prevalent malignancies in the world, and one which 
is responsible for over 500,000 deaths per year worldwide and nearly 15,000 deaths per year 
in the UK alone (http://www.cancerresearchuk.org/cancer-info/cancerstats), it is vital that 
novel treatment options are explored [577, 578]. Aggressive and invasive breast cancers have 
higher mortality rates, so a molecule which allows for metastatic targeting could offer 
improved prognosis for these patients – approximately 90% of all breast cancer-related deaths 
result from metastatic disease. Although not yet confirmed for breast cancer, a comparison of 
memHsp70 expression on biopsy tissue from primary and metastatic sites found that not only 
was memHsp70 expression retained, but it was actually higher in metastases than the primary 
tumour [532]. This may result in memHsp70 being an even better candidate for metastatic 
targeting. A minority of breast cancers are classified as triple negative, meaning that they do 
not express HER-2, oestrogen receptor or progesterone receptor. As such, currently available 
targeted strategies cannot be employed so any other specifically expressed molecule that may 
be able to offer new therapeutic targets should be welcomed. With memHsp70 present on 
around 50% of breast cancers, and could be exploited for imaging, inducing ADCC or as part of 
a theranostic and delivery platform, it is therefore a very attractive proposition. 
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The expression of membrane Hsp70 on a panel of human breast cancer cell lines (MDA-MB-
231, MCF7, T47D) having different characteristics that are relevant to clinical outcome was 
determined, and the internalisation and intracellular trafficking of the cmHsp70.1 mAb into 
these assessed.  
Cell Line HER2 ER PR Classification Disease severity 
represented 
MDA-MB-231 - - - TNBC +++ 
MCF7 - + Low Luminal A ++ 
T47D - + High Luminal A + 
 
Replication of Table 2.1: Characteristics of the human breast cancer cell lines selected 
A summary of the key differences between the three human-derived breast cancer cell lines used in this study, in 
terms of receptors expressed and disease severity represented. HER2 (also HER2/neu) = Human epidermal growth 
factor receptor 2. ER = Oestrogen receptor. PR = Progesterone receptor. 
 
Similar studies were performed using the mouse mammary carcinoma line 4T1, as this is a 
widely used murine model of aggressive and metastatic breast cancer [579]. Although no in 
vivo work was carried out in the current study, future work will examine the imaging and 
therapeutic potential of memHsp70 targeting in this model. It is one of the most widely used 
animal models of breast cancer, can be grown with ease in the correct anatomical site and as 
since it develops spontaneous metastases can be used as a model for aggressive disease [579]. 
As a comparator with previous studies, the mouse colorectal carcinoma line CT26 was also 
used. In addition to the binding of the cmHsp70.1 mAb to memHsp70+ tumours, this study 
clearly demonstrates the ability of cmHsp70.1 mAb to be internalised by memHsp70+ tumour 
cells. In vitro, the kinetics of uptake were dependent on the relative expression of memHsp70, 
with more rapid uptake into MDA-MB-231 and MCF7, those cell lines with high expression. The 
uptake of cmHsp70.1 mAb into tumours expressing memHsp70 could serve as a specific 
delivery vessel for cytotoxic agent(s). This could include the coupling of the cmHsp70.1 mAb to 
nanocarriers containing cytotoxic drugs or as part of an antibody-drug targeting complex. 
Nanocarriers are nano-scale transport vessels with no tumour specificity of their own, but 
which may be coupled to targeting molecules such as antibodies, and can be loaded with anti-
tumour agents (such as chemotherapeutic drugs). By packaging the cytotoxic agents in this 
way specific delivery to the tumour is favoured, resulting in high concentrations 
intratumourally, but low toxicity throughout the body, especially when compared to systemic 
administration of the free drug [580-582]. Other benefits are that the drug has protection from 
peripheral degradation prior to reaching the tumour target, as well as clearance through the 
kidneys being reduced, with the net result being that more of the drug remains available to 
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accumulate in the tumour [583, 584]. There are different forms of nanocarriers, including 
carbon nanotubes (cylindrical structures with ultra-high surface areas able to hold drugs in the 
cavity and on the surface, but exhibiting some toxicity issues due to their insolubility in all 
solvents [585-588] liposomes (membraneous lipid-bilayer structures which entirely 
encapsulate drugs, and can deliver both hydrophilic and hydrophobic compounds and have 
been highly favoured in pre-clinical investigations, but their administration can result in 
complement activation-related pseudoallergy and they offer limited control over the release of 
their contents [589-591]) and polymeric nanocarriers (polymer-based formations which can be 
presented in different structures and improve on the characteristics of liposomes being more 
stable, having longer circulation times, have higher capacities for loading and allow more 
control over content release [592, 593]).  
There are numerous studies involving all types of nanocarrier and these have been 
comprehensively reviewed elsewhere [594]. With regards to breast cancer, ongoing trials are 
assessing the use of these nanocarriers as drug delivery agents. Two phase I trials looking at 
doxorubicin in liposomes given to 29 pre-treated patients with recurring breast cancer found 
the treatment was well-tolerated, with half of patients showing a local response [595].  There 
has been FDA approval of one polymeric nanocarrier for use in breast cancer; abraxane, 
albumin–bound paclitaxel [596-599]. Although these strategies use nanocarriers, there is no 
specific tumour targeting via antibody conjugates however this is also a strategy being 
investigated. Using a doxorubicin-loaded, iron oxide nanoparticle conjugated to the anti-HER2 
monoclonal antibody Herceptin, specific uptake in to HER2+ breast cancer cell lines along with 
cell cytotoxicity has been demonstrated [600] and could offer a more efficient treatment 
option to patients in the future. In light of this, it is reasonable to think that a strategy of 
conjugating the cmHsp70.1 mAb to drug-loaded nanocarriers may be a viable one. 
The cmHsp70.1 mAb could also have a use in imaging tumours. As demonstrated herein, 
fluorescently-labelled cmHsp70.1 mAb is readily taken up into memHsp70+ tumour cells and 
the same has been shown to be true for memHsp70+ CT26 tumours implanted into mice. Given 
the broad expression of memHsp70 across a range of tumours this could prove useful for a 
large number of patients. Since fluorescence imaging is best conducted through short 
distances and will not be effective for imaging deep tumours in humans, this idea may be best 
translated by finding more appropriate labels for the antibody. 
7.2 The TKDNNLLGRFELSG peptide as a theranostic 
There has been an increased interest in the use of peptides in cancer therapeutics [558, 601-
604] due to their ability to penetrate tissue well, and their better biodistribution profiles over 
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alternatives such as antibodies. Furthermore, peptides can be produced at a relatively lower 
cost. One benefit of specific tumour-targeting peptides is their use as delivery vectors for anti-
tumour agents such as cytotoxic drugs. A 15-mer peptide derived from follicle stimulating 
hormone β specifically binds with high affinity to the follicle stimulating hormone receptor 
(FSHR) in the ovaries [605] and is subsequently taken up into cells. The specificity of binding 
and uptake led the authors to generate peptide-nanoparticle conjugates, with the 
nanoparticles containing paclitaxel, as a route to allow drug delivery specifically to cancer cells 
[606]. Between 50-70% of ovarian cancers express FSHR making this a treatment strategy of 
benefit to a large proportion of patients with this disease. However, this benefit is likely to be 
greater in patients with early stage disease, since secondary metastases have been found to be 
FSHR negative, despite the presence of FSHR on the patients primary tumour [606].   
Another example is the 17-mer peptide (termed BR2) [607] derived from buforin llb, itself a 
peptide derivative from histone H2A [608]. The peptide is known to interact with cells via 
surface gangliosides and is taken up into cells by lipid-mediated macropinocytosis. The authors 
have been developing the peptide as a drug delivery vehicle, using a fusion to a single-chain 
variable fragment directed to mutated K-ras, which is able to suppress Ras activity and induce 
cell death. Although this targeting is not restricted to one cancer type, the cancer specific 
cytotoxicity is very much determined by concentration. Increasing the peptide concentration 
eventually reaches a level where normal cells are affected, and this is obviously a concern 
when thinking of translating this into the clinic.  
Peptides may also themselves give direct anti-tumour effects, as seen in vitro with a (12-mer) 
peptide which, when taken up into SKOV3 cells down-regulates Bcl-2 in a caspase-dependent 
manner thereby inducing apoptosis [609] and in an in vivo breast cancer model using a 9-mer 
peptide which accumulates in MDA-MB-435 implanted tumours and induces cell death. 
However, the mechanism for this cytotoxic is unknown [610]. Targets currently under 
investigation for peptide-based tumour therapies typically express on specific tumour types 
and therefore are of potential benefit to a niche group of cancer patients.  
A 14-mer peptide derived from the region of Hsp70 that is available at the cell surface when it 
is in the membrane (TKDNNLLGRFELSG) form has already been used in a phase I clinical trial, 
whereby NK cells activated ex vivo in the presence of the TKDNNLLGRFELSG peptide in 
conjunction with low dose (100 IU/mL) IL-2 were investigated for their ability to target patient 
tumours [528]. The TKDNNLLGRFELSG peptide is now being used in a similar strategy in a 
phase II trial involving patients with memHsp70+ lung cancer [574]. As well being used in the 
activation of NK cells, the peptide can also be used directly where it can bind to, and be taken 
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up by memHsp70 on tumour cells [535], as has been demonstrated herein. The specificity of 
the binding and internalisation of TKDNNLLGRFELSG peptide has been further confirmed using 
an Hsp70 knockout (Hsp70-/-) 4T1 model, in which the proportion of cells taking up the 
TKDNNLLGRFELSG peptide falls from 49% for wild type cells to 1% in the knockout [535].  A key 
advantage of the TKDNNLLGRFELSG peptide over others that are currently available in the 
clinical setting, either as an imaging agent or drug delivery enhancer is that memHsp70 is 
selectively expressed on a broad range of tumour types, and therefore the profile potential 
recipients for whom this approach will be effective is markedly greater than that for other 
peptides whose targeting molecules are more restrictively expressed [557, 558, 601, 611, 612]. 
Furthermore, the expression of memHsp70 can be induced, enhanced by chemotherapy [290] 
and radiotherapy [613].  
Data shown herein confirm that the TKDNNLLGRFELSG peptide is able to bind to and be 
internalised by memHsp70. The fluorescently-labelled TKDNNLLGRFELSG peptide accumulates 
in the cells over time, at levels which correlate with the amount of memHsp70 expressed. 
Internalised TKDNNLLGRFELSG peptide is observed to be present in the cytoplasm of cells, as 
seen in confocal microscope imagery, as well as in distinct regions which appear to be vesicular 
structures. However, fixation and permeabilisation resulted in the TKDNNLLGRFELSG peptide 
being lost from cells and so the co-localisation of TKDNNLLGRFELSG peptide could not be 
determined. It was possible to determine the co-localisation of the TKDNNLLGRFELSG peptide 
with mitochondria, as these could be stained using a passively diffusing dye which can enter 
live cells without the need for fixation and permeabilisation steps. In future experiments, 
similar ‘live dyes’ could be employed to stain other intracellular structures in order to allow for 
a more comprehensive profile of TKDNNLLGRFELSG peptide trafficking.  
In all human and mouse cell lines studied, the TKDNNLLGRFELSG peptide was found to co-
localise with the mitochondria, with proportion of co-localisation increasing with increased 
memHsp70 expression levels. There have been reports of peptides and small molecules which 
exhibit anti-tumour effects by targeting the mitochondrial membrane. For example, take up of 
the 14-mer cationic α-helix forming peptide by breast cancer cell lines MCF7 and MDA-MB-231 
has been shown to result in a proportion of cells dying by apoptosis which is associated with a 
disruption of the mitochondrial membrane, as determined by Mitotracker Red staining [614]. 
Following compound screening, a small molecule within the class of triphenylphosphonium 
salts was found to induce G0/G1 cell cycle arrest following accumulation in the mitochondria of 
a number of pancreatic cancer cell lines, leading to an increase in reactive oxygen species 
(ROS) as well as cleavage of caspases and PARP-1 indicating apoptosis  [615]. However, the 
TKDNNLLGRFELSG peptide does not appear to have a direct anti-tumour effect. Cell lines 
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treated with TKDNNLLGRFELSG peptide (up to 750mg/mL, equivalent to 2M) showed no 
evidence of apoptosis on the basis of morphology, microscopy, cytochrome c release or 
caspase-3 activation [535]. Although not having any apparent direct anti-tumour effects, the 
TKDNNLLGRFELSG peptide still has potential for use in tumour imaging, or to aid the specific 
delivery of apoptotic agents to tumour cells, for example through the coupling of 
TKDNNLLGRFELSG peptide to cytotoxic drugs or to radionuclides [602]. 
The TKDNNLLGRFELSG peptide exhibits a rapid and progressive internalisation into 
memHsp70+ tumour cells. Unfortunately the current experimental setup makes direct 
comparison between the uptake kinetics of TKDNNLLGRFELSG peptide and cmHsp70.1 mAb 
highly problematic. The TKDNNLLGRFELSG peptide is conjugated during synthesis, whereby 
each 14-mer TKDNNLLGRFELSG peptide is labelled with one molecule of fluorescein. The 
cmHsp70.1 mAb used in the flow cytometric analyses is labelled with FITC in a post-synthesis 
conjugation reaction, with each antibody having an average of 3-4 FITC molecules. Without a 
directly comparable fluorescent label it is therefore not possible to accurately compare the 
internalisation kinetics of both molecules. This would be something to consider as a future 
extension to this work.  
The potential value of the TKDNNLLGRFELSG peptide in the management and treatment of 
cancers expressing the membrane form of Hsp70 is multifaceted. The specificity of peptide 
binding as well as the rapid uptake kinetics into memHsp70+ tumour cells means that the 
TKDNNLLGRFELSG peptide could be used for better tumour imaging, of both primary and 
metastatic tumours. Fluorescently labelled TKDNNLLGRFELSG peptide administered to mice 
with implanted memHsp70+ CT26 tumours has been shown to accumulate in the tumour site 
and was maintained for at least 24 hours [535].  Due to the specificity of binding and well 
characterised internalisation pathway of TKDNNLLGRFELSG peptide, the peptide could be 
coupled to other agents (such as nanocarriers for example) and used as a delivery vector, 
facilitating the delivering of cytotoxic or radiotherapeutic agents, for example. 
Key elements of this study have now been published [535], in which the TKDNNLLGRFELSG 
peptide has been termed, on the basis of the results, a tumour-penetrating peptide (TPP) and 
have underpinned further investigation of the peptide as a tool for in vivo tumour imaging 
[616]. A variety of tumour models (including those of colon, breast, pancreas, small-cell and 
non-small cell lung cancer, head and neck carcinoma and cervical cancer origin) and covering 
syngeneic, spontaneous, chemically-induced and xenograft models which were memHsp70+ 
were found to take up and accumulate the TPP in a highly tumour-specific manner. This 
occurred with greater specificity than the commercially available tumour targeting small 
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molecule IntegriSense (Perkin Elmer), which is marketed for in vivo tumour imaging and acts 
through binding ανβ3-integrin.  
Importantly, these approaches would work in conjunction with standard therapies such as 
chemotherapy or radiotherapy, since they are dependent only on the presence of memHsp70, 
the expression of which is can be enhanced following standard cancer therapies. This contrasts 
to potential considerations for peptides to be used in vaccination strategies, where 
effectiveness has been seen to be hampered by previous treatments efforts. For example, in a 
phase II clinical trial involving 42 patients with progressive, castrate-resistant prostate 
adenocarcinoma treated with a personalised peptide vaccine (formed as a combination of 2-4 
peptides selected from a list of 31 candidates depending on patient responsiveness), those 
patients who had received no prior docetaxel-based chemotherapy showed a significant 
overall survival benefit of 8 months [617]. 
7.3 Granzyme B 
Granzyme B is a serine protease which causes apoptosis by cleaving substrates within 
apoptotic pathways (including Bid, Bax and caspases). Granzyme B is a primary constituent of 
the cytotoxic granules of NK cells and T cells. Common understanding is that granzyme B acts 
in concert with perforin, a pore-forming protein, in order to allow uptake and subsequent 
cytoplasmic release [618]. Perforin is highly conserved within mammalian species and is 
encoded for by a single gene, PRF1.  
The ability of granzyme B to induce apoptosis in the absence of perforin is controversial. The 
concept is not widely accepted, and has at times been dismissed as an artefact of too high a 
granzyme B concentration. However there are published data to support the proposition that 
granzyme B can elicit cytotoxicity in the absence of perforin. Hagn et al [619] found that B cells 
can differentiate into cytotoxic plasma cells that are capable of secreting granzyme B in 
response to IL-21 produced by CD4+ T cell which lack co-stimulation and therefore do not 
express CD40L. However, these ‘cytotoxic B cells’ lack the perforin thought to be necessary for 
granzyme B uptake. Interestingly the authors found that over a co-incubation period of 3 days 
the B cell derived granzyme B was observed to transfer to and be taken up by HeLa cervical 
cancer cells and the malignant melanoma cell line G-361. The result is a reduction in cell 
viability by 41% and 21% respectively. Although the authors do not offer memHsp70 as a 
potential explanation for this, it was not an avenue that they explored and may offer an 
explanation for this phenomenon. 
Perforin causes pore formation in cell membranes in a calcium-dependent manner [620], 
although there remains some discussion as to the exact mechanism of action by perforin in 
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combination with granzymes. Two favoured hypotheses are that perforin punctures holes 
directly in the plasma membrane of target cells which are large enough to permit the influx of 
granzymes [621, 622]. An alternative mechanism is that both perforin and granzymes are 
endocytosed together into target cells, and perforin punctures the membrane of the endocytic 
vesicles allowing granzyme escape into the cytoplasm [623]. A third hypothesis is that perforin 
causes damage to the outer membrane of target cells and that during the process of 
membrane repair, granzymes can be taken up into vesicles [83]. This latter mechanism is a less 
favoured, as it offers no explanation for how granzymes may leave the vesicles and exert their 
effect [624]. Furthermore, previous studies have shown that recombinant Granzyme B 
generated in E. coli can only induce apoptosis in tumour cells in the presence of perforin [625].  
Five granzymes have been described in humans, with granzyme B being the most abundant 
and the most widely studied. Granzyme B is highly pro-apoptotic and has multiple substrates 
within apoptosis pathways [626]. One is the BH3 interacting-domain death agonist BID, upon 
proteolysis by granzyme B BID goes on to activate the apoptosis regulator Bax (bcl-2-like 
protein 4) and/or Bak (Bcl-2 homologous antagonist killer and consequently they oligomerise 
within the mitochondrial outer membrane [627-631]. This causes membrane permeabilisation 
which can directly induce apoptosis, but also leads to the subsequent escape of the 
mitochondrial protein cytochrome c into the cytoplasm [632] which triggers downstream 
effects in the form of formation of an Apaf-1/caspase-9 complex and cellular apoptosis [633-
635]. Granzyme B can also activate caspase-8 through the cleavage of procaspase-8, triggering 
caspase-7 activation as a precursor to apoptosis as well activation of caspase-3 (which can also 
occur directly through cleavage of procaspase-3 by granzyme B) which causes the inhibition of 
PARP and therefore apoptosis, and the cleavage of ICAD to CAD leading to DNA fragmentation 
and apoptosis [60, 559]. Another result of caspase-8 activation is the cleavage of BID into 
truncated BID (tBID) which can insert into, and permeabilise, the mitochondrial outer 
membrane as well as activating Bax and/or Bak causing the same. This intertwining of 
pathways containing multiple granzyme B substrates makes the situation a little confusing. For 
many years the mechanism of action has been difficult to decipher due a number of 
confounding factors such as the significance of difference substrates, the method of granzyme 
delivery in experiments, whether in vivo or in vitro experiments were performed, whether 
recombinant or purified protein was used, including taking into account species variations 
[624]. It is now clear that when human granzyme B is used in a human system, BID is a highly 
favoured substrate. However, if mouse granzyme B is used, then direct activation of caspase-3 
and caspase-8 is preferred [636].  
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 Granzyme B has been found to bind to Hsp70 [530] and the memHsp70+ cancer cell line CT26 
exhibited a degree of cell killing when incubated in the presence of granzyme B. However, an 
important finding has been that recombinant granzyme B can only kill membrane Hsp70 
positive tumour cells if it has been produced in a mammalian system; recombinant granzyme B 
generated in E. coli and Pischa pastoris [637] expression systems cannot induce apoptosis in 
memHsp70+ tumour cells in the absence of perforin. Mammalian posttranslational 
modifications and glycosylation are therefore crucial for effective memHsp70 mediated 
granzyme B uptake [531]. When administered i.v. to mice with implanted memHsp70+ CT26 
tumours, human recombinant granzyme B was found to reduce tumour burden via the 
induction of apoptosis of tumour cells, whereas no effect was seen on surrounding normal 
tissues and no adverse effects were observed in the mice [532]. The apoptotic regions were 
observed in areas of the tumours in close proximity to blood vessels, a finding which is 
consistent with the i.v. route of granzyme B administration which was used in this study. The 
human recombinant granzyme B used for these in vivo studies was produced using transfected 
HEK293 cells engineered to secrete inactive granzyme B into the supernatant with subsequent 
activation of the molecule being possible by way of enterokinase digestion cleaving the 
inactivation site. The same method was used to produce the granzyme B in this study. Whilst 
the CT26 cell line was included to allow comparisons with published data, the current study 
focussed on the uptake of granzyme B in breast cancer cell lines and its effects.  
The use of recombinant human granzyme B to directly induce the apoptosis of memHsp70+ 
tumour cells makes for a highly attractive platform on which to base new and/or enhance 
existing therapeutic approaches. As demonstrated herein, granzyme B is readily taken up into 
memHsp70+ tumour cells and causes death in a proportion of cells. Cell death was observed on 
the basis of cell numbers as well as morphological changes. However, in contrast to previous 
studies which used CT26 colon carcinoma cells [532], caspase-3 activation was not observed in 
the current study. This may be explained by the observation that granzyme B in a mouse 
system (as in the mouse colorectal carcinoma cell line CT26) favours caspase-3 activation 
[636]. In fact, the lack of caspase-3 involvement presented herein is supported by other 
published literature showing that the predominant route of action of granzyme B in a human 
system is in fact through the truncation of Bid and Bax, which leads to an alteration in the 
mitochondrial membrane potential and therefore the release of cytochrome c [638]. 
The confocal microscopical analysis of cells stained with Mito ID red (to visualise the 
mitochondria) and incubated with fluorescently labelled granzyme B provides evidence that 
granzyme B which is taken up via memHsp70 locates to the mitochondria. This is the first study 
to demonstrate the localisation of granzyme B to mitochondria.  When granzyme B acts in 
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conjunction with perforin, the granzyme B is internalised into early endosomes and then 
released into the cell cytoplasm [83]. Although some granzyme B locates to the nucleus, it is 
not known to directly traffic to the mitochondria [639]. However, in contrast to granzyme B, 
there is evidence that granzyme A can induce cell death with direct mitochondrial 
involvement. This process appears to involve the binding of granzyme A to the cytosolic 
chaperones hsp70 and hsp90 and subsequent docking to the mitochondrial membrane 
molecule Tom70 and this, in turn, mediating import into the mitochondria itself [66]. 
Granzyme A induced cell death can also occur in the absence of caspase involvement [67]. It 
might therefore be that the mechanism for granzyme A induced cell death may hold clues as to 
the mechanism of perforin-independent, memHsp70-mediated granzyme B induced apoptosis.  
A key and defining occurrence of the intrinsic (not surface death-receptor mediated) pathway 
of apoptosis is mitochondrial outer membrane permeabilisation, MOMP [640]. The fine details 
surrounding the instigation of MOMP are not yet completely elucidated although it involves 
activation of BAX and/or BAK, which itself often requires interaction with a member of the 
BH3-only protein family, or truncation of Bid (to tBid), all of which can be driven directly or 
through the upsteam activation of caspases [641]. Conformational changes allow activated 
BAX or BAK, or tBid oligomerisation into the mitochondrial outer membrane, triggering 
permeabilisation [642]. This is generally considered a point-of-no-return in apoptosis, with 
intra-mitochondrial proteins (including cytochrome c, Smac and HtrA2 amongst others) 
released into the cytosol, rapidly acting on a variety of substrates including numerous 
caspases, which quickly leads to cell death. That granzyme B internalised through memHsp70 
has been shown to traffic to the mitochondria, coupled with the knowledge that Bid is one of 
many possible substrates of human granzyme [636] begs the question of whether memHsp70-
mediated internalisation of granzyme B results directly in MOMP. Since intrinsic apoptosis and 
MOMP can occur in the absence of caspase activity [643], and very little caspase-3 activation 
was observed here, it would be useful to know whether memHsp70-mediated internalisation 
of granzyme B leads to caspase-independent intrinsic apoptosis. 
The use of mitochondrial stains which reveal mitochondrial membrane potential (such as JC-1) 
would be a useful next step to confirm whether permeabilisation is occurring. Since intrinsic 
apoptosis and MOMP can occur in the absence of caspase activity, and very little caspase-3 
activation was observed here, it would be useful to know whether this  
One concern for the therapeutic application of granzyme B is the potential systemic effects of 
administering a serine protease directly into the periphery. Granzyme B has shown high 
specificity to memHsp70 and should bind to and be taken up by only memHsp70+ cells. 
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Furthermore, the administration of granzyme B into mice bearing memHsp70+ CT26 tumours 
has been found to be well tolerated and did not result in adverse side-effects [532]. It is also 
worth noting that soluble granzyme B is readily detected in humans, the concentration of 
which can be used as a proxy measurement for NK cell and cytotoxic T cell activity. Spaeny-
Dekking and colleagues reported that soluble granzyme B is present in the circulation of 
healthy control subjects (median 11.5 pg/mL), and that levels were markedly elevated in 
patients with chronic inflammatory disorders (EBV patients 60 pg/mL, HIV patients 20 pg/mL, 
RA patients 20 pg/mL in plasma but over 3000 pg/mL in the synovial fluid of affected joints) 
[644]]. Similar patterns of increased concentrations of soluble granzyme B have also been 
observed in patients with breast cancer, with the increased concentration of granzyme B in 
patients potentially being evident of some anti-cancer immune response [645]. Interestingly, 
when granzyme B concentration was reassessed following chemotherapy, there was a near 
doubling in concentration (up to around 100pg/ml, or around 0.5ug per person) as well as 
there being a detectable presence of soluble cytochrome c and FasL. Although the 
concentration observed is much lower than that administered to mice [4ug/kg [532], it does 
highlight that granzyme B, as a naturally-occurring molecule, is tolerated within the periphery.  
Although there is much further study to be done, the concept of using granzyme B as a cancer 
therapeutic is an attractive one. Granzyme B itself acts directly on tumour cells to kill them 
without the immediate need for an effective immune system. This is important, as the majority 
of patients receive radiation therapy or chemotherapeutic as standard, both of which have 
long since been known to suppress the efficacy of protective anti-tumour immunity [646, 647]. 
This is one issue which has the potential to limit the protective effects of peptide-based anti-
cancer vaccines. In addition, if the resulting tumour cell death following granzyme B treatment 
could lead release of tumour antigen then it could potentially induce a subsequent increased 
anti-tumour immune response. Further study is necessary to demonstrate memHsp70-
mediated granzyme B-induced cell death is an immunogenic cell death conducive to eliciting 
an immune response [648].  
One point to consider is the issue of granzyme B inhibitors. In humans the action of granzyme 
is blocked by serpinB9 (also known as protease inhibitor 9 or simply PI9) [649], a protease 
abundantly expressed by T cells and NK cells as protection from granzyme B mediated 
apoptosis. The expression of serpinB9 in tumour cells is less well characterised, although 
published data has been shown that MDA-MB-231 cells have some expression (to a level 
around 300-fold less than that in T cells or NK cells) while MCF7 cells do not express it [650]. In 
an attempt to replicate these data, cell lysates from the three human breast cancer cell lines 
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produced using RIPA buffer were subjected to western blot analyses for serpin B9 expression, 
along with lysates from PBMC preparations as a positive control.  
 
Figure 7.1 Western blot analysis of serpin B9 expression in human breast cancer cell lines.  
Cell lysate containing 50μg of protein was used in SDS-page electrophoresis and transferred to PvDF membrane via 
semi-dry western blotting before staining for serpin B9 expression using mouse monoclonal (PI9-17) anti-serpin B9 
antibody (Abcam, used 1:500) followed by HRP anti-mouse antibody (Dako, 1:2000) with non-specific binding 
blocked using 5% milk powder and 0.5% Tween 20 in TBS. Expression was detected in the PBMC lysate but not in 
any of the human breast cancer cell lines. 
No serpin B9 expression was observed in the human breast cancer cell lines although it was 
present in the PBMC lysate. Previously published data showed that MDA-MB-231 cells do 
express serpin B9, but around 300 fold lower than in the T cells and NK cells found in PBMCs. 
The expression seen here in the PBMC preparation is weak so it is unlikely that a lower 
expression would be picked up. Use of a different serpin B9 antibody may result in clearer 
staining and thus may enable lower expressions to be seen. Even if low serpin B9 expression is 
present in MDA-MB-231 cells they still exhibited morphological characteristics associated with 
apoptosis, suggesting that either the level of serpinB9 expression was insufficient to inhibit all 
of the internalised granzyme B or that granzyme B internalised through memHsp70 is 
somehow able to exert its effects in a way which bypasses any potential blocking by serpinB9. 
This is an interesting mechanistic point and should be further investigated in the future.  
Of interest is to compare the kinetic of uptake of the three molecules – cmHsp70.1 antibody, 
TKDNNLLGRFELSG peptide and granzyme B. This is made more difficult since each is 
conjugated to a different fluorescent molecule and hence the brightness of any one of the 
molecules will vary. In this situation the most appropriate comparison to make is to look at the 
number of fluorescent spots observed to be internalised at different time-points (Figure 7.2, 
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see over). In all cell lines, although the antibody and granzyme B exhibited a similar number of 
fluorescent spots at each time-point internalisation of the TKDNNLLGRFELSG peptide resulted 
in around double the number of spots. This would suggest a more effective and efficient 
uptake of TKDNNLLGRFELSG peptide and would make this the molecule the main choice of the 
three to translate for tumour imaging, and potential drug delivery to memHsp70+ tumours. 
 
Figure 7.2 Comparing the kinetics of internalisation of cmHsp70.1, TKDNNLLGRFELSG and granzyme B into 
memHsp70+ cancer cell lines. 
Using the count of fluorescent spots following incubation with fluorescently labelled cmHsp70.1, TKDNNLLGRFELSG 
peptide and granzyme B, the rate of each uptake could be compared. The larger molecules were internalised at 
similar rates although the small peptide was internalised at double the rate.  
7.4 Lymphocytes and memHsp70 
Whilst the potential to target a large proportion of tumours through their memHsp70 
expression (be it via the cmHsp70.1 antibody, the TTP peptide or granzyme B) is highly 
exciting, the strategy will only be viable if the expression of memHsp70 is highly tumour 
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specific. When assessing the memHsp70 expression on tumour biopsies, Hantschel et al [569] 
also assessed the memHsp70 expression on cells from the surrounding healthy tissue and 
found it to be negative. This has been the case for all 1300+ patients that the Multhoff 
laboratory has assessed, and is also true for areas surrounding primary tumours and distant 
metastases. In terms of memHsp70 being present in other diseases states, the only finding 
thus far has been in arthritis. A link between rheumatoid arthritis (RA) and Hsp70 has been 
known for nearly two decades, with increased levels of circulating anti-Hsc70 antibodies [651], 
raised levels of released Hsp70 in synovial fluid, but not serum [652] and an increased 
expression of cytoplasmic Hsp70 in synovial tissue [653] in patients with RA. These findings 
prompted an investigation into whether RA patients also exhibited raised levels of membrane 
bound Hsp70. Nguyen et al used fluorescently-labelled cmHsp70.1 mAb to assess membrane 
Hsp70 expression on fibroblast-like synovial cells and found that around 40% were positive in 
patients with RA and JIA (juvenile idiopathic arthritis) [654], whereas there was no expression 
by synovial cells of healthy volunteers. Skin fibroblasts and peripheral blood lymphocytes 
served as a negative control, with less than 10% showing positive staining with cmHsp70.1 
mAb in either patient group. The authors also looked at other peripheral blood populations 
and the stand-out finding was that there was a high level of staining with cmHsp70.1 on 
monocytes (around 80% of cells) in healthy volunteers and patient populations. Whilst these 
could be interesting findings, the results are flawed due to a lack of an appropriate control 
antibody. The authors only used one Hsp70 antibody clone, cmHsp70.1, which is able to detect 
Hsp70 that is both in the membrane and bound to the cell surface. This lack of distinction 
means that the authors cannot claim to have shown memHsp70 expression with these data. 
Consequently further investigation is required in order to confirm the presence of memHsp70 
in RA and JIA patients, as well as on monocytes.  
There has been no other report of memHsp70 expression in non-cancer disease states or on 
healthy cells in the published literature. However, previous studies in the Immunobiology 
Research Group at University of Sheffield have observed that CD4+CD25+ immunoregulatory T 
(Treg) cells isolated from mouse splenocytes using a magnetic column protocol could be 
labelled with the cmHsp70.1 mAb (Sarah Haywood-Small, personal communication). This 
finding led us to enquire if this was an artefact or whether lymphocyte populations could 
indeed bind the cmHsp70.1 mAb, and if so, under what circumstances this could occur.   
Through the use of two Hsp70 antibody clones, no lymphocyte population was found to be 
reactive with the cmHsp70.1 mAb in peripheral blood when samples were stained using a 
whole blood technique. As previous investigations with mouse Treg cells have shown that 
reactivity with the cmHsp70.1 mAb could apparently be induced. PBMCs were isolated using 
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density gradient centrifugation and their reactivity with the cmHsp70.1 mAb determined by 
flow cytometry. This demonstrated that the process of density gradient separation induced a 
capacity for the cmHsp70.1 mAb to bind to T cell and NK cell populations. The capacity of cell 
activation using the polyclonal mitogen ConA and anti-CD3/CD28 mAb-coated beads, heat and 
hypoxia was also investigated. Although cells were confirmed to be activated following 
polyclonal stimulation (on the basis of CD69 and CD25 expression) they showed no reactivity 
with the cmHsp70.1 mAb. Nor did heat or hypoxia have any effect. It appears that the 
induction of reactivity to cmHsp70.1 mAb is an artefact of the density gradient centrifugation 
process, for reasons that are currently unclear. 
7.5 Conclusion 
MemHsp70 serves as a tumour specific marker and is present on around 50% of malignancies. 
As such it is a highly desirable candidate for the development of novel cancer therapeutics, as 
it could potentially be used to treat a large number of patients. The specific targeting of 
memHsp70 could come from the use of an antibody (cmHsp70.1), the 14-mer TTP peptide or 
granzyme B. 
A key advantage of developing therapeutic platforms on the basis of membrane Hsp70 
expression is the fact that the expression of this molecule is enhanced following standard 
radio(chemo)therapy. 
The fact that this specific targeting of memHsp70+ tumours could be conducted alongside the 
administration of standard cancer therapies would be a big advantage to patients, since this 
would form an additional, complimentary therapy and patient treatment would not be 
compromised. In fact additional benefits could be gained by delivering a cmHsp70.1 mAb-
based therapy concurrently with standard therapy. A side effect of the standard chemo-or 
radio-therapies is that memHsp70+ tumours upregulate that expression, but this could actually 
boost the effectiveness of a memHsp70-targeted therapeutic through increased availability of 
target molecules. Moreover, any direct killing of tumours can serve to facilitate the release of 
tumour antigens which can trigger an immune response. It has previously been shown that 
non-lethal chemotherapy and radiotherapy can increase the susceptibility of malignant cells to 
T cell mediated lysis [655-657] so this coupled with increased susceptibility to memHsp70 
directed therapies could result in a more efficient anti-tumour immune response.  
The use of the antibody and the peptide could be two fold, either as an imaging tool or a 
delivery vector for cytotoxic agents. The kinetics of uptake of antibody and peptide are reliant 
on the density of memHsp70, but this can be increased following standard cancer therapies. 
Granzyme B can be employed as a direct cytotoxic agent that will induce apoptosis in 
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memHsp70+ tumour cells. The killing of tumour cells may have a secondary result of boosting 
the patients’ anti-tumour immune response, if tumour cell death results in the release of 
tumour antigens.  
The next step is to further investigate the potential usage of antibody, peptide and granzyme B 
in mouse model of breast cancer with a view to moving into human clinical trials in the future.  
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Future Work  
When imaging the uptake of the cmHsp70.1 mAb, the TKDNNLLGRFELSG 14-mer peptide and 
granzyme B, the potential involvement of early endosomes was not clear, possibly due to the 
short amount of time that the molecules would co-localise with the early endosome 
compartment. Rather than imaging this point in the internalisation, involvement could be 
confirmed another way, by ultracentrifugation separation of the early endosomes following by 
Western blot analysis, or simply by fluorescent analysis using flow cytometry. Another possible 
method is to use a protein protection assay such as that described by Cihil et al allowing for 
the endocytic uptake of molecules and their subsequent recycling to the plasma membrane to 
be tracked [658]. 
With particular reference to the granzyme B uptake by memHsp70+ tumour cells, further study 
is required in order to fully elicit the action of granzyme B following memHsp70-mediated 
uptake. Granzyme B has many substrates and it is not clear which, or how many, are involved 
when granzyme B is taken up this way. One way could be through the use of proteomic 
analysis, using mass spectrometry, to study protein modifications (e.g. cleavage) and activation 
at different time-points following granzyme B internalisation.   
Although the use of the cmHsp70.1 antibody, the TKDNNLLGRFELSG peptide or granzyme B as 
targeting molecules for Hsp70+ breast cancer could offer new treatment avenues for patients, 
the current studies have been confined to in vitro experiments. The next step is to move into 
looking in vivo, starting with mouse models of breast cancer. Using implanted memHsp70+ 
tumour cell lines, the specificity of binding of the cmHsp70.1 antibody and the 
TKDNNLLGRFELSG peptide to tumours could be examined using in vivo imaging of the animals. 
The capacity of granzyme B to inhibit the growth of primary tumours and, in the appropriate 
models, metastatic disease will be examined, either in the presence or absence of existing 
therapies such as chemotherapy, radiotherapy or therapeutic antibody treatments. Allied to 
these studies would be to determine whether granzyme B promotes the release of tumour-
related antigens, against which protective, adaptive immune responses can be induced. This 
proposition could be examined on the basis of antigen/peptide-specific proliferation and 
activation assays, cytokine and granzyme B release from using multiplex bead and ELISpot 
assays, the identification of peptide-specific T cells using flow cytometric multimer platforms 
and the ability of cells from treated animals to kill appropriate tumour cells in vitro.  
The ultimate aim is to translate this research into the clinical setting and use the targeting of 
memHsp70 to improve tumour imaging and the management and treatments of patients with 
memHsp70+ cancers.  
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Appendix 
i. Reagents and Suppliers 
0.22µm filter Sarstedt AG & Co 
12x75mm polypropylene tubes Sarstedt AG & Co 
35mm glass bottom dishes MatTek Corporation 
5mL Bijous tubes Star Lab UK Ltd 
96 well plates Sarstedt AG & Co 
Ab anti-CD3 UCHT1 Qdot605 Molecular Probes®, Life 
Technologies 
Ab anti-CD3 UCHT1 Alexa Fluor 700 Biolegend, Inc 
Ab anti-CD4 RPA-T4 Pacific Blue Biolegend, Inc 
Ab anti-CD8 RPA-T8 V500 BD Bioscience 
Ab anti-CD8 RPA-T8 Alexa Fluor 700 Biolegend, Inc 
Ab anti-CD56 MEM-188 R-PE Biolegend, Inc 
Ab anti-CD69 FN50 PE/Cy7 Biolegend, Inc 
Ab anti-CD25 BC96 PerCP/Cy5.5 Biolegend, Inc 
Ab C92F3A-5 Stressgen®, Enzo Life Sciences Inc 
Ab cmHsp70.1 Multimmune Gmbh 
Ab Cy3 goat anti-rabbit Jackson ImmunoResearch Inc 
Ab Cy3 rabbit anti-goat Jackson ImmunoResearch Inc 
Ab HRP rabbit anti-mouse secondary Dako UK Ltd 
Ab Mouse IgG1 Isotypes Biolegend, Inc 
Ab Purified mouse anti-human Granzyme B primary 
BD Biosciences 
Ab Purified mouse anti-LAMP1 Biolegend, Inc 
Ab Purified mouse anti-phosphatidylserine 1H6 
Merck Millipore 
Ab Purified Mouse IgG Invitrogen™, Life Technologies 
Ab Rab4a sc312 Santa Cruz Biotechnology Inc 
Ab Rab5a sc309 Santa Cruz Biotechnology Inc 
Ab Rab7 sc10767 Santa Cruz Biotechnology Inc 
Ab Rab9a sc6562 Santa Cruz Biotechnology Inc 
Ab Rab11 sc6565 Santa Cruz Biotechnology Inc 
Ab Purified rabbit anti-LAMP2 Sigma-Aldrich Co LLC 
Amersham Rainbow Marker GE Healthcare Life 
Sciences 
Amicon Ultra Centrifugal filter tubes Merck Millipore 
Ammonium sulphate Sigma-Aldrich Co LLC 
Annexin V Alexa Fluor 647 Biolegend, Inc 
ArC Beads Molecular Probes®, Life Technologies 
BCA protein kit Pierce™, Thermo Fisher Scientific Inc 
BD™ CompBeads BD Biosciences 
Blotting Paper GE Healthcare Life Sciences 
Bradford Solution Sigma-Aldrich Co LLC 
Bromide Blue Sigma-Aldrich Co LLC 
Calcium Chloride Sigma-Aldrich Co LLC 
Caspase-3 Assay Kit BD Biosciences 
Cell Fix BD Biosciences 
Concanavalin A Sigma-Aldrich Co LLC 
Cover Slip Removal Fluid MatTek Corporation 
Culture Flasks Sarstedt AG & Co 
Culture Medium – OptiMem Life Technologies 
Culture Medium – RPMI 1640 Lonza, Ltd 
Dimethyl sulfoxide Sigma-Aldrich Co LLC 
Dynal Expander Beads Life Technologies 
ECL Substrate Pierce ™, Thermo Fisher Scientific Inc  
Enterokinase Sigma-Aldrich Co LLC 
Ethanol Thermo Fisher Scientific Inc 
Falcon tubes BD Biosciences 
Film GE Healthcare Life Sciences 
FIX & PERM® Cell permeabilisation kit Life 
Technologies 
Foetal Bovine Serum Lonza, Ltd 
Fucose Sigma-Aldrich Co LLC 
Galactose Sigma-Aldrich Co LLC 
Glucosamine Sigma-Aldrich Co LLC 
Glucose Sigma-Aldrich Co LLC 
Glycine Sigma-Aldrich Co LLC 
HEPES Sigma-Aldrich Co LLC 
HiTrap™ Heparin HP column GE Healthcare Life 
Sciences 
HisTrap™ FF Nickel column GE Healthcare Life 
Sciences 
Hydrogen Peroxide Sigma-Aldrich Co LLC 
Ι-Glutamine Lonza, Ltd 
Imidazole Sigma-Aldrich Co LLC 
Lightning Link conjugation kits Innova Bioscience Ltd 
Lithium-heparin vacutainer® tubes BD Biosciences 
Live/Dead Cell Stain Molecular Probes®, Life 
Technologies 
Lymphocyte Separation Medium 1077 PAA 
Laboratories GmbH 
Lysis Buffer BD Biosciences 
Magnesium Chloride Sigma-Aldrich Co LLC 
Mannose Sigma-Aldrich Co LLC 
Methanol Thermo Fisher Scientific Inc 
Microfuge Tubes Sarstedt AG & Co 
Microscopy Slides VWR International 
Milk Powder Co-operative Group Ltd 
MitoID ™®Red Enzo Life Sciences Inc 
MitoTracker ®Green Molecular Probes®, Life 
Technologies 
Mouse Serum Sigma-Aldrich Co LLC 
N-acetyl-Ile-Glu-Pro-Asp-ρ-nitroanilide Merck KGaA 
N-acetyl neuraminic acid Sigma-Aldrich Co LLC 
Nail varnish Boots plc 
Needles Terumo Medical Corporation 
NycoPrep™ 1.077 Axis-Shield plc 
Paraformaldehyde Sigma-Aldrich Co LLC 
PBS Lonza, Ltd 
Penicillin Lonza, Ltd 
Peptide NGLTLKNDFSRLEG EMC Microcollections 
Peptide TKDNNLLGRFELSG EMC Microcollections 
Propidium Iodide Sigma-Aldrich Co LLC 
PVDF membrane GE Healthcare Life Sciences 
Radi-Blue dye BioRad Laboratories Ltd 
Scalpels Swann Morton 
SFCA filter Nalgene™, Thermo Fisher Scientific Inc 
Sodium chloride Sigma-Aldrich Co LLC 
Sodium dodecyl sulphate Sigma-Aldrich Co LLC 
Sodium Pyruvate Sigma-Aldrich Co LLC 
Streptomycin Lonza, Ltd 
Suppression Inspector Beads Miltenyi Biotec Ltd 
Syringes Terumo Medical Corporation 
Tris-HCl Sigma-Aldrich Co LLC 
Trypan Blue Sigma-Aldrich Co LLC 
Trypsin-EDTA Lonza, Ltd 
Tween Sigma-Aldrich Co LLC 
VECTASHIELD mounting medium with DAPI Vector 
Laboratories 
Zeocin InvivoGen 
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ii. Publications arising from data herein 
 
A novel expression and purification system for the production of enzymatic and biologically 
active human granzyme B 
Gehrmann, M, Doss, B. T, Wagner, M, Zettlitz, K. A, Kontermann, R. E, .Foulds, G, Pockley, A. G, 
Multhoff, G. J Immunol Methods 2011 371 (1-2) 8-17 
The serine protease granzyme B (grB) has previously been shown to induce perforin-
independent apoptosis in membrane Hsp70 positive tumor cells in a number of in vitro 
experimental systems. Ongoing studies that are investigating the in vivo relevance of these 
findings by assessing the therapeutic potential of grB in a human xenograft tumor mouse 
model required the development of an expression system for the production of high yields of 
enzymatic and biologically active human grB. In order to maintain potentially important 
posttranslational modifications that occur in mammalian cells, human embryonal kidney cells 
(HEK293) were stably transfected with human grB. The HEK293 host cells were protected from 
apoptotic cell death by fusing an inactivation site coupled to a (His)(6) tag to the gene 
sequence of GrB. Inactive grB which was actively released from HEK293 cells by insertion of a 
Igkappa leader sequence was purified on a nickel column utilizing the (His)(6) tag. After 
enterokinase digestion and heparin affinity chromatography, high yields of enzymatic and 
biologically active human grB were obtained. The perforin-independent interaction of grB with 
membrane Hsp70 positive tumor cells appeared to be associated with mammalian 
glycosylation and mediated by the oligosaccharide moiety of neuraminic acid (NANA). 
 
 
Immunotherapeutic targeting of membrane Hsp70-expressing tumors using recombinant 
human granzyme B 
Gehrmann, M, Stangl, S, Kirschner, A, Foulds, G. A, Sievert, W, Doss, B. T, Walch, A, Pockley, A. 
G, Multhoff, G. PLoS One 2012 7(7) e41341 
BACKGROUND: We have previously reported that human recombinant granzyme B (grB) 
mediates apoptosis in membrane heat shock protein 70 (Hsp70)-positive tumor cells in a 
perforin-independent manner. METHODOLOGY/PRINCIPAL FINDINGS: Optical imaging of 
uptake kinetics revealed co-localization of grB with recycling endosomes (Rab9/11) as early as 
5 min after internalization, with late endosomes (Rab7) after 30 min, and the lysosomal 
compartment (LAMP1/2) after 60 to 120 min. Active caspase-3-mediated apoptosis was 
induced in mouse CT26 monolayer cells and 3D tumor spheroids, but not in normal mouse 
endothelial cells. Granzyme B selectively reduced the proportion of membrane Hsp70-positive 
cells in CT26 tumor spheroids. Consecutive i.v. injections of recombinant human grB into mice 
bearing membrane Hsp70-positive CT26 tumors resulted in significant tumor suppression, and 
a detailed inspection of normal mouse organs revealed that the administration of anti-tumoral 
concentrations of grB elicited no clinicopathological changes. CONCLUSIONS/SIGNIFICANCE: 
These findings support the future clinical evaluation of human grB as a potential adjuvant 
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Tumor imaging and targeting potential of an Hsp70-derived 14-mer peptide 
Gehrmann, M, Stangl, S, Foulds, G. A, Oellinger, R, Breuninger, S, Rad, R, Pockley, A. G, 
Multhoff, G. PLoS One 2014 9 (8) e105344 
BACKGROUND: We have previously used a unique mouse monoclonal antibody cmHsp70.1 to 
demonstrate the selective presence of a membrane-bound form of Hsp70 (memHsp70) on a 
variety of leukemia cells and on single cell suspensions derived from solid tumors of different 
entities, but not on non-transformed cells or cells from corresponding 'healthy' tissue. This 
antibody can be used to image tumors in vivo and target them for antibody-dependent cellular 
cytotoxicity. Tumor-specific expression of memHsp70 therefore has the potential to be 
exploited for theranostic purposes. Given the advantages of peptides as imaging and targeting 
agents, this study assessed whether a 14-mer tumor penetrating peptide (TPP; 
TKDNNLLGRFELSG), the sequence of which is derived from the oligomerization domain of 
Hsp70 which is expressed on the cell surface of tumor cells, can also be used for targeting 
membrane Hsp70 positive (memHsp70+) tumor cells, in vitro. METHODOLOGY/PRINCIPAL 
FINDINGS: The specificity of carboxy-fluorescein (CF-) labeled TPP (TPP) to Hsp70 was proven 
in an Hsp70 knockout mammary tumor cell system. TPP specifically binds to different 
memHsp70+ mouse and human tumor cell lines and is rapidly taken up via endosomes. Two to 
four-fold higher levels of CF-labeled TPP were detected in MCF7 (82% memHsp70+) and MDA-
MB-231 (75% memHsp70+) cells compared to T47D cells (29% memHsp70+) that exhibit a 
lower Hsp70 membrane positivity. After 90 min incubation, TPP co-localized with 
mitochondrial membranes in memHsp70+ tumors. Although there was no evidence that any 
given vesicle population was specifically localized, fluorophore-labeled cmHsp70.1 antibody 
and TPP preferentially accumulated in the proximity of the adherent surface of cultured cells. 
These findings suggest a potential association between membrane Hsp70 expression and 
cytoskeletal elements that are involved in adherence, the establishment of intercellular 
synapses and/or membrane reorganization. CONCLUSIONS/SIGNIFICANCE: This study 
demonstrates the specific binding and rapid internalization of TPP by tumor cells with a 
memHsp70+ phenotype. TPP might therefore have potential for targeting and imaging the 
large proportion of tumors (approximately 50%) that express memHsp70. 
 
 
 
 
